ASI,Des,CI,BFO,CURAB,ASSSUBCELFR,ASCT,T,RELAT,CONFSC,SRI,SASSI,CHEI,TISI,VAI
1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615117,,
2,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL615118,,
3,,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615119,,
4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,BAO_0000249,Autocuration,,,104729,H,4,1,,CHEMBL615120,,
5,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),163.0,BAO_0000219,Intermediate,,143B,80001,N,1,1,,CHEMBL615121,,
6,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),163.0,BAO_0000219,Intermediate,,143B,80001,N,1,1,,CHEMBL615122,,
7,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,163.0,BAO_0000219,Intermediate,,143B,80001,N,1,1,,CHEMBL615123,,
8,In vitro cell cytotoxicity was determined against 143B cell line,163.0,BAO_0000219,Expert,,143B,80001,N,1,1,,CHEMBL615124,,
9,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,163.0,BAO_0000219,Intermediate,,143B,80001,N,1,1,,CHEMBL615125,,
10,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,163.0,BAO_0000219,Intermediate,,143B,80001,N,1,1,,CHEMBL615126,,
11,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,163.0,BAO_0000219,Intermediate,,143B,80001,N,1,1,,CHEMBL615127,,
12,In vitro cell cytotoxicity was determined against 143B-LTK cell line,163.0,BAO_0000219,Expert,,143B,80001,N,1,1,,CHEMBL615128,,
13,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,Intermediate,,,50185,N,1,1,,CHEMBL857900,,
14,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,Intermediate,,,50185,N,1,1,,CHEMBL615129,,
15,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,Intermediate,,,50185,N,1,1,,CHEMBL615130,,
16,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,Intermediate,,,50185,N,1,1,,CHEMBL615131,,
17,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,BAO_0000357,Expert,,,100122,D,9,1,,CHEMBL884521,,
18,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615132,,
19,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,BAO_0000019,Autocuration,,,12054,H,8,1,,CHEMBL615133,,
20,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615134,,
21,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615135,,
22,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615136,,
23,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615137,,
24,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615138,,
25,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL836324,,
26,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615139,,
27,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615140,,
28,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,Autocuration,,,12426,H,8,1,,CHEMBL615141,,
29,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615142,,
30,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615143,,
31,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615144,,
32,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL872867,,
33,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615145,,
34,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615146,,
35,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL615147,,
36,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615148,,
37,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615149,,
38,Dissociation constant with dimeric 16S rRNA RNA construct B,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615150,,
39,Dissociation constant towards 16S rRNA construct A,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL615151,,
40,Dissociation constant towards 16S rRNA construct B,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL615152,,
41,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,BAO_0000225,Expert,,,100263,M,3,1,,CHEMBL615153,,
42,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,BAO_0000225,Expert,,,100263,M,3,1,,CHEMBL615154,,
43,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,Autocuration,,,13053,H,8,1,,CHEMBL615155,,
44,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,Autocuration,,,13053,H,8,1,,CHEMBL615156,,
45,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,Autocuration,,,20001,H,8,1,,CHEMBL615157,,
46,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,Autocuration,,,20001,H,8,1,,CHEMBL615158,,
47,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,Expert,,,12971,D,9,1,,CHEMBL615159,,
48,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,Expert,,,12971,D,9,1,,CHEMBL615172,,
49,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,Expert,,,12971,D,9,1,,CHEMBL615173,,
50,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,Expert,,,12971,D,9,1,,CHEMBL615174,,
51,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,Autocuration,,,13053,H,8,1,,CHEMBL884518,,
52,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,BAO_0000357,Autocuration,,,11512,H,8,1,,CHEMBL615175,,
53,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,BAO_0000357,Autocuration,,,11512,H,8,1,,CHEMBL615176,,
54,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,BAO_0000357,Autocuration,,,11512,H,8,1,,CHEMBL615177,,
55,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,BAO_0000249,Autocuration,Membranes,,104740,D,5,1,,CHEMBL615178,,
56,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615179,,
57,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,BAO_0000219,Autocuration,,Oocytes,104835,D,7,1,,CHEMBL615180,,
58,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,BAO_0000219,Autocuration,,Oocytes,104821,D,7,1,,CHEMBL615181,,
59,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,BAO_0000219,Autocuration,,Oocytes,104848,D,7,1,,CHEMBL615182,,
60,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,506.0,BAO_0000219,Expert,,1A9,80002,N,1,1,,CHEMBL615183,,
61,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615184,,
62,Cytotoxic activity against human ovarian cancer (1A9) cell line,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615185,,
63,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615186,,
64,Effective dose of compound against replication of 1A9 cell line was evaluated,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615187,,
65,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,506.0,BAO_0000219,Expert,,1A9,80002,N,1,1,,CHEMBL885343,,
66,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615188,,
67,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615189,,
68,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615190,,
69,Inhibitory activity against Taxol resistant 1A9 cell lines,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615191,,
70,Cytotoxicity against human ovarian cancer (1A9) cell lines.,506.0,BAO_0000219,Expert,,1A9,80002,N,1,1,,CHEMBL615192,,
71,Percentage inhibition of human ovarian cancer (1A9) cell lines.,506.0,BAO_0000219,Expert,,1A9,80002,N,1,1,,CHEMBL827083,,
72,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,506.0,BAO_0000219,Expert,,1A9,80002,N,1,1,,CHEMBL615193,,
73,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615194,,
74,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615195,,
75,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,506.0,BAO_0000219,Intermediate,,1A9,80002,N,1,1,,CHEMBL615196,,
76,Inhibitory concentration against Jurkat cells,503.0,BAO_0000219,Intermediate,,Jurkat,81072,N,1,1,,CHEMBL615197,,
77,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL615198,,
78,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,BAO_0000357,Expert,,,100121,D,9,1,,CHEMBL615199,,
79,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,Expert,,,11231,H,8,1,,CHEMBL615200,,
80,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,Expert,,,11231,H,8,1,,CHEMBL615201,,
81,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,BAO_0000357,Expert,,,11231,H,8,1,,CHEMBL615202,,
82,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,BAO_0000251,Autocuration,Microsomes,,11231,H,8,1,,CHEMBL615203,,
83,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,BAO_0000251,Autocuration,Microsomes,,11231,H,8,1,,CHEMBL615204,,
84,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,Autocuration,Microsomes,,11231,H,8,1,,CHEMBL615205,,
85,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,Autocuration,Microsomes,,11231,H,8,1,,CHEMBL615206,,
86,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",,BAO_0000251,Autocuration,Microsomes,,12083,H,8,1,,CHEMBL615207,2107.0,
87,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,BAO_0000019,Autocuration,,,11231,H,8,1,,CHEMBL827084,,
88,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,BAO_0000019,Autocuration,,,11231,H,8,1,,CHEMBL615208,,
89,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,BAO_0000019,Autocuration,,,11231,H,8,1,,CHEMBL615209,,
90,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",,BAO_0000251,Autocuration,Microsomes,,12083,D,9,1,,CHEMBL615210,2107.0,
91,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,BAO_0000251,Autocuration,Microsomes,,12083,D,9,1,,CHEMBL615211,2107.0,
92,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",,BAO_0000251,Autocuration,Microsomes,,12083,D,9,1,,CHEMBL615212,2107.0,
93,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,BAO_0000357,Expert,,,11377,H,8,1,,CHEMBL615213,,
94,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,BAO_0000357,Expert,,,11377,H,8,1,,CHEMBL615273,,
95,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,726.0,BAO_0000219,Expert,,HepG2,81020,N,1,1,,CHEMBL615274,,
96,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615275,,
97,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615276,,
98,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615277,,
99,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615326,,
100,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000218,Expert,,,50606,N,1,1,,CHEMBL883130,,
101,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL884519,,
102,Concentration required to inhibit 50% of 2.2.15 cell line,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615327,,
103,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615328,,
104,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615329,,
105,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615330,,
106,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,BAO_0000218,Expert,,2.2.15,50606,N,1,1,,CHEMBL615331,,
107,In vitro anti-HBV activity in 2.2.15 cells,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615332,,
108,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615333,,
109,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615334,,
110,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615335,,
111,Cytotoxicity in 2.2.15 cells,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615336,,
112,Cytotoxicity in 2.2.15 cells; Not determined,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615337,,
113,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615338,,
114,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615339,,
115,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,BAO_0000218,Intermediate,,2.2.15,50587,N,1,1,,CHEMBL615340,,
116,Antiviral activity against HBV was determined in 2.215 cell line,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615341,,
117,Inhibition of 20-HETE synthesis in human renal microsomes,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL615342,,
118,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615343,,
119,Inhibitory concentration against 2008 (ovarian) cells,388.0,BAO_0000219,Intermediate,,2008,80612,N,1,1,,CHEMBL615344,,
120,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,388.0,BAO_0000219,Intermediate,,2008,80612,N,1,1,,CHEMBL615345,,
121,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),388.0,BAO_0000219,Intermediate,,2008,80612,N,1,1,,CHEMBL615346,,
122,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,388.0,BAO_0000219,Intermediate,,2008,80612,N,1,1,,CHEMBL615347,,
123,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,388.0,BAO_0000219,Intermediate,,2008,80612,N,1,1,,CHEMBL615348,,
124,In vitro inhibition of 2008/R ovarian cancer cell line,561.0,BAO_0000219,Intermediate,,2008/R,80613,N,1,1,,CHEMBL827085,,
125,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,561.0,BAO_0000219,Intermediate,,2008/R,80613,N,1,1,,CHEMBL615349,,
126,In vitro inhibition of 2008/S ovarian cancer cell line,389.0,BAO_0000219,Intermediate,,2008/S,80614,N,1,1,,CHEMBL615350,,
127,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,389.0,BAO_0000219,Intermediate,,2008/S,80614,N,1,1,,CHEMBL615351,,
128,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,BAO_0000220,Expert,,,100256,S,2,1,,CHEMBL615352,,
129,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,BAO_0000220,Intermediate,,,100256,S,2,1,,CHEMBL615353,,
130,Inhibition of chymotrypsin-like activity of 20S proteasome,,BAO_0000220,Expert,,,100256,S,2,1,,CHEMBL615354,,
131,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,BAO_0000220,Expert,,,100256,S,2,1,,CHEMBL615355,,
132,Inhibitory activity against 20S proteosome,,BAO_0000220,Intermediate,,,100256,S,2,1,,CHEMBL615356,,
133,Compound was tested for inhibitory activity against tryptase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615357,,
134,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL615358,,
135,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,726.0,BAO_0000219,Intermediate,,HepG2,81020,N,1,1,,CHEMBL827086,,
136,Compound was tested for the inhibition of Alpha-glucosidase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615359,,
137,Inhibitory concentration against human neutrophil elastase (HNE),,BAO_0000357,Autocuration,,,235,H,8,1,,CHEMBL615360,,
138,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615361,948.0,
139,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,Autocuration,,,19640,H,8,1,,CHEMBL615362,,
140,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,Expert,,,19640,H,8,1,,CHEMBL615363,,
141,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000357,Autocuration,,,19640,H,8,1,,CHEMBL615364,,
142,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,Expert,,,19640,H,8,1,,CHEMBL615365,,
143,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,524.0,BAO_0000219,Intermediate,,P338,80360,N,1,1,,CHEMBL615366,,
144,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,524.0,BAO_0000219,Intermediate,,P338,80360,N,1,1,,CHEMBL615367,,
145,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,554.0,BAO_0000219,Intermediate,,PBL,80384,N,1,1,,CHEMBL615368,,
146,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615369,,
147,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615370,,
148,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,BAO_0000357,Autocuration,,,191,H,8,1,,CHEMBL615673,,
149,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615674,,
150,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615675,,
151,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,635.0,BAO_0000219,Autocuration,,CCRF-CEM,22226,U,0,1,,CHEMBL615676,,
152,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,635.0,BAO_0000219,Autocuration,,CCRF-CEM,22226,U,0,1,,CHEMBL615677,,
153,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,635.0,BAO_0000219,Autocuration,,CCRF-CEM,22226,U,0,1,,CHEMBL615678,,
154,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,635.0,BAO_0000219,Autocuration,,CCRF-CEM,22226,U,0,1,,CHEMBL615679,,
155,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615680,,
156,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615681,,
157,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,BAO_0000249,Autocuration,,,104290,H,6,1,,CHEMBL857972,,
158,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,BAO_0000218,Intermediate,,,50264,N,1,1,,CHEMBL857899,,
159,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,BAO_0000218,Intermediate,,,50527,N,1,1,,CHEMBL615371,,
160,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,468.0,BAO_0000218,Expert,,HEL,50527,N,1,1,,CHEMBL615372,,
161,Antiviral activity against 07/1 strain of VZV; ND: No data,,BAO_0000218,Intermediate,,,50527,N,1,1,,CHEMBL615373,,
162,Antiviral activity against 07/1 strain of VZV; ND=No data,,BAO_0000218,Intermediate,,,50527,N,1,1,,CHEMBL615374,,
163,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,BAO_0000218,Intermediate,,,50145,N,1,1,,CHEMBL615375,,
164,Ratio of Ki at A2 to Ki at A1 receptors,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615376,,
165,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,BAO_0000249,Expert,,,11143,H,8,1,,CHEMBL615377,,
166,"Inhibition of 1,3-beta-glucan synthase",,BAO_0000357,Expert,,,18077,H,8,1,,CHEMBL615378,,
167,Inhibition of growth of 1-87 human tumor cell line,832.0,BAO_0000219,Intermediate,,1-87 tumor cell line,80609,N,1,1,,CHEMBL615379,,
168,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,BAO_0000219,Expert,,,12166,D,9,1,,CHEMBL615380,,
169,Inhibitory activity against soybean 1-lipoxygenase (SLO),,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615381,,
170,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615382,,
171,% inhibition against soybean 1-lipoxygenase (SLO),,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615383,,
172,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615384,,
173,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615385,,
174,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615386,,
175,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615387,,
176,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615388,,
177,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615214,,
178,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL827087,,
179,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615215,,
180,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615216,,
181,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615217,,
182,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615218,,
183,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,BAO_0000357,Autocuration,,,100171,D,9,1,,CHEMBL615219,,
184,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615220,,
185,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),294.0,BAO_0000219,Intermediate,,C3H 10T1/2,80049,N,1,1,,CHEMBL615221,,
186,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL615222,,
187,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,Autocuration,,,11489,H,8,1,,CHEMBL615223,,
188,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,Autocuration,,,11862,H,8,1,,CHEMBL615224,,
189,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,BAO_0000357,Autocuration,,,11862,H,8,1,,CHEMBL615225,,
190,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,BAO_0000357,Autocuration,,,11489,H,8,1,,CHEMBL615226,,
191,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,BAO_0000357,Autocuration,,,11862,H,8,1,,CHEMBL615227,,
192,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,BAO_0000019,Expert,,,12347,D,9,1,,CHEMBL615228,,
193,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,BAO_0000357,Expert,,,100120,D,9,1,,CHEMBL615229,,
194,Inhibition of 11 beta-hydroxylase from rat adrenal gland,,BAO_0000357,Expert,,,100120,D,9,1,,CHEMBL615230,2369.0,
195,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,Expert,,,100120,D,9,1,,CHEMBL615231,,
196,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,Expert,,,100120,D,9,1,,CHEMBL884520,,
197,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,BAO_0000357,Expert,,,100120,D,9,1,,CHEMBL615232,,
198,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,BAO_0000019,Autocuration,,,10328,H,8,1,,CHEMBL615233,,
199,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,Autocuration,,,11490,H,8,1,,CHEMBL827088,,
200,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,Autocuration,,,11490,H,8,1,,CHEMBL615234,,
201,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615235,,
202,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615236,,
203,Compound was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615237,,
204,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615238,,
205,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615239,,
206,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,Autocuration,,,11134,D,9,1,,CHEMBL615240,,
207,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,BAO_0000019,Expert,,,11835,H,8,1,,CHEMBL615241,,
208,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,BAO_0000357,Expert,,,11601,H,8,1,,CHEMBL615242,,
209,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615243,,
210,Inhibitory activity against human platelet 12-lipoxygenase,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615244,,
211,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615245,,
212,% inhibition against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615246,,
213,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615247,,
214,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,BAO_0000019,Autocuration,,,11134,H,8,1,,CHEMBL615248,,
215,Inhibitory activity towards porcine 12-lipoxygenase,,BAO_0000357,Autocuration,,,11601,H,8,1,,CHEMBL615249,,
216,Tested for inhibition against porcine 12-LO,,BAO_0000357,Autocuration,,,11601,H,8,1,,CHEMBL615250,,
217,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615251,,
218,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615252,,
219,In vitro inhibition of rat platelet 12-lipoxygenase,,BAO_0000019,Expert,,,12052,H,8,1,,CHEMBL828340,,
220,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615253,,
221,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615254,,
222,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615255,,
223,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615256,,
224,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615257,,
225,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,BAO_0000019,Autocuration,,,12052,H,8,1,,CHEMBL615258,,
226,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,621.0,BAO_0000219,Intermediate,,41M,80007,N,1,1,,CHEMBL615259,,
227,In vitro antitumor activity against 41M cell line.,621.0,BAO_0000219,Expert,,41M,80007,N,1,1,,CHEMBL615260,,
228,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,621.0,BAO_0000219,Intermediate,,41M,80007,N,1,1,,CHEMBL615261,,
229,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,621.0,BAO_0000219,Intermediate,,41M,80007,N,1,1,,CHEMBL615262,,
230,In vitro antitumor activity against 41McisR cell line.,621.0,BAO_0000219,Expert,,41M,80007,N,1,1,,CHEMBL615263,,
231,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,621.0,BAO_0000219,Expert,,41M,80007,N,1,1,,CHEMBL838393,,
232,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,621.0,BAO_0000219,Intermediate,,41M,80007,N,1,1,,CHEMBL615264,,
233,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,BAO_0000357,Expert,,,84,D,9,1,,CHEMBL615265,,
234,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,Expert,,,68,D,9,1,,CHEMBL615266,,
235,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,Expert,,,68,H,8,1,,CHEMBL615267,,
236,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,Expert,,,10201,H,8,1,,CHEMBL615268,,
237,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,BAO_0000357,Expert,,,10201,H,8,1,,CHEMBL615269,,
238,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,Expert,,,10201,H,8,1,,CHEMBL615270,,
239,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,Autocuration,,,12220,H,8,1,,CHEMBL615271,,
240,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615272,,
241,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615103,,
242,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615104,,
243,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,Autocuration,,,12220,H,8,1,,CHEMBL615105,,
244,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,Autocuration,,,12220,H,8,1,,CHEMBL872866,,
245,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615106,,
246,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL615107,,
247,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615108,,
248,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615109,,
249,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615110,,
250,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL840105,,
251,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL615111,,
252,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL615112,,
253,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL615113,,
254,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL615114,,
255,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615115,,
256,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,Autocuration,,,11303,H,8,1,,CHEMBL615116,,
257,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,BAO_0000357,Autocuration,,,11303,H,8,1,,CHEMBL615698,,
258,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615699,,
259,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615700,,
260,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,BAO_0000357,Expert,,,100249,H,8,1,,CHEMBL615701,,
261,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615702,,
262,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615703,,
263,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615704,,
264,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL615705,,
265,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL615706,,
266,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL615707,2116.0,
267,Stimulatory activity of intragastric pressure was tested in the rat,,BAO_0000019,Expert,,,10623,H,8,1,,CHEMBL615708,,
268,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,BAO_0000357,Autocuration,,,121,H,8,1,,CHEMBL615709,,
269,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615710,,
270,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL615711,,
271,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,BAO_0000357,Expert,,,121,D,9,1,,CHEMBL615712,,
272,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,BAO_0000357,Expert,,,121,D,9,1,,CHEMBL836325,,
273,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,BAO_0000019,Autocuration,,,12198,H,8,1,,CHEMBL615713,,
274,Inhibition constant of high-affinity 5-HT uptake,,BAO_0000357,Autocuration,,,12198,H,8,1,,CHEMBL615714,,
275,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,BAO_0000019,Autocuration,,,12198,H,8,1,,CHEMBL615715,,
276,Maximum rate was determined for high affinity transport of 5-HT,,BAO_0000019,Autocuration,,,12198,H,8,1,,CHEMBL615716,,
277,Compound was tested for agonistic activity against 5-HT uptake,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL615717,,
278,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL881818,,
279,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL884540,,
280,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000224,Autocuration,,,104744,D,5,1,,CHEMBL615718,,
281,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615719,,
282,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,BAO_0000249,Autocuration,Membranes,,104744,H,4,1,,CHEMBL615720,,
283,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,BAO_0000249,Autocuration,Membranes,,104744,H,4,1,,CHEMBL615721,,
284,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615722,,
285,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615723,,
286,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615724,10000000.0,
287,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615725,10000000.0,
288,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615726,10000000.0,
289,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615727,,
290,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL615728,,
291,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL857971,,
292,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL615729,,
293,Efficacy against 5-hydroxytryptamine 2A receptor,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL615730,,
294,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL615731,,
295,Relative potency towards 5-HT2A receptor of rat tail artery,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL615732,,
296,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL615733,,
297,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL615734,,
298,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL615735,,
299,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL615736,,
300,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL615737,2116.0,
301,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL615738,2116.0,
302,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL615739,2116.0,
303,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,BAO_0000357,Autocuration,,,10623,H,8,1,,CHEMBL615278,,
304,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,Expert,,,10623,D,9,1,,CHEMBL615279,,
305,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,168,H,8,1,,CHEMBL615280,,
306,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615281,,
307,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615282,,
308,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615283,,
309,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,649.0,BAO_0000219,Autocuration,,HL-60,80156,N,1,1,,CHEMBL615284,,
310,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615285,,
311,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615286,,
312,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,BAO_0000219,Autocuration,,Oocytes,104703,D,7,1,,CHEMBL615287,,
313,Chymotryptic inhibitory activity against 26S proteasome,,BAO_0000220,Intermediate,,,100256,S,2,1,,CHEMBL615288,,
314,Inhibitory activity against 26S proteasome degradation of IkB,,BAO_0000220,Intermediate,,,100256,S,2,1,,CHEMBL615289,,
315,In vitro inhibition of 2780/DOX ovarian cancer cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL615290,,
316,In vitro inhibition of 2780/S ovarian cancer cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL884522,,
317,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615291,,
318,Association constant for binding to AATT 28-mer AATT hairpin,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL615292,,
319,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL615293,,
320,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL615294,,
321,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL615295,,
322,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL825021,,
323,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615296,,
324,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615297,,
325,Cytotoxicity against cell line 2SC/20 determined by MTT test,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615298,,
326,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615299,,
327,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615300,,
328,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,BAO_0000357,Autocuration,,,241,H,8,1,,CHEMBL615301,,
329,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,BAO_0000357,Expert,,,241,D,9,1,,CHEMBL615302,,
330,Selectivity ratio of ID50 in liver and heart,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615303,,
331,"Selectivity, ratio of relative ID50 in liver and heart",,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615304,,
332,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615305,,
333,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,Autocuration,,,12132,H,8,1,,CHEMBL615306,,
334,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,Autocuration,,,12132,H,8,1,,CHEMBL615307,,
335,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,Autocuration,,,12132,H,8,1,,CHEMBL615308,,
336,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,Autocuration,,,12132,H,8,1,,CHEMBL615309,,
337,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615310,,
338,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615311,,
339,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615312,,
340,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615313,,
341,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615314,,
342,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615315,,
343,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615316,,
344,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,BAO_0000218,Autocuration,,,12132,H,8,1,,CHEMBL615317,,
345,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,Autocuration,,,12132,H,8,1,,CHEMBL615318,,
346,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615319,,
347,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615320,,
348,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,Autocuration,,,12132,H,8,1,,CHEMBL615321,,
349,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615322,,
350,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615323,,
351,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615407,,
352,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL857267,,
353,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615408,,
354,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615409,,
355,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615410,,
356,Inhibition constant against 3-dehydroquinate synthase,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615411,,
357,Association rate constant against 3-dehydroquinate synthase,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615412,,
358,Rate constant against 3-dehydroquinate synthase,,BAO_0000357,Autocuration,,,19690,H,8,1,,CHEMBL615413,,
359,Inhibitory activity against fuc-TVII,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615414,,
360,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615415,2107.0,
361,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615416,2107.0,
362,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615417,2107.0,
363,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615418,2107.0,
364,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615419,2107.0,
365,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615420,2107.0,
366,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615421,2107.0,
367,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615422,2107.0,
368,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615423,2107.0,
369,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL872868,2107.0,
370,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,,BAO_0000251,Autocuration,Microsomes,,12236,D,9,1,,CHEMBL615424,2107.0,
371,Inhibitory activity against 3-phosphoglycerate kinase.,,BAO_0000224,Autocuration,,,104832,H,4,1,,CHEMBL825022,,
372,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,BAO_0000224,Autocuration,,,104832,H,4,1,,CHEMBL615425,,
373,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,BAO_0000224,Autocuration,,,104832,H,4,1,,CHEMBL615426,,
374,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,BAO_0000357,Expert,,,10612,D,9,1,,CHEMBL615427,,
375,Cytotoxicity on 3677 melanoma cells,844.0,BAO_0000219,Intermediate,,3677 melanoma cell line,80616,N,1,1,,CHEMBL615428,,
376,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,844.0,BAO_0000219,Intermediate,,3677 melanoma cell line,80616,N,1,1,,CHEMBL615429,,
377,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,700.0,BAO_0000219,Intermediate,,MC-38,80617,N,1,1,,CHEMBL615430,,
378,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL615431,,
379,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,798.0,BAO_0000218,Autocuration,,B16,22226,U,0,1,,CHEMBL615432,,
380,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,798.0,BAO_0000218,Autocuration,,B16,22226,U,0,1,,CHEMBL615433,,
381,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,BAO_0000019,Expert,,,12464,D,9,1,,CHEMBL615434,,
382,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,BAO_0000218,Intermediate,,,50085,N,1,1,,CHEMBL615435,,
383,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,BAO_0000218,Intermediate,,,50679,N,1,1,,CHEMBL615436,,
384,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,BAO_0000218,Intermediate,,,50679,N,1,1,,CHEMBL615437,,
385,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,Expert,,,12464,D,9,1,,CHEMBL615438,,
386,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,Expert,,,12464,D,9,1,,CHEMBL615439,,
387,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,Expert,,,12464,D,9,1,,CHEMBL615440,,
388,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,BAO_0000019,Expert,,,12464,D,9,1,,CHEMBL615441,,
389,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,BAO_0000218,Intermediate,,,50665,N,1,1,,CHEMBL615641,,
390,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,BAO_0000218,Intermediate,,,50665,N,1,1,,CHEMBL872065,,
391,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,BAO_0000218,Intermediate,,,50665,N,1,1,,CHEMBL825023,,
392,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,BAO_0000218,Intermediate,,,50665,N,1,1,,CHEMBL615642,,
393,Inhibition of human rhinovirus 3C protease,,BAO_0000357,Expert,,,12464,H,8,1,,CHEMBL615643,,
394,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615644,,
395,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),833.0,BAO_0000218,Intermediate,,3EM 37,80619,N,1,1,,CHEMBL615645,,
396,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),833.0,BAO_0000218,Intermediate,,3EM 37,80619,N,1,1,,CHEMBL615646,,
397,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),833.0,BAO_0000218,Intermediate,,3EM 37,80619,N,1,1,,CHEMBL615647,,
398,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),833.0,BAO_0000218,Intermediate,,3EM 37,80619,N,1,1,,CHEMBL615648,,
399,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,833.0,BAO_0000218,Intermediate,,3EM 37,80619,N,1,1,,CHEMBL615649,,
400,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,833.0,BAO_0000218,Intermediate,,3EM 37,80619,N,1,1,,CHEMBL615650,,
401,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,847.0,BAO_0000218,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615651,,
402,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,847.0,BAO_0000218,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615652,,
403,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,847.0,BAO_0000218,Expert,,3LL cell line,80620,N,1,1,,CHEMBL615653,,
404,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615654,,
405,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615655,,
406,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL825024,,
407,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615656,,
408,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615657,,
409,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615658,,
410,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615659,,
411,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615660,,
412,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615661,,
413,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615662,,
414,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615663,,
415,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615664,,
416,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615665,,
417,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615666,,
418,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615667,,
419,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615668,,
420,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615669,,
421,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615670,,
422,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL836739,,
423,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615671,,
424,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615672,,
425,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615791,,
426,spermine levels in 3LL cells after the treatment of 1 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615792,,
427,spermine levels in 3LL cells after the treatment of 10 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615793,,
428,spermine levels in 3LL cells after the treatment of 250 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615794,,
429,spermine levels in 3LL cells after the treatment of 50 uM of Compound,847.0,BAO_0000219,Intermediate,,3LL cell line,80620,N,1,1,,CHEMBL615795,,
430,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,971.0,BAO_0000219,Intermediate,,3LLD122,80621,N,1,1,,CHEMBL615590,,
431,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615591,,
432,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615592,,
433,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615593,,
434,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615594,,
435,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615595,,
436,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615596,,
437,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,723.0,BAO_0000219,Expert,,NIH3T3,11169,H,8,1,,CHEMBL615597,,
438,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615598,,
439,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615599,,
440,Effective dose against murine 3T3 fibroblasts cells,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615600,,
441,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615601,,
442,Cytotoxic effect on 3T3 cells,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615602,,
443,Cytotoxic effect on 3T3 cells,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615603,,
444,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615604,,
445,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615605,,
446,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615606,,
447,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL884526,,
448,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615607,,
449,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615608,,
450,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615609,,
451,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615682,,
452,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615683,,
453,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,723.0,BAO_0000218,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615684,,
454,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,BAO_0000219,Autocuration,,,104860,D,7,1,,CHEMBL615685,,
455,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615686,,
456,Inhibitory activity against 3T3 cell line,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615687,,
457,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL884523,,
458,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,BAO_0000019,Expert,,,11169,H,8,1,,CHEMBL615688,,
459,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615689,,
460,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615690,,
461,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,BAO_0000019,Expert,,,11169,H,8,1,,CHEMBL615691,,
462,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,BAO_0000019,Expert,,,11169,H,8,1,,CHEMBL615692,,
463,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615693,,
464,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615324,,
465,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,723.0,BAO_0000219,Expert,,NIH3T3,9,D,9,1,,CHEMBL615325,,
466,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),723.0,BAO_0000219,Expert,,NIH3T3,9,D,9,1,,CHEMBL615490,,
467,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,723.0,BAO_0000219,Expert,,NIH3T3,188,D,9,1,,CHEMBL615491,,
468,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),723.0,BAO_0000219,Expert,,NIH3T3,188,D,9,1,,CHEMBL615492,,
469,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615493,,
470,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615494,,
471,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615495,,
472,Inhibitory concentration was calculated on 3T3 cells by using growth assay,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615496,,
473,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615497,,
474,Inhibition of Swiss 3T3 mouse fibroblast proliferation,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615498,,
475,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615499,,
476,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL835522,,
477,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615500,,
478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615501,,
479,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615502,,
480,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615503,,
481,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615504,,
482,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615505,,
483,Inhibition of swiss 3T3 mouse fibroblast proliferation,723.0,BAO_0000219,Expert,,NIH3T3,80951,N,1,1,,CHEMBL615506,,
484,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,723.0,BAO_0000219,Intermediate,,NIH3T3,80951,N,1,1,,CHEMBL615507,,
485,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615508,,
486,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615509,,
487,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615510,,
488,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615511,,
489,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615512,,
490,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615513,,
491,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615514,,
492,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615515,,
493,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615516,,
494,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615517,,
495,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615518,,
496,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615519,,
497,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615520,,
498,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615521,,
499,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615522,,
500,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615523,,
501,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,620.0,BAO_0000218,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615524,,
502,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,BAO_0000218,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615525,,
503,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615526,,
504,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615527,,
505,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615528,,
506,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,BAO_0000218,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615529,,
507,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,BAO_0000218,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615530,,
508,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,620.0,BAO_0000218,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615531,,
509,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615532,,
510,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615533,,
511,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615534,,
512,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615535,,
513,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615536,,
514,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615537,,
515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615538,,
516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,620.0,BAO_0000218,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL836166,,
517,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,620.0,BAO_0000219,Expert,,3T3-L1,11214,H,8,1,,CHEMBL615539,,
518,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615540,,
519,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,620.0,BAO_0000219,Expert,,3T3-L1,11214,H,8,1,,CHEMBL615541,,
520,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615542,,
521,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,620.0,BAO_0000219,Intermediate,,3T3-L1,80006,N,1,1,,CHEMBL615543,,
522,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615544,,
523,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615545,,
524,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615546,,
525,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615547,,
526,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615548,,
527,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615549,,
528,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,620.0,BAO_0000219,Expert,,3T3-L1,80006,N,1,1,,CHEMBL615550,,
529,Inhibitory activity against rat fibroblast (3Y1) cell line,1118.0,BAO_0000219,Intermediate,,3Y1 cell line,80622,N,1,1,,CHEMBL615551,,
530,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1118.0,BAO_0000219,Expert,,3Y1 cell line,80622,N,1,1,,CHEMBL615552,,
531,Cytotoxicity in 3Y1 cells.,1118.0,BAO_0000219,Expert,,3Y1 cell line,80622,N,1,1,,CHEMBL615553,,
532,Cytostatic effect in 3Y1 cells.,1118.0,BAO_0000219,Expert,,3Y1 cell line,80622,N,1,1,,CHEMBL615554,,
533,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1118.0,BAO_0000219,Intermediate,,3Y1 cell line,80622,N,1,1,,CHEMBL615555,,
534,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1118.0,BAO_0000219,Expert,,3Y1 cell line,80622,N,1,1,,CHEMBL615556,,
535,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615557,,
536,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615558,,
537,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL872066,,
538,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,BAO_0000019,Expert,,,11607,D,9,1,,CHEMBL615559,,
539,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615560,,
540,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615561,,
541,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,BAO_0000019,Expert,,,11607,H,8,1,,CHEMBL857062,,
542,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,BAO_0000019,Expert,,,11607,H,8,1,,CHEMBL615562,,
543,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615563,,
544,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,BAO_0000357,Autocuration,,,11607,H,8,1,,CHEMBL615564,,
545,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615565,,
546,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615566,,
547,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,BAO_0000019,Expert,,,11607,D,9,1,,CHEMBL615567,,
548,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615568,,
549,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,BAO_0000357,Autocuration,,,11607,H,8,1,,CHEMBL615569,,
550,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615570,,
551,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,BAO_0000019,Autocuration,,,11607,H,8,1,,CHEMBL615571,,
552,Binding affinity against melatonin (MT1) receptor (pC1),,BAO_0000224,Autocuration,,,104733,H,4,1,,CHEMBL615572,,
553,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615573,,
554,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615574,,
555,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615575,,
556,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,BAO_0000357,Autocuration,,,10619,H,8,1,,CHEMBL615576,,
557,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10619,H,8,1,,CHEMBL615577,,
558,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615578,10000000.0,
559,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615579,,
560,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615580,,
561,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL615581,,
562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615582,10000000.0,
563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615583,10000000.0,
564,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615584,10000000.0,
565,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL833691,10000000.0,
566,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615585,10000000.0,
567,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615586,10000000.0,
568,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL884524,10000000.0,
569,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615587,10000000.0,
570,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615588,10000000.0,
571,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL615589,,
572,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,,BAO_0000221,Expert,,,51,H,8,1,,CHEMBL615442,10000000.0,
573,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615443,10000000.0,
574,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615444,10000000.0,
575,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,BAO_0000221,Expert,,,51,H,8,1,,CHEMBL615445,10000000.0,
576,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615446,10000000.0,
577,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615447,,
578,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,Expert,,,51,H,8,1,,CHEMBL615448,10000000.0,
579,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,BAO_0000221,Expert,,,51,H,8,1,,CHEMBL615449,10000000.0,
580,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615450,,
581,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,BAO_0000221,Expert,,,51,H,8,1,,CHEMBL615451,10000000.0,
582,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615452,,
583,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615453,10000000.0,
584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615454,10000000.0,
585,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615455,10000000.0,
586,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615456,10000000.0,
587,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615457,10000000.0,
588,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,BAO_0000218,Expert,,,51,H,8,1,,CHEMBL615458,10000000.0,
589,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Expert,,,51,H,8,1,,CHEMBL615459,10000000.0,
590,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615460,,
591,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615461,,
592,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615462,,
593,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615463,10000000.0,
594,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615464,2116.0,
595,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615465,2116.0,
596,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615466,2116.0,
597,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615467,2116.0,
598,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615468,2116.0,
599,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL615469,2116.0,
600,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615470,,
601,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615471,,
602,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615472,,
603,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,BAO_0000221,Autocuration,,,106,H,8,1,,CHEMBL883242,10000000.0,
604,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,,BAO_0000221,Autocuration,,,106,H,8,1,,CHEMBL615473,10000000.0,
605,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),449.0,BAO_0000218,Autocuration,,CHO,11863,H,8,1,,CHEMBL615474,,
606,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615475,,
607,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL615476,,
608,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL615477,,
609,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615478,,
610,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615160,,
611,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615161,,
612,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615162,,
613,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615163,,
614,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615164,,
615,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615165,,
616,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615166,,
617,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,BAO_0000219,Autocuration,,,51,H,8,1,,CHEMBL615167,,
618,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL615168,,
619,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL615169,,
620,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615170,,
621,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615171,,
622,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615694,,
623,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615695,,
624,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615696,,
625,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615697,,
626,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL859410,,
627,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615841,,
628,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615842,,
629,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL835003,,
630,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615843,,
631,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615979,,
632,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615980,,
633,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615981,,
634,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL615982,,
635,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL615983,,
636,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL615984,,
637,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL615985,,
638,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615986,,
639,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615987,,
640,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615988,,
641,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615989,,
642,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615990,,
643,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615991,,
644,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615992,,
645,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615993,,
646,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615994,,
647,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615995,,
648,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615996,,
649,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615997,,
650,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615998,,
651,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615999,,
652,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616000,,
653,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616001,,
654,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616002,,
655,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616003,,
656,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616004,,
657,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616005,,
658,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616006,,
659,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616007,,
660,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616008,,
661,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616009,,
662,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616010,,
663,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616011,,
664,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL615740,,
665,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615741,,
666,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL615742,,
667,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615743,,
668,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615744,,
669,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615745,,
670,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615746,,
671,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615747,,
672,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615748,,
673,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615749,,
674,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615750,,
675,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616259,,
676,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616260,,
677,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616261,,
678,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616262,,
679,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616263,,
680,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616264,,
681,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616265,,
682,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616266,,
683,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616267,,
684,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616268,,
685,Inhibition of human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616269,,
686,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL884528,,
687,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,722.0,BAO_0000219,Expert,,HEK293,105,D,9,1,,CHEMBL616270,,
688,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616271,,
689,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616272,,
690,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616273,,
691,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616274,,
692,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616275,,
693,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616276,,
694,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616277,,
695,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616278,,
696,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616279,,
697,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616280,,
698,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616281,,
699,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616282,,
700,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616283,,
701,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616284,,
702,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616285,,
703,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616286,,
704,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616287,,
705,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616288,,
706,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL616289,,
707,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615610,,
708,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615611,,
709,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615612,,
710,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615613,,
711,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615614,,
712,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL615615,,
713,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,BAO_0000019,Autocuration,,,105093,H,4,1,,CHEMBL615616,,
714,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,BAO_0000249,Autocuration,,,11923,H,8,1,,CHEMBL615617,1898.0,
715,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL615618,,
716,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL615619,,
717,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL615620,,
718,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL615621,,
719,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL615622,,
720,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL615623,,
721,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL615624,,
722,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL615625,,
723,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL767045,,
724,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL615626,,
725,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL615627,,
726,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL615628,,
727,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL615629,,
728,Inhibitory concentration against 5-lipoxygenase from human whole blood,,BAO_0000357,Expert,,,55,D,9,1,,CHEMBL615630,,
729,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL615631,,
730,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,Autocuration,,,17087,H,8,1,,CHEMBL615632,,
731,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,BAO_0000357,Autocuration,,,17087,H,8,1,,CHEMBL615633,,
732,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,Autocuration,,,17087,H,8,1,,CHEMBL615634,,
733,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,Expert,,,55,H,8,1,,CHEMBL615635,,
734,In vitro inhibition of rat 5-Lipoxygenase,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL615636,,
735,Inhibitory activity against 5-Lipoxygenase,,BAO_0000357,Expert,,,12166,D,9,1,,CHEMBL615637,,
736,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL615638,,
737,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL615639,,
738,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL615640,,
739,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL615796,,
740,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL615845,,
741,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL615846,,
742,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL615847,,
743,The compound was tested for inhibition of isolated 5-Lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL615848,,
744,Ratio of IC50 against 5-LO and COX,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615849,,
745,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL615850,,
746,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL615851,,
747,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL615852,,
748,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL615853,,
749,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,BAO_0000357,Autocuration,,,120,H,8,1,,CHEMBL884527,2367.0,
750,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL872871,,
751,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615854,,
752,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL767046,,
753,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,BAO_0000357,Autocuration,,,10732,H,8,1,,CHEMBL615855,,
754,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,BAO_0000019,Expert,,,12198,D,9,1,,CHEMBL615856,,
755,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,Expert,,,12198,D,9,1,,CHEMBL615857,,
756,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,Expert,,,12198,D,9,1,,CHEMBL615858,,
757,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615859,10000000.0,
758,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615860,,
759,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615861,,
760,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615862,,
761,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615863,,
762,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615864,,
763,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615865,10000000.0,
764,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615866,10000000.0,
765,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615867,10000000.0,
766,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,BAO_0000249,Autocuration,Membranes,,104744,H,4,1,,CHEMBL615868,,
767,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,BAO_0000249,Autocuration,,,104744,D,5,1,,CHEMBL615869,,
768,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,BAO_0000019,Autocuration,,,104744,D,5,1,,CHEMBL615870,,
769,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,BAO_0000019,Autocuration,,,104744,D,5,1,,CHEMBL615871,,
770,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615872,,
771,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL833492,10000000.0,
772,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615873,10000000.0,
773,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615479,,
774,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615480,,
775,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,BAO_0000249,Autocuration,,,104744,D,5,1,,CHEMBL615481,,
776,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL872869,,
777,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615482,,
778,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615483,955.0,
779,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615484,955.0,
780,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615485,,
781,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,BAO_0000224,Autocuration,,,104744,D,5,1,,CHEMBL615486,,
782,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615487,,
783,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615488,,
784,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615489,,
785,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615389,,
786,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615390,,
787,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615391,,
788,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615392,,
789,Affinity for 5-hydroxytryptamine 1 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615393,,
790,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615394,955.0,
791,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615395,955.0,
792,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,BAO_0000224,Autocuration,,,104744,H,4,1,,CHEMBL615396,,
793,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615397,955.0,
794,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615398,,
795,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615399,,
796,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615400,,
797,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,BAO_0000019,Autocuration,,,104744,D,5,1,,CHEMBL615401,,
798,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615402,,
799,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615403,,
800,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615404,955.0,
801,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,BAO_0000019,Autocuration,,,104744,H,4,1,,CHEMBL615781,,
802,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,BAO_0000220,Autocuration,,,104744,H,4,1,,CHEMBL615782,955.0,
803,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,BAO_0000221,Autocuration,,,104744,H,4,1,,CHEMBL615783,955.0,
804,Compound was tested for binding affinity against 5-HT1 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL873481,,
805,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL615784,,
806,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615785,,
807,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL615786,,
808,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615787,,
809,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615788,,
810,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL767044,,
811,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615789,,
812,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615790,,
813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615813,,
814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,BAO_0000219,Autocuration,,,10576,H,8,1,,CHEMBL615814,,
815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,BAO_0000219,Expert,,,51,H,8,1,,CHEMBL615815,,
816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,BAO_0000219,Autocuration,,,10576,H,8,1,,CHEMBL615816,,
817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615817,,
818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615818,10000000.0,
819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615819,10000000.0,
820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,BAO_0000249,Expert,Membranes,,10576,H,8,1,,CHEMBL615820,,
821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL615821,10000000.0,
822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL615822,10000000.0,
823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615823,10000000.0,
824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL615824,10000000.0,
825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL615825,10000000.0,
826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615826,,
827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615827,,
828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615828,10000000.0,
829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615829,10000000.0,
830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615830,10000000.0,
831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615831,10000000.0,
832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615832,,
833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615833,,
834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615834,10000000.0,
835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,BAO_0000249,Intermediate,,,10576,H,8,1,,CHEMBL615835,,
836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL615836,10000000.0,
837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL615837,,
838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL615838,,
839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615839,,
840,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL884525,,
841,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL615840,,
842,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615405,10000000.0,
843,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615406,,
844,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615900,10000000.0,
845,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615901,10000000.0,
846,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615902,,
847,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615903,10000000.0,
848,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615904,,
849,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615905,,
850,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615906,,
851,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615907,,
852,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615908,,
853,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615909,10000000.0,
854,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615910,,
855,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615911,,
856,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615912,,
857,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615913,,
858,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615914,,
859,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615915,10000000.0,
860,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615916,,
861,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615917,,
862,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615918,,
863,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615919,10000000.0,
864,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL615920,10000000.0,
865,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615921,,
866,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615922,,
867,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,Expert,,,10576,D,9,1,,CHEMBL881290,,
868,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615923,10000000.0,
869,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615924,10000000.0,
870,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615925,10000000.0,
871,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL615926,,
872,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL615927,,
873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615928,10000000.0,
874,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL615929,,
875,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615930,10000000.0,
876,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615931,,
877,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615932,,
878,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615933,,
879,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615934,,
880,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615935,,
881,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615936,,
882,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615937,,
883,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615938,,
884,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615797,,
885,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615798,,
886,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL872870,,
887,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615799,,
888,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615800,,
889,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL615801,,
890,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615802,,
891,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615803,,
892,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL835002,,
893,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615804,,
894,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,308.0,BAO_0000219,Expert,,HeLa,51,H,8,1,,CHEMBL615805,,
895,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615806,,
896,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL615807,,
897,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615808,,
898,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL615809,,
899,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL615810,,
900,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615811,,
901,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615812,,
902,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615751,,
903,Binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615752,,
904,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL615753,,
905,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL615754,,
906,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615755,,
907,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615756,,
908,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615757,,
909,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615758,,
910,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615759,,
911,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615760,,
912,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,H,8,1,,CHEMBL615761,,
913,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL872104,,
914,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615762,,
915,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615763,,
916,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615764,,
917,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1167.0,BAO_0000219,Autocuration,,Cell line,51,H,8,1,,CHEMBL615765,,
918,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL615766,,
919,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615767,,
920,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615768,,
921,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615769,,
922,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615770,,
923,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615771,,
924,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615772,,
925,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615773,,
926,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615774,,
927,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615775,,
928,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615776,,
929,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL615777,,
930,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,BAO_0000219,Autocuration,,,51,H,8,1,,CHEMBL615778,,
931,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL615779,,
932,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL615780,,
933,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616298,,
934,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616299,,
935,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,51,H,8,1,,CHEMBL616300,,
936,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,51,H,8,1,,CHEMBL616301,,
937,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616302,,
938,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616117,,
939,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616118,,
940,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616119,,
941,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL616120,,
942,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616121,,
943,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616122,,
944,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616123,,
945,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616124,,
946,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616125,,
947,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616126,,
948,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616127,,
949,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616128,,
950,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616129,,
951,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616130,,
952,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616131,,
953,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL616132,,
954,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL616133,,
955,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616134,,
956,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616135,,
957,Affinity for 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616136,,
958,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616137,,
959,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL872105,,
960,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616138,,
961,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616139,,
962,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616140,,
963,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616141,,
964,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616142,,
965,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616143,,
966,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL616144,,
967,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL616145,,
968,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL616012,,
969,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,308.0,BAO_0000219,Autocuration,,HeLa,51,H,8,1,,CHEMBL616013,,
970,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616014,,
971,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616015,,
972,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616016,,
973,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,BAO_0000218,Autocuration,,,51,H,8,1,,CHEMBL616017,,
974,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616018,,
975,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616019,,
976,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616020,,
977,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL858018,,
978,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616021,,
979,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616022,,
980,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616023,,
981,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616024,,
982,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616025,,
983,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616026,,
984,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616027,,
985,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616028,,
986,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616029,,
987,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,449.0,BAO_0000219,Expert,,CHO,51,H,8,1,,CHEMBL616030,,
988,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616031,,
989,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616032,,
990,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL616033,,
991,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616034,,
992,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616035,,
993,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616036,,
994,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616037,,
995,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616038,,
996,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616039,,
997,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616040,,
998,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL616041,,
999,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL616042,,
1000,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL616043,,
1001,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616044,,
1002,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616045,,
1003,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616046,,
1004,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616047,,
1005,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616048,,
1006,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL616049,,
1007,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616050,,
1008,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,BAO_0000219,Expert,,,51,H,8,1,,CHEMBL616051,,
1009,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,BAO_0000219,Autocuration,,,51,H,8,1,,CHEMBL616212,,
1010,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616213,,
1011,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,BAO_0000219,Expert,,,51,H,8,1,,CHEMBL616214,,
1012,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,BAO_0000219,Expert,,,51,H,8,1,,CHEMBL616215,,
1013,Binding activity radioligand.,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616216,,
1014,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616217,,
1015,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616218,,
1016,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616219,,
1017,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616220,,
1018,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL833493,,
1019,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616221,,
1020,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL616222,,
1021,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616223,,
1022,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616224,,
1023,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616225,,
1024,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,722.0,BAO_0000219,Expert,,HEK293,51,D,9,1,,CHEMBL616226,,
1025,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616227,,
1026,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616228,,
1027,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616229,,
1028,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616230,,
1029,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616231,,
1030,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616232,,
1031,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616233,,
1032,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL857973,,
1033,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,BAO_0000219,Autocuration,,,51,H,8,1,,CHEMBL616234,,
1034,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616235,,
1035,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,308.0,BAO_0000219,Expert,,HeLa,51,H,8,1,,CHEMBL616236,,
1036,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616237,,
1037,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616238,,
1038,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616239,,
1039,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,BAO_0000219,Autocuration,,,51,H,8,1,,CHEMBL616240,,
1040,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,308.0,BAO_0000219,Expert,,HeLa,51,D,9,1,,CHEMBL616241,,
1041,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616242,,
1042,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,51,H,8,1,,CHEMBL616243,,
1043,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616244,,
1044,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,D,9,1,,CHEMBL616245,,
1045,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616246,,
1046,Binding affinity against 5-HT1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616247,,
1047,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616248,,
1048,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL616249,,
1049,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616250,,
1050,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616251,,
1051,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,BAO_0000218,Autocuration,,,11863,H,8,1,,CHEMBL616252,,
1052,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,BAO_0000218,Autocuration,,,11863,H,8,1,,CHEMBL616253,,
1053,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,BAO_0000218,Autocuration,,,11863,H,8,1,,CHEMBL616254,,
1054,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,BAO_0000218,Expert,,,11863,D,9,1,,CHEMBL616255,,
1055,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,BAO_0000218,Expert,,,11863,D,9,1,,CHEMBL832872,,
1056,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,BAO_0000218,Expert,,,11863,D,9,1,,CHEMBL616256,,
1057,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,BAO_0000218,Expert,,,11863,D,9,1,,CHEMBL616257,,
1058,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,BAO_0000218,Expert,,,11863,D,9,1,,CHEMBL616258,,
1059,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,BAO_0000218,Expert,,,11863,D,9,1,,CHEMBL616384,,
1060,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,BAO_0000221,Autocuration,,,11863,H,8,1,,CHEMBL616385,10000000.0,
1061,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,BAO_0000357,Expert,,,11863,H,8,1,,CHEMBL616386,,
1062,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,BAO_0000221,Expert,,,11863,D,9,1,,CHEMBL616387,10000000.0,
1063,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,BAO_0000221,Autocuration,,,11863,H,8,1,,CHEMBL616388,10000000.0,
1064,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,,BAO_0000221,Expert,,,11863,D,9,1,,CHEMBL616389,10000000.0,
1065,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,BAO_0000221,Autocuration,,,11863,H,8,1,,CHEMBL616390,10000000.0,
1066,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616391,,
1067,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,BAO_0000221,Expert,,,11863,D,9,1,,CHEMBL616392,10000000.0,
1068,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616393,,
1069,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616394,,
1070,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616395,,
1071,Compound was evaluated for the binding affinity at 5- HT1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616396,,
1072,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL872907,,
1073,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616397,,
1074,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616398,,
1075,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616399,,
1076,Binding activity radioligand.,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL857065,,
1077,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616400,,
1078,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616401,,
1079,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,BAO_0000019,Expert,,,10624,H,8,1,,CHEMBL616402,,
1080,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616403,,
1081,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL616404,10000000.0,
1082,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,BAO_0000249,Autocuration,,,51,H,8,1,,CHEMBL616405,,
1083,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616406,,
1084,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,BAO_0000019,Expert,,,51,H,8,1,,CHEMBL616407,,
1085,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616408,,
1086,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,BAO_0000249,Expert,,,10576,D,9,1,,CHEMBL616409,,
1087,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616410,10000000.0,
1088,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616411,,
1089,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616412,,
1090,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616413,10000000.0,
1091,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616414,10000000.0,
1092,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616415,10000000.0,
1093,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616416,,
1094,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616417,,
1095,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616418,,
1096,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,Autocuration,,,10576,H,8,1,,CHEMBL616419,,
1097,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616420,,
1098,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,Autocuration,Membranes,,10576,H,8,1,,CHEMBL616421,,
1099,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,Autocuration,Membranes,,10576,H,8,1,,CHEMBL616422,,
1100,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,BAO_0000249,Expert,Membranes,,10576,H,8,1,,CHEMBL616423,,
1101,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616424,,
1102,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616425,,
1103,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616426,,
1104,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616427,10000000.0,
1105,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616428,10000000.0,
1106,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616290,10000000.0,
1107,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616052,,
1108,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616053,,
1109,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616054,,
1110,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616055,,
1111,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616056,,
1112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616057,,
1113,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616058,955.0,
1114,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616059,955.0,
1115,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616060,,
1116,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616061,10000000.0,
1117,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616062,10000000.0,
1118,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616063,,
1119,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616064,2435.0,
1120,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616065,,
1121,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616066,,
1122,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616067,10000000.0,
1123,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616068,10000000.0,
1124,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Intermediate,,,10576,H,8,1,,CHEMBL616069,10000000.0,
1125,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616070,,
1126,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616071,10000000.0,
1127,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616072,10000000.0,
1128,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616073,10000000.0,
1129,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616074,10000000.0,
1130,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616075,,
1131,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616076,,
1132,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616077,,
1133,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616078,,
1134,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616079,,
1135,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,10576,D,9,1,,CHEMBL616080,,
1136,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616081,,
1137,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616082,10000000.0,
1138,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616083,10000000.0,
1139,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616084,,
1140,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616085,,
1141,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616086,,
1142,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616087,10000000.0,
1143,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616088,,
1144,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616089,,
1145,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616090,,
1146,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616091,,
1147,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,BAO_0000249,Autocuration,Membranes,,10576,H,8,1,,CHEMBL616092,2435.0,
1148,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616093,,
1149,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL616094,,
1150,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616095,955.0,
1151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616096,,
1152,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616097,,
1153,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616098,,
1154,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616099,10000000.0,
1155,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616100,10000000.0,
1156,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616101,,
1157,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616102,,
1158,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616103,,
1159,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616104,,
1160,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616105,,
1161,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616106,,
1162,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616107,,
1163,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616108,,
1164,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616109,10000000.0,
1165,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616110,,
1166,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,449.0,BAO_0000219,Expert,,CHO,10576,H,8,1,,CHEMBL616111,,
1167,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616112,,
1168,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616113,10000000.0,
1169,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616114,,
1170,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616115,,
1171,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616116,,
1172,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615844,955.0,
1173,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615939,10000000.0,
1174,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615940,,
1175,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615941,10000000.0,
1176,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615942,10000000.0,
1177,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615943,10000000.0,
1178,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615944,10000000.0,
1179,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615945,10000000.0,
1180,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615946,10000000.0,
1181,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615947,10000000.0,
1182,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615948,10000000.0,
1183,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615949,10000000.0,
1184,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615950,10000000.0,
1185,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615951,10000000.0,
1186,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615952,10000000.0,
1187,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615953,10000000.0,
1188,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615954,10000000.0,
1189,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL615955,10000000.0,
1190,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615956,10000000.0,
1191,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL615957,10000000.0,
1192,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615958,,
1193,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615959,,
1194,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615960,,
1195,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615961,,
1196,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL615962,955.0,
1197,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615963,,
1198,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615964,,
1199,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615965,,
1200,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,449.0,BAO_0000219,Expert,,CHO,10576,H,8,1,,CHEMBL615966,,
1201,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615967,,
1202,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615968,,
1203,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),449.0,BAO_0000218,Autocuration,,CHO,10576,H,8,1,,CHEMBL615969,,
1204,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615970,,
1205,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL615971,,
1206,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,Expert,Membranes,,10576,H,8,1,,CHEMBL615972,,
1207,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL615973,,
1208,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL615974,,
1209,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL615975,,
1210,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL615976,,
1211,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL872106,10000000.0,
1212,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615977,,
1213,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615978,,
1214,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616166,,
1215,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616167,,
1216,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616168,,
1217,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616169,,
1218,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616170,,
1219,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616171,,
1220,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616172,,
1221,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616173,,
1222,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616174,,
1223,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616175,,
1224,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616176,,
1225,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616177,,
1226,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616178,,
1227,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616179,,
1228,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616180,,
1229,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616181,,
1230,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616182,,
1231,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616183,10000000.0,
1232,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL615874,,
1233,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,10576,D,9,1,,CHEMBL615875,,
1234,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615876,,
1235,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615877,,
1236,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL615878,,
1237,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615879,,
1238,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL615880,,
1239,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615881,,
1240,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL615882,,
1241,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615883,,
1242,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615884,,
1243,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615885,,
1244,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615886,,
1245,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615887,,
1246,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615888,,
1247,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615889,,
1248,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615890,,
1249,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615891,,
1250,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615892,,
1251,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615893,,
1252,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615894,,
1253,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615895,,
1254,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615896,,
1255,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,BAO_0000218,Autocuration,,,10576,H,8,1,,CHEMBL615897,,
1256,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL615898,,
1257,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL615899,,
1258,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616291,,
1259,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616292,,
1260,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616293,,
1261,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616294,10000000.0,
1262,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616295,10000000.0,
1263,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616296,955.0,
1264,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616297,,
1265,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616605,,
1266,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616606,,
1267,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616607,,
1268,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616608,,
1269,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616609,,
1270,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616610,,
1271,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616611,,
1272,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616612,,
1273,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616613,,
1274,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616614,,
1275,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616615,,
1276,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616616,,
1277,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616617,,
1278,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616618,,
1279,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616619,,
1280,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616620,,
1281,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616621,,
1282,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616622,,
1283,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616146,,
1284,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL832873,,
1285,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616147,,
1286,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL872872,,
1287,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616148,,
1288,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616149,10000000.0,
1289,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616150,10000000.0,
1290,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616151,,
1291,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL872873,10000000.0,
1292,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616670,10000000.0,
1293,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616671,10000000.0,
1294,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,Expert,,,10576,D,9,1,,CHEMBL884861,,
1295,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616672,,
1296,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616673,,
1297,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616674,,
1298,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616675,,
1299,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616676,10000000.0,
1300,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616677,10000000.0,
1301,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616678,10000000.0,
1302,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616679,,
1303,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616680,10000000.0,
1304,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616681,10000000.0,
1305,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616682,10000000.0,
1306,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616683,10000000.0,
1307,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616684,10000000.0,
1308,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616685,10000000.0,
1309,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616686,955.0,
1310,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616687,,
1311,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616688,,
1312,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616689,10000000.0,
1313,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616690,,
1314,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616691,,
1315,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616692,10000000.0,
1316,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616693,,
1317,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616694,,
1318,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616695,10000000.0,
1319,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616696,,
1320,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616697,,
1321,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616698,,
1322,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616949,,
1323,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616950,10000000.0,
1324,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL832875,,
1325,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616951,955.0,
1326,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616952,955.0,
1327,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616953,,
1328,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616954,,
1329,GTPgammaS radioligand binding assay,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616955,,
1330,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616956,,
1331,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616957,,
1332,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616958,,
1333,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616959,,
1334,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616960,,
1335,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616961,,
1336,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,308.0,BAO_0000219,Expert,,HeLa,106,H,8,1,,CHEMBL616962,,
1337,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,308.0,BAO_0000219,Autocuration,,HeLa,106,H,8,1,,CHEMBL616963,,
1338,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616524,,
1339,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616525,,
1340,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL872908,,
1341,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616526,,
1342,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616527,,
1343,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,Expert,,,106,H,8,1,,CHEMBL616528,,
1344,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616529,,
1345,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616530,,
1346,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,H,8,1,,CHEMBL616531,,
1347,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616532,,
1348,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616533,,
1349,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,H,8,1,,CHEMBL616534,,
1350,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,Expert,,,106,H,8,1,,CHEMBL616535,,
1351,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616536,,
1352,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616537,,
1353,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,106,H,8,1,,CHEMBL616538,,
1354,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616539,,
1355,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616540,,
1356,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616429,,
1357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,H,8,1,,CHEMBL616430,,
1358,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,BAO_0000219,Expert,,,106,D,9,1,,CHEMBL616431,,
1359,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616432,,
1360,Affinity for 5-hydroxytryptamine 1B receptor subtype,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616433,,
1361,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616434,,
1362,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616435,,
1363,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616436,,
1364,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,308.0,BAO_0000219,Autocuration,,HeLa,106,H,8,1,,CHEMBL616437,,
1365,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,308.0,BAO_0000219,Autocuration,,HeLa,106,H,8,1,,CHEMBL616438,,
1366,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,308.0,BAO_0000219,Autocuration,,HeLa,106,H,8,1,,CHEMBL616439,,
1367,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616440,,
1368,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,485.0,BAO_0000219,Autocuration,,CHO-K1,106,H,8,1,,CHEMBL616441,,
1369,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,BAO_0000357,Expert,,,106,H,8,1,,CHEMBL616442,,
1370,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616443,,
1371,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,485.0,BAO_0000219,Expert,,CHO-K1,106,H,8,1,,CHEMBL616444,,
1372,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616445,,
1373,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616446,,
1374,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Expert,,CHO,106,D,9,1,,CHEMBL616447,,
1375,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616448,,
1376,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616449,,
1377,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616450,,
1378,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL857974,,
1379,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616451,,
1380,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616452,,
1381,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616453,,
1382,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616454,,
1383,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616455,,
1384,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616456,,
1385,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616457,,
1386,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616458,,
1387,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616459,,
1388,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616460,,
1389,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616461,,
1390,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616462,,
1391,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616463,,
1392,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616464,,
1393,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616465,,
1394,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,17105,H,8,1,,CHEMBL832874,,
1395,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616184,,
1396,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616185,,
1397,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,BAO_0000019,Intermediate,,,106,H,8,1,,CHEMBL616186,,
1398,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616187,,
1399,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,Expert,,,10577,H,8,1,,CHEMBL616188,,
1400,Binding affinity for 5-hydroxytryptamine 1B receptor,,BAO_0000357,Intermediate,,,10577,D,9,1,,CHEMBL873475,,
1401,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,,BAO_0000019,Expert,,,10577,D,9,1,,CHEMBL616189,2435.0,
1402,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,Expert,,,10577,H,8,1,,CHEMBL616190,,
1403,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616191,,
1404,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616192,,
1405,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616193,,
1406,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616194,,
1407,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616195,,
1408,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616196,,
1409,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616197,10000000.0,
1410,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,Intermediate,,,10576,H,8,1,,CHEMBL616198,,
1411,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616199,10000000.0,
1412,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616200,10000000.0,
1413,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616201,10000000.0,
1414,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616202,10000000.0,
1415,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616203,10000000.0,
1416,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616204,10000000.0,
1417,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616205,10000000.0,
1418,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616206,10000000.0,
1419,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616207,,
1420,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616208,,
1421,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616209,,
1422,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616210,,
1423,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616211,10000000.0,
1424,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616504,10000000.0,
1425,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616505,10000000.0,
1426,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616506,,
1427,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL872107,10000000.0,
1428,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616507,10000000.0,
1429,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616303,,
1430,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616304,10000000.0,
1431,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616305,10000000.0,
1432,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,BAO_0000221,Intermediate,,,10576,H,8,1,,CHEMBL616306,10000000.0,
1433,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616307,,
1434,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL881829,10000000.0,
1435,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616308,,
1436,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616309,,
1437,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616310,,
1438,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,10576,H,8,1,,CHEMBL616311,,
1439,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616312,,
1440,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616313,,
1441,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616314,10000000.0,
1442,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616315,10000000.0,
1443,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616567,10000000.0,
1444,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616568,10000000.0,
1445,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,BAO_0000019,Intermediate,,,10576,H,8,1,,CHEMBL616569,,
1446,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616570,,
1447,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616571,,
1448,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616572,10000000.0,
1449,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616573,,
1450,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616574,,
1451,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616575,10000000.0,
1452,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL872108,10000000.0,
1453,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616576,,
1454,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616577,,
1455,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616578,,
1456,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616579,,
1457,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616580,,
1458,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616581,,
1459,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616582,10000000.0,
1460,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616583,10000000.0,
1461,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616584,10000000.0,
1462,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616585,,
1463,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616586,10000000.0,
1464,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616587,10000000.0,
1465,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616588,10000000.0,
1466,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616589,10000000.0,
1467,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616590,10000000.0,
1468,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",449.0,BAO_0000219,Expert,,CHO,10576,H,8,1,,CHEMBL616591,,
1469,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616592,,
1470,The inhibition activity of 5-HT1A at 1 uM,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616593,,
1471,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",485.0,BAO_0000219,Expert,,CHO-K1,10576,H,8,1,,CHEMBL616594,,
1472,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616595,,
1473,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616596,,
1474,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616597,10000000.0,
1475,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,BAO_0000221,Expert,,,10576,H,8,1,,CHEMBL616598,10000000.0,
1476,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616599,,
1477,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616600,10000000.0,
1478,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616601,,
1479,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616602,,
1480,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616603,,
1481,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616604,,
1482,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616316,,
1483,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616317,,
1484,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616318,,
1485,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616319,10000000.0,
1486,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616320,10000000.0,
1487,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616321,10000000.0,
1488,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616322,,
1489,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616323,,
1490,Ratio of binding affinity to 5-HT 1A and D2 receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616324,,
1491,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616325,10000000.0,
1492,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616326,10000000.0,
1493,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616327,10000000.0,
1494,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616328,,
1495,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL858110,,
1496,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616329,,
1497,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616330,,
1498,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616331,,
1499,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616332,,
1500,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL857063,955.0,
1501,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616333,,
1502,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616334,,
1503,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616335,10000000.0,
1504,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616336,,
1505,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL616337,,
1506,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616338,,
1507,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616339,10000000.0,
1508,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616340,10000000.0,
1509,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616341,,
1510,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,D,9,1,,CHEMBL616342,,
1511,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,BAO_0000019,Expert,,,10576,D,9,1,,CHEMBL616343,,
1512,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616344,,
1513,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616345,,
1514,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616346,,
1515,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616347,10000000.0,
1516,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616348,,
1517,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616349,,
1518,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,BAO_0000249,Expert,Membranes,,10576,D,9,1,,CHEMBL616152,,
1519,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL616153,,
1520,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,BAO_0000019,Expert,,,10576,H,8,1,,CHEMBL616154,,
1521,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616155,,
1522,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616156,10000000.0,
1523,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,,BAO_0000221,Expert,,,10576,D,9,1,,CHEMBL616157,10000000.0,
1524,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616158,10000000.0,
1525,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL616159,,
1526,pKi value against rat 5-hydroxytryptamine 1A receptor.,,BAO_0000357,Expert,,,10576,H,8,1,,CHEMBL616160,,
1527,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616161,,
1528,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616162,,
1529,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL616163,,
1530,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,Expert,Membranes,,10626,H,8,1,,CHEMBL616164,,
1531,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616165,955.0,
1532,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,BAO_0000019,Autocuration,,,51,H,8,1,,CHEMBL616355,,
1533,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616356,,
1534,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL616357,955.0,
1535,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,Autocuration,,,10576,H,8,1,,CHEMBL616358,,
1536,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616359,,
1537,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616360,,
1538,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616361,,
1539,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616362,,
1540,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,BAO_0000249,Autocuration,Brain membranes,,51,H,8,1,,CHEMBL616363,,
1541,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616364,,
1542,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616365,,
1543,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL616366,,
1544,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL872906,,
1545,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616367,,
1546,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616368,,
1547,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616369,,
1548,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616370,,
1549,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,BAO_0000357,Expert,,,51,D,9,1,,CHEMBL616371,,
1550,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,51,H,8,1,,CHEMBL616372,,
1551,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,BAO_0000219,Expert,,,51,H,8,1,,CHEMBL616373,,
1552,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000218,Autocuration,,,51,H,8,1,,CHEMBL616374,,
1553,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,BAO_0000221,Autocuration,,,51,H,8,1,,CHEMBL616375,10000000.0,
1554,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616376,,
1555,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,BAO_0000357,Expert,,,51,H,8,1,,CHEMBL857064,,
1556,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616377,,
1557,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616378,,
1558,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616379,,
1559,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616380,,
1560,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616381,,
1561,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616382,,
1562,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616383,,
1563,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,449.0,BAO_0000219,Expert,,CHO,11863,D,9,1,,CHEMBL616350,,
1564,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616351,,
1565,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616352,,
1566,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616353,,
1567,Binding affinity against serotonergic 5-HT1a receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616354,,
1568,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616508,,
1569,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,11863,D,9,1,,CHEMBL616559,,
1570,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616560,,
1571,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616561,,
1572,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,11863,H,8,1,,CHEMBL616562,,
1573,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,449.0,BAO_0000219,Autocuration,,CHO,11863,H,8,1,,CHEMBL616563,,
1574,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616564,,
1575,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616565,,
1576,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,BAO_0000218,Autocuration,,,11863,H,8,1,,CHEMBL616566,,
1577,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616989,,
1578,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL857975,,
1579,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Expert,,,11863,D,9,1,,CHEMBL616990,,
1580,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616991,,
1581,Tested against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616992,,
1582,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,11863,H,8,1,,CHEMBL616993,,
1583,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616994,,
1584,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616995,,
1585,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,722.0,BAO_0000219,Intermediate,,HEK293,105571,D,9,1,,CHEMBL616996,,
1586,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,Autocuration,,,106,H,8,1,,CHEMBL616997,,
1587,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,Autocuration,,,106,H,8,1,,CHEMBL616998,,
1588,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616999,,
1589,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617000,,
1590,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617001,,
1591,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL858111,,
1592,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617002,,
1593,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617003,,
1594,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617004,,
1595,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,BAO_0000019,Expert,,,106,D,9,1,,CHEMBL617005,,
1596,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,106,D,9,1,,CHEMBL616623,,
1597,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616624,,
1598,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL883243,,
1599,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616625,,
1600,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616626,,
1601,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616627,,
1602,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616628,,
1603,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616629,,
1604,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616630,,
1605,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,Expert,,,106,H,8,1,,CHEMBL616631,,
1606,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616632,,
1607,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL616633,,
1608,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616634,,
1609,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616635,,
1610,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL885358,,
1611,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,106,D,9,1,,CHEMBL616636,,
1612,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616637,,
1613,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616638,,
1614,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616639,,
1615,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616640,,
1616,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616641,,
1617,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616642,,
1618,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616643,,
1619,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616644,,
1620,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616645,,
1621,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616646,,
1622,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616647,,
1623,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616509,,
1624,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616510,,
1625,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616511,,
1626,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL616512,,
1627,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616513,,
1628,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616514,2435.0,
1629,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL616515,,
1630,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616516,,
1631,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616517,,
1632,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616518,,
1633,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616519,,
1634,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616520,,
1635,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616521,,
1636,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616522,,
1637,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL884531,,
1638,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616523,,
1639,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616731,2435.0,
1640,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616732,,
1641,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616733,,
1642,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616734,,
1643,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,BAO_0000249,Autocuration,,,105,H,8,1,,CHEMBL616735,,
1644,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,BAO_0000249,Autocuration,,,105,H,8,1,,CHEMBL616736,,
1645,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616737,,
1646,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616738,,
1647,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616739,,
1648,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616740,,
1649,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616741,,
1650,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL616742,,
1651,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616743,,
1652,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616744,,
1653,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616745,,
1654,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616746,,
1655,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616747,,
1656,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616748,,
1657,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616648,,
1658,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Intermediate,,,105570,D,9,1,,CHEMBL616649,,
1659,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,Intermediate,,,105570,D,9,1,,CHEMBL616650,,
1660,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,Intermediate,,,105570,D,9,1,,CHEMBL616651,,
1661,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,Intermediate,,,105570,D,9,1,,CHEMBL616652,,
1662,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,Intermediate,,,105570,D,9,1,,CHEMBL616653,,
1663,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,BAO_0000218,Intermediate,,,105570,D,9,1,,CHEMBL616654,,
1664,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,BAO_0000019,Intermediate,,,105570,D,9,1,,CHEMBL616655,,
1665,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,BAO_0000357,Intermediate,,,105570,D,9,1,,CHEMBL616656,,
1666,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616657,,
1667,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,,BAO_0000357,Intermediate,,,105570,D,9,1,,CHEMBL616658,2435.0,
1668,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,BAO_0000357,Intermediate,,,105570,D,9,1,,CHEMBL616659,,
1669,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL616660,,
1670,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616661,,
1671,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616662,,
1672,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616663,,
1673,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616664,,
1674,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL881820,,
1675,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616665,,
1676,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616666,,
1677,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616667,,
1678,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616668,,
1679,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL616669,,
1680,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL617040,,
1681,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL617041,,
1682,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL617042,,
1683,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL617043,,
1684,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617044,,
1685,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL617045,,
1686,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL617046,,
1687,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL617047,,
1688,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL617048,,
1689,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616897,,
1690,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,BAO_0000019,Expert,,,105,D,9,1,,CHEMBL616898,,
1691,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL858201,,
1692,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616899,,
1693,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,BAO_0000219,Autocuration,,,105,H,8,1,,CHEMBL616900,,
1694,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616901,,
1695,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616902,,
1696,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL616903,,
1697,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616904,,
1698,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616905,,
1699,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616906,,
1700,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616907,,
1701,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616908,,
1702,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL616909,,
1703,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL616910,,
1704,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616911,,
1705,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL616912,,
1706,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616913,,
1707,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL616914,,
1708,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616915,,
1709,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616916,,
1710,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616917,,
1711,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616918,,
1712,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,Expert,,,105,H,8,1,,CHEMBL616919,,
1713,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616920,,
1714,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL872914,,
1715,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616921,,
1716,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL616922,,
1717,Binding affinity towards 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616923,,
1718,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL616924,,
1719,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL875909,,
1720,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616925,,
1721,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616926,,
1722,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616927,,
1723,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,105,H,8,1,,CHEMBL616928,,
1724,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,BAO_0000219,Expert,,,105,D,9,1,,CHEMBL616929,,
1725,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616930,,
1726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616931,,
1727,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616932,,
1728,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL616933,,
1729,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,BAO_0000219,Expert,,,105,D,9,1,,CHEMBL616934,,
1730,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616935,,
1731,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616936,,
1732,Affinity for 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616937,,
1733,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616938,,
1734,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616939,,
1735,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616940,,
1736,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616941,,
1737,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL616942,,
1738,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL616943,,
1739,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,104802,H,4,1,,CHEMBL616944,,
1740,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616945,,
1741,Binding activity radioligand.,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616946,,
1742,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616947,,
1743,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,485.0,BAO_0000219,Expert,,CHO-K1,105,H,8,1,,CHEMBL616948,,
1744,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616851,,
1745,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616852,,
1746,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616853,,
1747,Binding activity against human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616854,,
1748,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Expert,,CHO,105,D,9,1,,CHEMBL616855,,
1749,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616856,,
1750,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616857,,
1751,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616858,,
1752,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616859,,
1753,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616860,,
1754,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL616861,,
1755,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL616541,,
1756,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL616542,,
1757,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616543,,
1758,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL616544,,
1759,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616545,,
1760,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616546,,
1761,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616547,,
1762,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",449.0,BAO_0000219,Autocuration,,CHO,105,H,8,1,,CHEMBL616548,,
1763,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616549,,
1764,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,BAO_0000019,Expert,,,105,H,8,1,,CHEMBL616550,,
1765,Binding affinity against 5-HT2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL857066,,
1766,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616551,,
1767,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616552,,
1768,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL832876,,
1769,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL616553,,
1770,Binding affinity towards 5-HT1B was determined,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616554,,
1771,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL616555,,
1772,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL616556,,
1773,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616557,,
1774,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL616558,,
1775,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,BAO_0000019,Expert,,,10577,D,9,1,,CHEMBL616749,,
1776,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616750,,
1777,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616751,,
1778,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,Autocuration,,,10577,H,8,1,,CHEMBL616752,,
1779,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616753,2435.0,
1780,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,10577,D,9,1,,CHEMBL616754,,
1781,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616755,,
1782,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616756,2435.0,
1783,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616757,2435.0,
1784,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616758,2435.0,
1785,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,Autocuration,,,10577,H,8,1,,CHEMBL616759,,
1786,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616760,,
1787,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616761,2435.0,
1788,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616762,2435.0,
1789,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616763,,
1790,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,BAO_0000357,Expert,,,10577,H,8,1,,CHEMBL872909,,
1791,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616764,,
1792,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,10577,D,9,1,,CHEMBL616765,,
1793,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616766,2435.0,
1794,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616767,2435.0,
1795,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616768,,
1796,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616769,,
1797,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616770,,
1798,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616771,,
1799,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616772,2435.0,
1800,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL616773,,
1801,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616774,,
1802,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616775,,
1803,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,Autocuration,,,10577,H,8,1,,CHEMBL616776,,
1804,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616777,,
1805,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616778,,
1806,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,BAO_0000249,Expert,,,10577,D,9,1,,CHEMBL616779,,
1807,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,10577,D,9,1,,CHEMBL616780,,
1808,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616781,,
1809,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616782,,
1810,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616783,,
1811,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,BAO_0000019,Expert,,,10577,H,8,1,,CHEMBL616784,2435.0,
1812,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616785,,
1813,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,Autocuration,,,10577,H,8,1,,CHEMBL857067,955.0,
1814,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616786,,
1815,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,Autocuration,,,10577,H,8,1,,CHEMBL616787,955.0,
1816,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616788,,
1817,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616789,,
1818,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,BAO_0000019,Expert,,,10577,D,9,1,,CHEMBL616790,,
1819,Binding affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,Expert,,,10577,H,8,1,,CHEMBL616791,,
1820,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL616792,,
1821,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,BAO_0000249,Expert,,,10577,D,9,1,,CHEMBL616793,,
1822,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616794,,
1823,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL616795,,
1824,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616796,,
1825,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616797,,
1826,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,BAO_0000249,Autocuration,Brain membranes,,106,H,8,1,,CHEMBL616798,,
1827,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616799,,
1828,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616800,,
1829,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616801,,
1830,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616802,,
1831,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616803,,
1832,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,BAO_0000357,Expert,,,106,H,8,1,,CHEMBL857068,,
1833,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616804,,
1834,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616805,,
1835,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616806,,
1836,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616807,,
1837,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616808,,
1838,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616809,,
1839,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616810,,
1840,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,BAO_0000224,Autocuration,,,104802,H,4,1,,CHEMBL616811,,
1841,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616812,,
1842,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616813,,
1843,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616814,,
1844,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616815,,
1845,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616816,,
1846,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616817,,
1847,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616818,,
1848,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL616819,,
1849,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL616820,,
1850,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL616821,,
1851,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616822,,
1852,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL616823,,
1853,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616824,,
1854,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616825,,
1855,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616826,,
1856,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,BAO_0000019,Expert,,,12689,D,9,1,,CHEMBL616827,,
1857,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616828,,
1858,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616829,,
1859,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,Autocuration,,,12689,D,9,1,,CHEMBL616830,,
1860,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,Expert,,,12689,D,9,1,,CHEMBL616831,,
1861,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,Autocuration,,,12689,D,9,1,,CHEMBL616832,,
1862,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,Autocuration,,,12689,D,9,1,,CHEMBL616833,,
1863,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,Expert,,,12689,D,9,1,,CHEMBL616834,,
1864,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,Autocuration,,,12689,D,9,1,,CHEMBL829595,,
1865,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616835,,
1866,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,BAO_0000249,Autocuration,,,12689,D,9,1,,CHEMBL872910,,
1867,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL616836,,
1868,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,BAO_0000357,Autocuration,,,12689,D,9,1,,CHEMBL616837,,
1869,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,Autocuration,,,12689,D,9,1,,CHEMBL616466,,
1870,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,722.0,BAO_0000219,Autocuration,,HEK293,12689,D,9,1,,CHEMBL616467,,
1871,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616468,,
1872,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616469,,
1873,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL616470,,
1874,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL616471,,
1875,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL616472,,
1876,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL616473,,
1877,Binding affinity against serotonergic 5-HT1c receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL616474,,
1878,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL616475,,
1879,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL616476,,
1880,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL616477,,
1881,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616478,,
1882,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616479,,
1883,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616480,,
1884,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL616481,,
1885,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,BAO_0000249,Autocuration,,,104686,D,5,1,,CHEMBL616482,,
1886,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,Autocuration,,,104686,D,5,1,,CHEMBL884713,955.0,
1887,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616483,,
1888,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616484,,
1889,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616485,,
1890,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616486,,
1891,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616487,,
1892,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616488,,
1893,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616489,,
1894,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616490,,
1895,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616491,,
1896,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616492,,
1897,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616493,,
1898,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616494,,
1899,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616495,,
1900,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616496,,
1901,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616497,,
1902,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616498,,
1903,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616499,,
1904,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616500,,
1905,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,Autocuration,,,104686,D,5,1,,CHEMBL616501,955.0,
1906,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL616502,955.0,
1907,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL884529,,
1908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL616503,,
1909,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616964,,
1910,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL616965,,
1911,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616966,,
1912,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616967,,
1913,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL616968,,
1914,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616969,,
1915,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL884530,,
1916,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616970,,
1917,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616971,,
1918,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616972,,
1919,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616973,,
1920,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616974,,
1921,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616975,,
1922,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616976,,
1923,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616977,,
1924,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616978,,
1925,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616979,,
1926,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616980,,
1927,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL616981,,
1928,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL616982,,
1929,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616983,,
1930,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616984,,
1931,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL616985,,
1932,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616986,,
1933,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL616987,,
1934,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL616988,,
1935,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617243,,
1936,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617244,,
1937,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Autocuration,,CHO-K1,104686,D,5,1,,CHEMBL617245,,
1938,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL617246,,
1939,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617546,,
1940,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,BAO_0000249,Autocuration,Brain membranes,,104686,H,4,1,,CHEMBL617547,,
1941,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,Autocuration,,,104686,H,4,1,,CHEMBL617548,,
1942,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617549,,
1943,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617550,,
1944,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617551,,
1945,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL617552,,
1946,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL617553,,
1947,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617554,1515.0,
1948,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617555,,
1949,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617556,,
1950,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL617557,,
1951,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL617558,,
1952,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,Expert,,,17106,H,8,1,,CHEMBL617559,,
1953,Binding affinity for 5-hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,17106,D,9,1,,CHEMBL617560,,
1954,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,Autocuration,,,17106,H,8,1,,CHEMBL617561,,
1955,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,Autocuration,,,17106,H,8,1,,CHEMBL617562,,
1956,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,BAO_0000357,Autocuration,,,17106,H,8,1,,CHEMBL617563,2435.0,
1957,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,17106,H,8,1,,CHEMBL617564,,
1958,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,BAO_0000019,Expert,,,17106,H,8,1,,CHEMBL617565,,
1959,Binding activity radioligand.,,BAO_0000357,Autocuration,,,17106,H,8,1,,CHEMBL856076,,
1960,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,Autocuration,,,17106,H,8,1,,CHEMBL617566,,
1961,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,Expert,,,17106,H,8,1,,CHEMBL875911,,
1962,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,Autocuration,,,17106,H,8,1,,CHEMBL617567,,
1963,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,Autocuration,,,17106,H,8,1,,CHEMBL617568,,
1964,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,BAO_0000019,Expert,,,17106,H,8,1,,CHEMBL617569,,
1965,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,BAO_0000249,Expert,,,17106,H,8,1,,CHEMBL617570,,
1966,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,BAO_0000357,Autocuration,,,17106,H,8,1,,CHEMBL617571,,
1967,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617572,,
1968,The compound was tested for intrinsic activity against 5-HT1D receptor,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL617573,,
1969,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617574,,
1970,The compound was tested for binding affinity against 5-HT1D receptor,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL617575,,
1971,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,BAO_0000357,Autocuration,,,10578,H,8,1,,CHEMBL617576,,
1972,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,BAO_0000019,Autocuration,,,10578,H,8,1,,CHEMBL617577,,
1973,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,BAO_0000019,Autocuration,,,10578,H,8,1,,CHEMBL617578,,
1974,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,10578,H,8,1,,CHEMBL617579,,
1975,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,Expert,,,10578,H,8,1,,CHEMBL617580,,
1976,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,Autocuration,,,10578,H,8,1,,CHEMBL617581,,
1977,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,BAO_0000357,Autocuration,,,10578,H,8,1,,CHEMBL617582,,
1978,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,BAO_0000019,Expert,,,10578,H,8,1,,CHEMBL617583,,
1979,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617584,,
1980,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617585,,
1981,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL875912,,
1982,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617586,,
1983,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617587,,
1984,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617588,,
1985,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL857980,,
1986,Tested against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617589,,
1987,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617590,,
1988,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL617591,,
1989,Binding affinity against 5-Hydroxytryptamine 1D receptor,,BAO_0000357,Expert,,,105,D,9,1,,CHEMBL617592,,
1990,,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617593,,
1991,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,106,H,8,1,,CHEMBL617594,,
1992,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL617595,,
1993,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL617596,,
1994,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,722.0,BAO_0000219,Autocuration,,HEK293,105,H,8,1,,CHEMBL617597,,
1995,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617598,,
1996,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL872916,,
1997,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL617599,,
1998,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617091,,
1999,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",485.0,BAO_0000219,Expert,,CHO-K1,105,H,8,1,,CHEMBL617092,,
2000,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL617093,,
2001,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617094,,
2002,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617095,,
2003,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617096,,
2004,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617097,,
2005,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617098,,
2006,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617301,,
2007,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617302,,
2008,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617303,,
2009,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL617304,,
2010,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,BAO_0000219,Expert,,CHO,105,H,8,1,,CHEMBL617305,,
2011,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,BAO_0000219,Autocuration,,,105,D,9,1,,CHEMBL617306,,
2012,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,BAO_0000357,Autocuration,,,17106,H,8,1,,CHEMBL617307,,
2013,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,105,H,8,1,,CHEMBL617308,,
2014,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617309,,
2015,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617310,,
2016,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617311,,
2017,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617312,,
2018,Affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL617313,,
2019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL617314,,
2020,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617315,,
2021,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,722.0,BAO_0000219,Autocuration,,HEK293,106,H,8,1,,CHEMBL617316,,
2022,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,722.0,BAO_0000219,Autocuration,,HEK293,106,H,8,1,,CHEMBL617317,,
2023,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL617318,,
2024,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL617319,,
2025,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL617320,,
2026,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL617321,,
2027,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,Expert,,,106,D,9,1,,CHEMBL617322,,
2028,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616862,,
2029,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,Autocuration,,,106,H,8,1,,CHEMBL616863,,
2030,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,449.0,BAO_0000219,Autocuration,,CHO,106,H,8,1,,CHEMBL616864,,
2031,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,106,H,8,1,,CHEMBL616865,,
2032,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,106,H,8,1,,CHEMBL616866,,
2033,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616867,,
2034,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",485.0,BAO_0000219,Expert,,CHO-K1,106,H,8,1,,CHEMBL616868,,
2035,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL616869,,
2036,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",449.0,BAO_0000219,Expert,,CHO,106,H,8,1,,CHEMBL616870,,
2037,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL616871,,
2038,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL616872,,
2039,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL616873,,
2040,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,485.0,BAO_0000219,Autocuration,,CHO-K1,105,H,8,1,,CHEMBL616838,,
2041,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616839,,
2042,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,106,H,8,1,,CHEMBL616840,,
2043,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616841,,
2044,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL616842,,
2045,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,Expert,,,105,H,8,1,,CHEMBL857976,,
2046,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616843,,
2047,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,BAO_0000357,Expert,,,10618,D,9,1,,CHEMBL616844,,
2048,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616845,,
2049,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,BAO_0000357,Expert,,,10618,D,9,1,,CHEMBL616846,,
2050,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616847,,
2051,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,BAO_0000019,Autocuration,,,10618,H,8,1,,CHEMBL616848,,
2052,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616849,,
2053,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL872911,,
2054,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,BAO_0000019,Autocuration,,,10618,H,8,1,,CHEMBL616850,,
2055,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,10618,D,9,1,,CHEMBL616699,,
2056,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616700,,
2057,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616701,,
2058,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616702,,
2059,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616703,,
2060,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616704,,
2061,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616705,,
2062,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616706,,
2063,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616707,,
2064,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616708,,
2065,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616709,,
2066,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616710,,
2067,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616711,,
2068,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",449.0,BAO_0000219,Autocuration,,CHO,10618,H,8,1,,CHEMBL616712,,
2069,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616713,,
2070,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616714,,
2071,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616715,,
2072,Binding affinity towards 5-hydroxytryptamine 1E receptor,,BAO_0000357,Autocuration,,,10618,H,8,1,,CHEMBL616716,,
2073,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,BAO_0000019,Autocuration,,,279,H,8,1,,CHEMBL616717,,
2074,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,BAO_0000019,Expert,,,279,H,8,1,,CHEMBL616718,,
2075,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,Autocuration,,,279,H,8,1,,CHEMBL875905,,
2076,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,BAO_0000019,Autocuration,,,279,H,8,1,,CHEMBL616719,,
2077,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,BAO_0000019,Expert,,,279,H,8,1,,CHEMBL616720,,
2078,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616721,,
2079,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL616722,,
2080,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616723,,
2081,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL616724,,
2082,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616725,,
2083,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616726,,
2084,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616727,,
2085,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616728,,
2086,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL616729,,
2087,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,Expert,,,279,H,8,1,,CHEMBL616730,,
2088,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL617125,,
2089,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL857977,,
2090,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL617126,,
2091,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL617127,,
2092,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL617128,,
2093,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL617129,,
2094,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL617130,,
2095,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL617131,,
2096,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL617132,,
2097,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",449.0,BAO_0000219,Autocuration,,CHO,279,H,8,1,,CHEMBL617133,,
2098,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL617134,,
2099,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL617135,,
2100,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,BAO_0000357,Autocuration,,,279,H,8,1,,CHEMBL617136,,
2101,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617137,,
2102,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617138,,
2103,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617139,,
2104,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617140,,
2105,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,BAO_0000218,Autocuration,,,104686,H,4,1,,CHEMBL617141,,
2106,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL858112,,
2107,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,BAO_0000019,Intermediate,,,17005,H,8,1,,CHEMBL617142,,
2108,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617143,,
2109,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617144,,
2110,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617145,,
2111,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617146,,
2112,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,BAO_0000019,Autocuration,,,104784,H,4,1,,CHEMBL617147,,
2113,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,BAO_0000019,Autocuration,,,104784,H,4,1,,CHEMBL617148,,
2114,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,BAO_0000019,Autocuration,,,104784,H,4,1,,CHEMBL617149,,
2115,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617150,,
2116,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617151,,
2117,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617201,,
2118,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL617202,,
2119,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,Autocuration,,,104826,H,4,1,,CHEMBL617203,,
2120,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,Autocuration,,,104826,H,4,1,,CHEMBL617204,,
2121,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,BAO_0000224,Autocuration,,,104826,H,4,1,,CHEMBL617205,,
2122,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,BAO_0000019,Autocuration,,,104826,D,5,1,,CHEMBL617206,,
2123,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,Autocuration,,,104826,H,4,1,,CHEMBL617207,,
2124,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,BAO_0000019,Autocuration,,,104826,D,5,1,,CHEMBL617208,,
2125,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104826,H,4,1,,CHEMBL617209,,
2126,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,BAO_0000224,Autocuration,,,104826,H,4,1,,CHEMBL617210,,
2127,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,BAO_0000224,Autocuration,,,104826,H,4,1,,CHEMBL617211,,
2128,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,Autocuration,,,104826,D,5,1,,CHEMBL617212,,
2129,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617213,,
2130,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617214,,
2131,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,Autocuration,,,22226,U,0,1,,CHEMBL617215,,
2132,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,Autocuration,,,22226,U,0,1,,CHEMBL617216,,
2133,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617217,,
2134,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617218,,
2135,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL872913,,
2136,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,BAO_0000019,Autocuration,,,104826,H,4,1,,CHEMBL617219,,
2137,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL873482,,
2138,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617220,,
2139,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617221,,
2140,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617222,,
2141,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL875906,,
2142,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617223,,
2143,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617224,,
2144,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617225,,
2145,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617226,,
2146,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617227,,
2147,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617228,,
2148,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617229,,
2149,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617230,,
2150,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617231,,
2151,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617232,,
2152,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617233,,
2153,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617234,,
2154,Compound was tested for the inhibition of quipazine induced head twitches in rats,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617235,,
2155,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617236,,
2156,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL617237,10000000.0,
2157,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL617238,10000000.0,
2158,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,,BAO_0000221,Autocuration,,,104686,D,5,1,,CHEMBL617239,955.0,
2159,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617240,,
2160,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL617241,,
2161,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,Autocuration,Membranes,,104686,H,4,1,,CHEMBL875907,,
2162,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617242,,
2163,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617152,,
2164,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,,BAO_0000221,Autocuration,,,104686,D,5,1,,CHEMBL617153,955.0,
2165,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,BAO_0000249,Autocuration,Membranes,,104686,D,5,1,,CHEMBL617154,,
2166,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL617155,955.0,
2167,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617156,,
2168,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617157,,
2169,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617158,,
2170,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617159,,
2171,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617160,,
2172,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL858113,,
2173,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,BAO_0000220,Autocuration,,,104686,H,4,1,,CHEMBL617247,955.0,
2174,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617248,,
2175,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,BAO_0000249,Autocuration,,,104686,H,4,1,,CHEMBL617249,955.0,
2176,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617250,,
2177,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617251,,
2178,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617252,,
2179,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617006,,
2180,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617007,,
2181,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617008,,
2182,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617009,,
2183,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617010,,
2184,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL857978,,
2185,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617011,,
2186,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617012,,
2187,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617013,,
2188,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,BAO_0000249,Autocuration,,,104686,H,4,1,,CHEMBL617014,,
2189,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617015,,
2190,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617016,,
2191,pKi value for 5-hydroxytryptamine 2 receptor binding site,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617017,,
2192,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL617018,955.0,
2193,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617019,,
2194,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,105075,H,4,1,,CHEMBL617020,,
2195,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,105075,H,4,1,,CHEMBL617021,,
2196,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,105075,H,4,1,,CHEMBL617022,,
2197,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,105075,H,4,1,,CHEMBL617023,,
2198,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,105075,H,4,1,,CHEMBL617024,,
2199,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,105075,H,4,1,,CHEMBL617025,,
2200,Hill coefficient of compound was determined,,BAO_0000224,Autocuration,,,105075,H,4,1,,CHEMBL617026,,
2201,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617027,,
2202,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617028,,
2203,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617029,,
2204,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL875908,,
2205,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617030,,
2206,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617031,,
2207,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617032,,
2208,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617033,,
2209,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617034,,
2210,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617035,,
2211,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617036,,
2212,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617037,,
2213,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL617038,,
2214,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,BAO_0000219,Autocuration,,,104784,H,4,1,,CHEMBL617039,,
2215,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617161,,
2216,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617162,,
2217,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617163,,
2218,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617164,,
2219,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,BAO_0000249,Autocuration,Brain membranes,,104784,H,4,1,,CHEMBL617165,,
2220,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617166,,
2221,Binding affinity towards 5-HT2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617167,,
2222,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL872912,,
2223,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617168,,
2224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617169,,
2225,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617170,,
2226,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617171,,
2227,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617172,,
2228,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617173,,
2229,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617174,,
2230,5-hydroxytryptamine 2 receptor binding affinity,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617175,,
2231,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617176,,
2232,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617177,,
2233,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617178,,
2234,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617179,,
2235,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617180,,
2236,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617181,,
2237,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617182,,
2238,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617183,,
2239,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617184,,
2240,Binding affinity against serotonergic 5-HT2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617185,,
2241,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617186,,
2242,Compound was evaluated for the binding affinity at 5- HT2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617187,,
2243,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617188,,
2244,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,BAO_0000218,Autocuration,,,17005,H,8,1,,CHEMBL617189,,
2245,Inhibitory activity against cloned human 5-HT2 receptor,,BAO_0000224,Autocuration,,,104784,D,5,1,,CHEMBL617190,,
2246,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",449.0,BAO_0000219,Autocuration,,CHO,104784,D,5,1,,CHEMBL617191,,
2247,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",449.0,BAO_0000219,Autocuration,,CHO,104784,D,5,1,,CHEMBL617192,,
2248,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",449.0,BAO_0000219,Autocuration,,CHO,104784,D,5,1,,CHEMBL617193,,
2249,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",449.0,BAO_0000219,Autocuration,,CHO,104784,D,5,1,,CHEMBL617194,,
2250,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL617195,,
2251,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,Autocuration,,,104784,H,4,1,,CHEMBL881830,,
2252,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000357,Autocuration,,,17005,H,8,1,,CHEMBL617196,,
2253,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617197,,
2254,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,BAO_0000357,Expert,,,17005,H,8,1,,CHEMBL617198,,
2255,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,17005,H,8,1,,CHEMBL873476,,
2256,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,BAO_0000019,Expert,,,17005,H,8,1,,CHEMBL617199,,
2257,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617200,,
2258,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL617484,,
2259,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617485,,
2260,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL617486,,
2261,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL858022,,
2262,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617049,,
2263,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,BAO_0000219,Expert,,CHO,107,D,9,1,,CHEMBL617050,,
2264,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,Autocuration,,,107,H,8,1,,CHEMBL617051,,
2265,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,BAO_0000219,Autocuration,,,107,H,8,1,,CHEMBL617052,,
2266,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,Autocuration,,,107,H,8,1,,CHEMBL617053,,
2267,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617054,,
2268,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617055,,
2269,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL882924,,
2270,Inhibition of human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617056,,
2271,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617057,,
2272,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,BAO_0000219,Expert,,,107,H,8,1,,CHEMBL617058,,
2273,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617059,,
2274,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617060,,
2275,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,449.0,BAO_0000219,Expert,,CHO,107,H,8,1,,CHEMBL617061,,
2276,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,307.0,BAO_0000219,Expert,,L929,107,H,8,1,,CHEMBL617062,,
2277,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,107,H,8,1,,CHEMBL617063,,
2278,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617064,,
2279,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617065,,
2280,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617066,,
2281,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617067,,
2282,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617068,,
2283,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617069,,
2284,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617070,,
2285,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617071,,
2286,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL872915,,
2287,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617072,,
2288,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617073,,
2289,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617074,,
2290,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,107,H,8,1,,CHEMBL617075,,
2291,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617076,,
2292,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,BAO_0000019,Expert,,,107,D,9,1,,CHEMBL617077,,
2293,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617078,,
2294,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617079,,
2295,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617080,,
2296,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,107,H,8,1,,CHEMBL617081,,
2297,Binding affinity towards human 5-HT2A receptor in BEK cells,,BAO_0000219,Expert,,,107,H,8,1,,CHEMBL617082,,
2298,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617083,,
2299,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617084,,
2300,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617085,,
2301,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617086,,
2302,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,BAO_0000219,Autocuration,,,107,H,8,1,,CHEMBL617087,,
2303,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617088,,
2304,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617089,,
2305,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,BAO_0000019,Expert,,,107,H,8,1,,CHEMBL617090,,
2306,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617513,,
2307,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL617514,,
2308,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617515,,
2309,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617516,,
2310,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617517,,
2311,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,107,D,9,1,,CHEMBL617518,,
2312,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617519,,
2313,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617520,,
2314,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617521,,
2315,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617522,,
2316,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617523,,
2317,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617524,,
2318,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617525,,
2319,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617526,,
2320,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617527,,
2321,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617528,,
2322,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617529,,
2323,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617530,,
2324,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617531,,
2325,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617532,,
2326,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617533,,
2327,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617534,,
2328,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617535,,
2329,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617536,,
2330,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617537,,
2331,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617538,,
2332,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,Autocuration,,,104686,H,4,1,,CHEMBL617539,,
2333,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617540,,
2334,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617541,,
2335,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617542,,
2336,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617543,,
2337,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Autocuration,,CHO-K1,104686,D,5,1,,CHEMBL617544,,
2338,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Autocuration,,CHO-K1,104686,D,5,1,,CHEMBL617545,,
2339,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617413,,
2340,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617414,,
2341,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617415,,
2342,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617416,,
2343,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617417,,
2344,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617418,,
2345,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617419,,
2346,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617420,,
2347,Affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617421,,
2348,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617422,,
2349,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617423,,
2350,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617424,,
2351,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617425,,
2352,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617426,,
2353,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,BAO_0000218,Autocuration,,,104686,H,4,1,,CHEMBL617427,,
2354,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL617428,955.0,
2355,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617429,,
2356,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617430,,
2357,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617431,,
2358,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617432,1870.0,
2359,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617433,,
2360,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617434,,
2361,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617435,,
2362,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617436,,
2363,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617437,2435.0,
2364,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617438,,
2365,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617439,,
2366,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617440,,
2367,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617441,,
2368,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL872918,,
2369,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617442,,
2370,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617443,,
2371,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617444,,
2372,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617445,,
2373,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617446,,
2374,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,BAO_0000249,Autocuration,,,104686,H,4,1,,CHEMBL617447,,
2375,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617448,,
2376,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617449,,
2377,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617450,,
2378,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617451,,
2379,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617452,,
2380,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617453,,
2381,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617660,,
2382,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617661,,
2383,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617662,,
2384,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL872919,,
2385,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617663,,
2386,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617664,,
2387,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617665,,
2388,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617666,,
2389,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617667,,
2390,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,BAO_0000249,Autocuration,,,104686,H,4,1,,CHEMBL617668,,
2391,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,BAO_0000249,Autocuration,,,104686,H,4,1,,CHEMBL617669,,
2392,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617670,,
2393,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617671,,
2394,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617672,,
2395,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617673,,
2396,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617674,,
2397,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617675,,
2398,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617676,,
2399,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617677,,
2400,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,BAO_0000019,Autocuration,,,104686,D,5,1,,CHEMBL617678,,
2401,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617679,,
2402,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617680,,
2403,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617681,,
2404,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,BAO_0000221,Autocuration,,,104686,H,4,1,,CHEMBL617682,955.0,
2405,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617683,,
2406,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617684,,
2407,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,D,5,1,,CHEMBL617685,,
2408,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617686,,
2409,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617687,,
2410,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,Autocuration,,,104686,H,4,1,,CHEMBL617688,,
2411,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617689,,
2412,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,Autocuration,,,104686,H,4,1,,CHEMBL617690,,
2413,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,Autocuration,,,104686,H,4,1,,CHEMBL617691,,
2414,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,Autocuration,,,104686,H,4,1,,CHEMBL617692,,
2415,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,Autocuration,,,104686,H,4,1,,CHEMBL617693,,
2416,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,Autocuration,,,104686,H,4,1,,CHEMBL617694,,
2417,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,BAO_0000221,Expert,,,12687,H,8,1,,CHEMBL857985,955.0,
2418,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617695,,
2419,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617696,,
2420,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617697,,
2421,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617257,,
2422,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL617258,,
2423,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617259,,
2424,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617260,,
2425,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL617261,,
2426,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617262,,
2427,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617263,,
2428,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617264,,
2429,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617265,,
2430,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,BAO_0000249,Autocuration,Membranes,,12687,H,8,1,,CHEMBL617266,,
2431,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617267,,
2432,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617268,,
2433,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,449.0,BAO_0000219,Autocuration,,CHO,12687,H,8,1,,CHEMBL617269,,
2434,Kinetic inhibition constant evaluated by measuring serotonergic activity,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617323,,
2435,Serotonergic activity of the compound.,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617324,,
2436,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,BAO_0000249,Autocuration,,,12687,H,8,1,,CHEMBL617325,,
2437,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617326,,
2438,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,BAO_0000249,Expert,,,12687,H,8,1,,CHEMBL617327,,
2439,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617328,,
2440,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617329,,
2441,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617330,,
2442,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617331,,
2443,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617332,,
2444,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617333,,
2445,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617334,,
2446,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617335,,
2447,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617336,,
2448,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617337,,
2449,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617338,,
2450,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617339,,
2451,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617340,,
2452,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617341,,
2453,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617342,,
2454,Affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617343,,
2455,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,723.0,BAO_0000219,Expert,,NIH3T3,107,H,8,1,,CHEMBL617344,,
2456,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617345,,
2457,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617346,,
2458,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617347,,
2459,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617348,,
2460,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617349,,
2461,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617350,,
2462,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL872339,,
2463,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617351,,
2464,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617352,,
2465,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617353,,
2466,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617354,,
2467,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617355,,
2468,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,449.0,BAO_0000219,Expert,,CHO,107,H,8,1,,CHEMBL617356,,
2469,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617357,,
2470,Binding affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617358,,
2471,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617359,,
2472,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617360,,
2473,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL875913,,
2474,Affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617361,,
2475,Binding affinity against 5-Hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL617362,,
2476,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617363,,
2477,Tested against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617364,,
2478,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,Autocuration,,,105075,H,4,1,,CHEMBL617365,,
2479,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,BAO_0000224,Autocuration,,,105075,H,4,1,,CHEMBL617366,,
2480,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,BAO_0000224,Autocuration,,,105075,H,4,1,,CHEMBL617367,,
2481,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,Autocuration,,,105075,H,4,1,,CHEMBL617368,,
2482,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617369,,
2483,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617370,,
2484,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,BAO_0000219,Expert,,CHO,227,D,9,1,,CHEMBL617371,,
2485,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617372,,
2486,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,BAO_0000357,Expert,,,227,D,9,1,,CHEMBL617373,,
2487,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617374,,
2488,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617375,,
2489,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617376,,
2490,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617377,,
2491,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617378,,
2492,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617379,,
2493,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617380,,
2494,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617381,,
2495,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617382,,
2496,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617383,,
2497,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617384,,
2498,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617385,,
2499,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617386,,
2500,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617387,,
2501,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,BAO_0000219,Autocuration,,NIH3T3,107,H,8,1,,CHEMBL617388,,
2502,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,BAO_0000219,Autocuration,,CHO,107,H,8,1,,CHEMBL617389,,
2503,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,BAO_0000219,Expert,,CHO,107,D,9,1,,CHEMBL617390,,
2504,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,BAO_0000224,Autocuration,,,104817,H,4,1,,CHEMBL617391,,
2505,Binding activity radioligand.,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617392,,
2506,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617393,,
2507,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,307.0,BAO_0000219,Autocuration,,L929,107,H,8,1,,CHEMBL617394,,
2508,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,307.0,BAO_0000219,Expert,,L929,107,H,8,1,,CHEMBL617395,,
2509,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,307.0,BAO_0000219,Expert,,L929,107,H,8,1,,CHEMBL617396,,
2510,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,307.0,BAO_0000219,Autocuration,,L929,107,H,8,1,,CHEMBL617397,,
2511,Binding affinity against 5-HT2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617398,,
2512,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL617399,,
2513,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL617400,,
2514,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL617401,,
2515,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL617402,,
2516,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL617403,,
2517,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617404,,
2518,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL857981,,
2519,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL617405,,
2520,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL617253,,
2521,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617254,,
2522,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL617255,,
2523,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL617256,,
2524,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL616874,,
2525,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL616875,,
2526,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,722.0,BAO_0000219,Expert,,HEK293,107,H,8,1,,CHEMBL616876,,
2527,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",722.0,BAO_0000219,Expert,,HEK293,107,H,8,1,,CHEMBL616877,,
2528,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL616878,,
2529,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,722.0,BAO_0000219,Expert,,HEK293,107,H,8,1,,CHEMBL616879,,
2530,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,722.0,BAO_0000219,Expert,,HEK293,107,H,8,1,,CHEMBL616880,,
2531,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,722.0,BAO_0000219,Expert,,HEK293,107,D,9,1,,CHEMBL616881,,
2532,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,723.0,BAO_0000219,Autocuration,,NIH3T3,107,H,8,1,,CHEMBL616882,,
2533,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,BAO_0000219,Autocuration,,NIH3T3,107,H,8,1,,CHEMBL616883,,
2534,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,BAO_0000219,Autocuration,,NIH3T3,107,H,8,1,,CHEMBL616884,,
2535,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL616885,,
2536,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,485.0,BAO_0000219,Autocuration,,CHO-K1,107,H,8,1,,CHEMBL616886,,
2537,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,485.0,BAO_0000219,Expert,,CHO-K1,107,H,8,1,,CHEMBL616887,,
2538,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,107,D,9,1,,CHEMBL616888,,
2539,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL616889,,
2540,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL616890,,
2541,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,449.0,BAO_0000219,Expert,,CHO,107,D,9,1,,CHEMBL616891,,
2542,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL616892,,
2543,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,107,H,8,1,,CHEMBL616893,,
2544,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,723.0,BAO_0000219,Autocuration,,NIH3T3,10620,H,8,1,,CHEMBL616894,,
2545,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,723.0,BAO_0000219,Expert,,NIH3T3,107,H,8,1,,CHEMBL616895,,
2546,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,10620,H,8,1,,CHEMBL616896,,
2547,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,10621,H,8,1,,CHEMBL617099,,
2548,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,BAO_0000357,Autocuration,,,10621,H,8,1,,CHEMBL617100,,
2549,Binding affinity against rabbit aorta 5-HT2A receptor,,BAO_0000357,Autocuration,,,107,H,8,1,,CHEMBL884532,,
2550,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617101,,
2551,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617102,,
2552,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,107,H,8,1,,CHEMBL617103,,
2553,The compound was tested for binding affinity against 5-HT2A receptor,,BAO_0000357,Expert,,,107,H,8,1,,CHEMBL617104,,
2554,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,10576,H,8,1,,CHEMBL857979,,
2555,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL857502,,
2556,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617105,,
2557,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL858021,945.0,
2558,Binding affinity for 5-HT 2A in rat stomach fundus,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL875910,945.0,
2559,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617106,,
2560,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,723.0,BAO_0000219,Expert,,NIH3T3,12687,H,8,1,,CHEMBL617107,,
2561,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617108,,
2562,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617109,,
2563,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617110,,
2564,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617111,,
2565,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617112,,
2566,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617113,,
2567,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617114,,
2568,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617115,,
2569,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,Autocuration,,,12687,H,8,1,,CHEMBL617116,,
2570,Efficacy at 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617117,,
2571,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617118,,
2572,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL617119,,
2573,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL617120,,
2574,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,Expert,,,12687,D,9,1,,CHEMBL617121,,
2575,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,Autocuration,,,12687,H,8,1,,CHEMBL617122,,
2576,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617123,,
2577,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617124,,
2578,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,BAO_0000249,Expert,,,12687,H,8,1,,CHEMBL617600,,
2579,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617601,,
2580,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL882923,,
2581,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617602,,
2582,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617603,,
2583,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617604,,
2584,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617605,,
2585,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617606,,
2586,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617607,,
2587,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,12687,H,8,1,,CHEMBL617455,,
2588,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617456,,
2589,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617457,,
2590,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL617458,,
2591,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617459,,
2592,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617460,,
2593,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617461,,
2594,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617462,,
2595,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617463,,
2596,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617464,,
2597,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617465,,
2598,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617466,,
2599,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617467,,
2600,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617468,,
2601,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617469,,
2602,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617470,,
2603,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617471,,
2604,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,723.0,BAO_0000219,Expert,,NIH3T3,12687,H,8,1,,CHEMBL617472,,
2605,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617473,,
2606,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617474,,
2607,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617475,,
2608,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,BAO_0000221,Autocuration,,,12687,H,8,1,,CHEMBL617476,955.0,
2609,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617477,,
2610,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,723.0,BAO_0000219,Expert,,NIH3T3,12687,H,8,1,,CHEMBL617478,,
2611,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,BAO_0000221,Autocuration,,,12687,H,8,1,,CHEMBL617479,,
2612,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617480,,
2613,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617481,,
2614,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617482,,
2615,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617483,,
2616,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL621528,,
2617,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,723.0,BAO_0000219,Expert,,NIH3T3,12687,D,9,1,,CHEMBL621529,,
2618,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL621530,,
2619,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL621531,,
2620,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL621532,,
2621,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL621533,,
2622,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,12687,H,8,1,,CHEMBL621534,,
2623,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL621535,,
2624,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL621536,,
2625,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL621537,,
2626,Binding affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL621538,,
2627,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL621539,,
2628,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL621540,,
2629,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL621541,,
2630,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL621542,,
2631,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL621543,,
2632,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL621544,,
2633,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL621545,,
2634,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL621546,,
2635,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL621547,,
2636,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,723.0,BAO_0000219,Expert,,NIH3T3,12687,H,8,1,,CHEMBL618692,,
2637,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618693,,
2638,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL872922,,
2639,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618694,,
2640,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL618695,,
2641,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618696,,
2642,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL618697,,
2643,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618892,,
2644,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618893,,
2645,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618894,,
2646,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,723.0,BAO_0000219,Expert,,NIH3T3,12687,H,8,1,,CHEMBL618895,,
2647,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL618896,,
2648,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL618897,5383.0,
2649,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618898,,
2650,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618899,,
2651,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618900,,
2652,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL618901,,
2653,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618902,,
2654,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,,BAO_0000221,Expert,,,12687,D,9,1,,CHEMBL618903,10000000.0,
2655,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618904,,
2656,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618905,,
2657,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL618906,,
2658,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,723.0,BAO_0000219,Expert,,NIH3T3,12687,H,8,1,,CHEMBL618907,,
2659,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL618908,,
2660,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617909,,
2661,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617910,,
2662,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,BAO_0000221,Autocuration,,,12687,H,8,1,,CHEMBL617911,955.0,
2663,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,12687,H,8,1,,CHEMBL872923,,
2664,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,12687,H,8,1,,CHEMBL617912,,
2665,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617913,,
2666,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,Expert,,,12687,H,8,1,,CHEMBL617914,,
2667,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,12687,H,8,1,,CHEMBL617915,,
2668,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,12687,H,8,1,,CHEMBL617916,,
2669,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617917,,
2670,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617918,,
2671,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617919,,
2672,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617920,,
2673,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617921,,
2674,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,BAO_0000224,Expert,,,105102,D,5,1,,CHEMBL617922,,
2675,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617923,,
2676,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617924,,
2677,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617925,,
2678,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,BAO_0000357,Expert,,,12687,D,9,1,,CHEMBL617926,,
2679,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617927,,
2680,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617928,,
2681,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617929,,
2682,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617930,,
2683,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617931,,
2684,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617932,,
2685,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,449.0,BAO_0000219,Autocuration,,CHO,12687,H,8,1,,CHEMBL617933,,
2686,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617934,,
2687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617935,,
2688,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617936,,
2689,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617937,,
2690,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617938,,
2691,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,BAO_0000218,Autocuration,,,12687,H,8,1,,CHEMBL617939,,
2692,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,BAO_0000218,Autocuration,,,12687,H,8,1,,CHEMBL617940,,
2693,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,BAO_0000218,Autocuration,,,12687,H,8,1,,CHEMBL617941,,
2694,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617942,,
2695,Ratio of pKi of 5-HT2A to that of D2 receptor,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617943,,
2696,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,Expert,,,105093,H,4,1,,CHEMBL617944,,
2697,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,Expert,,,105093,H,4,1,,CHEMBL617945,,
2698,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,BAO_0000224,Expert,,,105075,H,4,1,,CHEMBL617946,,
2699,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617947,,
2700,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,BAO_0000357,Expert,,,12687,H,8,1,,CHEMBL617948,,
2701,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL858116,,
2702,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617949,,
2703,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617950,,
2704,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617951,1515.0,
2705,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617952,1515.0,
2706,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617953,1515.0,
2707,Binding activity radioligand.,,BAO_0000357,Autocuration,,,12687,H,8,1,,CHEMBL617954,,
2708,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617955,,
2709,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL857071,,
2710,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,BAO_0000019,Expert,,,12687,H,8,1,,CHEMBL617270,,
2711,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,339.0,BAO_0000219,Autocuration,,N1E-115,12687,H,8,1,,CHEMBL617271,,
2712,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,339.0,BAO_0000219,Autocuration,,N1E-115,12687,H,8,1,,CHEMBL617272,,
2713,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617273,,
2714,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,BAO_0000019,Expert,,,12687,D,9,1,,CHEMBL617274,,
2715,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617275,,
2716,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617276,,
2717,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617277,,
2718,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617278,,
2719,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617279,,
2720,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617280,,
2721,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617281,,
2722,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617282,,
2723,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617283,,
2724,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617284,,
2725,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617285,,
2726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617286,,
2727,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,BAO_0000357,Expert,,,108,D,9,1,,CHEMBL617287,,
2728,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617288,,
2729,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617289,,
2730,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL872917,,
2731,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617290,,
2732,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,108,H,8,1,,CHEMBL617291,,
2733,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,449.0,BAO_0000219,Autocuration,,CHO,108,H,8,1,,CHEMBL617292,,
2734,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,723.0,BAO_0000219,Autocuration,,NIH3T3,108,H,8,1,,CHEMBL617293,,
2735,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,BAO_0000219,Expert,,CHO,108,D,9,1,,CHEMBL617294,,
2736,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617295,,
2737,Binding activity radioligand.,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617296,,
2738,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617297,,
2739,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617298,,
2740,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617299,,
2741,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,449.0,BAO_0000219,Autocuration,,CHO,108,H,8,1,,CHEMBL617300,,
2742,Binding affinity against 5-HT2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617454,,
2743,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617505,,
2744,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,722.0,BAO_0000219,Expert,,HEK293,108,D,9,1,,CHEMBL617506,,
2745,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,722.0,BAO_0000219,Expert,,HEK293,108,D,9,1,,CHEMBL617507,,
2746,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617508,,
2747,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,722.0,BAO_0000219,Expert,,HEK293,108,D,9,1,,CHEMBL857982,,
2748,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,722.0,BAO_0000219,Expert,,HEK293,108,D,9,1,,CHEMBL617509,,
2749,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,722.0,BAO_0000219,Expert,,HEK293,108,D,9,1,,CHEMBL617510,,
2750,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617511,,
2751,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617512,,
2752,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617749,,
2753,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617750,,
2754,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617751,,
2755,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,722.0,BAO_0000219,Expert,,HEK293,108,H,8,1,,CHEMBL617752,,
2756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617753,,
2757,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",722.0,BAO_0000219,Expert,,HEK293,108,H,8,1,,CHEMBL617754,,
2758,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,722.0,BAO_0000219,Expert,,HEK293,108,D,9,1,,CHEMBL617755,,
2759,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617756,,
2760,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,722.0,BAO_0000219,Expert,,HEK293,108,H,8,1,,CHEMBL617757,,
2761,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,722.0,BAO_0000219,Expert,,HEK293,108,H,8,1,,CHEMBL617758,,
2762,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,723.0,BAO_0000219,Autocuration,,NIH3T3,108,H,8,1,,CHEMBL617759,,
2763,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617760,,
2764,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,108,H,8,1,,CHEMBL617761,,
2765,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,D,9,1,,CHEMBL617762,,
2766,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617763,,
2767,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL857983,,
2768,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617764,,
2769,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,308.0,BAO_0000219,Autocuration,,HeLa,108,H,8,1,,CHEMBL617765,,
2770,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617766,,
2771,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,BAO_0000221,Autocuration,,,108,H,8,1,,CHEMBL617767,10000000.0,
2772,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617768,,
2773,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,108,H,8,1,,CHEMBL617769,,
2774,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,11864,H,8,1,,CHEMBL858023,,
2775,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,BAO_0000019,Autocuration,,,11864,H,8,1,,CHEMBL617770,945.0,
2776,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,BAO_0000019,Autocuration,,,11864,H,8,1,,CHEMBL617771,945.0,
2777,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,625.0,BAO_0000219,Autocuration,,A9,11864,H,8,1,,CHEMBL617772,,
2778,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,723.0,BAO_0000219,Autocuration,,NIH3T3,11864,H,8,1,,CHEMBL617773,,
2779,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,723.0,BAO_0000219,Autocuration,,NIH3T3,11864,H,8,1,,CHEMBL617850,,
2780,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,723.0,BAO_0000219,Autocuration,,NIH3T3,11864,H,8,1,,CHEMBL617851,,
2781,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,BAO_0000019,Autocuration,,,11864,H,8,1,,CHEMBL617852,,
2782,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL858024,945.0,
2783,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,,BAO_0000019,Expert,,,12689,D,9,1,,CHEMBL617853,945.0,
2784,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617854,,
2785,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL873477,,
2786,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617855,,
2787,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617856,,
2788,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617857,,
2789,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,BAO_0000249,Autocuration,,,108,H,8,1,,CHEMBL617858,,
2790,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617859,,
2791,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617860,,
2792,Binding activity radioligand.,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617861,,
2793,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617862,,
2794,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617863,,
2795,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,BAO_0000249,Autocuration,,,108,H,8,1,,CHEMBL617864,,
2796,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,BAO_0000249,Autocuration,,,108,H,8,1,,CHEMBL617649,,
2797,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617650,,
2798,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,Expert,,,108,H,8,1,,CHEMBL617651,,
2799,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617652,,
2800,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL857072,,
2801,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617653,,
2802,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,Autocuration,,,12687,H,8,1,,CHEMBL617654,,
2803,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617655,,
2804,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL617656,,
2805,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617657,,
2806,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617658,,
2807,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,12689,D,9,1,,CHEMBL617659,,
2808,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,12689,D,9,1,,CHEMBL617838,,
2809,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,BAO_0000249,Expert,Brain membranes,,12689,D,9,1,,CHEMBL617839,,
2810,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617840,,
2811,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617841,,
2812,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL875915,,
2813,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,BAO_0000219,Expert,,,12689,H,8,1,,CHEMBL617842,,
2814,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,723.0,BAO_0000219,Expert,,NIH3T3,12689,H,8,1,,CHEMBL617843,,
2815,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL617844,,
2816,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL617845,,
2817,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,723.0,BAO_0000219,Expert,,NIH3T3,12689,H,8,1,,CHEMBL617846,,
2818,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617847,,
2819,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL617848,,
2820,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617849,,
2821,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL621507,,
2822,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL621508,,
2823,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL621509,,
2824,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL621510,,
2825,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL621511,,
2826,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,625.0,BAO_0000219,Expert,,A9,12689,H,8,1,,CHEMBL621512,,
2827,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621513,,
2828,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL621514,,
2829,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,BAO_0000219,Expert,,,12689,H,8,1,,CHEMBL621515,,
2830,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,BAO_0000219,Autocuration,,,12689,H,8,1,,CHEMBL621516,,
2831,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL621517,5383.0,
2832,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621518,,
2833,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL621519,,
2834,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621520,,
2835,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621521,,
2836,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621522,,
2837,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,BAO_0000219,Expert,,,12689,H,8,1,,CHEMBL621523,,
2838,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621524,,
2839,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,BAO_0000357,Expert,,,12689,D,9,1,,CHEMBL621525,,
2840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL872921,,
2841,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL621526,,
2842,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,BAO_0000219,Expert,,,12689,H,8,1,,CHEMBL621527,,
2843,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,Expert,,,12689,D,9,1,,CHEMBL617865,,
2844,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617866,,
2845,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617867,,
2846,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617487,,
2847,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,12689,H,8,1,,CHEMBL617488,,
2848,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617489,,
2849,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617490,,
2850,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617491,,
2851,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617492,,
2852,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617493,,
2853,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617494,,
2854,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,BAO_0000019,Expert,,,12689,D,9,1,,CHEMBL617495,,
2855,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617496,,
2856,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,485.0,BAO_0000219,Autocuration,,CHO-K1,12689,H,8,1,,CHEMBL617497,,
2857,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617498,,
2858,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,BAO_0000357,Autocuration,,,12689,H,8,1,,CHEMBL617499,,
2859,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,BAO_0000019,Autocuration,,,12689,H,8,1,,CHEMBL617500,,
2860,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617501,,
2861,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617502,,
2862,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617503,,
2863,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617504,,
2864,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617406,,
2865,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,BAO_0000019,Expert,,,227,D,9,1,,CHEMBL617407,,
2866,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617408,,
2867,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617409,,
2868,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617410,,
2869,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617411,,
2870,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617412,,
2871,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,BAO_0000357,Expert,,,227,D,9,1,,CHEMBL617774,,
2872,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617775,,
2873,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617776,,
2874,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,BAO_0000219,Expert,,CHO,227,D,9,1,,CHEMBL617777,,
2875,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,449.0,BAO_0000219,Expert,,CHO,227,D,9,1,,CHEMBL617778,,
2876,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617779,,
2877,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,722.0,BAO_0000219,Expert,,HEK293,227,H,8,1,,CHEMBL617780,,
2878,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617781,,
2879,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617782,,
2880,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617783,,
2881,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617784,,
2882,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617785,,
2883,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,722.0,BAO_0000219,Expert,,HEK293,227,H,8,1,,CHEMBL857984,,
2884,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,722.0,BAO_0000219,Expert,,HEK293,227,H,8,1,,CHEMBL617786,,
2885,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,722.0,BAO_0000219,Expert,,HEK293,227,H,8,1,,CHEMBL617787,,
2886,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617788,,
2887,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,722.0,BAO_0000219,Expert,,HEK293,227,D,9,1,,CHEMBL617789,,
2888,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617790,,
2889,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,485.0,BAO_0000219,Expert,,CHO-K1,227,H,8,1,,CHEMBL617791,,
2890,Binding affinity against 5-hydroxytryptamine 2B receptor,,BAO_0000357,Expert,,,227,H,8,1,,CHEMBL617608,,
2891,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617609,,
2892,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617610,,
2893,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617611,,
2894,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617612,,
2895,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,227,H,8,1,,CHEMBL617613,,
2896,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,BAO_0000019,Autocuration,,,227,H,8,1,,CHEMBL617614,,
2897,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,BAO_0000019,Expert,,,12688,H,8,1,,CHEMBL617615,945.0,
2898,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,BAO_0000357,Expert,,,12688,H,8,1,,CHEMBL858114,945.0,
2899,Affinity against serotonergic receptor in the isolated rat stomach fundus,,BAO_0000357,Autocuration,,,12688,H,8,1,,CHEMBL617616,945.0,
2900,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,,BAO_0000019,Expert,,,12688,D,9,1,,CHEMBL617617,945.0,
2901,Antagonistic against 5-hydroxytryptamine 2B receptor,,BAO_0000019,Expert,,,12688,D,9,1,,CHEMBL875914,,
2902,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617618,945.0,
2903,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,,BAO_0000357,Expert,,,12688,D,9,1,,CHEMBL617619,945.0,
2904,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617620,,
2905,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617621,,
2906,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617622,,
2907,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,Expert,,,12688,D,9,1,,CHEMBL617623,945.0,
2908,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,Expert,,,12688,D,9,1,,CHEMBL617624,945.0,
2909,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,Expert,,,12688,D,9,1,,CHEMBL617625,945.0,
2910,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,,BAO_0000357,Expert,,,12688,D,9,1,,CHEMBL617626,945.0,
2911,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617627,945.0,
2912,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,Expert,,,12688,H,8,1,,CHEMBL617628,945.0,
2913,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617629,945.0,
2914,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL858115,945.0,
2915,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,,BAO_0000019,Expert,,,12688,D,9,1,,CHEMBL617630,945.0,
2916,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,BAO_0000019,Autocuration,,,12688,H,8,1,,CHEMBL617631,1515.0,
2917,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,Autocuration,,,12688,H,8,1,,CHEMBL617632,,
2918,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,BAO_0000357,Expert,,,12688,H,8,1,,CHEMBL617633,,
2919,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,Autocuration,,,12688,H,8,1,,CHEMBL617634,,
2920,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,Autocuration,,,12688,H,8,1,,CHEMBL617635,,
2922,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,BAO_0000019,Autocuration,,,12688,D,9,1,,CHEMBL617637,945.0,
2923,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617638,,
2924,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617639,,
2925,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617640,,
2926,Evaluated for the binding affinity to 5-HT 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617641,,
2927,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617642,,
2928,Binding affinities against 5-hydroxytryptamine 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617643,,
2929,Binding affinities towards 5-hydroxytryptamine 2B receptor,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617644,,
2930,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,BAO_0000357,Autocuration,,,227,H,8,1,,CHEMBL617645,,
2931,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617646,,
2932,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617647,,
2933,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617648,,
2934,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617875,,
2935,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617876,,
2936,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617877,,
2937,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL617878,,
2938,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617879,,
2939,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617880,,
2940,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL617881,2435.0,
2941,Binding affinity against 5-HT1A receptor,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL857073,,
2942,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617882,,
2943,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,449.0,BAO_0000219,Expert,,CHO,108,D,9,1,,CHEMBL617883,,
2944,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,BAO_0000219,Autocuration,,,108,H,8,1,,CHEMBL617884,,
2945,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,449.0,BAO_0000219,Autocuration,,CHO,108,H,8,1,,CHEMBL617885,,
2946,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",449.0,BAO_0000219,Autocuration,,CHO,108,H,8,1,,CHEMBL617886,,
2947,Inhibition of human 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,D,9,1,,CHEMBL617887,,
2948,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617888,,
2949,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617889,,
2950,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617890,,
2951,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617891,,
2952,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617892,,
2953,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617893,,
2954,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617894,,
2955,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617895,,
2956,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,449.0,BAO_0000219,Autocuration,,CHO,108,H,8,1,,CHEMBL617896,,
2957,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,BAO_0000357,Expert,,,108,D,9,1,,CHEMBL617897,,
2958,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617898,,
2959,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617899,,
2960,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL617900,,
2961,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617901,,
2962,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617902,,
2963,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000019,Autocuration,,,108,H,8,1,,CHEMBL617903,,
2964,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617904,,
2965,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617905,,
2966,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617906,,
2967,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617907,,
2968,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL617908,,
2969,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,108,H,8,1,,CHEMBL620617,,
2970,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,BAO_0000019,Expert,,,108,D,9,1,,CHEMBL620618,,
2971,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL620619,,
2972,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,D,9,1,,CHEMBL620620,,
2973,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620621,,
2974,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,BAO_0000249,Autocuration,Membranes,,104698,D,7,1,,CHEMBL872920,,
2975,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620622,,
2976,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL620623,,
2977,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620624,,
2978,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620625,,
2979,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,BAO_0000219,Autocuration,,,104698,H,6,1,,CHEMBL620626,,
2980,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL621307,,
2981,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL621308,,
2982,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL621309,,
2983,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL621310,,
2984,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL621311,,
2985,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL621502,,
2986,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL621503,,
2987,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,BAO_0000249,Autocuration,Membranes,,104698,H,6,1,,CHEMBL621504,,
2988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL621505,,
2989,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL621506,,
2990,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL619781,,
2991,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL619782,,
2992,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619783,,
2993,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL619784,,
2994,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL619785,,
2995,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL619786,,
2996,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619787,,
2997,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL872925,,
2998,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619788,,
2999,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL619789,,
3000,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL619790,,
3001,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619791,,
3002,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619792,,
3003,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,BAO_0000249,Autocuration,Membranes,,104698,H,6,1,,CHEMBL619793,,
3004,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL619794,,
3005,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,BAO_0000221,Autocuration,,,104698,H,6,1,,CHEMBL619795,955.0,
3006,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619796,,
3007,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620448,,
3008,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620449,,
3009,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620450,,
3010,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620451,,
3011,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620631,,
3012,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620632,,
3013,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620633,,
3014,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620634,,
3015,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620635,,
3016,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620636,,
3017,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620637,,
3018,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620638,,
3019,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620639,,
3020,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620640,,
3021,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620641,,
3022,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620642,,
3023,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620643,,
3024,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620644,,
3025,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620645,,
3026,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620646,,
3027,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620647,,
3028,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620648,,
3029,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620649,,
3030,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620650,,
3031,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620651,,
3032,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL872875,,
3033,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL620652,,
3034,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620653,,
3035,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL857076,,
3036,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL620654,,
3037,Binding activity radioligand.,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL620655,,
3038,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,BAO_0000249,Autocuration,Brain membranes,,104698,H,6,1,,CHEMBL620656,,
3039,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,BAO_0000249,Autocuration,Brain membranes,,104698,H,6,1,,CHEMBL620657,,
3040,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620658,,
3041,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620659,,
3042,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620660,,
3043,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620661,,
3044,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620662,,
3045,Affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL620663,,
3046,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620664,,
3047,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL620665,,
3048,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620666,,
3049,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620667,,
3050,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL620668,,
3051,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620669,,
3052,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL620670,,
3053,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620671,,
3054,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620672,,
3055,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620673,,
3056,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620674,,
3057,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620675,,
3058,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL620676,,
3059,Affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL621382,,
3060,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,D,9,1,,CHEMBL621383,,
3061,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL621384,,
3062,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL621385,,
3063,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL617989,,
3064,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,BAO_0000019,Expert,,,104714,H,4,1,,CHEMBL617990,,
3065,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL875085,2116.0,
3066,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617991,,
3067,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617992,,
3068,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617993,2116.0,
3069,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617994,2116.0,
3070,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617995,,
3071,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617996,,
3072,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617997,,
3073,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617998,,
3074,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617999,,
3075,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618000,,
3076,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617815,2116.0,
3077,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617816,2116.0,
3078,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617817,2116.0,
3079,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617818,2116.0,
3080,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617819,2116.0,
3081,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL617820,,
3082,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617821,2116.0,
3083,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617822,2116.0,
3084,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617823,2116.0,
3085,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617824,2116.0,
3086,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617825,2116.0,
3087,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617826,2116.0,
3088,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617827,2116.0,
3089,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617828,2116.0,
3090,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617829,2116.0,
3091,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617830,2116.0,
3092,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617831,2116.0,
3093,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617832,2116.0,
3094,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL617833,,
3095,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,BAO_0000357,Autocuration,,,51,H,8,1,,CHEMBL617834,,
3096,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,BAO_0000223,Expert,,,104714,D,5,1,,CHEMBL617835,,
3097,Binding affinity towards 5-HT3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL617836,,
3098,Binding activity radioligand.,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL617837,,
3099,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL620392,,
3100,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL620393,,
3101,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL620394,,
3102,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL620395,,
3103,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620396,,
3104,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,433.0,BAO_0000219,Expert,,NG108-15,105030,H,4,1,,CHEMBL620582,,
3105,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,BAO_0000218,Autocuration,,,105030,H,4,1,,CHEMBL620583,,
3106,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,Autocuration,,,105030,H,4,1,,CHEMBL620584,,
3107,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,BAO_0000224,Autocuration,,,105030,H,4,1,,CHEMBL620585,,
3108,Compound was evaluated for the binding affinity at 5- HT3 receptor,,BAO_0000224,Autocuration,,,105030,H,4,1,,CHEMBL620586,,
3109,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,Autocuration,,,105030,H,4,1,,CHEMBL620587,,
3110,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,Autocuration,,,105030,H,4,1,,CHEMBL620588,,
3111,5-hydroxytryptamine 3 receptor agonism in mouse,,BAO_0000218,Autocuration,,,105030,H,4,1,,CHEMBL620589,,
3112,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,BAO_0000219,Autocuration,,,105030,H,4,1,,CHEMBL620590,,
3113,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,Autocuration,,,105030,H,4,1,,CHEMBL617956,,
3114,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,Autocuration,,,105030,H,4,1,,CHEMBL617957,,
3115,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,BAO_0000224,Autocuration,,,105030,H,4,1,,CHEMBL617958,,
3116,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,Autocuration,,,105030,H,4,1,,CHEMBL617959,,
3117,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,Autocuration,,,105030,H,4,1,,CHEMBL617960,,
3118,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000224,Autocuration,,,105030,H,4,1,,CHEMBL617961,,
3119,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,BAO_0000219,Autocuration,,,105030,H,4,1,,CHEMBL617962,,
3120,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,339.0,BAO_0000219,Autocuration,,N1E-115,105030,H,4,1,,CHEMBL617963,,
3121,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,Autocuration,,,11765,H,8,1,,CHEMBL617964,,
3122,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,BAO_0000219,Autocuration,,,11765,H,8,1,,CHEMBL617965,,
3123,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,BAO_0000357,Autocuration,,,10630,D,9,1,,CHEMBL617966,,
3124,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,Autocuration,,,17106,H,8,1,,CHEMBL857074,,
3125,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL617967,,
3126,Binding activity radioligand.,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL617968,,
3127,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL617969,,
3128,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL617970,,
3129,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL617971,,
3130,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617972,,
3131,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617973,,
3132,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617974,,
3133,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),,BAO_0000221,Autocuration,,,104714,H,4,1,,CHEMBL617975,2116.0,
3134,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617976,,
3135,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617977,,
3136,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617978,,
3137,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL617979,,
3138,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,104714,H,4,1,,CHEMBL617980,,
3139,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617981,,
3140,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL617982,,
3141,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,BAO_0000357,Autocuration,,,12020,H,8,1,,CHEMBL617983,,
3142,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617984,,
3143,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617985,,
3144,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617986,948.0,
3145,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617987,948.0,
3146,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617988,948.0,
3147,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617792,948.0,
3148,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617793,948.0,
3149,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617794,,
3150,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617795,,
3151,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617796,,
3152,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617797,,
3153,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000218,Autocuration,,,104698,D,7,1,,CHEMBL617798,,
3154,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617799,,
3155,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,D,7,1,,CHEMBL617800,,
3156,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617801,,
3157,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,BAO_0000218,Autocuration,,,104698,D,7,1,,CHEMBL617802,,
3158,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617803,,
3159,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617804,,
3160,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617805,,
3161,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL617806,,
3162,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617807,,
3163,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617808,,
3164,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL617809,,
3165,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617810,,
3166,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL617811,955.0,
3167,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,BAO_0000221,Autocuration,,,104698,H,6,1,,CHEMBL617812,955.0,
3168,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL617813,,
3169,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL617814,,
3170,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617698,,
3171,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617699,,
3172,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617700,,
3173,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL617701,,
3174,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617702,,
3175,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,BAO_0000249,Autocuration,Membranes,,104698,H,6,1,,CHEMBL617703,,
3176,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617704,,
3177,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL617705,,
3178,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL617706,,
3179,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),433.0,BAO_0000219,Autocuration,,NG108-15,104698,H,6,1,,CHEMBL617707,,
3180,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,433.0,BAO_0000219,Autocuration,,NG108-15,104698,H,6,1,,CHEMBL617708,,
3181,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617709,,
3182,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617710,,
3183,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL882925,,
3184,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617711,,
3185,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617712,,
3186,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL617713,,
3187,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL617714,,
3188,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617715,,
3189,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617716,,
3190,Inhibition of 5-HT evoked reflex bradycardia in rat.,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617717,,
3191,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617718,,
3192,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617719,,
3193,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617720,,
3194,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,D,7,1,,CHEMBL617721,,
3195,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617722,,
3196,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617723,,
3197,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617724,,
3198,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617725,,
3199,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617726,,
3200,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617727,,
3201,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617728,,
3202,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617729,,
3203,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617730,,
3204,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617731,,
3205,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617732,,
3206,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617733,,
3207,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617734,,
3208,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL872874,,
3209,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617735,,
3210,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617736,,
3211,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617737,,
3212,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617738,,
3213,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617739,,
3214,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617740,,
3215,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617741,,
3216,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617742,,
3217,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617743,,
3218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617744,,
3219,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617745,,
3220,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617746,,
3221,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617747,,
3222,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL617748,,
3223,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL618909,,
3224,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL618910,,
3225,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL618911,,
3226,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL618912,,
3227,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,BAO_0000218,Autocuration,,,104698,H,6,1,,CHEMBL618913,,
3228,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618914,,
3229,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618915,,
3230,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL618916,,
3231,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618917,,
3232,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,BAO_0000221,Intermediate,,,104698,D,7,1,,CHEMBL618918,10000000.0,
3233,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL618919,,
3234,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL618920,,
3235,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL618921,,
3236,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618922,,
3237,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618923,,
3238,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618924,,
3239,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618925,,
3240,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618926,,
3241,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL618927,2116.0,
3242,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL618928,2116.0,
3243,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL618929,2116.0,
3244,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL618930,2116.0,
3245,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL618931,2116.0,
3246,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619594,2116.0,
3247,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619595,2116.0,
3248,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619596,2116.0,
3249,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619755,2116.0,
3250,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619756,2116.0,
3251,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619757,2116.0,
3252,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619758,2116.0,
3253,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619759,2116.0,
3254,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619760,2116.0,
3255,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619761,2116.0,
3256,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619762,2116.0,
3257,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619763,2116.0,
3258,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL617868,2116.0,
3259,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL617869,,
3260,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,Intermediate,,,20033,D,9,1,,CHEMBL882926,2435.0,
3261,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,Intermediate,,,20033,D,9,1,,CHEMBL617870,2435.0,
3262,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL617871,2435.0,
3263,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL617872,2435.0,
3264,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL617873,2435.0,
3265,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL617874,2435.0,
3266,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619067,2116.0,
3267,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619068,2116.0,
3268,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619069,2116.0,
3269,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619070,,
3270,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619071,,
3271,Agonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619072,,
3272,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619073,,
3273,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619074,,
3274,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619075,,
3275,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619076,2435.0,
3276,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619077,2435.0,
3277,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,Intermediate,,,20033,D,9,1,,CHEMBL619078,2435.0,
3278,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,,BAO_0000249,Intermediate,,,20033,D,9,1,,CHEMBL619079,2435.0,
3279,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619080,2116.0,
3280,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,BAO_0000357,Expert,,,20033,D,9,1,,CHEMBL619081,,
3281,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619082,,
3282,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619083,,
3283,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619084,,
3284,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL859397,2116.0,
3285,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619085,2116.0,
3286,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619086,2116.0,
3287,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619087,2116.0,
3288,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619088,2116.0,
3289,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619089,,
3290,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL619090,,
3291,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619091,,
3292,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619092,,
3293,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619093,,
3294,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,722.0,BAO_0000219,Autocuration,,HEK293,168,H,8,1,,CHEMBL619094,,
3295,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619095,,
3296,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL857988,,
3297,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619096,,
3298,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619097,2435.0,
3299,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619098,10000000.0,
3300,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619751,,
3301,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619752,,
3302,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL875096,2116.0,
3303,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,BAO_0000357,Autocuration,,,108,H,8,1,,CHEMBL619004,,
3304,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL619005,,
3305,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL619006,,
3306,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,308.0,BAO_0000219,Autocuration,,HeLa,168,H,8,1,,CHEMBL619007,,
3307,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL619008,,
3308,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL619009,,
3309,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",308.0,BAO_0000219,Autocuration,,HeLa,168,H,8,1,,CHEMBL619010,,
3310,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,BAO_0000357,Autocuration,,,10622,H,8,1,,CHEMBL619011,,
3311,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,BAO_0000357,Autocuration,,,10622,H,8,1,,CHEMBL619012,,
3312,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,BAO_0000219,Autocuration,,,10622,H,8,1,,CHEMBL619013,,
3313,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,BAO_0000357,Autocuration,,,10622,H,8,1,,CHEMBL619014,,
3314,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,BAO_0000019,Autocuration,,,11249,H,8,1,,CHEMBL857503,2081.0,
3315,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,BAO_0000019,Autocuration,,,11249,H,8,1,,CHEMBL619015,2081.0,
3316,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,11249,H,8,1,,CHEMBL619016,,
3317,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,BAO_0000221,Autocuration,,,11249,H,8,1,,CHEMBL619017,10000000.0,
3318,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,,BAO_0000221,Autocuration,,,168,H,8,1,,CHEMBL619018,10000000.0,
3319,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL619019,,
3320,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,10623,D,9,1,,CHEMBL619020,,
3321,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619021,,
3322,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,BAO_0000357,Autocuration,,,10623,H,8,1,,CHEMBL619022,,
3323,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,BAO_0000357,Autocuration,,,10623,H,8,1,,CHEMBL619023,,
3324,lntrinsic activity relative to 5-HT receptor,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619024,,
3325,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619025,,
3326,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,BAO_0000019,Expert,,,10623,H,8,1,,CHEMBL619026,,
3327,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619027,,
3328,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619028,,
3329,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619029,,
3330,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619030,,
3331,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,BAO_0000357,Expert,,,10623,H,8,1,,CHEMBL619031,,
3332,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619032,,
3333,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,10623,D,9,1,,CHEMBL619033,,
3334,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000357,Autocuration,,,10623,H,8,1,,CHEMBL619034,,
3335,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,BAO_0000357,Autocuration,,,10623,H,8,1,,CHEMBL619035,,
3336,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,BAO_0000357,Autocuration,,,10623,H,8,1,,CHEMBL619036,,
3337,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,BAO_0000019,Expert,,,10623,D,9,1,,CHEMBL619037,,
3338,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,BAO_0000249,Autocuration,,,10623,H,8,1,,CHEMBL619038,2435.0,
3339,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,BAO_0000249,Autocuration,,,10623,H,8,1,,CHEMBL619039,,
3340,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,BAO_0000249,Expert,,,10623,H,8,1,,CHEMBL619040,,
3341,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,BAO_0000019,Expert,,,10623,D,9,1,,CHEMBL619041,2435.0,
3342,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619042,2435.0,
3343,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,BAO_0000249,Expert,,,10623,H,8,1,,CHEMBL619043,2435.0,
3344,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,BAO_0000019,Expert,,,10623,H,8,1,,CHEMBL619044,2435.0,
3345,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,BAO_0000249,Expert,,,10623,H,8,1,,CHEMBL619045,2435.0,
3346,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,BAO_0000249,Expert,,,10623,H,8,1,,CHEMBL619046,2435.0,
3347,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,BAO_0000249,Expert,,,10623,H,8,1,,CHEMBL619047,,
3348,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,BAO_0000221,Autocuration,,,10623,H,8,1,,CHEMBL619048,955.0,
3349,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL859398,,
3350,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619049,,
3351,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL857886,,
3352,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL619050,,
3353,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL620591,,
3354,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,10623,D,9,1,,CHEMBL620592,,
3355,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,BAO_0000249,Expert,,,10623,H,8,1,,CHEMBL620593,2435.0,
3356,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,BAO_0000019,Expert,,,10623,D,9,1,,CHEMBL620594,,
3357,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,BAO_0000019,Expert,,,10623,H,8,1,,CHEMBL875079,,
3358,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,Expert,,,10623,H,8,1,,CHEMBL620595,,
3359,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,BAO_0000019,Expert,,,10623,D,9,1,,CHEMBL620596,,
3360,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL620597,,
3361,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,BAO_0000019,Expert,,,10623,H,8,1,,CHEMBL620598,,
3362,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,BAO_0000218,Expert,,,10623,H,8,1,,CHEMBL620599,,
3363,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,Autocuration,,,10623,H,8,1,,CHEMBL620600,,
3364,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL620601,,
3365,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL620602,,
3366,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620603,,
3367,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620604,,
3368,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620605,,
3369,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620606,,
3370,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL620607,,
3371,In vitro binding affinity towards 5-HT4 receptor was determined,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620608,,
3372,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL620609,,
3373,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL620610,,
3374,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620611,,
3375,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620612,,
3376,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620613,,
3377,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620614,,
3378,Binding affinity against 5-Hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,168,H,8,1,,CHEMBL620615,,
3379,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,BAO_0000249,Autocuration,Brain membranes,,104698,H,6,1,,CHEMBL857075,,
3380,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,BAO_0000249,Autocuration,Brain membranes,,104698,H,6,1,,CHEMBL620616,,
3381,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,BAO_0000249,Autocuration,Brain membranes,,104698,H,6,1,,CHEMBL619411,,
3382,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619412,,
3383,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL619413,,
3384,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,BAO_0000221,Autocuration,,,104698,H,6,1,,CHEMBL619414,10000000.0,
3385,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619415,,
3386,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619416,,
3387,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619417,,
3388,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL619418,,
3389,Binding affinity against 5-Hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL619419,,
3390,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619420,,
3391,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL619421,,
3392,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,BAO_0000019,Autocuration,,,104698,D,7,1,,CHEMBL619422,,
3393,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619423,,
3394,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL875080,,
3395,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL619424,,
3396,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL619425,,
3397,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL619426,,
3398,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL619427,,
3399,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,D,7,1,,CHEMBL619645,,
3400,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,BAO_0000249,Expert,,,10576,D,9,1,,CHEMBL619646,,
3401,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,BAO_0000221,Autocuration,,,12020,H,8,1,,CHEMBL619647,955.0,
3402,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL619648,,
3403,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL619165,,
3404,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,BAO_0000218,Autocuration,,,12020,H,8,1,,CHEMBL620719,,
3405,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL872924,,
3406,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,12020,H,8,1,,CHEMBL620720,,
3407,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL620721,,
3408,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL620722,,
3409,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL620723,,
3410,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,Autocuration,,,12020,H,8,1,,CHEMBL620724,,
3411,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,BAO_0000249,Autocuration,,,104698,H,6,1,,CHEMBL620725,,
3412,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,BAO_0000019,Autocuration,,,12020,D,9,1,,CHEMBL620726,,
3413,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,Expert,,,144,H,8,1,,CHEMBL620727,,
3414,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL620728,,
3415,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620729,,
3416,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL858288,,
3417,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL620730,,
3418,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL620731,,
3419,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL620732,,
3420,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618042,,
3421,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618043,,
3422,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618044,,
3423,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618045,,
3424,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618046,,
3425,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618047,,
3426,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL875084,,
3427,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618048,,
3428,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618049,,
3429,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL619764,,
3430,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL619765,,
3431,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL619766,,
3432,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL619767,,
3433,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL619768,,
3434,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL619769,,
3435,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL619770,,
3436,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL619771,,
3437,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,BAO_0000219,Autocuration,,,104714,H,4,1,,CHEMBL619772,,
3438,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL619773,,
3439,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,433.0,BAO_0000219,Autocuration,,NG108-15,104714,H,4,1,,CHEMBL619774,,
3440,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL875083,,
3441,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,433.0,BAO_0000219,Autocuration,,NG108-15,104714,H,4,1,,CHEMBL620718,,
3442,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618127,,
3443,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618128,,
3444,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,BAO_0000219,Autocuration,,,104714,H,4,1,,CHEMBL618129,,
3445,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618130,,
3446,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618131,,
3447,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618132,,
3448,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618133,,
3449,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618134,,
3450,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618135,,
3451,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618136,,
3452,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618137,,
3453,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618138,,
3454,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618139,,
3455,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618140,,
3456,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618141,,
3457,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,Expert,,,108,H,8,1,,CHEMBL873478,,
3458,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104698,H,6,1,,CHEMBL618142,,
3459,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618143,,
3460,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618144,,
3461,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618145,,
3462,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618146,,
3463,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618147,,
3464,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618148,,
3465,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,Autocuration,,,144,H,8,1,,CHEMBL618149,,
3466,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL872927,,
3467,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618150,,
3468,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618151,,
3469,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL875094,,
3470,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,Autocuration,,,144,H,8,1,,CHEMBL618152,,
3471,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618153,,
3472,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618888,,
3473,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,BAO_0000019,Autocuration,,,144,H,8,1,,CHEMBL618889,,
3474,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL618890,,
3475,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,BAO_0000019,Autocuration,,,144,H,8,1,,CHEMBL618891,,
3476,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,BAO_0000019,Autocuration,,,144,H,8,1,,CHEMBL619054,,
3477,Binding affinity against the 5-hydroxytryptamine 3 receptor,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL619055,,
3478,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL619056,,
3479,Percent efficacy against 5-hydroxytryptamine 3A receptor,,BAO_0000019,Autocuration,,,144,H,8,1,,CHEMBL619057,,
3480,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,Autocuration,,,144,H,8,1,,CHEMBL619058,,
3481,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,BAO_0000219,Expert,,Oocytes,12020,D,9,1,,CHEMBL619059,,
3482,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,BAO_0000219,Expert,,Oocytes,12020,D,9,1,,CHEMBL619060,,
3483,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,BAO_0000219,Expert,,Oocytes,12020,D,9,1,,CHEMBL875095,,
3484,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619061,2116.0,
3485,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619062,2116.0,
3486,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,BAO_0000019,Intermediate,,,20033,D,9,1,,CHEMBL619063,,
3487,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619064,2116.0,
3488,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL619065,,
3489,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,,BAO_0000221,Intermediate,,,20033,D,9,1,,CHEMBL619066,2116.0,
3490,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,BAO_0000221,Autocuration,,,10209,H,8,1,,CHEMBL619775,2116.0,
3491,Affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619776,,
3492,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,Autocuration,,,104841,H,4,1,,CHEMBL619777,,
3493,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,Autocuration,,,104841,H,4,1,,CHEMBL619778,,
3494,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,,BAO_0000221,Autocuration,,,104841,H,4,1,,CHEMBL619779,2116.0,
3495,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,Autocuration,,,104841,H,4,1,,CHEMBL619780,,
3496,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,Autocuration,,,104841,H,4,1,,CHEMBL619166,,
3497,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,Autocuration,,,104841,H,4,1,,CHEMBL619167,,
3498,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,Autocuration,,,104841,H,4,1,,CHEMBL619168,,
3499,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,,BAO_0000219,Expert,,,168,D,9,1,,CHEMBL619169,2081.0,
3500,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,,BAO_0000219,Expert,,,168,D,9,1,,CHEMBL619170,2081.0,
3501,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,BAO_0000019,Autocuration,,,104841,D,5,1,,CHEMBL619171,,
3502,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",,BAO_0000219,Expert,,,168,D,9,1,,CHEMBL619172,2081.0,
3503,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL619173,,
3504,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL619174,,
3505,5-hydroxytryptamine receptor binding affinity was determined in rats,,BAO_0000019,Autocuration,,,104705,H,4,1,,CHEMBL619175,,
3506,Binding affinity at rat 5-hydroxytryptamine receptor.,,BAO_0000224,Autocuration,,,104705,H,4,1,,CHEMBL619176,,
3507,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,BAO_0000019,Autocuration,,,104705,H,4,1,,CHEMBL619177,,
3508,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,BAO_0000224,Autocuration,,,104705,H,4,1,,CHEMBL619178,,
3509,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,BAO_0000224,Autocuration,,,104705,H,4,1,,CHEMBL619179,,
3510,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,BAO_0000019,Autocuration,,,104705,H,4,1,,CHEMBL619180,945.0,
3511,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,BAO_0000019,Autocuration,,,104705,H,4,1,,CHEMBL619181,945.0,
3512,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,Autocuration,,,104705,H,4,1,,CHEMBL619182,,
3513,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,BAO_0000224,Autocuration,,,104705,H,4,1,,CHEMBL619183,,
3514,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,BAO_0000224,Autocuration,,,104705,H,4,1,,CHEMBL619184,,
3515,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL619185,10000000.0,
3516,Binding affinity for rat 5-hydroxytryptamine transporter.,,BAO_0000357,Expert,,,12198,H,8,1,,CHEMBL619186,,
3517,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,BAO_0000019,Autocuration,,,104705,H,4,1,,CHEMBL619187,,
3518,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,BAO_0000019,Autocuration,,,104705,D,5,1,,CHEMBL619188,,
3519,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,BAO_0000224,Autocuration,,,104705,D,5,1,,CHEMBL619189,,
3520,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,,BAO_0000019,Expert,,,12198,D,9,1,,CHEMBL619190,955.0,
3521,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,,BAO_0000221,Expert,,,12198,D,9,1,,CHEMBL619191,2037.0,
3522,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,BAO_0000019,Autocuration,,,104705,D,5,1,,CHEMBL619192,,
3523,Percent binding affinity against 5-hydroxytryptamine receptor,,BAO_0000224,Autocuration,,,104705,D,5,1,,CHEMBL619193,,
3524,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL619194,,
3525,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,BAO_0000224,Autocuration,,,104705,D,5,1,,CHEMBL619195,,
3526,Affinity against 5-hydroxytryptamine receptor was determined,,BAO_0000224,Autocuration,,,104705,D,5,1,,CHEMBL619196,,
3527,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,,BAO_0000019,Autocuration,,,104705,D,5,1,,CHEMBL619197,945.0,
3528,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,Expert,,,121,D,9,1,,CHEMBL619198,,
3529,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,Expert,,,121,D,9,1,,CHEMBL875081,,
3530,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,BAO_0000357,Autocuration,,,18065,H,8,1,,CHEMBL884712,,
3531,Inhibition of 5-hydroxytryptamine reuptake,,BAO_0000357,Expert,,,121,H,8,1,,CHEMBL884710,,
3532,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,Autocuration,,,18065,H,8,1,,CHEMBL619199,,
3533,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,BAO_0000019,Autocuration,,,18065,H,8,1,,CHEMBL619200,,
3534,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,BAO_0000019,Autocuration,,,18065,H,8,1,,CHEMBL619201,,
3535,Tested for 5-hydroxytryptamine receptor uptake,,BAO_0000019,Autocuration,,,18065,H,8,1,,CHEMBL619202,,
3536,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,449.0,BAO_0000219,Expert,,CHO,51,D,9,1,,CHEMBL619203,,
3537,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,BAO_0000019,Expert,,,51,D,9,1,,CHEMBL619204,,
3538,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,BAO_0000249,Autocuration,,,10576,H,8,1,,CHEMBL619205,,
3539,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,BAO_0000357,Autocuration,,,10576,H,8,1,,CHEMBL619206,,
3540,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,Expert,,,10576,H,8,1,,CHEMBL619207,,
3541,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619208,2435.0,
3542,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619209,2435.0,
3543,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619210,2435.0,
3544,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619211,2435.0,
3545,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619212,2435.0,
3546,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620681,2435.0,
3547,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620682,2435.0,
3548,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620683,2435.0,
3549,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620684,2435.0,
3550,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620685,2435.0,
3551,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620686,2435.0,
3552,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620687,349.0,
3553,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620688,349.0,
3554,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620689,349.0,
3555,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620690,349.0,
3556,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620691,349.0,
3557,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620692,349.0,
3558,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL620693,349.0,
3559,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,168,H,8,1,,CHEMBL620694,,
3560,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,Autocuration,,,168,H,8,1,,CHEMBL857986,,
3561,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620695,,
3562,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,BAO_0000357,Expert,,,168,H,8,1,,CHEMBL620696,,
3563,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620697,,
3564,Binding affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620698,,
3565,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620699,,
3566,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,Autocuration,,,168,H,8,1,,CHEMBL620700,,
3567,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,643.0,BAO_0000219,Autocuration,,COS-7,168,H,8,1,,CHEMBL620701,,
3568,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,643.0,BAO_0000219,Autocuration,,COS-7,168,H,8,1,,CHEMBL875082,,
3569,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,643.0,BAO_0000219,Autocuration,,COS-7,168,H,8,1,,CHEMBL620702,,
3570,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,643.0,BAO_0000219,Autocuration,,COS-7,168,H,8,1,,CHEMBL620703,,
3571,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,673.0,BAO_0000219,Autocuration,,C6,168,H,8,1,,CHEMBL620704,,
3572,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,673.0,BAO_0000219,Expert,,C6,168,H,8,1,,CHEMBL620705,,
3573,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,673.0,BAO_0000219,Expert,,C6,168,H,8,1,,CHEMBL620706,,
3574,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,673.0,BAO_0000219,Expert,,C6,168,H,8,1,,CHEMBL620707,,
3575,Binding affinity towards 5-hydroxytryptamine 5 receptor,,BAO_0000357,Expert,,,10624,H,8,1,,CHEMBL620708,,
3576,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,BAO_0000357,Autocuration,,,105,H,8,1,,CHEMBL620709,,
3577,Binding affinity against 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10624,D,9,1,,CHEMBL620710,,
3578,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,10624,H,8,1,,CHEMBL620711,,
3579,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,BAO_0000357,Expert,,,10624,D,9,1,,CHEMBL620712,,
3580,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10624,D,9,1,,CHEMBL620713,,
3581,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,BAO_0000357,Expert,,,10624,D,9,1,,CHEMBL620714,,
3582,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10624,D,9,1,,CHEMBL620715,,
3583,Binding affinity towards 5-HT5A receptor,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL620716,,
3584,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,Expert,,,10624,H,8,1,,CHEMBL620717,,
3585,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL618072,,
3586,Binding affinity towards cloned human 5-HT5A receptor was determined,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL857987,,
3587,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10624,H,8,1,,CHEMBL618073,,
3588,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,722.0,BAO_0000219,Autocuration,,HEK293,10624,H,8,1,,CHEMBL618074,,
3589,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),722.0,BAO_0000219,Autocuration,,HEK293,10624,H,8,1,,CHEMBL618075,,
3590,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10625,D,9,1,,CHEMBL618076,,
3591,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,Expert,,,10625,D,9,1,,CHEMBL618077,,
3592,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,BAO_0000357,Expert,,,10625,D,9,1,,CHEMBL618078,,
3593,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,BAO_0000357,Expert,,,10625,D,9,1,,CHEMBL881821,,
3594,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10625,D,9,1,,CHEMBL618079,,
3595,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,Expert,,,10625,H,8,1,,CHEMBL618080,,
3596,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,10576,H,8,1,,CHEMBL618081,,
3597,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,722.0,BAO_0000219,Autocuration,,HEK293,10626,H,8,1,,CHEMBL618082,,
3598,Binding affinity towards 5-HT5a receptor,,BAO_0000357,Expert,,,10624,H,8,1,,CHEMBL618083,,
3599,Binding affinity towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10624,D,9,1,,CHEMBL618084,,
3600,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,BAO_0000357,Expert,,,10624,H,8,1,,CHEMBL618085,,
3601,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,BAO_0000357,Expert,,,10624,H,8,1,,CHEMBL618086,,
3602,Binding affinities against 5-hydroxytryptamine 5A receptor,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL875092,,
3603,Binding affinities towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL618087,,
3604,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,BAO_0000357,Autocuration,,,10624,H,8,1,,CHEMBL872926,,
3605,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,Autocuration,,,104714,H,4,1,,CHEMBL618088,,
3606,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,BAO_0000223,Autocuration,,,104714,H,4,1,,CHEMBL618089,,
3607,Inhibition of human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618090,,
3608,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618091,,
3609,Inhibition against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL618092,,
3610,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618093,,
3611,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,308.0,BAO_0000219,Expert,,HeLa,10627,H,8,1,,CHEMBL618094,,
3612,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618095,,
3613,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL875093,,
3614,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618096,,
3615,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618118,,
3616,Binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618119,,
3617,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,H,8,1,,CHEMBL618120,,
3618,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL618121,,
3619,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",722.0,BAO_0000219,Expert,,HEK293,10627,H,8,1,,CHEMBL618122,,
3620,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL618123,,
3621,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,722.0,BAO_0000219,Expert,,HEK293,10627,H,8,1,,CHEMBL618124,,
3622,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL618125,,
3623,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,722.0,BAO_0000219,Expert,,HEK293,10627,D,9,1,,CHEMBL618126,,
3624,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,Expert,,,10627,H,8,1,,CHEMBL618236,,
3625,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,Expert,,,10627,H,8,1,,CHEMBL618237,,
3626,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,643.0,BAO_0000219,Expert,,COS-7,10627,H,8,1,,CHEMBL618238,,
3627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL618239,,
3628,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,BAO_0000019,Autocuration,,,10627,H,8,1,,CHEMBL618240,,
3629,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL618241,,
3630,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,722.0,BAO_0000219,Autocuration,,HEK293,10627,H,8,1,,CHEMBL859399,,
3631,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,BAO_0000019,Autocuration,,,10627,H,8,1,,CHEMBL618242,,
3632,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL857991,,
3633,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,H,8,1,,CHEMBL619951,,
3634,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,308.0,BAO_0000219,Expert,,HeLa,10627,D,9,1,,CHEMBL619952,,
3635,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,308.0,BAO_0000219,Expert,,HeLa,10627,D,9,1,,CHEMBL619953,,
3636,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL619954,,
3637,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL619955,,
3638,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL619956,,
3639,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,449.0,BAO_0000219,Autocuration,,CHO,10627,H,8,1,,CHEMBL619957,,
3640,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10627,H,8,1,,CHEMBL619958,,
3641,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,722.0,BAO_0000219,Autocuration,,HEK293,10627,H,8,1,,CHEMBL620627,,
3642,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,722.0,BAO_0000219,Autocuration,,HEK293,10627,H,8,1,,CHEMBL620628,,
3643,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL620629,,
3644,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620630,,
3645,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL620782,,
3646,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620783,,
3647,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,H,8,1,,CHEMBL620784,,
3648,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,308.0,BAO_0000219,Expert,,HeLa,10627,H,8,1,,CHEMBL620785,,
3649,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL857992,,
3650,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,BAO_0000219,Autocuration,,,10627,H,8,1,,CHEMBL620786,,
3651,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL620787,,
3652,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL620788,,
3653,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL620789,,
3654,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",308.0,BAO_0000219,Autocuration,,HeLa,10627,H,8,1,,CHEMBL620790,,
3655,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,10628,H,8,1,,CHEMBL620791,,
3656,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,BAO_0000019,Autocuration,,,10628,H,8,1,,CHEMBL620792,,
3657,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10628,H,8,1,,CHEMBL620793,,
3658,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,Autocuration,,,10628,H,8,1,,CHEMBL620794,,
3659,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,308.0,BAO_0000219,Autocuration,,HeLa,10627,D,9,1,,CHEMBL620795,,
3660,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,H,8,1,,CHEMBL620796,,
3661,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620797,,
3662,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,Expert,,,10627,D,9,1,,CHEMBL620798,,
3663,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620799,,
3664,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,H,8,1,,CHEMBL620800,,
3665,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620801,,
3666,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL875100,,
3667,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620802,,
3668,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,BAO_0000019,Expert,,,10627,H,8,1,,CHEMBL620803,,
3669,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,Expert,,,10627,H,8,1,,CHEMBL620804,,
3670,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620805,,
3671,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620806,,
3672,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620807,,
3673,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620808,,
3674,Binding affinities against 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620809,,
3675,Binding affinities towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620810,,
3676,Binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,Expert,,,10627,D,9,1,,CHEMBL620811,,
3677,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620812,,
3678,Affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620813,,
3679,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,BAO_0000357,Autocuration,,,10627,H,8,1,,CHEMBL620814,,
3680,Inhibition of human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL620815,,
3681,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL620816,,
3682,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL620817,,
3683,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL620818,,
3684,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,722.0,BAO_0000219,Expert,,HEK293,10209,H,8,1,,CHEMBL620819,,
3685,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL620820,,
3686,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,449.0,BAO_0000219,Autocuration,,CHO,10209,H,8,1,,CHEMBL620821,,
3687,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL620822,,
3688,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL620823,,
3689,Binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL620824,,
3690,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,10209,H,8,1,,CHEMBL620825,,
3691,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL872930,,
3692,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL620826,,
3693,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL620827,,
3694,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL620828,,
3695,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL620829,,
3696,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,722.0,BAO_0000219,Expert,,HEK293,10209,H,8,1,,CHEMBL620830,,
3697,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,Expert,,,10209,H,8,1,,CHEMBL620831,,
3698,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,Expert,,,10209,H,8,1,,CHEMBL620832,,
3699,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL621548,,
3700,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,BAO_0000019,Autocuration,,,10209,H,8,1,,CHEMBL621549,,
3701,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL621550,,
3702,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,449.0,BAO_0000219,Autocuration,,CHO,10209,H,8,1,,CHEMBL621551,,
3703,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,BAO_0000019,Autocuration,,,10209,H,8,1,,CHEMBL621552,,
3704,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL857077,,
3705,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL618158,,
3706,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,643.0,BAO_0000219,Expert,,COS-7,10209,D,9,1,,CHEMBL618159,,
3707,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,643.0,BAO_0000219,Autocuration,,COS-7,10209,H,8,1,,CHEMBL875101,,
3708,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,722.0,BAO_0000219,Expert,,HEK293,10209,D,9,1,,CHEMBL618160,,
3709,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,BAO_0000357,Expert,,,10209,H,8,1,,CHEMBL618161,,
3710,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,722.0,BAO_0000219,Expert,,HEK293,10209,H,8,1,,CHEMBL618162,,
3711,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,BAO_0000357,Expert,,,10209,H,8,1,,CHEMBL618163,,
3712,Binding affinity against 5-hydroxytryptamine 7 human receptors,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL618164,,
3713,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,BAO_0000219,Expert,,,10209,H,8,1,,CHEMBL618165,,
3714,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL618166,,
3715,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL857989,,
3716,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619888,,
3717,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619889,,
3718,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619890,,
3719,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,449.0,BAO_0000219,Autocuration,,CHO,10209,H,8,1,,CHEMBL619891,,
3720,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619892,,
3721,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,722.0,BAO_0000219,Expert,,HEK293,10209,D,9,1,,CHEMBL619893,,
3722,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619894,,
3723,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,722.0,BAO_0000219,Intermediate,,HEK293,10209,D,9,1,,CHEMBL619895,,
3724,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,BAO_0000357,Intermediate,,,10209,D,9,1,,CHEMBL619896,,
3725,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,643.0,BAO_0000219,Autocuration,,COS-7,10209,H,8,1,,CHEMBL619897,,
3726,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619898,,
3727,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,722.0,BAO_0000219,Expert,,HEK293,10209,H,8,1,,CHEMBL619899,,
3728,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL619900,,
3729,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,722.0,BAO_0000219,Expert,,HEK293,10209,D,9,1,,CHEMBL619901,,
3730,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL620580,,
3731,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL620581,,
3732,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",722.0,BAO_0000219,Autocuration,,HEK293,10209,H,8,1,,CHEMBL620733,,
3733,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,BAO_0000357,Autocuration,,,10209,D,9,1,,CHEMBL620734,,
3734,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,Expert,,,10022,D,9,1,,CHEMBL620735,,
3735,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,BAO_0000019,Autocuration,,,10209,H,8,1,,CHEMBL620736,,
3736,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620737,,
3737,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620738,,
3738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620739,,
3739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620740,,
3740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620741,,
3741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620742,,
3742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620743,,
3743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620744,,
3744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620745,,
3745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620746,,
3746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620747,,
3747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620748,,
3748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620749,,
3749,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,11923,H,8,1,,CHEMBL620750,,
3750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,Expert,,,11923,D,9,1,,CHEMBL620751,,
3751,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,11923,H,8,1,,CHEMBL620752,,
3752,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,BAO_0000019,Autocuration,,,11923,H,8,1,,CHEMBL872929,,
3753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,BAO_0000357,Expert,,,11923,D,9,1,,CHEMBL620753,,
3754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,11923,D,9,1,,CHEMBL620754,,
3755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,449.0,BAO_0000219,Expert,,CHO,11923,D,9,1,,CHEMBL620755,,
3756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,11923,H,8,1,,CHEMBL620756,,
3757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,11923,H,8,1,,CHEMBL620757,,
3758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620758,,
3759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620759,,
3760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620760,,
3761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,449.0,BAO_0000219,Autocuration,,CHO,11923,H,8,1,,CHEMBL620761,,
3762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,BAO_0000221,Autocuration,,,11923,H,8,1,,CHEMBL620762,2116.0,
3763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,BAO_0000221,Autocuration,,,11923,H,8,1,,CHEMBL620763,2116.0,
3764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,BAO_0000221,Autocuration,,,11923,H,8,1,,CHEMBL620764,2116.0,
3765,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,BAO_0000249,Expert,Membranes,,11923,D,9,1,,CHEMBL857990,,
3766,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,Autocuration,,,11923,H,8,1,,CHEMBL620765,,
3767,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,BAO_0000357,Expert,,,11923,H,8,1,,CHEMBL620766,,
3768,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,BAO_0000019,Expert,,,11923,H,8,1,,CHEMBL620767,1898.0,
3769,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,Autocuration,,,11923,H,8,1,,CHEMBL620768,,
3770,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,BAO_0000249,Expert,,,11923,H,8,1,,CHEMBL619051,1898.0,
3771,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,11923,H,8,1,,CHEMBL619052,,
3772,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,722.0,BAO_0000219,Expert,,HEK293,11923,D,9,1,,CHEMBL619053,,
3773,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,722.0,BAO_0000219,Expert,,HEK293,11923,D,9,1,,CHEMBL619703,,
3774,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,722.0,BAO_0000219,Autocuration,,HEK293,11923,D,9,1,,CHEMBL619704,,
3775,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,H,8,1,,CHEMBL619851,,
3776,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619852,,
3777,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619853,,
3778,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,D,9,1,,CHEMBL619854,,
3779,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,H,8,1,,CHEMBL619855,,
3780,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619856,,
3781,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619857,,
3782,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,BAO_0000019,Expert,,,10209,H,8,1,,CHEMBL619858,,
3783,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619859,,
3784,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619860,,
3785,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619861,,
3786,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,H,8,1,,CHEMBL619862,,
3787,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619863,,
3788,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619864,,
3789,Binding affinities against 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL872928,,
3790,Binding affinities towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619865,,
3791,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,Expert,,,10209,H,8,1,,CHEMBL619866,,
3792,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,BAO_0000357,Autocuration,,,10209,H,8,1,,CHEMBL619867,,
3793,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,BAO_0000221,Autocuration,,,10209,H,8,1,,CHEMBL619868,2116.0,
3794,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619869,,
3795,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,BAO_0000019,Expert,,,55,D,9,1,,CHEMBL619870,,
3796,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619871,,
3797,In vitro inhibition of human recombinant lipoxygenase enzyme,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619872,,
3798,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619873,,
3799,Inhibition of 5-lipoxygenase in human whole blood.,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL619874,178.0,
3800,Inhibition of 5-lipoxygenase in human whole blood.,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL619875,178.0,
3801,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619876,,
3802,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619877,,
3803,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,BAO_0000219,Expert,,,55,H,8,1,,CHEMBL619878,,
3804,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619879,178.0,
3805,In vitro inhibition of 5-lipoxygenase from human polymorphs,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619880,,
3806,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619881,,
3807,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL619882,,
3808,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619883,,
3809,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),,BAO_0000357,Expert,,,55,D,9,1,,CHEMBL619884,178.0,
3810,In vitro potency against human 5-Lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL619885,,
3811,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,BAO_0000019,Expert,,,55,D,9,1,,CHEMBL619886,,
3812,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619887,178.0,
3813,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL875097,,
3814,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618001,,
3815,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618002,,
3816,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618003,,
3817,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618004,,
3818,Inhibition of human 5-lipoxygenase in human cells,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618005,,
3819,Inhibition of human neutrophil 5-lipoxygenase,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618006,,
3820,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL875086,,
3821,Inhibition of 5-lipoxygenase from human whole blood,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618007,178.0,
3822,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618008,,
3823,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618009,,
3824,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618010,,
3825,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618011,,
3826,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618012,,
3827,Tested against 5-lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL882927,,
3828,Tested for activity against 5-Lipoxygenase (5-LO),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618013,,
3829,Tested for activity against 5-lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618014,,
3830,Tested for inhibition of 5-HPETE production by human 5-LO,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618015,,
3831,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618016,,
3832,Inhibition of Human 5-lipoxygenase,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618017,,
3833,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618018,,
3834,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL875087,,
3835,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618019,,
3836,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618020,,
3837,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618021,,
3838,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618022,178.0,
3839,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618023,,
3840,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618024,,
3841,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,BAO_0000019,Expert,,,55,H,8,1,,CHEMBL873950,,
3842,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618025,,
3843,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618026,,
3844,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618027,,
3845,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618028,,
3846,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL618029,,
3847,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618030,,
3848,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618031,,
3849,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618032,,
3850,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618033,,
3851,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618034,,
3852,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL875088,,
3853,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618035,,
3854,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618036,,
3855,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618037,,
3856,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618038,,
3857,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618761,,
3858,Inhibition of lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618762,,
3859,Inhibition of lipoxygenase at the concentration of 1 uM,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618763,,
3860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618764,,
3861,Inhibition of 5-Lipoxygenase (5-LOX),,BAO_0000357,Expert,,,55,D,9,1,,CHEMBL618765,,
3862,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,Expert,,,17087,H,8,1,,CHEMBL618766,,
3863,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,Expert,,,17087,H,8,1,,CHEMBL618767,,
3864,Inhibitory activity against lipoxygenase-2 in mice,,BAO_0000357,Autocuration,,,17087,H,8,1,,CHEMBL619380,,
3865,Inhibitory activity against murine lipoxygenase-2.,,BAO_0000357,Expert,,,17087,H,8,1,,CHEMBL619381,,
3866,Inhibition of 5-lipoxygenase from mouse macrophage,,BAO_0000357,Expert,,,17087,D,9,1,,CHEMBL619382,,
3867,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,BAO_0000357,Autocuration,,,17087,H,8,1,,CHEMBL619383,,
3868,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619384,,
3869,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619385,,
3870,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL882928,,
3871,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,BAO_0000019,Expert,,,12166,D,9,1,,CHEMBL619386,,
3872,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619387,,
3873,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619388,,
3874,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619389,,
3875,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619390,,
3876,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619391,,
3877,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619392,,
3878,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619393,,
3879,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619394,,
3880,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619395,,
3881,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619396,,
3882,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619397,,
3883,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619398,,
3884,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619399,,
3885,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619400,,
3886,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619401,,
3887,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619402,,
3888,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,663.0,BAO_0000219,Expert,,RBL-2H3,12166,D,9,1,,CHEMBL619403,,
3889,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619404,,
3890,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619405,,
3891,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619406,,
3892,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL619407,,
3893,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619408,,
3894,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619409,,
3895,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619410,,
3896,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619753,,
3897,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619754,,
3898,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619903,,
3899,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619904,,
3900,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619905,,
3901,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619906,,
3902,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619907,,
3903,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619908,,
3904,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619909,,
3905,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619910,,
3906,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL882929,,
3907,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619911,,
3908,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619912,,
3909,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,Expert,,,12166,D,9,1,,CHEMBL619913,,
3910,In vitro inhibitory activity against RBL-1 5-LO,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619914,,
3911,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619915,,
3912,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619916,,
3913,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,BAO_0000218,Autocuration,,,12166,H,8,1,,CHEMBL619917,,
3914,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619918,,
3915,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,BAO_0000218,Autocuration,,,12166,H,8,1,,CHEMBL619919,,
3916,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL883710,,
3917,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619920,178.0,
3918,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619921,,
3919,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619922,,
3920,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL619923,,
3921,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619924,,
3922,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619925,,
3923,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619926,,
3924,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619927,,
3925,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619928,,
3926,In vitro inhibition of RBL-1 5-lipoxygenase,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619929,,
3927,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL875089,,
3928,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619930,,
3929,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619931,,
3930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619932,,
3931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619933,,
3932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619934,,
3933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619935,,
3934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619936,,
3935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619937,,
3936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619938,,
3937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619939,,
3938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619940,,
3939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL875090,,
3940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619941,,
3941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619942,,
3942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL883711,,
3943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619943,,
3944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619944,,
3945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619945,,
3946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619946,,
3947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619947,,
3948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619948,,
3949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619949,,
3950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619950,,
3951,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL618050,,
3952,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,663.0,BAO_0000219,Expert,,RBL-2H3,12166,H,8,1,,CHEMBL875091,,
3953,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,663.0,BAO_0000219,Expert,,RBL-2H3,12166,H,8,1,,CHEMBL618051,,
3954,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL618052,,
3955,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL618053,,
3956,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL618054,,
3957,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL618055,,
3958,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL618056,,
3959,In vitro inhibitory activity against 5-lipoxygenase was determined,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL618057,,
3960,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618058,,
3961,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL618059,,
3962,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,BAO_0000019,Expert,,,12166,D,9,1,,CHEMBL618060,,
3963,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618061,,
3964,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL618062,,
3965,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL618063,,
3966,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL618064,,
3967,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL618065,,
3968,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL618066,,
3969,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618067,,
3970,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618068,,
3971,Inhibition of 5-lipoxygenase in rat RBL-1 cells,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL618069,,
3972,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL618070,,
3973,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL618071,349.0,
3974,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619247,349.0,
3975,Approximate dose levels for a half maximal reduction of 5-HTP levels,,BAO_0000019,Autocuration,,,10825,H,8,1,,CHEMBL619248,,
3976,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL619249,10000000.0,
3977,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,BAO_0000221,Autocuration,,,10576,H,8,1,,CHEMBL619250,10000000.0,
3978,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,Autocuration,,,10577,H,8,1,,CHEMBL619251,,
3979,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619252,178.0,
3980,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL619253,178.0,
3981,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL619254,,
3982,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,BAO_0000219,Expert,,,17140,H,8,1,,CHEMBL619255,,
3983,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,BAO_0000219,Expert,,,17140,H,8,1,,CHEMBL619256,,
3984,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,BAO_0000219,Autocuration,,,17140,H,8,1,,CHEMBL875418,,
3985,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,Expert,,,17140,H,8,1,,CHEMBL619257,,
3986,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,Autocuration,,,17140,H,8,1,,CHEMBL619258,,
3987,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,BAO_0000357,Expert,,,17140,H,8,1,,CHEMBL619259,,
3988,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,BAO_0000357,Expert,,,17140,H,8,1,,CHEMBL619260,,
3989,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619261,178.0,
3990,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619263,178.0,
3991,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619264,178.0,
3992,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619265,178.0,
3993,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619266,178.0,
3994,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619902,178.0,
3995,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620058,178.0,
3996,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620059,178.0,
3997,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620060,178.0,
3998,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620061,178.0,
3999,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620062,178.0,
4000,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620063,178.0,
4001,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620064,178.0,
4002,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620065,178.0,
4003,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620066,178.0,
4004,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620067,178.0,
4005,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620068,178.0,
4006,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620069,178.0,
4007,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620070,178.0,
4008,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620071,178.0,
4009,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620072,178.0,
4010,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620036,178.0,
4011,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL857702,178.0,
4012,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620037,178.0,
4013,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620038,178.0,
4014,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620039,178.0,
4015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620040,178.0,
4016,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620041,178.0,
4017,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620042,178.0,
4018,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620043,178.0,
4019,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620044,178.0,
4020,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620045,178.0,
4021,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620046,178.0,
4022,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620047,178.0,
4023,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620048,178.0,
4024,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL857703,178.0,
4025,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620049,178.0,
4026,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620050,178.0,
4027,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620051,178.0,
4028,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619213,178.0,
4029,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619214,178.0,
4030,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619804,178.0,
4031,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619805,178.0,
4032,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619806,178.0,
4033,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619807,178.0,
4034,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619808,178.0,
4035,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619809,,
4036,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619810,,
4037,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL619811,,
4038,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620769,,
4039,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620770,,
4040,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620771,,
4041,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620772,,
4042,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620773,,
4043,Ability to inhibit 5-lipoxygenase in guinea pig,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620774,,
4044,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL620775,,
4045,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620776,,
4046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",,BAO_0000218,Autocuration,,,55,H,8,1,,CHEMBL620777,178.0,
4047,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620778,,
4048,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620779,,
4049,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,Expert,,,55,H,8,1,,CHEMBL621500,,
4050,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,Expert,,,55,H,8,1,,CHEMBL621501,,
4051,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618098,,
4052,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618099,,
4053,Inhibitory activity against 5-lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618100,,
4054,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618101,,
4055,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618102,,
4056,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618103,,
4057,Inhibitory activity uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618104,,
4058,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,BAO_0000219,Autocuration,,,55,H,8,1,,CHEMBL883712,,
4059,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618105,,
4060,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618106,,
4061,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618107,,
4062,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618108,,
4063,Inhibitory activity uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618109,,
4064,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618110,,
4065,Inhibitory activity uM,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618111,,
4066,Inhibitory activity uM,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618112,,
4067,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,Autocuration,,,55,H,8,1,,CHEMBL618113,,
4068,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618114,,
4069,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,,BAO_0000221,Expert,,,55,H,8,1,,CHEMBL620871,2116.0,
4070,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620872,,
4071,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620873,,
4072,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL620874,,
4073,In vitro inhibition of human 5-Lipoxygenase.,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL620875,,
4074,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620876,2107.0,
4075,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620877,2107.0,
4076,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL857854,2107.0,
4077,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620878,2107.0,
4078,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620879,2107.0,
4079,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620880,2107.0,
4080,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620881,2107.0,
4081,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620882,2107.0,
4082,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620883,2107.0,
4083,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620884,2107.0,
4084,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620885,2107.0,
4085,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620886,2107.0,
4086,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620887,2107.0,
4087,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618039,2107.0,
4088,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618040,2107.0,
4089,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618041,2107.0,
4090,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618216,2107.0,
4091,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618217,2107.0,
4092,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618218,2107.0,
4093,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618219,2107.0,
4094,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618220,2107.0,
4095,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618221,2107.0,
4096,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618222,2107.0,
4097,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618223,2107.0,
4098,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618224,2107.0,
4099,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618225,2107.0,
4100,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618226,2107.0,
4101,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618227,2107.0,
4102,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618228,2107.0,
4103,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618229,2107.0,
4104,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618230,2107.0,
4105,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618231,2107.0,
4106,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618232,2107.0,
4107,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618233,2107.0,
4108,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618234,2107.0,
4109,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618235,2107.0,
4110,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618115,2107.0,
4111,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618116,2107.0,
4112,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL618117,2107.0,
4113,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619968,2107.0,
4114,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619969,2107.0,
4115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619970,2107.0,
4116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619971,2107.0,
4117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619972,2107.0,
4118,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619973,2107.0,
4119,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619974,2107.0,
4120,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619975,2107.0,
4121,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619976,,
4122,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619977,2107.0,
4123,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619978,2107.0,
4124,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619979,2107.0,
4125,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619980,2107.0,
4126,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619981,2107.0,
4127,In vitro inhibition of 7226/S myeloma cancer cell line,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619982,,
4128,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),993.0,BAO_0000219,Intermediate,,BEL-7404 tumor cell line,80698,N,1,1,,CHEMBL619983,,
4129,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL620031,,
4130,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL620032,,
4131,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,505.0,BAO_0000219,Expert,,V79,81264,N,1,1,,CHEMBL620033,,
4132,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,505.0,BAO_0000219,Expert,,V79,81264,N,1,1,,CHEMBL620034,,
4133,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1119.0,BAO_0000219,Intermediate,,7800C1 cell line,80635,N,1,1,,CHEMBL620035,,
4134,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1119.0,BAO_0000219,Intermediate,,7800C1 cell line,80635,N,1,1,,CHEMBL618318,,
4135,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1119.0,BAO_0000219,Intermediate,,7800C1 cell line,80635,N,1,1,,CHEMBL618319,,
4136,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1119.0,BAO_0000219,Intermediate,,7800C1 cell line,80635,N,1,1,,CHEMBL618320,,
4137,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1119.0,BAO_0000219,Intermediate,,7800C1 cell line,80635,N,1,1,,CHEMBL618321,,
4138,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1119.0,BAO_0000219,Intermediate,,7800C1 cell line,80635,N,1,1,,CHEMBL883118,,
4139,In vitro antitumor activity against renal 786-0 tumor cell lines,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL883795,,
4140,Cytotoxic activity against 786-0 Renal cancer cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL618322,,
4141,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL618323,,
4142,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL618324,,
4143,In vitro antitumor activity against human renal 786-0 cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL618325,,
4144,Inhibition of Renal cancer in 786-0 cancer cell lines,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL875416,,
4145,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL618326,,
4146,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL618327,,
4147,inhibition of the growth of renal cancer(786-0) cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619215,,
4148,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619216,,
4149,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619217,,
4150,The IC50 value was measured on 786-0 cell line in ovarian tumor,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619218,,
4151,The IC50 value was measured on 786-0 cell line in ovarian tumor t,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619219,,
4152,The IC50 value was measured on 786-0 cell line in renal tumor type.,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619220,,
4153,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619221,,
4154,Tested for cytotoxic activity against renal cancer 786-0 cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619222,,
4155,Compound was tested for growth inhibitory activity against 786-0 cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL857454,,
4156,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619223,,
4157,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619224,,
4158,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619225,,
4159,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619226,,
4160,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619227,,
4161,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619228,,
4162,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL619229,,
4163,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619230,,
4164,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619231,,
4165,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619232,,
4166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619233,,
4167,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619234,,
4168,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619235,,
4169,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,BAO_0000019,Expert,,,12166,D,9,1,,CHEMBL619236,,
4170,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619237,,
4171,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619238,,
4172,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL619239,,
4173,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619240,,
4174,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL875417,,
4175,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619241,,
4176,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619242,,
4177,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL883796,,
4178,Tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619243,,
4179,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL619244,,
4180,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619245,,
4181,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619246,,
4182,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619984,,
4183,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619985,,
4184,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619986,,
4185,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL619987,,
4186,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,BAO_0000218,Autocuration,,,12166,H,8,1,,CHEMBL619988,,
4187,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619989,,
4188,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL619990,,
4189,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL619991,,
4190,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL619992,,
4191,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,BAO_0000218,Autocuration,,,12166,H,8,1,,CHEMBL619993,,
4192,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,663.0,BAO_0000219,Autocuration,,RBL-2H3,12166,H,8,1,,CHEMBL619994,,
4193,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,663.0,BAO_0000219,Autocuration,,RBL-2H3,12166,H,8,1,,CHEMBL619995,,
4194,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619996,,
4195,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619997,,
4196,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619998,,
4197,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,Expert,,,12166,H,8,1,,CHEMBL619999,,
4198,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620000,,
4199,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620001,,
4200,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,BAO_0000357,Expert,,,12166,D,9,1,,CHEMBL620002,,
4201,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620003,,
4202,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL620004,,
4203,Compound was evaluated for the inhibition of 5-lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL874063,,
4204,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620005,,
4205,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620006,,
4206,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620007,,
4207,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620008,,
4208,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL620009,,
4209,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620010,,
4210,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620011,,
4211,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620677,,
4212,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620678,,
4213,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620679,,
4214,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620680,,
4215,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,Expert,,,12166,D,9,1,,CHEMBL620838,,
4216,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL620839,,
4217,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL620840,,
4218,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL620841,,
4219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620842,,
4220,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620843,,
4221,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620844,,
4222,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620845,,
4223,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620846,,
4224,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL873951,,
4225,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL620847,,
4226,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620848,,
4227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620849,,
4228,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620850,,
4229,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620851,,
4230,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620852,,
4231,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL875098,,
4232,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL620853,,
4233,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620854,,
4234,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620855,,
4235,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL839884,,
4236,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620856,,
4237,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620857,,
4238,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620858,,
4239,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620859,,
4240,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620860,,
4241,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620861,,
4242,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,BAO_0000357,Expert,,,12166,H,8,1,,CHEMBL620862,,
4243,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL620863,,
4244,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL620864,,
4245,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620865,,
4246,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620866,,
4247,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,663.0,BAO_0000219,Autocuration,,RBL-2H3,12166,H,8,1,,CHEMBL620867,,
4248,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,663.0,BAO_0000219,Autocuration,,RBL-2H3,12166,H,8,1,,CHEMBL620868,,
4249,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,663.0,BAO_0000219,Autocuration,,RBL-2H3,12166,H,8,1,,CHEMBL620869,,
4250,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL873952,,
4251,The compound was tested for inhibition of isolated 5-lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL875099,,
4252,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,663.0,BAO_0000219,Autocuration,,RBL-2H3,12166,H,8,1,,CHEMBL620870,,
4253,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL618261,,
4254,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL618262,,
4255,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619428,,
4256,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619429,,
4257,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL619430,,
4258,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620017,,
4259,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620018,,
4260,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620019,,
4261,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620020,,
4262,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620021,,
4263,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620022,,
4264,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620023,,
4265,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620024,,
4266,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620025,,
4267,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620026,,
4268,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL620027,,
4269,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,BAO_0000019,Expert,,,12166,D,9,1,,CHEMBL620028,,
4270,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL620029,,
4271,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL620030,,
4272,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL875415,,
4273,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618256,,
4274,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618257,,
4275,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618258,,
4276,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618259,,
4277,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,Autocuration,,,12166,H,8,1,,CHEMBL618260,,
4278,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618215,,
4279,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618390,,
4280,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618391,,
4281,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618392,,
4282,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618393,,
4283,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,BAO_0000219,Autocuration,,,12166,H,8,1,,CHEMBL618394,,
4284,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),702.0,BAO_0000219,Expert,,RBL-1,12166,H,8,1,,CHEMBL618395,,
4285,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL618396,,
4286,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),702.0,BAO_0000219,Expert,,RBL-1,12166,D,9,1,,CHEMBL858253,,
4287,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,Autocuration,,,12166,D,9,1,,CHEMBL618397,,
4288,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,BAO_0000357,Autocuration,,,12054,H,8,1,,CHEMBL618398,,
4289,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL618399,,
4290,In vitro inhibition of 5-Lipoxygenase; Inactive.,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618400,,
4291,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618401,,
4292,Inhibitory concentration against 5-lipoxygenase; No inhibition,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618402,,
4293,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,702.0,BAO_0000219,Autocuration,,RBL-1,55,H,8,1,,CHEMBL876400,,
4294,Inhibitory activity against 5-lipoxygenase.,,BAO_0000357,Expert,,,55,H,8,1,,CHEMBL618403,,
4295,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618404,,
4296,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618405,,
4297,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618406,,
4298,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,BAO_0000019,Expert,,,55,H,8,1,,CHEMBL618407,,
4299,Tested for the inhibitory activity against 5-lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618408,,
4300,Compound was tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618409,,
4301,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618410,,
4302,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618411,,
4303,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,BAO_0000357,Autocuration,,,55,H,8,1,,CHEMBL618412,,
4304,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,702.0,BAO_0000219,Autocuration,,RBL-1,12166,H,8,1,,CHEMBL618413,,
4305,,,BAO_0000357,Autocuration,,,12166,H,8,1,,CHEMBL618414,,
4306,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,BAO_0000357,Autocuration,,,10102,H,8,1,,CHEMBL618415,,
4307,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,BAO_0000019,Autocuration,,,10102,H,8,1,,CHEMBL618416,,
4308,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,BAO_0000357,Autocuration,,,10102,H,8,1,,CHEMBL876401,,
4309,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,BAO_0000357,Expert,,,10102,H,8,1,,CHEMBL618417,,
4310,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,BAO_0000357,Autocuration,,,10102,H,8,1,,CHEMBL618418,,
4311,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,BAO_0000357,Autocuration,,,10102,H,8,1,,CHEMBL618419,,
4312,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,BAO_0000357,Autocuration,,,10102,H,8,1,,CHEMBL618420,,
4313,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,BAO_0000357,Autocuration,,,10102,H,8,1,,CHEMBL618421,,
4314,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,BAO_0000019,Autocuration,,,11238,H,8,1,,CHEMBL618422,,
4315,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,BAO_0000019,Autocuration,,,11238,H,8,1,,CHEMBL618423,,
4316,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,BAO_0000019,Autocuration,,,11238,H,8,1,,CHEMBL618424,,
4317,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,BAO_0000220,Intermediate,,,100284,S,2,1,,CHEMBL618425,,
4318,The dark toxicity against 543 human galactophore carcinoma cells,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL618426,,
4319,Tested in vitro for cytotoxicity against 56 human tumor cell lines,390.0,BAO_0000219,Expert,,Panel (56 tumour cell lines),80623,N,1,1,,CHEMBL618427,,
4320,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,345.0,BAO_0000219,Expert,,5637,80008,N,1,1,,CHEMBL618428,,
4321,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,345.0,BAO_0000219,Intermediate,,5637,80008,N,1,1,,CHEMBL618429,,
4322,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",345.0,BAO_0000219,Intermediate,,5637,80008,N,1,1,,CHEMBL618430,,
4323,Growth inhibition against human 5637 cell lines,345.0,BAO_0000219,Expert,,5637,80008,N,1,1,,CHEMBL618431,,
4324,Antitumor activity against human bladder carcinoma 5637 cells.,345.0,BAO_0000219,Expert,,5637,80008,N,1,1,,CHEMBL883799,,
4325,Antitumor activity against human bladder carcinoma 5637 cells,345.0,BAO_0000219,Intermediate,,5637,80008,N,1,1,,CHEMBL618432,,
4326,Antitumor activity against human bladder carcinoma 5637 cells,345.0,BAO_0000219,Intermediate,,5637,80008,N,1,1,,CHEMBL618433,,
4327,In vitro inhibition of bovine trypsin(Trp).,,BAO_0000357,Expert,,,10443,D,9,1,,CHEMBL618434,,
4328,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,407.0,BAO_0000219,Expert,,CV-1,240,H,8,1,,CHEMBL618435,,
4329,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,BAO_0000357,Autocuration,,,10577,H,8,1,,CHEMBL876402,,
4330,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,BAO_0000019,Autocuration,,,104698,H,6,1,,CHEMBL618436,,
4331,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL618437,,
4332,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,BAO_0000357,Intermediate,,,20033,D,9,1,,CHEMBL618438,,
4333,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,Expert,Microsomes,,17045,H,8,1,,CHEMBL883800,,
4334,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,Expert,Microsomes,,17045,H,8,1,,CHEMBL618439,,
4335,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL618440,,
4336,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL618441,,
4337,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,BAO_0000019,Expert,,,11938,H,8,1,,CHEMBL618442,,
4338,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,BAO_0000019,Autocuration,,,11938,H,8,1,,CHEMBL618443,,
4339,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,BAO_0000019,Expert,,,11938,H,8,1,,CHEMBL619158,,
4340,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,BAO_0000019,Autocuration,,,11938,H,8,1,,CHEMBL620974,,
4341,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,BAO_0000357,Autocuration,,,11938,H,8,1,,CHEMBL620975,,
4342,Average inhibitory concentration against 60 human cell lines was reported,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL620976,,
4343,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,BAO_0000019,Expert,,,22226,U,0,1,,CHEMBL620977,,
4344,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,542.0,BAO_0000219,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),80315,N,1,1,,CHEMBL620978,,
4345,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,542.0,BAO_0000219,Intermediate,,Panel NCI-60 (60 carcinoma cell lines),80315,N,1,1,,CHEMBL620979,,
4346,In vitro mean growth inhibitory activity against 60-cell panel,542.0,BAO_0000219,Expert,,Panel NCI-60 (60 carcinoma cell lines),80315,N,1,1,,CHEMBL620980,,
4347,In vitro mean growth lethal concentration against 60-cell panel,542.0,BAO_0000219,Expert,,Panel NCI-60 (60 carcinoma cell lines),80315,N,1,1,,CHEMBL620981,,
4348,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,542.0,BAO_0000219,Expert,,Panel NCI-60 (60 carcinoma cell lines),80315,N,1,1,,CHEMBL620982,,
4349,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,542.0,BAO_0000219,Expert,,Panel NCI-60 (60 carcinoma cell lines),80315,N,1,1,,CHEMBL620983,,
4350,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,Autocuration,,,104775,H,4,1,,CHEMBL620984,,
4351,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,Autocuration,,,104775,H,4,1,,CHEMBL620985,,
4352,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,BAO_0000357,Expert,,,275,H,8,1,,CHEMBL620986,,
4353,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,BAO_0000218,Expert,,,50425,N,1,1,,CHEMBL620987,,
4354,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,BAO_0000218,Expert,,,50425,N,1,1,,CHEMBL620988,,
4355,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,Expert,,,50425,N,1,1,,CHEMBL620989,,
4356,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,Expert,,,50425,N,1,1,,CHEMBL620990,,
4357,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,Intermediate,,,50425,N,1,1,,CHEMBL620991,,
4358,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL620992,,
4359,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL620993,,
4360,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL620994,,
4361,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL620995,,
4362,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL620996,,
4363,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL875581,,
4364,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620997,,
4365,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620998,,
4366,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620999,,
4367,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621000,,
4368,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621001,,
4369,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621002,,
4370,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621003,,
4371,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621004,,
4372,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621005,,
4373,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621006,,
4374,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621007,,
4375,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621008,,
4376,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621009,,
4377,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL857705,,
4378,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619828,,
4379,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619829,,
4380,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619830,,
4381,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619831,,
4382,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619832,,
4383,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619833,,
4384,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619834,,
4385,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619835,,
4386,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619836,,
4387,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL619837,,
4388,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619838,,
4389,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619839,,
4390,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL619840,,
4391,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL619841,,
4392,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),850.0,BAO_0000218,Expert,,6C3HED,80628,N,1,1,,CHEMBL857704,,
4393,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),850.0,BAO_0000218,Intermediate,,6C3HED,80628,N,1,1,,CHEMBL619842,,
4394,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),850.0,BAO_0000218,Expert,,6C3HED,80628,N,1,1,,CHEMBL619843,,
4395,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL619844,,
4396,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL857855,2107.0,
4397,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619845,2107.0,
4398,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619846,2107.0,
4399,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619847,2107.0,
4400,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL619848,2107.0,
4401,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620893,2107.0,
4402,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620894,2107.0,
4403,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620895,2107.0,
4404,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620896,2107.0,
4405,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620897,2107.0,
4406,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620898,2107.0,
4407,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,,BAO_0000251,Autocuration,Microsomes,,22226,U,0,1,,CHEMBL620899,2107.0,
4408,The apparent total plasma clearance in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620900,1969.0,
4409,Compound was evaluated for Hepatic clearance in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620901,,
4410,Lower clearance in monkey (i.v.) at 0.5 mpk,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620902,,
4411,Plasma clearance in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620903,,
4412,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620904,,
4413,Plasma clearance of compound was determined in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620905,,
4414,Plasma clearance was calculated in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620906,,
4415,Plasma clearance in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875420,,
4416,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620907,,
4417,Plasma clearance was evaluated in rhesus,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620908,,
4418,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620909,,
4419,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620910,,
4420,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620911,,
4421,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620912,,
4422,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620913,,
4423,Cmax in monkey after administration of 1 mg/kg iv,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620914,,
4424,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620915,,
4425,Cmax in cynomolgus monkey by iv administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620916,,
4426,Cmax in cynomolgus monkey by po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620917,,
4427,Cmax value evaluated in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620918,,
4428,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620919,,
4429,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620920,1969.0,
4430,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620921,1969.0,
4431,Maximal plasma concentration in squirrel monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620922,1969.0,
4432,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620923,,
4433,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620924,1969.0,
4434,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620925,,
4435,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620926,,
4436,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620927,,
4437,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620928,,
4438,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620929,,
4439,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620930,1969.0,
4440,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620931,,
4441,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620932,,
4442,Absolute bioavailability was evaluated in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620933,,
4443,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620934,,
4444,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620935,,
4445,Bioavailability of compound was determined in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620936,,
4446,Bioavailability determined after oral administration in marmoset,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620937,,
4447,Oral bioavailability in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620938,,
4448,Bioavailability in monkey (p.o.) at 2.0 mpk,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620939,,
4449,Bioavailability was evaluated after oral administration in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620940,,
4450,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620941,,
4451,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620942,,
4452,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620943,,
4453,Bioavailability of the compound was determined in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620944,,
4454,Bioavailability in squirrel monkey (dose 5 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620945,,
4455,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620946,,
4456,Oral bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620947,,
4457,Compound was tested for bioavailability in squirrel monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620948,,
4458,Oral bioavailability in Rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620949,,
4459,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620950,,
4460,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620951,,
4461,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620952,,
4462,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875421,,
4463,Oral bioavailability of compound at 5 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620953,,
4464,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873491,,
4465,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620954,,
4466,Plasma half life determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620955,1969.0,
4467,Plasma half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618097,1969.0,
4468,Plasma half-life in Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618268,1969.0,
4469,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618269,1969.0,
4470,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618270,1969.0,
4471,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618271,,
4472,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873493,,
4473,Tested for the half life period in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621031,,
4474,Tested for the half life period in dog at dosage of 10 mpk,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621032,,
4475,The compound was tested for half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621033,,
4476,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621034,1969.0,
4477,The half life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621035,,
4478,The plasma half-life in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621036,1969.0,
4479,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621037,1969.0,
4480,Half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619812,,
4481,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619813,,
4482,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873335,,
4483,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619814,,
4484,Cmax in ferrets after 30 mg/kg oral dose,,BAO_0000218,Expert,,,50506,N,1,1,,CHEMBL619815,,
4485,Emesis in ferrets at 30 mg/kg oral dose,,BAO_0000218,Expert,,,50506,N,1,1,,CHEMBL619816,,
4486,Bioavailability in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619817,,
4487,Volume of distribution in cynomolgus,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL619818,,
4488,AUC tested in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619819,1969.0,
4489,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619820,,
4490,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875419,,
4491,AUC in guinea pig after 3mg/kg oral dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619821,1969.0,
4492,Bioavailability in guinea pig was tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619822,,
4493,Tested for oral bioavailability in guinea pig at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619823,,
4494,Tested for the oral bioavailability of the compound,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619824,,
4495,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619825,,
4496,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619826,,
4497,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619827,2048.0,
4498,Cmax in guinea pig after 3mg/kg oral dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618167,,
4499,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618168,178.0,
4500,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618169,955.0,
4501,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618170,,
4502,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618171,160.0,
4503,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618172,2113.0,
4504,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618173,2107.0,
4505,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618174,,
4506,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875408,2106.0,
4507,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL839827,,
4508,Partition coefficient was measured as -log (counts per min ),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618175,,
4509,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618176,,
4510,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618177,,
4511,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618178,,
4512,"Tested for the half life period of the compound, intravenously",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618179,,
4513,Half-life was measured,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL873489,,
4514,The time required for onset of inotropy after addition of a single dose of delta F75,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618180,,
4515,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618181,,
4516,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618182,,
4517,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618183,,
4518,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618184,,
4519,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618185,,
4520,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618186,,
4521,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618187,,
4522,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618188,,
4523,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875409,,
4524,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618189,,
4525,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618190,178.0,
4526,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618191,178.0,
4527,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618192,178.0,
4528,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618193,10000001.0,
4529,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618194,10000001.0,
4530,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618195,10000001.0,
4531,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618196,955.0,
4532,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618197,955.0,
4533,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618198,955.0,
4534,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618199,948.0,
4535,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618200,948.0,
4536,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618201,948.0,
4537,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618202,160.0,
4538,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618203,160.0,
4539,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618204,160.0,
4540,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618205,2113.0,
4541,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618206,2113.0,
4542,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618207,2113.0,
4543,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618208,2107.0,
4544,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618932,2107.0,
4545,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618933,2107.0,
4546,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618934,2048.0,
4547,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618935,2048.0,
4548,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618936,2048.0,
4549,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618937,2385.0,
4550,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618938,2385.0,
4551,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619104,2385.0,
4552,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619105,2106.0,
4553,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619106,2106.0,
4554,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619107,2106.0,
4555,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875410,945.0,
4556,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619108,945.0,
4557,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619109,945.0,
4558,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619110,,
4559,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619111,,
4560,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619112,,
4561,MRT value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619113,,
4562,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619114,,
4563,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619115,,
4564,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619116,,
4565,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619117,,
4566,Compound was evaluated for cytotoxicity against A2780 cell lines.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619118,,
4567,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619119,,
4568,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619120,,
4569,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619121,,
4570,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619122,,
4571,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619123,,
4572,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619124,,
4573,Compound was evaluated for cytotoxicity against A2780 cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619125,,
4574,In vitro inhibitory activity against human tumor cell line A2780,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL875411,,
4575,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619126,,
4576,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619127,,
4577,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619128,,
4578,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619129,,
4579,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619130,,
4580,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619131,,
4581,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619132,,
4582,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,BAO_0000218,Expert,,A2780,81034,N,1,1,,CHEMBL619133,,
4583,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619134,,
4584,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619135,,
4585,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619136,,
4586,Relative resistance factor in A2780 cisplatin-resistant line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619137,,
4587,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL883713,,
4588,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL875412,,
4589,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,BAO_0000218,Expert,,A2780,81034,N,1,1,,CHEMBL619138,,
4590,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,478.0,BAO_0000218,Expert,,A2780,81034,N,1,1,,CHEMBL619262,,
4591,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619139,,
4592,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619140,,
4593,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619141,,
4594,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619142,,
4595,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619143,,
4596,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619144,,
4597,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619145,,
4598,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619146,,
4599,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619147,,
4600,Antiproliferative effect of compound on A2780/DX cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619148,,
4601,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619149,,
4602,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619150,,
4603,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619151,,
4604,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL883794,,
4605,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619152,,
4606,In vitro cytotoxicity against A2780ADR cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619153,,
4607,In vitro cytotoxicity against A2780CIS cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619154,,
4608,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619155,,
4609,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619156,,
4610,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619157,,
4611,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619797,,
4612,Oral bioavailability of compound in rhesus macaques,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619798,,
4613,Oral bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619799,,
4614,Oral bioavailability evaluated in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619800,,
4615,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619801,,
4616,Oral bioavailability in Rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619802,,
4617,Oral bioavailability was calculated in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619803,,
4618,Oral bioavailability in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619965,,
4619,Oral bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619966,,
4620,Oral bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619967,,
4621,Oral bioavailability in monkey (dose 1 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620073,,
4622,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620074,,
4623,Oral bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620075,,
4624,Oral bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620076,,
4625,Oral bioavailability in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620077,,
4626,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620078,,
4627,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620079,,
4628,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620080,,
4629,Oral bioavailability in Rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620081,,
4630,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620082,,
4631,Oral bioavailability in monkey at 10 mg/kg of the compound,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620083,,
4632,Bioavailability in Rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620084,,
4633,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620085,,
4634,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL874595,,
4635,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL873352,,
4636,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620086,,
4637,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620087,,
4638,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620088,,
4639,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620089,,
4640,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620090,,
4641,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620091,,
4642,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620092,,
4643,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620093,,
4644,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620094,,
4645,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620095,,
4646,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620096,,
4647,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620097,,
4648,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620098,,
4649,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620099,,
4650,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620100,,
4651,Elimination Half-life of compound was determined in monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620101,,
4652,Half life of compound was determined in rhesus monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620102,,
4653,Half life in monkey plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL620103,1969.0,
4654,Half life in monkey plasma; Not detected,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL620104,1969.0,
4655,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL874596,,
4656,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL873490,,
4657,Terminal half life of the compound.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620105,,
4658,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620780,,
4659,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620781,,
4660,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620956,,
4661,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620957,1088.0,
4662,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620958,1088.0,
4663,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620959,,
4664,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620960,,
4665,Volume of distribution was evaluated in rhesus,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620961,,
4666,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620962,,
4667,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620963,,
4668,Bioavailability in hamster was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620964,,
4669,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620965,,
4670,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620966,,
4671,Half life of compound was determined in hamster blood,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL620967,178.0,
4672,Michaelis-Menten constant of the compound.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620968,,
4673,Vmax value was measured at 0 uM concentration of silyl ether.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874597,,
4674,Vmax value was measured at 10 uM concentration of silyl ether.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620969,,
4675,Vmax value was measured at 5 uM concentration of silyl ether.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620970,,
4676,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,BAO_0000357,Expert,,,235,D,9,1,,CHEMBL620971,,
4677,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620972,,
4678,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620973,,
4679,Active metabolite of ifosfamide determined in humans; A-Active,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618243,,
4680,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618244,,
4681,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618245,,
4682,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618246,,
4683,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618247,,
4684,Compound was evaluated for oral bioavailability in human,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618248,,
4685,Metabolite of ifosfamide determined in urine; NF-Not found,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618249,1088.0,
4686,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618250,,
4687,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874598,,
4688,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618251,,
4689,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618252,,
4690,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618253,,
4691,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618254,,
4692,Percent of compound in healthy individuals (Group D),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618255,,
4693,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618983,2107.0,
4694,Binding towards human plasma protein at 10 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618984,,
4695,Binding towards human plasma protein at 100 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618985,,
4696,Human plasma protein binding activity was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618986,,
4697,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618987,,
4698,Percent binding of compound towards human plasma protein was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618988,,
4699,Plasma clearance in human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618989,2107.0,
4700,In vitro intrinsic clearance in human liver microsome,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618990,2107.0,
4701,In vitro intrinsic clearance in human liver microsome,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618991,2107.0,
4702,In vitro microsome metabolism clearance in human was determined,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL876725,,
4703,In vitro microsome metabolism clearance in human was determined; High,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618992,,
4704,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618993,,
4705,Pharmacokinetic property (clearance) in human liver microsome,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618994,2107.0,
4706,Plasma clearance in human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618995,2107.0,
4707,In vitro clearance in human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618996,2107.0,
4708,Intrinsic clearance in human liver microsomes was determined,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618997,2107.0,
4709,Intrinsic clearance in human liver microsomes was determined,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618998,2107.0,
4710,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618999,,
4711,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620223,,
4712,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620224,,
4713,Stability in human plasma 2 hr after incubation expressed as percent concentration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620225,,
4714,Stability in human plasma 4 hr after incubation expressed as percent concentration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620226,,
4715,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620227,1088.0,
4716,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876726,1088.0,
4717,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620228,1088.0,
4718,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620229,1088.0,
4719,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620230,,
4720,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620231,,
4721,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620232,,
4722,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620233,,
4723,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620234,,
4724,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620235,,
4725,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620236,,
4726,In vitro metabolic potential in mouse liver microsomes,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620237,2107.0,
4727,Ability of compound to bind to plasma protein was evaluated in HSA cells,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620238,,
4728,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620239,2369.0,
4729,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620240,955.0,
4730,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620241,955.0,
4731,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876727,,
4732,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620242,2113.0,
4733,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620243,,
4734,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620244,,
4735,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620245,1977.0,
4736,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620246,1977.0,
4737,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620247,1977.0,
4738,Half life of compound was determined in plasma of mice at 24 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620248,1969.0,
4739,Half life of compound was determined in plasma of mice at 40 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL873497,1969.0,
4740,Half life of compound was determined in plasma of mice at 5 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620249,1969.0,
4741,Half life after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620250,,
4742,Half life after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620251,,
4743,Half life after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620252,,
4744,Half life after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620253,,
4745,Half life after intravenous administration in mice at 23 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620254,,
4746,Half life after intravenous administration in mice at 24 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620255,,
4747,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620256,,
4748,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876728,,
4749,Maximum time required to reach Cp max was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620257,,
4750,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620258,,
4751,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620259,,
4752,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620260,,
4753,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620261,178.0,
4754,Half life at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620262,,
4755,Half life at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620263,,
4756,Half life in ob/ob mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620264,,
4757,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620265,,
4758,Half-life was measured in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620266,,
4759,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620267,,
4760,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619364,,
4761,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619365,,
4762,T2 in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619366,955.0,
4763,T2 in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619367,2113.0,
4764,T2 in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619368,2107.0,
4765,T2 in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619369,2048.0,
4766,T2 in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876729,2106.0,
4767,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619370,,
4768,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619371,,
4769,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619372,,
4770,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620012,,
4771,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620013,,
4772,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL620014,,
4773,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL620015,,
4774,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621010,,
4775,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621011,,
4776,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621012,,
4777,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621013,,
4778,In vitro cytotoxicity against A2780TAX cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621014,,
4779,In vitro inhibitory activity against human tumor cell line A2780cis,481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618154,,
4780,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618155,,
4781,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618156,,
4782,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618157,,
4783,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618328,,
4784,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618329,,
4785,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618330,,
4786,In vitro antitumor activity against A2780cisR cell line.,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618331,,
4787,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618332,,
4788,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618333,,
4789,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618334,,
4790,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618335,,
4791,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,BAO_0000019,Expert,,,11736,D,9,1,,CHEMBL618336,,
4792,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,Expert,,,11736,H,8,1,,CHEMBL618337,,
4793,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,Expert,,,11736,D,9,1,,CHEMBL618338,,
4794,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,722.0,BAO_0000219,Expert,,HEK293,278,D,9,1,,CHEMBL618339,,
4795,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,722.0,BAO_0000219,Expert,,HEK293,278,D,9,1,,CHEMBL618340,,
4796,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,BAO_0000019,Expert,,,11831,D,9,1,,CHEMBL618341,,
4797,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,Expert,,,11831,H,8,1,,CHEMBL618342,,
4798,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,Expert,,,11831,D,9,1,,CHEMBL618343,,
4799,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,BAO_0000357,Expert,,,280,H,8,1,,CHEMBL621038,,
4800,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),574.0,BAO_0000219,Autocuration,,T-cells,22226,U,0,1,,CHEMBL621039,,
4801,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,574.0,BAO_0000219,Autocuration,,T-cells,22226,U,0,1,,CHEMBL621040,,
4802,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL621041,,
4803,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL621042,,
4804,In vitro antitumor activity against A375cell line extracted form melanoma,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL621043,,
4805,Inhibition of cell growth in (A375) melan cell line,455.0,BAO_0000219,Expert,,A-375,80018,N,1,1,,CHEMBL621044,,
4806,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL621045,,
4807,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL621046,,
4808,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL621047,,
4809,Antiproliferative activity measured against A427 human lung carcinoma,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621048,,
4810,Antiproliferative activity measured against A427 human lung carcinoma,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL883798,,
4811,Cytotoxicity against lung carcinoma A427 tumor cell lines,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621049,,
4812,Inhibition of large cell lung carcinoma (A427),797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621050,,
4813,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621051,,
4814,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621052,,
4815,Inhibitory concentration in human lung carcinoma A427 cell line,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621053,,
4816,Inhibitory concentration in human lung carcinoma A427/VCR cell line,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL621054,,
4817,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621055,,
4818,Tested for volume of distribution upon iv administration to african green monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL876398,,
4819,Volume of distribution in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621056,,
4820,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621057,,
4821,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621058,,
4822,Pharmacokinetic property(Vdss) in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621059,,
4823,The distribution volume after intravenous administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621060,,
4824,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621061,,
4825,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621062,,
4826,Volume displacement was calculated in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621063,,
4827,Volume of distribution in steady state was determined in rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621064,,
4828,Volume of distribution of compound was determined in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621065,,
4829,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621066,,
4830,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621067,,
4831,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621068,,
4832,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL876399,,
4833,Volume distribution in monkey after administration of 1 mg/kg iv,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621069,,
4834,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621070,,
4835,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621071,,
4836,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621072,,
4837,Oral systemic bioavailability upon iv administration to african green monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618209,,
4838,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618210,,
4839,Baboon plasma free fraction. ,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618211,,
4840,Area under the curve was calculated in rhesus monkey after iv administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618212,,
4841,Area under the curve was calculated in rhesus monkey after peroral administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618213,,
4842,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618214,,
4843,Half life period in monkey after 5 mg/kg dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL873492,,
4844,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618272,,
4845,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618273,,
4846,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618274,1969.0,
4847,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618275,,
4848,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618276,,
4849,Compound was evaluated for terminal half life in monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618277,,
4850,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618278,,
4851,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618279,1969.0,
4852,Half life of compound was determined in squirrel monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618280,,
4853,Half life after iv administration in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618281,,
4854,Half life in monkey plasma after administration of 1 mg/kg iv,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618282,1969.0,
4855,Half life was calculated in rhesus monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618283,,
4856,Half life in monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618284,,
4857,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618285,,
4858,Half life was evaluated in rhesus,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618286,,
4859,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618287,,
4860,Half life period was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618288,,
4861,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL876393,,
4862,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618289,,
4863,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618290,,
4864,Half-life was calculated in monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618291,,
4865,Half-life in Squirrel monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618292,,
4866,Half-life in rhesus monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618293,,
4867,Half-life was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618294,,
4868,Half-life period after intravenous administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618295,,
4869,Half-life period after oral administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618296,,
4870,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618297,,
4871,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618298,1088.0,
4872,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618299,1088.0,
4873,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618300,1088.0,
4874,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618301,1088.0,
4875,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618302,1088.0,
4876,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876394,1088.0,
4877,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618303,1088.0,
4878,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618304,1088.0,
4879,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618305,,
4880,Oral bioavailability in human,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618306,,
4881,Compound was tested for human plasma protein binding,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618307,,
4882,Compound was tested for human plasma protein binding; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618308,,
4883,Protein binding activity of compound in human plasma; % Free,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618309,,
4884,Unbound fraction (plasma),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618310,,
4885,Half life for the hydrolysis of compound in human blood serum,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL873353,1969.0,
4886,Half life period in human plasma using phosphate buffer (0.08 M),,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618311,1969.0,
4887,Half life period in human plasma using phosphate buffer (0.1 M),,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618312,1969.0,
4888,Half-life in human plasma was determined,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618313,1969.0,
4889,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618314,,
4890,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618315,,
4891,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618316,,
4892,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618317,,
4893,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620138,,
4894,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL858280,,
4895,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620139,,
4896,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620140,,
4897,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620141,,
4898,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620142,,
4899,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620143,,
4900,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620144,,
4901,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620145,,
4902,Metabolism of compound in human microsomes; Trace,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620146,,
4903,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620147,2107.0,
4904,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620148,,
4905,In vitro metabolic potential in human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL620149,2107.0,
4906,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876412,,
4907,Tested for human plasma protein binding of the compound; Not tested,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619352,,
4908,Compound was tested for percent protein binding (PB) in human,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619353,,
4909,Protein binding in human plasma,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619354,1969.0,
4910,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619355,,
4911,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619356,,
4912,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619357,,
4913,In vitro rate of absorption observed as Caco-2 permeability in humans,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619358,,
4914,Cellular permeability of compound was determined in Caco-2 cells; High,495.0,BAO_0000219,Autocuration,,Caco-2,22224,U,0,1,,CHEMBL619359,,
4915,Permeability in Caco-2 cells of compound,495.0,BAO_0000219,Autocuration,,Caco-2,22224,U,0,1,,CHEMBL619360,,
4916,Permeability coefficient (A to B) in Caco-2 cell,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619361,,
4917,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619362,,
4918,Permeability coefficient (Papp) (Caco-2 cell monolayer),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619363,,
4919,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618942,,
4920,Compound was tested for protein binding in human plasma,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618943,,
4921,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618944,,
4922,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618945,1088.0,
4923,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618946,,
4924,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876413,,
4925,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618947,,
4926,Time taken to reach maximum concentration in plasma upon oral administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618948,1969.0,
4927,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618949,1969.0,
4928,Tmax after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618950,,
4929,Tmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618951,,
4930,Tmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618952,,
4931,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618953,,
4932,Tmax in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618954,955.0,
4933,Tmax in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618955,2113.0,
4934,Tmax in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618956,2107.0,
4935,Tmax in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618957,2048.0,
4936,Tmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618958,,
4937,Tmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618959,,
4938,Tmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618960,,
4939,Tmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876723,,
4940,Tmax in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618961,2106.0,
4941,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618962,,
4942,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618963,,
4943,Tmax value in IRC mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618964,,
4944,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618965,,
4945,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618966,,
4946,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618967,1088.0,
4947,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618968,1088.0,
4948,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618969,1088.0,
4949,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618970,,
4950,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618971,,
4951,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618972,,
4952,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618973,,
4953,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618974,,
4954,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618975,,
4955,Vd in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618976,,
4956,Volume of distribution in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618977,,
4957,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876724,,
4958,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618978,,
4959,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618979,,
4960,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618980,,
4961,Pharmacokinetic property (vdss) was measured in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618981,,
4962,Value distribution upon iv administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618982,,
4963,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620150,,
4964,Volume of distribution was evaluated in mice after intravenous administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620151,,
4965,Volume of distribution was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620152,,
4966,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620153,,
4967,Steady state volume of distribution was determined in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876395,,
4968,Volume distribution (steady state) of compound was determined in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620154,,
4969,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620155,,
4970,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620156,,
4971,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620157,,
4972,Biodistribution of compound (oxidized form) in in kidney tissue,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620158,2113.0,
4973,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620159,178.0,
4974,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620160,178.0,
4975,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620161,178.0,
4976,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL620162,,
4977,Inhibition of A431 human squamous cell carcinoma cell proliferation,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL620163,,
4978,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL620833,,
4979,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL876396,,
4980,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL620834,,
4981,Inhibition of A431 human carcinoma cell proliferation,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL620835,,
4982,In vitro inhibition of A431 (human carcinoma) cell basal growth.,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL620836,,
4983,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL620837,,
4984,In vitro cytotoxicity against epidermoid carcinoma cell line,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621017,,
4985,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",500.0,BAO_0000218,Expert,,A-431,9,D,9,1,,CHEMBL621018,,
4986,Antiproliferative activity of compound was measured on human tumor cell line A431.,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621019,,
4987,Antiproliferative effect of compound on A431 cell line expressing mutant p53,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621020,,
4988,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621021,,
4989,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,500.0,BAO_0000219,Expert,,A-431,9,H,8,1,,CHEMBL621022,,
4990,Tested for antiproliferative activity against human A431 cells,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL621023,,
4991,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621024,,
4992,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL621025,,
4993,Inhibition of A431 cell proliferation,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL621026,,
4994,Cytotoxic effect on A431 human epidermoid carcinoma cells,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL621027,,
4995,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL876397,,
4996,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL883797,,
4997,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621028,,
4998,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621029,,
4999,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621030,,
5000,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,BAO_0000219,Expert,,A-431,9,H,8,1,,CHEMBL621147,,
5001,In vivo antiproliferative activity against A431 cell line,500.0,BAO_0000218,Intermediate,,A-431,80852,N,1,1,,CHEMBL621148,,
5002,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621149,,
5003,Inhibition of A431 human epidermoid carcinoma cell proliferation,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL621150,,
5004,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621151,,
5005,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621152,,
5006,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621153,,
5007,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL884000,,
5008,Inhibition of EGFR overexpressing A431 cell proliferation,,BAO_0000019,Expert,,,9,D,9,1,,CHEMBL621154,,
5009,Inhibition of A431 cell proliferation,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL621155,,
5010,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621156,,
5011,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621157,,
5012,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),500.0,BAO_0000219,Expert,,A-431,9,H,8,1,,CHEMBL621158,,
5013,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621159,,
5014,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621160,,
5015,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621161,,
5016,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621162,,
5017,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621163,,
5018,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621164,,
5019,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621165,,
5020,Half-life period in cynomolgus monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619159,,
5021,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL619160,1969.0,
5022,Longer half-life in monkey (i.v.) at 0.5 mpk,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619161,,
5023,Plasma half life in monkey,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL619162,1969.0,
5024,Plasma half-life in rhesus monkey,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL619163,1969.0,
5025,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619164,1969.0,
5026,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619320,1969.0,
5027,Tested for half life upon iv administration to african green monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619321,,
5028,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL873336,,
5029,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619322,,
5030,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619323,,
5031,The time for peak concentration value after oral administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619324,,
5032,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619325,,
5033,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876411,,
5034,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619326,,
5035,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619327,,
5036,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619328,,
5037,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619329,,
5038,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619330,,
5039,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619331,,
5040,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619332,,
5041,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619333,,
5042,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619334,,
5043,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619335,,
5044,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619336,,
5045,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619337,,
5046,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619338,,
5047,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619339,,
5048,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619340,,
5049,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873496,1969.0,
5050,AUC value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619341,1969.0,
5051,AUC value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619342,1969.0,
5052,Cmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619343,,
5053,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619344,,
5054,Tmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619345,,
5055,Vc value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619346,,
5056,Half life period in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619347,,
5057,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619348,,
5058,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619349,,
5059,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619350,,
5060,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619351,,
5061,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875953,,
5062,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621716,,
5063,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621717,,
5064,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621718,,
5065,Area under curve after 1 mpk peroral administration to beagles,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621719,,
5066,Area under curve after 2 mpk peroral administration to beagles,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621720,,
5067,Cmax value after 1 mpk peroral administration to beagles,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621721,,
5068,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621722,1088.0,
5069,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621723,1088.0,
5070,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621724,1088.0,
5071,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623443,1088.0,
5072,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623444,1088.0,
5073,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623445,1088.0,
5074,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623446,1088.0,
5075,Metabolic stability observed at 30 min after administration in human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL623447,2107.0,
5076,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623448,,
5077,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623449,,
5078,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623450,,
5079,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL623451,2107.0,
5080,Metabolic stability (% remaining at 30 mins) in human S9.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623452,,
5081,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623453,,
5082,Percent parent compound remaining after 20 min incubation with human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL623454,2107.0,
5083,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL623455,2107.0,
5084,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL624371,2107.0,
5085,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624372,,
5086,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624373,,
5087,Percent remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624374,,
5088,The percent remaining in human plasma after 30 min was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624556,,
5089,Conversion rate of the prodrug in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL624557,1969.0,
5090,Conversion rate of the prodrug in human plasma; ND means no data,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL624558,1969.0,
5091,Half life of compound was determined in human blood,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL624559,178.0,
5092,Half life of compound was determined in man with once daily dosing,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624560,,
5093,Half life in human microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL624561,,
5094,Half life in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL624562,1969.0,
5095,Half life in human plasma; Not detected,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL624563,1969.0,
5096,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624564,,
5097,Half-life for oxidative metabolic stability was determined using rat liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL624565,2107.0,
5098,Half-life in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL875152,1969.0,
5099,Half-life of the parent prodrug in plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL624566,1969.0,
5100,In vitro half life in human plasma was determined,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL873805,1969.0,
5101,The compound was tested In Vitro for half life in human liver microsomes.,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL624567,2107.0,
5102,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624568,,
5103,Observed volume of distribution,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624569,,
5104,Oral bioavailability in human,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624570,,
5105,Tested for human plasma protein binding of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624571,,
5106,"First order rate constant, k was determined in human plasma",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624572,,
5107,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624573,,
5108,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875153,,
5109,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL624574,2107.0,
5110,The compound was tested for the plasma binding in human,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624575,,
5111,Plasma protein binding (human),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624576,,
5112,Compound was evaluated for half-life in human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL624577,2107.0,
5113,Half life measured in vitro for its stability in human blood,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL624578,178.0,
5114,Half life in human serum,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622796,1977.0,
5115,Half life in human serum; ND=not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622797,1977.0,
5116,Half life were determined in CEM-SS cell extract in decomposition step 1,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622798,,
5117,Half life were determined in CEM-SS cell extract in decomposition step 2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622799,,
5118,Half life of the in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL622800,1969.0,
5119,Half life period in human hepatic S9 fraction was determined,,BAO_0000220,Autocuration,S9,,22224,U,0,1,,CHEMBL622801,,
5120,Half life period in human liver microsome was determined,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL622802,2107.0,
5121,Half life period was determined; 6-7,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622803,,
5122,Half life period was evaluated in human,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875154,,
5123,Half life time in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL622804,1969.0,
5124,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622805,955.0,
5125,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622611,948.0,
5126,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622612,948.0,
5127,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875160,2113.0,
5128,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622613,2113.0,
5129,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622614,2113.0,
5130,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622615,2107.0,
5131,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622616,2107.0,
5132,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622617,2107.0,
5133,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622618,2106.0,
5134,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622619,2106.0,
5135,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622620,2106.0,
5136,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622621,955.0,
5137,Biodistribution of compound (oxidized form) in blood tissue,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622622,178.0,
5138,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622623,178.0,
5139,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622624,178.0,
5140,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622625,178.0,
5141,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622626,178.0,
5142,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622627,178.0,
5143,Biodistribution of compound (oxidized form) in brain tissue of mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622628,955.0,
5144,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622629,955.0,
5145,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622630,955.0,
5146,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622631,955.0,
5147,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622632,955.0,
5148,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622633,955.0,
5149,Biodistribution of compound (oxidized form) in heart tissue of mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622634,948.0,
5150,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622635,948.0,
5151,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875161,948.0,
5152,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622636,948.0,
5153,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623335,948.0,
5154,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623336,948.0,
5155,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623337,2113.0,
5156,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623338,2113.0,
5157,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623339,2113.0,
5158,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623524,2113.0,
5159,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623525,2113.0,
5160,Biodistribution of compound (oxidized form) in liver tissue,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623526,2107.0,
5161,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623527,2107.0,
5162,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623528,2107.0,
5163,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL624615,,
5164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621672,,
5165,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL621673,,
5166,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL621674,,
5167,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL884002,,
5168,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621850,,
5169,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL621851,,
5170,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621852,,
5171,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL621853,,
5172,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL621854,,
5173,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL621855,,
5174,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623724,,
5175,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623725,,
5176,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623726,,
5177,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL623727,,
5178,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,500.0,BAO_0000219,Expert,,A-431,9,H,8,1,,CHEMBL623728,,
5179,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623729,,
5180,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623730,,
5181,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623731,,
5182,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623732,,
5183,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623733,,
5184,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623734,,
5185,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",500.0,BAO_0000218,Expert,,A-431,80852,N,1,1,,CHEMBL623735,,
5186,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL623736,,
5187,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL623737,,
5188,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL623738,,
5189,Dose giving a 50% decrease in the living cell number (A437 cells),500.0,BAO_0000219,Intermediate,,A-431,80852,N,1,1,,CHEMBL875168,,
5190,In vitro inhibitory concentration against proliferation of A459 cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL623739,,
5191,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623740,,
5192,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624424,,
5193,In vitro antitumor activity against renal A498 tumor cell lines,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624425,,
5194,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624426,,
5195,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624427,,
5196,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624428,,
5197,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624429,,
5198,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624620,,
5199,Cytotoxicity on kidney carcinoma (A-498) cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624621,,
5200,Compound was evaluated against Human cell line renal A498,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624622,,
5201,Compound was tested for inhibition of A498 human renal cancer cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624623,,
5202,Growth inhibitory activity against A498 human cancer cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL874365,,
5203,In vitro antitumor activity against human renal A498 cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624624,,
5204,In vitro cytotoxic activity against renal (A498) cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624625,,
5205,In vitro cytotoxic activity against human renal cancer (A498) cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624626,,
5206,Tested for cytostatic activity against renal A498 cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624627,,
5207,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL883157,,
5208,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,624.0,BAO_0000219,Expert,,A498,80021,N,1,1,,CHEMBL624628,,
5209,Cmax value after 2 mpk peroral administration to beagles,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624629,,
5210,Bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623551,,
5211,Bioavailability after 1 mpk peroral administration to beagles,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623552,,
5212,Bioavailability after 2 mpk peroral administration to beagles,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623553,,
5213,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623554,,
5214,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623555,,
5215,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623556,,
5216,Solubility against bovine alpha-chymotrypsin,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623557,,
5217,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623558,,
5218,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623559,,
5219,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623560,2106.0,
5220,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623561,,
5221,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623562,,
5222,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623563,,
5223,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623564,2106.0,
5224,Half life in presence of 2 mg/mL BSA at pH 8.8,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL873806,,
5225,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623565,,
5226,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623566,,
5227,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623567,,
5228,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623568,,
5229,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623569,1969.0,
5230,AUC after administration at 100 mg/kg/day in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623570,1969.0,
5231,AUC in dog at 0-24 hr by peroral administration at 3 mpk,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624254,1969.0,
5232,AUC value after 15 mg/kg iv dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624255,1969.0,
5233,AUC value after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624256,1969.0,
5234,AUC value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624257,1969.0,
5235,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624258,1969.0,
5236,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875277,,
5237,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622667,,
5238,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622668,,
5239,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622669,,
5240,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622670,,
5241,Area under curve determined in dogs after oral administration of 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622671,,
5242,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622672,,
5243,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL622673,,
5244,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL622674,,
5245,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622675,,
5246,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622676,,
5247,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622677,,
5248,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622678,,
5249,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622679,,
5250,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622680,,
5251,Area under curve was determine after peroral administration at 10 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622681,,
5252,Area under curve was determine after peroral administration at 5 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875278,,
5253,Area under curve was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622682,,
5254,Area under curve in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622683,,
5255,Area under curve in dogs at 10 mg/kg dose fo oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622684,,
5256,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622685,,
5257,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622686,,
5258,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618344,,
5259,Area under curve value in dog at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875582,,
5260,Area under curve was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618345,,
5261,Area under curve was determined after 0.3 mg/kg po administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618346,,
5262,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618347,,
5263,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618348,,
5264,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618349,,
5265,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618350,,
5266,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618351,,
5267,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618352,,
5268,Time taken to reduce 50% of the concentration of compound in blood plasma,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL873494,178.0,
5269,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618353,1969.0,
5270,Half life in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618354,1969.0,
5271,Half life in human plasma was reported,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL875583,1969.0,
5272,Half life in human serum,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618355,1977.0,
5273,Half life upon exposure to human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618356,1969.0,
5274,t1/2 in human microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618357,,
5275,Half life period in 80% human plasma at 37 degree Centigrade,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618358,1969.0,
5276,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL618359,14.0,
5277,Half-life measured in in vitro Cathepsin B assay in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618360,1969.0,
5278,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618361,,
5279,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618362,2107.0,
5280,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618363,1969.0,
5281,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618364,1969.0,
5282,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL875584,1969.0,
5283,Half-life in the CEM cell extracts,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618365,,
5284,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL873495,1969.0,
5285,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618366,1969.0,
5286,Half-life was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618367,,
5287,Half-life (human blood stability),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL618368,178.0,
5288,Half-life (human blood stability); no data,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL618369,178.0,
5289,Half-life in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618370,1969.0,
5290,CYP3A4 metabolism half-life (t1/2),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618371,,
5291,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL618372,178.0,
5292,In vitro half life in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618373,1969.0,
5293,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618374,1969.0,
5294,In vitro hydrolysis in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618375,1969.0,
5295,In vitro hydrolysis in human plasma; no data,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618376,1969.0,
5296,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL618377,2107.0,
5297,Plasma half life in human,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618378,1969.0,
5298,Stability after incubation with human plasma (at 37 degree C),,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618379,1969.0,
5299,T1/2 was evaluated in human plasma,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618380,1969.0,
5300,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618381,1969.0,
5301,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL618382,1969.0,
5302,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618383,,
5303,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618384,,
5304,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618385,,
5305,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL619099,1969.0,
5306,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL619100,1969.0,
5307,Time taken for 50% to be consumed by serum PON1 was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619101,,
5308,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619102,,
5309,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL619103,2107.0,
5310,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619268,,
5311,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619269,,
5312,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619270,,
5313,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619271,,
5314,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875585,,
5315,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619272,,
5316,Compound tested for growth inhibition of renal cancer cell line 786-0,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619273,,
5317,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619274,,
5318,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,391.0,BAO_0000219,Expert,,786-0,80640,N,1,1,,CHEMBL619275,,
5319,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619276,,
5320,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619277,,
5321,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619278,,
5322,Tested for cytotoxicity against 786-0 cell lines in renal cancer,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619279,,
5323,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL858458,,
5324,Cytotoxic effect on renal cancer line 786-0,391.0,BAO_0000219,Expert,,786-0,80640,N,1,1,,CHEMBL619280,,
5325,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619281,,
5326,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619282,,
5327,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619283,,
5328,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619284,,
5329,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619285,,
5330,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619286,,
5331,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619287,,
5332,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL857455,,
5333,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL883801,,
5334,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619288,,
5335,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619289,,
5336,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619290,,
5337,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619291,,
5338,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619292,,
5339,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619293,,
5340,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619294,,
5341,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619295,,
5342,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619296,,
5343,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,972.0,BAO_0000219,Intermediate,,791T cell line,80641,N,1,1,,CHEMBL619297,,
5344,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,391.0,BAO_0000219,Intermediate,,786-0,80640,N,1,1,,CHEMBL619298,,
5345,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL619299,,
5346,Inhibition of cell growth in drug resistant 8226 myeloma cell line,741.0,BAO_0000219,Expert,,RPMI-8226,80433,N,1,1,,CHEMBL619300,,
5347,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,741.0,BAO_0000219,Expert,,RPMI-8226,80433,N,1,1,,CHEMBL619301,,
5348,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619302,,
5349,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619303,,
5350,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619304,,
5351,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL857706,,
5352,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619305,,
5353,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619306,,
5354,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619307,,
5355,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619308,,
5356,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619309,,
5357,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL619310,,
5358,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619311,,
5359,Compound was tested for the growth inhibition of A498 renal tumor cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619312,,
5360,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619313,,
5361,In vitro inhibitory concentration against renal cancer cell line A498,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619314,,
5362,Cytotoxicity against A 498 tumor cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619959,,
5363,In vitro antitumor activity against A498 human cancer cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619960,,
5364,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619961,,
5365,Inhibitory dose required against A498 human tumor cell lines,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619962,,
5366,Anticancer activity against one renal cancer (A498 cell line),624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL875586,,
5367,In vitro cytotoxicity against melanoma A498 cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619963,,
5368,Compound was tested for growth inhibitory activity against A498 cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619964,,
5369,Compound tested for growth inhibition of renal cancer cell line A498,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620108,,
5370,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620109,,
5371,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620110,,
5372,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620111,,
5373,Tested for cytotoxicity against A498 cell lines in renal cancer,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620112,,
5374,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620113,,
5375,Cytotoxic effect on renal cancer lines A498,624.0,BAO_0000219,Expert,,A498,80021,N,1,1,,CHEMBL620114,,
5376,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620115,,
5377,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620116,,
5378,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620117,,
5379,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620118,,
5380,Cytotoxicity against human kidney carcinoma cell lines A4982LM,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620119,,
5381,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL620120,,
5382,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620121,,
5383,Antitumor activity against A549 human lung carcinoma cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620122,,
5384,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620123,,
5385,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620124,,
5386,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620125,,
5387,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620126,,
5388,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL883027,,
5389,In vitro cytotoxic activity against human lung A549 cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620127,,
5390,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620128,,
5391,In vitro cytotoxic activity against human lung A549 cell line),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620129,,
5392,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620130,,
5393,In vitro cytotoxicity against human non small-cell-lung cell line A549.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620131,,
5394,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620132,,
5395,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620133,,
5396,Inhibition of A549 human lung carcinoma cell proliferation,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620134,,
5397,Inhibitory activity against A549 lung adenocarcinoma cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620135,,
5398,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620136,,
5399,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620137,,
5400,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620268,,
5401,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620269,,
5402,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620270,,
5403,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620271,,
5404,Inhibition of A549 cancer cell proliferation,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620272,,
5405,Inhibition of A549 cancer cell proliferation (Not tested),646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620273,,
5406,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620274,,
5407,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620275,,
5408,Antiproliferative potency determined as inhibitory concentration against A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620276,,
5409,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620277,,
5410,Cytotoxicity against Renal cell lines A549 was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620278,,
5411,Area under curve was determined in dog after a 3 mg/kg of oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620279,,
5412,Area under curve was determined in dog after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620280,,
5413,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620281,,
5414,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620282,,
5415,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621134,,
5416,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621135,,
5417,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621136,,
5418,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621137,,
5419,Area under plasma concentration time curve in dog upon oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621138,1969.0,
5420,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875587,1969.0,
5421,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621139,,
5422,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621140,,
5423,Area under the curve for the compound was obtained when tested in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621141,,
5424,Area under the curve at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621142,,
5425,Area under the curve at a dose of 1 mg/kg (oral),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621143,,
5426,Area under the curve at i.v. dose of 0.2 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621144,,
5427,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621145,,
5428,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621146,,
5429,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622567,,
5430,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622568,,
5431,Compound was evaluated for area under the curve in dog blood.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622569,,
5432,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622570,,
5433,AUC in dog after oral dose (1 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622571,1969.0,
5434,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622572,,
5435,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622573,,
5436,Pharmacokinetic parameter AUC after intravenous administration to dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622574,,
5437,Pharmacokinetic parameter AUC after oral administration to dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622575,,
5438,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622576,,
5439,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622577,,
5440,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622578,,
5441,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622579,,
5442,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622580,,
5443,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622581,,
5444,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622582,,
5445,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622583,,
5446,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622584,,
5447,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622585,,
5448,Compound was evaluated for oral bioavailability in dog; 90-100,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622586,,
5449,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623281,,
5450,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623282,,
5451,PAPP (membrane permeability) in dog kidney cell monolayer assay,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623283,,
5452,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623284,,
5453,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623285,,
5454,Plasma protein binding towards dog plasma at 10 uM,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623463,1969.0,
5455,Plasma protein binding towards dog plasma at 100 uM,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875952,1969.0,
5456,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621705,,
5457,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621706,,
5458,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621707,,
5459,Bioavailability in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621708,,
5460,Bioavailability,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621709,,
5461,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621710,,
5462,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621711,,
5463,Bioavailability in dog (dose 10.0 mg/kg p.o.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621712,,
5464,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621713,,
5465,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621714,,
5466,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621715,,
5467,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623717,2107.0,
5468,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623718,2107.0,
5469,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623719,2107.0,
5470,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623720,,
5471,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623721,,
5472,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623722,2385.0,
5473,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623723,2385.0,
5474,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618543,2385.0,
5475,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618544,2106.0,
5476,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875155,2106.0,
5477,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618545,,
5478,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618546,,
5479,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623529,,
5480,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623530,,
5481,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621764,,
5482,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621765,,
5483,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621766,2037.0,
5484,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621767,1870.0,
5485,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621768,,
5486,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621769,2435.0,
5487,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621770,,
5488,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621771,2037.0,
5489,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621772,1870.0,
5490,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621773,,
5491,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621774,2435.0,
5492,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621775,,
5493,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621776,1969.0,
5494,Half life period was evaluated in monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621777,,
5495,Half-life in rhesus monkeys by intravenous administration of dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875162,,
5496,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621778,1969.0,
5497,AUC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621779,1969.0,
5498,AUC value was determined after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622479,1969.0,
5499,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622480,,
5500,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622481,,
5501,Area under curve by ioral administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622482,,
5502,Area under curve by iv administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622483,,
5503,Area under curve at 0-8 hr in IRC mice after peroral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622484,,
5504,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622641,,
5505,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622642,,
5506,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622643,,
5507,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622644,,
5508,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL622645,,
5509,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL622646,,
5510,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL621238,,
5511,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL621239,,
5512,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL621240,,
5513,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL621241,,
5514,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL621242,,
5515,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620350,,
5516,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620351,,
5517,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620352,,
5518,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620353,,
5519,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620354,,
5520,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620355,,
5521,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620356,,
5522,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620357,,
5523,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620358,,
5524,In vitro inhibition of human 8226 myeloma tumor cell line growth.,741.0,BAO_0000219,Expert,,RPMI-8226,80433,N,1,1,,CHEMBL620359,,
5525,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620360,,
5526,Cytotoxicity of compound against 8226/DOX1V cells,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620361,,
5527,Cytotoxicity of compound against 8226/S cells,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620362,,
5528,Inhibitory concentration against 8226 myeloma cancer cell line,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620363,,
5529,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,741.0,BAO_0000219,Intermediate,,RPMI-8226,80433,N,1,1,,CHEMBL620364,,
5530,Inhibition of cell growth was studied in human teratocarcinoma (833K).,854.0,BAO_0000219,Intermediate,,833K,80647,N,1,1,,CHEMBL620365,,
5531,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',854.0,BAO_0000219,Intermediate,,833K,80647,N,1,1,,CHEMBL620366,,
5532,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,854.0,BAO_0000219,Expert,,833K,80647,N,1,1,,CHEMBL620367,,
5533,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,854.0,BAO_0000219,Intermediate,,833K,80647,N,1,1,,CHEMBL620368,,
5534,Inhibitory activity against caspase-1,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620369,,
5535,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,BAO_0000357,Autocuration,,,45,H,8,1,,CHEMBL620370,,
5536,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,705.0,BAO_0000219,Intermediate,,8701-BC,80648,N,1,1,,CHEMBL620371,,
5537,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,705.0,BAO_0000219,Intermediate,,8701-BC,80648,N,1,1,,CHEMBL620372,,
5538,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL876492,,
5539,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL620373,,
5540,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,BAO_0000019,Intermediate,,,22226,U,0,1,,CHEMBL620374,,
5541,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620375,,
5542,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL857902,,
5543,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620376,,
5544,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,BAO_0000357,Autocuration,,,11922,H,8,1,,CHEMBL620377,,
5545,Tested for in vitro cytotoxic potency of compound in 9KB assay,324.0,BAO_0000219,Intermediate,,KB ,81115,N,1,1,,CHEMBL620378,,
5546,Tested for in vitro cytotoxic potency of compound in 9KB assay,324.0,BAO_0000219,Intermediate,,KB ,81115,N,1,1,,CHEMBL620379,,
5547,In vitro cytotoxicity of compound was tested against 9KB cells.,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL620380,,
5548,Cytotoxic concentration against 9L cells was determined on day 3,392.0,BAO_0000219,Intermediate,,9L,80653,N,1,1,,CHEMBL884006,,
5549,Tested in vitro for anticancer activity against 9L cells,392.0,BAO_0000219,Expert,,9L,80653,N,1,1,,CHEMBL620381,,
5550,Tested in vitro for anticancer activity against 9L cells; Not determined,392.0,BAO_0000219,Expert,,9L,80653,N,1,1,,CHEMBL620382,,
5551,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620383,,
5552,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876493,,
5553,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620384,,
5554,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620385,,
5555,Cytotoxicity against human lung carcinoma A549 cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620386,,
5556,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,646.0,BAO_0000219,Expert,,A549,25,D,9,1,,CHEMBL620387,,
5557,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",646.0,BAO_0000219,Expert,,A549,25,D,9,1,,CHEMBL621404,,
5558,"In vitro growth inhibition of A549, lung carcinoma",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621405,,
5559,"In vitro growth inhibition of A549, lung carcinoma.",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621406,,
5560,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621407,,
5561,Cytotoxic activity against human lung cancer A549 cell line was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621408,,
5562,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL885345,,
5563,Cytotoxicity concentration against human lung carcinoma A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621409,,
5564,Cytotoxicity in A549 (human carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL876034,,
5565,Cytotoxicity on lung carcinoma (A-549) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621410,,
5566,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621411,,
5567,Effective dose of compound against replication of A549 cell line was evaluated,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621412,,
5568,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621413,,
5569,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621414,,
5570,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621415,,
5571,The compound was evaluated for antiproliferative activity against A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621416,,
5572,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621417,,
5573,Concentration required for growth inhibition of human lung carcinoma cell line A549,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621418,,
5574,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621419,,
5575,Growth inhibition against A549 cell line was evaluated,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621420,,
5576,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL875823,,
5577,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621421,,
5578,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621422,,
5579,Chemosensitivity against DT-diaphorase rich A549 cell lines,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL884014,,
5580,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621423,,
5581,In vitro cytotoxicity against human A549 (lung cancer) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621424,,
5582,In vitro antitumor activity against A549 (lung) human tumor cell lines.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621425,,
5583,In vitro cytotoxic activity against human lung carcinoma A549 cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621426,,
5584,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621427,,
5585,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621428,,
5586,Tested against A549 lung carcinoma in the sulforhodamine B assay.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621429,,
5587,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621430,,
5588,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621431,,
5589,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621432,,
5590,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621433,,
5591,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL875824,,
5592,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621434,,
5593,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621435,,
5594,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621436,,
5595,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621437,,
5596,Compound was tested for the growth inhibition of A549 lung tumor cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621438,,
5597,Growth inhibition of human non-small-lung carcinoma (A549) cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621439,,
5598,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621440,,
5599,Oral bioavailability in dog (conscious),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621441,,
5600,Compound was evaluated for the oral bioavailability after oral administration in dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621442,,
5601,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621443,,
5602,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621444,,
5603,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625133,,
5604,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625134,,
5605,Oral bioavailability in dog (fasted),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625135,,
5606,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625136,,
5607,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625137,,
5608,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625138,,
5609,Percent bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625139,,
5610,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL872264,,
5611,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625140,,
5612,The compound was evaluated for bioavailability in dogs; 34-44,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624436,,
5613,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624437,,
5614,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL872261,,
5615,8 hour trough Blood level in dog was measured after administration of compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624438,,
5616,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624439,1969.0,
5617,C24 after oral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624440,,
5618,Clearance after oral and iv dosing in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624441,,
5619,Clearance of the drug was measured in the plasma of dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624442,1969.0,
5620,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624443,,
5621,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624444,,
5622,Clearance of compound was determined in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624445,,
5623,Clearance on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624446,,
5624,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624447,,
5625,Plasma clearance in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624448,,
5626,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624449,,
5627,Plasma clearance in dog after administration of 0.25 mg/kg iv,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624450,,
5628,Plasma clearance in dog after administration of 1 mg/kg iv,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875942,,
5629,Plasma clearance in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624451,,
5630,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624452,,
5631,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624453,,
5632,Plasma clearance after 15 mg/kg iv dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624454,,
5633,Plasma clearance after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624455,,
5634,Plasma administration to dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624456,,
5635,Plasma clearance was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624457,,
5636,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624458,,
5637,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624459,,
5638,Intrinsic clearance in human liver microsomes,,BAO_0000251,Intermediate,Microsomes,,102164,S,2,1,,CHEMBL624460,2107.0,
5639,Intrinsic clearance in human liver microsomes,,BAO_0000251,Intermediate,Microsomes,,102164,S,2,1,,CHEMBL624461,2107.0,
5640,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875943,,
5641,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624462,,
5642,Clearance in dog (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624463,,
5643,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624464,,
5644,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624465,,
5645,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624466,,
5646,Plasma clearance after peroral administration at 5 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624467,,
5647,Plasma clearance after peroral administration at 5 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624468,,
5648,Plasma clearance was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624469,,
5649,Plasma clearance was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624470,,
5650,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624471,,
5651,Total clearance was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624472,,
5652,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622775,,
5653,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622776,,
5654,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622777,,
5655,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622778,,
5656,Clearance by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622779,,
5657,Clearance by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622780,,
5658,Clearance value was evaluated in dog plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622781,1969.0,
5659,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622782,,
5660,Compound was tested for plasma clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622783,1969.0,
5661,Pharmacokinetic property (Plasma clearance) was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622784,,
5662,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622785,,
5663,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622786,,
5664,Area under curve value in mouse at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622787,,
5665,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875949,,
5666,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622788,,
5667,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622789,,
5668,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622790,,
5669,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622791,,
5670,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622792,,
5671,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622793,,
5672,Area under curve was determined for the compound at 24 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622794,,
5673,Area under curve was determined for the compound at 40 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622795,,
5674,Area under curve was determined for the compound at 5 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621803,,
5675,Area under the curve for the compound is obtained at dose 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621804,,
5676,Area under the curve for the compound was obtained when tested in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621805,,
5677,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621806,,
5678,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621807,,
5679,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621808,,
5680,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621809,,
5681,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621810,,
5682,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875164,,
5683,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621811,,
5684,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621812,,
5685,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621813,,
5686,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621814,,
5687,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621815,,
5688,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621816,,
5689,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621817,,
5690,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621818,,
5691,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621819,,
5692,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621820,,
5693,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621821,,
5694,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621822,,
5695,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619474,,
5696,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619475,,
5697,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619476,,
5698,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619477,,
5699,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619478,,
5700,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619479,,
5701,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619480,,
5702,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619481,,
5703,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619482,,
5704,Area under the curve was evaluated in mice after intravenous administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619483,,
5705,Area under the curve was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619484,,
5706,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619485,1969.0,
5707,AUC total value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619486,1969.0,
5708,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619487,,
5709,AUMC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619488,,
5710,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620106,178.0,
5711,The compound was tested in vitro for anticancer activity against 9L cells,392.0,BAO_0000219,Intermediate,,9L,80653,N,1,1,,CHEMBL620107,,
5712,Anti proliferation activity determined; Weak effect,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620283,,
5713,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL875176,,
5714,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL620284,,
5715,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL623515,,
5716,The cytotoxic activity was in vitro tested by 9PS assay method,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL623516,,
5717,The cytotoxic activity was in vitro tested by 9PS assay method.,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL623517,,
5718,Partition coefficient (logD6.5),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL857878,,
5719,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL623518,,
5720,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL624195,,
5721,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL624196,,
5722,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,500.0,BAO_0000219,Expert,,A-431,9,D,9,1,,CHEMBL624197,,
5723,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL624198,,
5724,in vitro cytotoxicity against A 498 cancer cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL621287,,
5725,In vitro cytotoxic activity against renal (A 498) cancer cell line.,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL621288,,
5726,Cytotoxic activity against A 498 renal cancer cell lines.,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL876496,,
5727,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL621289,,
5728,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL621290,,
5729,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL621291,,
5730,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL621292,,
5731,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL621293,,
5732,Inhibitory concentration required against A 549 lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621294,,
5733,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621295,,
5734,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL884007,,
5735,In vitro cytotoxicity against lung cancer A 549 cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621296,,
5736,Compound was tested for its cytotoxicity against A 549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621297,,
5737,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL839828,,
5738,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620397,,
5739,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620398,,
5740,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620399,,
5741,In vitro inhibition of A549 (human lung cancer) cell growth.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620400,,
5742,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620401,,
5743,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620402,,
5744,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620403,,
5745,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,BAO_0000218,Autocuration,,,22226,U,0,1,,CHEMBL620404,,
5746,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,BAO_0000218,Autocuration,,,104694,H,4,1,,CHEMBL620405,,
5747,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,Autocuration,,,104694,H,4,1,,CHEMBL620406,,
5748,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,BAO_0000218,Autocuration,,,104694,H,4,1,,CHEMBL620407,,
5749,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,Autocuration,,,104694,H,4,1,,CHEMBL620408,,
5750,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,BAO_0000218,Autocuration,,,104694,H,4,1,,CHEMBL620409,,
5751,Inhibition of A-498 human Renal cell proliferation,624.0,BAO_0000219,Expert,,A498,80021,N,1,1,,CHEMBL620410,,
5752,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620411,,
5753,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL620412,,
5754,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,BAO_0000019,Autocuration,,,22226,U,0,1,,CHEMBL876596,,
5755,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,622.0,BAO_0000219,Expert,,A 172,80012,N,1,1,,CHEMBL620413,,
5756,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL620414,,
5757,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL620415,,
5758,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620416,,
5759,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620417,,
5760,Cytotoxic activity evaluated against A549 tumor cells,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620418,,
5761,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620419,,
5762,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620420,,
5763,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620421,,
5764,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620422,,
5765,Cytotoxicity of compound against A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620423,,
5766,Cytotoxicity against human lung cell carcinoma A549 cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620424,,
5767,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620425,,
5768,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620426,,
5769,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620427,,
5770,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620428,,
5771,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620429,,
5772,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620430,,
5773,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL839887,,
5774,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620431,,
5775,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL884010,,
5776,In vitro cytotoxicity against A549 (human lung cancer),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620538,,
5777,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620539,,
5778,In vivo antiproliferative activity against A549 cell line,646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL623373,,
5779,Inhibition of non-small-cell lung adenocarcinoma (A549),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623374,,
5780,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623375,,
5781,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623376,,
5782,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623377,,
5783,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623378,,
5784,Inhibitory activity of compound against human A549 lung carcinoma cell line.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623379,,
5785,Inhibitory activity against A549 lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623380,,
5786,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623381,,
5787,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623382,,
5788,Inhibitory concentration against A549 (lung cancer) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623383,,
5789,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL623384,,
5790,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623385,,
5791,Activity against A549 cancer cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL623386,,
5792,The compound was evaluated for cytotoxicity against A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL884105,,
5793,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623387,,
5794,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621568,,
5795,Growth inhibitory activity was measured for human A549 tumor cell line.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621569,,
5796,Inhibitory activity against A549 lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621570,,
5797,Inhibitory activity against A549 cell line; inactive,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621571,,
5798,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621572,,
5799,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621573,,
5800,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621574,,
5801,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621575,,
5802,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621576,,
5803,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621577,,
5804,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621578,,
5805,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621579,,
5806,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621580,,
5807,Plasma clearance (in vivo) in mongrel dogs was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621581,,
5808,Plasma clearance was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621582,,
5809,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621583,,
5810,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621584,,
5811,Tested for plasma clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621585,1969.0,
5812,The compound was tested for clearance in dog plasma.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621586,,
5813,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875835,,
5814,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621587,,
5815,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621588,1969.0,
5816,In vitro clearance in dog liver microsomes,,BAO_0000218,Intermediate,Microsomes,,50588,N,1,1,,CHEMBL621589,2107.0,
5817,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621590,,
5818,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621591,,
5819,Plasma clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621592,,
5820,Clearance rate in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621593,,
5821,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621594,1969.0,
5822,Clearance in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621595,,
5823,Plasma clearance in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621596,,
5824,Plasma clearance was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621597,,
5825,Lower clearance in dog (i.v.) at 0.5 mpk,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621598,,
5826,Plasma clearance in Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621599,,
5827,Plasma clearance (Clp) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875836,,
5828,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621600,,
5829,Plasma clearance (pharmacokinetic parameter) in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621601,,
5830,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618474,,
5831,Plasma clearance of compound was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618475,,
5832,Plasma clearance after intravenous administration of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624524,,
5833,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624525,,
5834,Plasma clearance in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624526,,
5835,Plasma clearance was calculated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624527,,
5836,Plasma clearance at the dose of 2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624528,,
5837,Plasma clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624529,,
5838,Plasma clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624530,,
5839,Plasma clearance in dog; Unable to calculate,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624531,,
5840,Plasma clearance in rhesus monkey,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624532,,
5841,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624533,,
5842,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624534,,
5843,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624535,,
5844,Plasma clearance was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624536,,
5845,Plasma clearance was evaluated in dog; Not tested,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624537,,
5846,Plasma clearance was evaluated in rhesus,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624538,,
5847,Plasma clearance was evaluated in rhesus; Not tested,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624539,,
5848,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624540,,
5849,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624541,,
5850,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624542,,
5851,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624543,,
5852,Clearance value at a dose of 0.2 mg/kg i.v.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624544,,
5853,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624545,1969.0,
5854,Cmax after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624546,,
5855,Cmax after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875957,,
5856,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624547,,
5857,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624548,,
5858,Cmax in dog after administration of 1 mg/kg iv,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624549,,
5859,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624550,1969.0,
5860,Cmax on p.o. administration of 10 mg/kg was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621613,,
5861,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621614,,
5862,Cmax was determine after peroral administration at 5 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623431,,
5863,Cmax was determine after peroral administration at 5 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623432,,
5864,Cmax after 0.3 mg/kg po administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623433,,
5865,Cmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623434,,
5866,Cmax in dog after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623435,,
5867,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623436,,
5868,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875958,,
5869,Cmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623437,,
5870,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623438,178.0,
5871,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623439,178.0,
5872,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623440,10000001.0,
5873,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623441,10000001.0,
5874,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623442,10000001.0,
5875,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623469,,
5876,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623470,,
5877,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623471,,
5878,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623472,948.0,
5879,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623473,948.0,
5880,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623474,948.0,
5881,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623475,2113.0,
5882,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623476,2113.0,
5883,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623477,2113.0,
5884,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621896,160.0,
5885,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621897,160.0,
5886,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621898,160.0,
5887,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621899,2107.0,
5888,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621900,2107.0,
5889,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621901,2107.0,
5890,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621902,2048.0,
5891,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621903,2048.0,
5892,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622587,2048.0,
5893,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620285,2385.0,
5894,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875285,2385.0,
5895,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620286,2385.0,
5896,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620287,,
5897,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620288,,
5898,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620289,,
5899,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620290,160.0,
5900,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620291,160.0,
5901,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620292,160.0,
5902,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620293,2106.0,
5903,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620294,2106.0,
5904,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618614,2106.0,
5905,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618615,945.0,
5906,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618616,945.0,
5907,Cytotoxicity against A-172 human tumor cell lines,622.0,BAO_0000219,Expert,,A 172,80012,N,1,1,,CHEMBL618617,,
5908,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL618618,,
5909,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,623.0,BAO_0000219,Intermediate,,A204,80014,N,1,1,,CHEMBL618619,,
5910,Tested for antiproliferative activity against A-2780 tumoral cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618620,,
5911,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL618621,,
5912,Tested in vitro against A-375 cell line human melanoma,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL618622,,
5913,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,797.0,BAO_0000219,Expert,,A-427,80019,N,1,1,,CHEMBL618623,,
5914,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL618624,,
5915,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,797.0,BAO_0000219,Expert,,A-427,80019,N,1,1,,CHEMBL618625,,
5916,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL618626,,
5917,Antitumor activity on A-427 lung carcinoma cell lines,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL618627,,
5918,Cytotoxic activity against human A-427 lung tumor cell line,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL618628,,
5919,In vitro antitumor effects against human A-427 cell lines.,797.0,BAO_0000219,Expert,,A-427,80019,N,1,1,,CHEMBL618629,,
5920,In vitro inhibition of A-427 (human lung cancer) cell growth.,797.0,BAO_0000219,Expert,,A-427,80019,N,1,1,,CHEMBL618630,,
5921,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL618631,,
5922,Cytotoxic activity of compound against A-427 lung human tumor cell line,797.0,BAO_0000219,Intermediate,,A-427,80019,N,1,1,,CHEMBL618632,,
5923,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,500.0,BAO_0000219,Expert,,A-431,80852,N,1,1,,CHEMBL618633,,
5924,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619315,,
5925,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,624.0,BAO_0000219,Expert,,A498,80021,N,1,1,,CHEMBL619316,,
5926,Cytotoxicity against human kidney carcinoma A-498cell lines,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619317,,
5927,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619318,,
5928,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619319,,
5929,Antitumor cytotoxic activity against A-498 cell line was determined,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619739,,
5930,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619740,,
5931,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL883158,,
5932,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL884012,,
5933,In vitro inhibitory activity against A-498 ovarian cancer cell lines,624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619741,,
5934,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",624.0,BAO_0000219,Intermediate,,A498,80021,N,1,1,,CHEMBL619742,,
5935,Inhibition of growth lung non-small cell carcinoma A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876610,,
5936,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619743,,
5937,In vitro antiproliferative activity against human A-549 NSCL cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619744,,
5938,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619745,,
5939,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619746,,
5940,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619747,,
5941,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619748,,
5942,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619749,,
5943,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619750,,
5944,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624014,,
5945,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624015,,
5946,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL885344,,
5947,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623224,,
5948,Cytotoxic activity against A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL623225,,
5949,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622698,,
5950,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622699,,
5951,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL622700,,
5952,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622701,,
5953,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622702,,
5954,Cytotoxic activity against human lung carcinoma (A-549) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622703,,
5955,Cytotoxic activity towards A-549 cells,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL622704,,
5956,"In vitro percent inhibition of A549, lung carcinoma.",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622705,,
5957,"In vitro percent inhibition of A549, lung carcinoma",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622706,,
5958,"In vitro percent inhibition of A549, lung carcinoma.",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622707,,
5959,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622708,,
5960,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622709,,
5961,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622710,,
5962,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622711,,
5963,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL622712,,
5964,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL622713,,
5965,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL622714,,
5966,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL622715,,
5967,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL622716,,
5968,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622717,,
5969,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL622718,,
5970,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL622719,,
5971,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622720,,
5972,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622721,,
5973,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622722,,
5974,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876030,,
5975,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620206,,
5976,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620207,,
5977,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620208,,
5978,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620209,,
5979,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620210,,
5980,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621639,,
5981,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621640,,
5982,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621641,,
5983,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL621642,,
5984,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621643,,
5985,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621644,,
5986,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621645,,
5987,In vitro antiproliferative activity against A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621646,,
5988,Synergism with indomethacin in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621647,,
5989,Synergism with tolmetin in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621648,,
5990,Synergism with sulindac in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621649,,
5991,Antagonism of indomethacin in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621650,,
5992,Antagonism of sulindac in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621651,,
5993,Antagonism of tolmetin in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621652,,
5994,Synergism with indomethacin in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621653,,
5995,Synergism with sulindac in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621654,,
5996,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL621655,,
5997,Cmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621656,,
5998,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621657,,
5999,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621658,,
6000,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621659,,
6001,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621660,,
6002,Cmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621661,,
6003,Cmax value in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621662,,
6004,Cmax value in dogs after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621663,,
6005,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621664,,
6006,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621665,1969.0,
6007,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621666,1969.0,
6008,Concentration maxima after oral dosing in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621667,,
6009,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876738,,
6010,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621668,,
6011,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621669,,
6012,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621670,,
6013,In vivo maximal concentration was calculated at 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621671,,
6014,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622360,,
6015,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622361,,
6016,Cmax in dog plasma after oral dose (1 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622362,1969.0,
6017,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622363,1969.0,
6018,Maximal plasma concentration at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622364,1969.0,
6019,Maximal plasma concentration at a dose of 1 mg/kg (oral),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622365,1969.0,
6020,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622533,1969.0,
6021,Maximum concentration of compound in dog was evaluated.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622534,,
6022,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622535,,
6023,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876739,,
6024,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622536,,
6025,Maximum concentration obtained in dog plasma was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622537,1969.0,
6026,Maximum concentration was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622538,,
6027,Maximum concentration at the dose of 2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627867,,
6028,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627868,,
6029,Maximum concentration was evaluated in dog plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627869,1969.0,
6030,Maximum concentration was evaluated after 75 min after administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627870,,
6031,Maximum plasma concentration determined in dog after oral administration of 17b,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627871,1969.0,
6032,Maximum plasma concentration determined in dog after oral administration of 2b,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627872,1969.0,
6033,Maximum plasma concentration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627873,1969.0,
6034,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627874,1969.0,
6035,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627875,1969.0,
6036,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627876,1969.0,
6037,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627877,1969.0,
6038,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627878,1969.0,
6039,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627879,1969.0,
6040,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875355,1969.0,
6041,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627880,1969.0,
6042,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627881,1969.0,
6043,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627882,1969.0,
6044,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627883,1969.0,
6045,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628526,1969.0,
6046,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628527,1969.0,
6047,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628528,1969.0,
6048,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628529,1969.0,
6049,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628530,1969.0,
6050,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625243,1969.0,
6051,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL625244,1969.0,
6052,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625245,,
6053,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625246,,
6054,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625247,945.0,
6055,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625248,1088.0,
6056,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625249,1088.0,
6057,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625250,1088.0,
6058,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625251,,
6059,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875356,,
6060,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625252,,
6061,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625253,178.0,
6062,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625254,,
6063,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625255,,
6064,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625256,,
6065,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625257,178.0,
6066,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625258,178.0,
6067,Compound was evaluated for washout rate in mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625259,,
6068,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625260,,
6069,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625261,,
6070,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625262,,
6071,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622639,,
6072,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622640,,
6073,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622812,,
6074,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622813,,
6075,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622814,,
6076,Time at maximum activity in mice (Radiolabeled compound),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622815,,
6077,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625342,,
6078,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625343,,
6079,Binding towards mouse plasma protein at 10 uM,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL877591,,
6080,Binding towards mouse plasma protein at 100 uM,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625344,,
6081,Bioavailability was evaluated in mice after intravenous administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625345,,
6082,Bioavailability was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625346,,
6083,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625347,,
6084,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625348,,
6085,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625349,,
6086,Oral bioavailability in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625350,,
6087,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL882952,,
6088,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625351,955.0,
6089,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625352,955.0,
6090,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL877592,955.0,
6091,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625353,955.0,
6092,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625354,955.0,
6093,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626019,955.0,
6094,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626020,948.0,
6095,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626021,948.0,
6096,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626022,948.0,
6097,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626192,948.0,
6098,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626193,,
6099,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL626194,,
6100,Cytotoxicity against human lung carcinoma A-549 cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626195,,
6101,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626196,,
6102,In vitro cytotoxicity against human lung carcinoma cell line A-549,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626197,,
6103,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626198,,
6104,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626199,,
6105,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626200,,
6106,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626201,,
6107,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626202,,
6108,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626203,,
6109,In vitro cytotoxicity against A-549 human lung cancer cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL626204,,
6110,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624701,,
6111,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624702,,
6112,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624703,,
6113,Tested in vitro for cytotoxicity against A-549 lung cancer cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624704,,
6114,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624705,,
6115,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624706,,
6116,Antitumor cytotoxic activity against A-549 cell line was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624707,,
6117,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624708,,
6118,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624709,,
6119,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL884107,,
6120,Antitumoral activity was assayed against A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624710,,
6121,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624711,,
6122,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624712,,
6123,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624713,,
6124,Compound was tested for inhibition of cell growth of A-549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624714,,
6125,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624715,,
6126,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624716,,
6127,In vitro cytotoxicity against A549-human lung carcinoma cells.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619505,,
6128,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619506,,
6129,Cytotoxic activity against A-549 cell lines.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619507,,
6130,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619508,,
6131,Cytotoxicity against human A549 non small cell lung cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619509,,
6132,Inhibition of cell growth in (A-549) lung cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619510,,
6133,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619511,,
6134,In vitro antitumor activity against A-549 tumor cells.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619512,,
6135,In vitro antitumor effects against human A-549 cell lines.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619513,,
6136,In vitro cytotoxic activity of compound against A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619514,,
6137,In vitro cytotoxicity against human lung carcinoma A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619515,,
6138,In vitro cytotoxicity against human non-small cell lung carcinoma A549,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619516,,
6139,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL884005,,
6140,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619517,,
6141,Inhibitory concentration of compound against A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619518,,
6142,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619519,,
6143,cytotoxic activity against leukemia (A-549) cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876489,,
6144,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619520,,
6145,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619521,,
6146,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619522,,
6147,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619523,,
6148,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619524,,
6149,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619525,,
6150,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619526,,
6151,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619527,,
6152,Cytotoxicity against A549 cells; No cytotoxicity,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619528,,
6153,Cytotoxicity against human lung carcinoma (A549) cell lines,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619529,,
6154,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619530,,
6155,In vitro anticancer activity against human lung (A549) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876490,,
6156,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619531,,
6157,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619532,,
6158,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619533,,
6159,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619534,,
6160,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620164,,
6161,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620165,,
6162,Inhibition of A549 human lung tumor cell proliferation,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620166,,
6163,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620167,,
6164,In vitro cytotoxicity against human tumor cell line A549,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL620168,,
6165,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620338,,
6166,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620339,,
6167,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620340,,
6168,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620341,,
6169,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876491,,
6170,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620342,,
6171,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620343,,
6172,% inhibition against A549 cells (lung cancer) at 4 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620344,,
6173,In vitro anticancer activity against human lung (A549) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620345,,
6174,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620346,,
6175,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620347,,
6176,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620348,,
6177,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620349,,
6178,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL618667,,
6179,Percentage inhibition of human lung carcinoma (A549) cell lines,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL618668,,
6180,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876031,,
6181,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL618759,,
6182,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL618760,,
6183,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619000,,
6184,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619001,,
6185,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619002,,
6186,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619003,,
6187,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619597,,
6188,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619598,,
6189,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619599,,
6190,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619600,,
6191,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619601,,
6192,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619602,,
6193,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619603,,
6194,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619604,,
6195,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619605,,
6196,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619606,,
6197,Pharmacokinetic activity (Cmax) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876032,,
6198,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619607,,
6199,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619608,,
6200,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619609,,
6201,Cmax in dog plasma after 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619610,1969.0,
6202,Tested for the peak blood level in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619611,178.0,
6203,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619612,,
6204,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619613,,
6205,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619614,178.0,
6206,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619615,,
6207,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619616,,
6208,Final plasma concentration in dogs after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619617,1969.0,
6209,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619618,,
6210,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876033,,
6211,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619619,,
6212,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619620,,
6213,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619621,1088.0,
6214,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619622,1088.0,
6215,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618874,1088.0,
6216,Absolute bioavailability was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618875,,
6217,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618876,,
6218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618877,,
6219,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618878,,
6220,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618879,,
6221,Bioavailability after intravenous administration in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618880,,
6222,Bioavailability after peroral administration in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618881,,
6223,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618882,,
6224,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624226,,
6225,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624227,1969.0,
6226,Bioavailability,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624228,,
6227,Bioavailability,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624229,,
6228,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624230,,
6229,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624231,,
6230,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624232,,
6231,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625127,,
6232,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625128,,
6233,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621675,,
6234,Bioavailability in dog (p.o.) at 2.0 mpk,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621676,,
6235,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621677,,
6236,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621678,,
6237,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621679,,
6238,Bioavailability was evaluated after oral administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621680,,
6239,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621681,,
6240,Bioavailability was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876740,,
6241,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621682,,
6242,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621683,,
6243,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621684,,
6244,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621685,,
6245,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621686,,
6246,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621687,,
6247,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621688,,
6248,Bioavailability of compound in dog was determined after peroral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621689,,
6249,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621690,,
6250,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621691,,
6251,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875941,,
6252,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621692,,
6253,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621693,,
6254,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621694,,
6255,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621695,948.0,
6256,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621696,948.0,
6257,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621697,2113.0,
6258,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621698,2113.0,
6259,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623420,2113.0,
6260,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623421,2113.0,
6261,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623422,2113.0,
6262,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623423,2113.0,
6263,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623424,2107.0,
6264,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623425,2107.0,
6265,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623426,2107.0,
6266,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623427,2107.0,
6267,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623428,2107.0,
6268,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875947,2107.0,
6269,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623429,2048.0,
6270,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623430,2048.0,
6271,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622588,2048.0,
6272,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622589,2048.0,
6273,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622751,2048.0,
6274,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622752,2048.0,
6275,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622753,,
6276,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622647,,
6277,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL875163,,
6278,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622648,,
6279,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622649,,
6280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622650,955.0,
6281,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622651,955.0,
6282,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622652,955.0,
6283,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622653,955.0,
6284,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622654,955.0,
6285,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622655,948.0,
6286,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622656,948.0,
6287,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622657,948.0,
6288,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622658,948.0,
6289,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL622659,948.0,
6290,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624630,2113.0,
6291,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624631,2113.0,
6292,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624632,2113.0,
6293,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624633,,
6294,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624634,,
6295,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624635,,
6296,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624636,,
6297,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL857055,,
6298,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624637,,
6299,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624638,,
6300,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL874366,,
6301,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624639,,
6302,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL624640,,
6303,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624641,,
6304,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624642,,
6305,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624643,,
6306,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624644,,
6307,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL624645,,
6308,The compound was evaluated for its cytotoxic potency against A-549 cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619445,,
6309,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL839886,,
6310,Cytotoxic activity of compound against A-549 tumor cell line.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619446,,
6311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619447,,
6312,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619448,,
6313,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619449,,
6314,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619450,,
6315,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619451,,
6316,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619452,,
6317,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619453,,
6318,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL874367,,
6319,Cytotoxic concentration against A-549 tumor cells.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619454,,
6320,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619455,,
6321,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619456,,
6322,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,BAO_0000218,Expert,,,50191,N,1,1,,CHEMBL619457,,
6323,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,Intermediate,,,50192,N,1,1,,CHEMBL619458,,
6324,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,Expert,,,50274,N,1,1,,CHEMBL619459,,
6325,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,Expert,,,50274,N,1,1,,CHEMBL619460,,
6326,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,BAO_0000218,Intermediate,,,50416,N,1,1,,CHEMBL619461,,
6327,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,BAO_0000218,Intermediate,,,50416,N,1,1,,CHEMBL619462,,
6328,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,Intermediate,,,50416,N,1,1,,CHEMBL620388,,
6329,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,Intermediate,,,50416,N,1,1,,CHEMBL620389,,
6330,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,Intermediate,,,50416,N,1,1,,CHEMBL620390,,
6331,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,Expert,,,50416,N,1,1,,CHEMBL620391,,
6332,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,Expert,,,50416,N,1,1,,CHEMBL621073,,
6333,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL621074,,
6334,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL621075,,
6335,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL619554,,
6336,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL619555,,
6337,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,BAO_0000218,Intermediate,,,50169,N,1,1,,CHEMBL619556,,
6338,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,BAO_0000218,Intermediate,,,50169,N,1,1,,CHEMBL619557,,
6339,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,BAO_0000218,Intermediate,,,50169,N,1,1,,CHEMBL619558,,
6340,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619559,,
6341,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619560,,
6342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619561,,
6343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619562,,
6344,% inhibition against A549 cells (lung cancer) at 4 ug/mL,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619563,,
6345,GI values against A549 cells (lung cancer),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL857457,,
6346,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619564,,
6347,Inhibitory activity against A549 human adenocarcinoma,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619565,,
6348,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL619566,,
6349,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL619567,,
6350,Inhibitory activity against A549 lung adenocarcinoma cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619568,,
6351,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619569,,
6352,Cytotoxicity against human A549 lung cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619570,,
6353,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,646.0,BAO_0000218,Intermediate,,A549,80682,N,1,1,,CHEMBL619571,,
6354,Growth inhibition of A549 (human lung carcinoma) cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619572,,
6355,Effective dose required for inhibitory activity against A549 human tumor cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619573,,
6356,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619574,,
6357,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619575,,
6358,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL619576,,
6359,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619577,,
6360,In vitro inhibitory activity against A549 tumor cell culture,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619578,,
6361,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL884009,,
6362,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619579,,
6363,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619580,,
6364,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619581,,
6365,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619582,,
6366,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619583,,
6367,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL876502,,
6368,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619584,,
6369,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619585,,
6370,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619586,,
6371,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619587,,
6372,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619588,,
6373,Tested in vitro for cytotoxicity in A549/ATCC cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619589,,
6374,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619590,,
6375,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619591,,
6376,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619592,,
6377,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL619593,,
6378,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620217,,
6379,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620218,,
6380,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620219,,
6381,Antitumor activity against A549/ATCC cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL620220,,
6382,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL625141,,
6383,In vitro cytotoxicity against A549/ATCC cell line.,646.0,BAO_0000219,Expert,,A549,80682,N,1,1,,CHEMBL625142,,
6384,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL625143,,
6385,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL625144,,
6386,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL622474,,
6387,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,646.0,BAO_0000219,Intermediate,,A549,80682,N,1,1,,CHEMBL884104,,
6388,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL622475,,
6389,Compound was tested for oral bioavailability in dogs,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL622476,,
6390,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875831,,
6391,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622477,,
6392,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622478,,
6393,Compound was tested for the oral bioavailability in dog; No availability,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623172,,
6394,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623173,,
6395,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623174,,
6396,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623175,,
6397,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623340,,
6398,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623341,,
6399,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623342,,
6400,Oral bioavailability of active FTIs in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623343,,
6401,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623344,,
6402,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL623345,,
6403,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875832,,
6404,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623346,,
6405,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623347,,
6406,Oral bioavailability of compound was determined in dog; Not tested,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623348,,
6407,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623349,,
6408,Oral bioavailability (10 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623350,,
6409,Oral bioavailability,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623351,,
6410,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623352,,
6411,Oral bioavailability administered in solution in rats,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623353,,
6412,Oral bioavailability after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875833,,
6413,Oral bioavailability at a dose of 1 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623354,,
6414,Oral bioavailability in dog (dose 1 mg/kg p.o.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623355,,
6415,Oral bioavailability in Dog; ND = not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623356,,
6416,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623357,,
6417,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623358,,
6418,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623359,,
6419,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623360,,
6420,Oral bioavailability in dogs; No data,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623361,,
6421,Oral bioavailability measured in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623362,,
6422,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623363,,
6423,Oral bioavailability was calculated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623364,,
6424,Oral bioavailability after 0.3 mg/kg po administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875834,,
6425,Oral bioavailability in dog (i.v. dosing),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623365,,
6426,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623366,,
6427,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623367,,
6428,Oral bioavailability in Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623368,,
6429,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623369,,
6430,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623370,,
6431,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623371,,
6432,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623372,,
6433,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621351,,
6434,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621352,,
6435,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621353,,
6436,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621354,,
6437,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621355,,
6438,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621356,,
6439,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621357,,
6440,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621358,,
6441,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621359,,
6442,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621360,,
6443,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621361,,
6444,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621362,,
6445,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621363,,
6446,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621364,,
6447,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621166,,
6448,Oral bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621167,,
6449,Oral bioavailability (F) in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621168,,
6450,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621169,,
6451,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875950,,
6452,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621170,,
6453,Oral bioavailability after peroral administration at 5 mpk in Dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621171,,
6454,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621172,,
6455,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621173,,
6456,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621174,2113.0,
6457,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621175,2113.0,
6458,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621176,2107.0,
6459,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621177,2107.0,
6460,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621178,2107.0,
6461,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621179,2107.0,
6462,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621180,2107.0,
6463,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL875951,2048.0,
6464,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621181,2048.0,
6465,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621182,2048.0,
6466,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621183,2048.0,
6467,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621184,2048.0,
6468,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621185,,
6469,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621186,,
6470,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621187,,
6471,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621188,,
6472,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621189,,
6473,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621190,2106.0,
6474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL618520,2106.0,
6475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621739,2106.0,
6476,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621740,2106.0,
6477,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621741,2106.0,
6478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621742,,
6479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621743,,
6480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621744,,
6481,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621745,,
6482,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621746,,
6483,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621747,,
6484,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621748,,
6485,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621749,,
6486,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621750,,
6487,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621751,,
6488,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621752,948.0,
6489,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621753,948.0,
6490,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL875955,948.0,
6491,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621754,948.0,
6492,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621755,948.0,
6493,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL621756,2107.0,
6494,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624199,2107.0,
6495,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624200,2107.0,
6496,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624375,2107.0,
6497,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624376,2107.0,
6498,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624377,2048.0,
6499,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624378,2048.0,
6500,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,Intermediate,,,50067,N,1,1,,CHEMBL857901,,
6501,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,Intermediate,,,50067,N,1,1,,CHEMBL875274,,
6502,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,Intermediate,,,50067,N,1,1,,CHEMBL624379,,
6503,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,Intermediate,,,50067,N,1,1,,CHEMBL624380,,
6504,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,Intermediate,,,50192,N,1,1,,CHEMBL624381,,
6505,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,BAO_0000218,Intermediate,,,50714,N,1,1,,CHEMBL624382,,
6506,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,BAO_0000218,Intermediate,,,50714,N,1,1,,CHEMBL624383,,
6507,Chlorohexidine coefficient for Actinomyces naeslundii 631,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624384,,
6508,Chlorohexidine coefficient for Actinomyces naeslundii B74,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624385,,
6509,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624386,,
6510,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624387,,
6511,Plaque bactericidal index against Actinomyces naeslundii 631,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624388,,
6512,Plaque bactericidal index against Actinomyces naeslundii N/9,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624389,,
6513,Plaque bactericidal index against Actinomyces naeslundii B74,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL624390,,
6514,Plaque bactericidal index against Actinomyces naeslundii N/3,,BAO_0000218,Intermediate,,,50296,N,1,1,,CHEMBL875275,,
6515,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,BAO_0000218,Intermediate,,,50056,N,1,1,,CHEMBL624391,,
6516,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,BAO_0000218,Intermediate,,,50056,N,1,1,,CHEMBL623636,,
6517,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623637,,
6518,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623638,,
6519,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623639,,
6520,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623640,,
6521,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623641,,
6522,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623642,,
6523,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623643,,
6524,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623644,,
6525,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623645,,
6526,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623646,,
6527,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623647,,
6528,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,BAO_0000218,Intermediate,,,50532,N,1,1,,CHEMBL623648,,
6529,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623649,,
6530,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623650,,
6531,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623651,,
6532,Chlorohexidine coefficient for Actinomyces viscosus M-100,,BAO_0000218,Expert,,,50366,N,1,1,,CHEMBL623652,,
6533,Chlorohexidine coefficient for Actinomyces viscosus M-626,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623653,,
6534,Chlorohexidine coefficient for Actinomyces viscosus T14V,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623654,,
6535,Plaque bactericidal index against Actinomyces viscosus 8A06,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623655,,
6536,Plaque bactericidal index against Actinomyces viscosus M-100,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623656,,
6537,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,BAO_0000218,Expert,,,50366,N,1,1,,CHEMBL623657,,
6538,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623658,,
6539,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623659,,
6540,Plaque bactericidal index against Actinomyces viscosus 626,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623660,,
6541,Plaque bactericidal index against Actinomyces viscosus T14V,,BAO_0000218,Intermediate,,,50366,N,1,1,,CHEMBL623661,,
6542,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL875281,,
6543,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL623662,,
6544,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL623663,,
6545,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL623664,,
6546,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL623665,,
6547,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,165.0,BAO_0000219,Intermediate,,A673,80023,N,1,1,,CHEMBL621856,,
6548,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,645.0,BAO_0000219,Intermediate,,A704,80661,N,1,1,,CHEMBL620432,,
6549,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL620433,,
6550,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL620434,,
6551,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL620435,,
6552,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL620436,,
6553,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL876597,,
6554,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,874.0,BAO_0000219,Expert,,Human ovarian carcinoma cell line,81037,N,1,1,,CHEMBL620437,,
6555,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",625.0,BAO_0000219,Expert,,A9,80024,N,1,1,,CHEMBL620438,,
6556,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,625.0,BAO_0000219,Expert,,A9,80024,N,1,1,,CHEMBL620439,,
6557,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,625.0,BAO_0000219,Expert,,A9,80024,N,1,1,,CHEMBL619657,,
6558,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL619658,,
6559,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL619659,,
6560,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,BAO_0000019,Expert,,,10649,H,8,1,,CHEMBL619660,,
6561,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL619661,,
6562,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,625.0,BAO_0000219,Intermediate,,A9,80024,N,1,1,,CHEMBL619662,,
6563,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,975.0,BAO_0000219,Intermediate,,AA6,80663,N,1,1,,CHEMBL619663,,
6564,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL619664,,
6565,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,BAO_0000219,Autocuration,,,22226,U,0,1,,CHEMBL619665,,
6566,Anti -HIV activity was measured against AA5/HIV-1(IIIB),974.0,BAO_0000219,Intermediate,,AA5,80662,N,1,1,,CHEMBL883244,,
6567,Cytotoxicity was measured against AA5/HIV-1(IIIB),974.0,BAO_0000219,Intermediate,,AA5,80662,N,1,1,,CHEMBL884011,,
6568,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,974.0,BAO_0000219,Intermediate,,AA5,80662,N,1,1,,CHEMBL619666,,
6569,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,379.0,BAO_0000219,Intermediate,,U-937,80566,N,1,1,,CHEMBL619667,,
6570,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,274.0,BAO_0000219,Intermediate,,UV4,80578,N,1,1,,CHEMBL619668,,
6571,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL619669,,
6572,Average intracellular compound concentration when the hypoxic SER=1.6,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL876608,,
6573,Average intracellular compound concentration when the hypoxic SER=1.6.,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619670,,
6574,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619671,,
6575,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619672,,
6576,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619673,,
6577,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619674,,
6578,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619675,,
6579,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619676,,
6580,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619677,,
6581,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619678,,
6582,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL619679,,
6583,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL619680,,
6584,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL621457,,
6585,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL876609,,
6586,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL621458,,
6587,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL621459,,
6588,Aerobic growth inhibition in Chinese hamster cell line AA8,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL621460,,
6589,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL621461,,
6590,Inhibition of growth under aerobic conditions in AA8 cells,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL621462,,
6591,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621463,,
6592,Oral bioavailability in dog at 10 mg/kg of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621464,,
6593,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621465,,
6594,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621466,,
6595,Oral bioavailability in dog (mongrel),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621467,,
6596,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621468,,
6597,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876734,,
6598,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618476,,
6599,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618477,,
6600,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618478,,
6601,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618479,,
6602,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618480,,
6603,Bioavailability in dog (dose 3-10 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618481,,
6604,The compound was tested for bioavailability of compound in plasma of dog; Complete,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618482,1969.0,
6605,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618483,,
6606,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618484,,
6607,Bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618485,,
6608,oral bioavailability was measured in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618486,,
6609,Compound was tested for plasma protein binding in dog; Not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618487,,
6610,Compound was tested for plasma protein binding of dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618488,,
6611,Compound was tested for plasma protein binding of dog; Not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876735,,
6612,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618489,,
6613,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618490,,
6614,Half life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618491,,
6615,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618492,,
6616,Half life was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873354,,
6617,Half life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618493,,
6618,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618494,,
6619,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618495,948.0,
6620,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618496,2113.0,
6621,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618497,2107.0,
6622,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618498,2048.0,
6623,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618499,2106.0,
6624,LogP in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876736,,
6625,Partition coefficient (logP),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618500,,
6626,Partition coefficient in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL857831,,
6627,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618501,,
6628,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618502,,
6629,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618503,,
6630,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618504,,
6631,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618505,,
6632,Metabolism of compound in dog S9 microsomes; Trace,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618506,,
6633,In vitro metabolic potential in dog liver microsomes,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618507,2107.0,
6634,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876737,,
6635,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618508,,
6636,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618509,,
6637,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618510,,
6638,The compound was tested for bioavailability in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618511,,
6639,The compound was tested for oral bioavailability in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618512,,
6640,Oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618513,,
6641,Compound was tested for percent protein binding (PB) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618514,,
6642,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620052,,
6643,Compound was evaluated for plasma clearance.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620053,1969.0,
6644,The compound was tested for plasma clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620054,1969.0,
6645,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620055,1969.0,
6646,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620056,,
6647,In vitro relative rate of metabolism was determined in dog liver microsomes,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620057,2107.0,
6648,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618939,,
6649,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618940,,
6650,Half life after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618941,,
6651,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624473,2048.0,
6652,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624474,2048.0,
6653,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624475,2048.0,
6654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL624476,,
6655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL623478,,
6656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL623479,,
6657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL623480,,
6658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,42.0,BAO_0000218,Intermediate,,CCRF S-180,50594,N,1,1,,CHEMBL623481,,
6659,C2 in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623482,955.0,
6660,C2 in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623483,2113.0,
6661,C2 in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623484,2107.0,
6662,C2 in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623485,2048.0,
6663,C2 in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623486,2106.0,
6664,Plasma clearance in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623487,,
6665,Clearance of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623488,,
6666,Clearance from mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623489,,
6667,Clearance was evaluated in mice after intravenous administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875157,,
6668,Clearance was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623490,,
6669,Pharmacokinetic property (Plasma clearance) was measured in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623491,,
6670,Plasma clearance of compound was determined at 40 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623492,,
6671,Plasma clearance of at 24 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623493,,
6672,Plasma clearance at 24 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623494,,
6673,Plasma clearance at 5 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623495,,
6674,Plasma clearance in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623496,,
6675,Plasma clearance value upon iv administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623497,,
6676,Total plasma clearance in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623498,1969.0,
6677,Clearance in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623499,,
6678,Clearance value was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623500,,
6679,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623501,,
6680,Calculated partition coefficient (clogP),,BAO_0000100,Intermediate,,,22229,U,0,1,,CHEMBL875158,,
6681,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623502,,
6682,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623503,,
6683,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623504,,
6684,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623505,,
6685,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623506,,
6686,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623507,,
6687,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623508,,
6688,Cmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623509,,
6689,Cmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875159,,
6690,Cmax in brain of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623510,955.0,
6691,Cmax in kidney of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623511,2113.0,
6692,Cmax in liver of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623512,2107.0,
6693,Cmax in lungs of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623513,2048.0,
6694,Cmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623514,,
6695,Cmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622609,,
6696,Cmax in mice at 24 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622610,,
6697,Cmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621823,,
6698,Cmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621824,,
6699,Cmax in spleen of mice at the oral dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621825,2106.0,
6700,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621826,,
6701,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621827,,
6702,Cmax value was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621828,,
6703,Cmax value in IRC mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621829,,
6704,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621830,,
6705,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621831,,
6706,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621832,1969.0,
6707,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624579,1969.0,
6708,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624580,,
6709,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL624581,,
6710,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL624582,,
6711,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,BAO_0000218,Intermediate,,,50535,N,1,1,,CHEMBL624583,,
6712,Inhibitory activity against human tumor cell line A0375 melanoma.,455.0,BAO_0000219,Intermediate,,A-375,80018,N,1,1,,CHEMBL624584,,
6713,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,BAO_0000249,Expert,Brain membranes,,12512,D,9,1,,CHEMBL624585,,
6714,Forskolin-induced cAMP production at human A1 adenosine receptor,,BAO_0000019,Expert,,,114,D,9,1,,CHEMBL875165,,
6715,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619490,,
6716,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619491,,
6717,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,449.0,BAO_0000219,Expert,,CHO,114,H,8,1,,CHEMBL619492,,
6718,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,449.0,BAO_0000219,Expert,,CHO,114,H,8,1,,CHEMBL619493,,
6719,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619494,,
6720,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619495,,
6721,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619496,,
6722,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,449.0,BAO_0000219,Expert,,CHO,114,D,9,1,,CHEMBL619497,,
6723,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619498,,
6724,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619499,,
6725,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,449.0,BAO_0000219,Expert,,CHO,114,H,8,1,,CHEMBL619500,,
6726,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619501,,
6727,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,449.0,BAO_0000219,Expert,,CHO,114,H,8,1,,CHEMBL619502,,
6728,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619503,,
6729,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL619504,,
6730,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL621298,,
6731,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,449.0,BAO_0000219,Expert,,CHO,114,H,8,1,,CHEMBL621299,,
6732,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL621300,,
6733,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,449.0,BAO_0000219,Autocuration,,CHO,114,H,8,1,,CHEMBL621301,,
6734,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,449.0,BAO_0000219,Expert,,CHO,114,H,8,1,,CHEMBL621302,,
6735,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,164.0,BAO_0000219,Intermediate,,A10,80013,N,1,1,,CHEMBL621303,,
6736,In vitro potassium channel opening activity in A10 (smooth muscle) cells,164.0,BAO_0000219,Autocuration,,A10,22226,U,0,1,,CHEMBL621304,,
6737,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,164.0,BAO_0000219,Autocuration,,A10,22226,U,0,1,,CHEMBL621305,,
6738,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,164.0,BAO_0000219,Intermediate,,A10,80013,N,1,1,,CHEMBL621306,,
6739,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,164.0,BAO_0000219,Intermediate,,A10,80013,N,1,1,,CHEMBL618444,,
6740,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,164.0,BAO_0000219,Intermediate,,A10,80013,N,1,1,,CHEMBL618445,,
6741,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618446,,
6742,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618447,,
6743,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618448,,
6744,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618449,,
6745,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618637,,
6746,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618638,,
6747,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618639,,
6748,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL618640,,
6749,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL618641,,
6750,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618642,,
6751,Inhibitory activity against aerobic growth of AA8 cells.,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL618643,,
6752,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL884013,,
6753,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL622723,,
6754,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622724,,
6755,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL622725,,
6756,Cytotoxicity against AA8 cell line,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL622726,,
6757,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622727,,
6758,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622728,,
6759,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622729,,
6760,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622730,,
6761,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622731,,
6762,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622732,,
6763,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,185.0,BAO_0000219,Intermediate,,CHO-AA8,80089,N,1,1,,CHEMBL622733,,
6764,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622734,,
6765,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL622735,,
6766,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618746,,
6767,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618747,,
6768,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL620540,,
6769,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL620541,,
6770,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL620542,,
6771,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL620543,,
6772,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618832,,
6773,Concentration required to reduce AA8 cell survival by 10%,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL618833,,
6774,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618834,,
6775,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618835,,
6776,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618836,,
6777,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618837,,
6778,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618838,,
6779,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618839,,
6780,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618840,,
6781,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618841,,
6782,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618842,,
6783,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL618843,,
6784,Half life period after 15 mg/kg iv dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618844,,
6785,Half life period after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618845,,
6786,Half life was measured after oral 2b administration (tested in 6 dogs),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618846,,
6787,Half life was measured in dog after oral 17b administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618847,,
6788,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618848,,
6789,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618849,,
6790,Tmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618850,,
6791,Tmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618851,,
6792,Compound was evaluated for its half life when administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873815,,
6793,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618852,1969.0,
6794,Elimination Half-life of compound was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618853,,
6795,Half life of compound in dog following oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618854,,
6796,Half life of compound was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618855,,
6797,Half life of compound was determined in dog blood,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618856,178.0,
6798,Half life after oral and iv dosing in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875827,,
6799,Half life in dogs in hours,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618857,,
6800,Half life on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618858,,
6801,t1/2 in dog after oral dose (1 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618859,,
6802,Half life was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618860,,
6803,Half life period of compound was determined after intravenous administration at 2 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618861,,
6804,Half life period of compound was determined after peroral administration at 2 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622539,,
6805,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622540,,
6806,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873803,,
6807,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873804,,
6808,Half life period by po administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624311,,
6809,Half life period in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624312,,
6810,Half life period in dogs after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624313,,
6811,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624314,,
6812,Half-life of compound was determined in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624315,,
6813,Half-life in dog plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624316,1969.0,
6814,Half-life in mongrel dogs was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624317,,
6815,Half-life in dog upon oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624318,,
6816,Half-life in dog upon oral administration; Unable to calculate,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624319,,
6817,Half-life was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624496,,
6818,Half-life was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624497,,
6819,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624498,,
6820,Oral half life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624499,,
6821,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624500,1969.0,
6822,Plasma half life was evaluated,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624501,1969.0,
6823,Plasma half life was evaluated in Dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623666,1969.0,
6824,Plasma half life was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623667,1969.0,
6825,T1/2 (Half-life) was after oral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623668,,
6826,Tested for the half life value in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623669,,
6827,Maximum time at the dose of 2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623670,,
6828,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623671,,
6829,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875945,178.0,
6830,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623672,178.0,
6831,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623673,,
6832,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623674,,
6833,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623675,,
6834,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL872526,,
6835,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623676,,
6836,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623677,1969.0,
6837,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623678,1969.0,
6838,Time taken for maximum plasma concentration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623679,1969.0,
6839,Time to reach Cmax after oral administration to dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623680,,
6840,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623681,1969.0,
6841,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623682,,
6842,Tmax after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623683,,
6843,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL623684,,
6844,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622745,,
6845,Tmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622746,,
6846,In vivo Cmax in mice at dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622747,,
6847,In vivo Cmax in mice at dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622748,,
6848,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622749,,
6849,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622750,1969.0,
6850,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623411,1969.0,
6851,Maximum concentration obtained in mouse plasma was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875946,1969.0,
6852,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623412,1969.0,
6853,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623413,1969.0,
6854,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623414,1969.0,
6855,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623415,1969.0,
6856,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623416,1969.0,
6857,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623417,1969.0,
6858,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623418,1969.0,
6859,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623419,1969.0,
6860,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622816,,
6861,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623313,,
6862,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623314,,
6863,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876788,,
6864,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623315,,
6865,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623316,,
6866,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623317,,
6868,Cmax in male mice after 2 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623319,,
6869,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623320,,
6870,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623321,,
6871,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623322,,
6872,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623323,,
6873,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623324,,
6874,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623325,,
6875,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623326,,
6876,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623327,,
6877,Maximum concentration in plasma upon oral administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623328,1969.0,
6878,Maximum plasma concentration was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623329,1969.0,
6879,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623330,1969.0,
6880,Dose at which the compound induced fecal excretion in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876789,,
6893,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,164.0,BAO_0000219,Expert,,A10,80013,N,1,1,,CHEMBL623333,,
6894,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,164.0,BAO_0000219,Expert,,A10,80013,N,1,1,,CHEMBL623334,,
6895,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,164.0,BAO_0000219,Expert,,A10,80013,N,1,1,,CHEMBL627536,,
6896,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,164.0,BAO_0000219,Expert,,A10,80013,N,1,1,,CHEMBL627537,,
6897,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),164.0,BAO_0000219,Intermediate,,A10,80013,N,1,1,,CHEMBL627538,,
6898,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL884106,,
6899,Anticancer activity against human ovarian carcinoma A121 cells,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL625294,,
6900,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL625295,,
6901,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL625296,,
6902,Growth inhibition of human ovarian carcinoma (A121) cell line,393.0,BAO_0000219,Expert,,A121,80655,N,1,1,,CHEMBL625297,,
6903,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,393.0,BAO_0000219,Expert,,A121,80655,N,1,1,,CHEMBL625298,,
6904,Cytotoxicity against human A121 ovarian cells,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL625960,,
6905,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL625961,,
6906,In vitro cytotoxicity against human ovarian carcinoma A21,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL625962,,
6907,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL624717,,
6908,Inhibitory activity of compound against human A121 ovarian cell line.,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL624718,,
6909,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL624719,,
6910,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,393.0,BAO_0000219,Intermediate,,A121,80655,N,1,1,,CHEMBL624720,,
6911,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL624721,,
6912,In vitro cytotoxicity against A172 human tumor cell lines.,622.0,BAO_0000219,Expert,,A 172,80012,N,1,1,,CHEMBL624722,,
6913,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL877597,,
6914,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL624723,,
6915,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,622.0,BAO_0000219,Intermediate,,A 172,80012,N,1,1,,CHEMBL624724,,
6916,Association constant against A2 adenosine receptor,,BAO_0000224,Autocuration,,,104729,H,4,1,,CHEMBL624725,,
6917,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1085.0,BAO_0000219,Intermediate,,A2,80656,N,1,1,,CHEMBL624726,,
6918,Ratio of Ki for adenosine A2 and A1 receptor binding,,BAO_0000224,Autocuration,,,104713,D,5,1,,CHEMBL857535,,
6919,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,623.0,BAO_0000219,Expert,,A204,80014,N,1,1,,CHEMBL624727,,
6920,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,623.0,BAO_0000219,Expert,,A204,80014,N,1,1,,CHEMBL624728,,
6921,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,404.0,BAO_0000219,Intermediate,,A2058,80015,N,1,1,,CHEMBL624729,,
6922,Growth inhibition against Human squamous cell line(A 253),973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL624730,,
6923,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL624731,,
6924,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL624732,,
6925,Growth inhibition of A253 cell lines.,973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL883245,,
6926,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL624733,,
6927,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL624734,,
6928,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,973.0,BAO_0000219,Intermediate,,A253 cell line,80657,N,1,1,,CHEMBL624735,,
6929,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621780,,
6930,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL877598,,
6931,Cytotoxic activity against A2780 human ovarian carcinoma cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621781,,
6932,Cytotoxicity against human cancer cell lines A2780 (ovarian),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621782,,
6933,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621783,,
6934,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621784,,
6935,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621785,,
6936,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621968,,
6937,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621969,,
6938,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621970,,
6939,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621971,,
6940,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621972,,
6941,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL884108,,
6942,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623826,,
6943,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623827,,
6944,Evaluated for growth inhibition of AA8 cells under aerobic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623828,,
6945,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623829,,
6946,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623830,,
6947,Growth inhibition against CHO-derived cell line AA8,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623831,,
6948,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623832,,
6949,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL623833,,
6950,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL623834,,
6951,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623835,,
6952,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623836,,
6953,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,185.0,BAO_0000219,Autocuration,,CHO-AA8,22224,U,0,1,,CHEMBL623837,,
6954,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,185.0,BAO_0000219,Expert,,CHO-AA8,80089,N,1,1,,CHEMBL623838,,
6955,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,BAO_0000019,Autocuration,,,12675,H,8,1,,CHEMBL623839,,
6956,Number of binding sites (n) of isolated serum protein AAG,,BAO_0000019,Autocuration,,,12675,H,8,1,,CHEMBL623840,,
6957,Association constant for binding to AATT duplex,,BAO_0000225,Intermediate,,,22222,M,3,1,,CHEMBL623841,,
6958,Inhibition of ABAE human fibroblast cell proliferation,416.0,BAO_0000219,Expert,,ABAE,100090,N,1,1,,CHEMBL623842,,
6959,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1064.0,BAO_0000218,Intermediate,,AC755,80668,N,1,1,,CHEMBL623843,,
6960,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,BAO_0000218,Expert,,,102444,D,9,1,,CHEMBL618669,,
6961,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,BAO_0000218,Expert,,,102444,D,9,1,,CHEMBL618670,,
6962,Inhibitory activity against angiotensin-converting enzyme (ACE).,,BAO_0000357,Autocuration,,,69,H,8,1,,CHEMBL618671,,
6963,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,BAO_0000357,Autocuration,,,69,H,8,1,,CHEMBL618672,,
6964,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,978.0,BAO_0000219,Intermediate,,ACH-2 cell line,80669,N,1,1,,CHEMBL618673,,
6965,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),978.0,BAO_0000219,Intermediate,,ACH-2 cell line,80669,N,1,1,,CHEMBL618674,,
6966,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,998.0,BAO_0000219,Autocuration,,T cell line,22224,U,0,1,,CHEMBL618675,,
6967,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),998.0,BAO_0000219,Autocuration,,T cell line,22224,U,0,1,,CHEMBL618676,,
6968,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),998.0,BAO_0000219,Autocuration,,T cell line,22224,U,0,1,,CHEMBL618677,,
6969,Inhibition of growth of renal cancer ACHN cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618678,,
6970,Inhibition of growth of ACHN renal cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618679,,
6971,Inhibitory concentration required against ACHN renal cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618680,,
6972,Concentration required to inhibit growth of human renal (ACHN) cell line,626.0,BAO_0000219,Expert,,ACHN,80025,N,1,1,,CHEMBL618681,,
6973,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618682,,
6974,Cytotoxic activity against ACHN Renal cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618683,,
6975,Cytotoxicity evaluation against ACHN renal cancer cells,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618684,,
6976,In vitro antitumor activity against human renal ACHN cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618685,,
6977,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL876499,,
6978,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618686,,
6979,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618687,,
6980,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618688,,
6981,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,626.0,BAO_0000219,Expert,,ACHN,80025,N,1,1,,CHEMBL618689,,
6982,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618690,,
6983,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL618691,,
6984,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL619373,,
6985,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL884008,,
6986,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL619374,,
6987,Compound was tested for the growth inhibition of ACHN renal tumor cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL619375,,
6988,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL619376,,
6989,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL619377,,
6990,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL619378,,
6991,Tmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL872527,,
6992,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876500,,
6993,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619379,,
6994,Volume distribution after 15 mg/kg iv dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619538,,
6995,Volume distribution after 30 mg/kg po dose in Dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619539,,
6996,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619540,,
6997,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619541,,
6998,Volume of distribution was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619542,,
6999,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619543,,
7000,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL619544,,
7001,The compound was tested for volume of distribution in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619545,,
7002,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619546,,
7003,Vd (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619547,,
7004,Vd in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619548,,
7005,Volume distribution was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619549,,
7006,Volume of distribution in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619550,,
7007,Volume of distribution by as 4 fold increase by iv administration in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876501,,
7008,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619551,,
7009,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619552,,
7010,Volume distribution at the dose of 2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619553,,
7011,Steady state volume of distribution was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618722,,
7012,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618723,,
7013,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618724,,
7014,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618725,,
7015,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618726,,
7016,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618727,,
7017,Pharmacokinetic property (vdss) was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624233,,
7018,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624234,,
7019,Vdss was determined after iv 0.1 mg/kg administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624235,,
7020,Volume displacement was calculated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624236,,
7021,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624237,,
7022,Volume distribution constant was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624238,,
7023,Volume distribution at a dose of 1 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624239,,
7024,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875829,,
7025,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624240,,
7026,Volume distribution (Vdss) was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624241,,
7027,Volume distribution (Vdss) was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624242,,
7028,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624243,,
7029,Volume of distribution in steady state was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624244,,
7030,Volume of distribution of compound was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624245,,
7031,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624246,,
7032,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624247,,
7033,Volume of distribution (Vdss) was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624248,,
7034,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624249,,
7035,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624250,,
7036,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624251,,
7037,Maximum rate of depolarization of the upstroke of the action potential,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624252,,
7038,Steady state volume distribution in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624253,,
7039,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624950,,
7040,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624951,,
7041,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875830,,
7042,Volume distribution in dog after administration of 1 mg/kg iv,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624952,,
7043,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624953,,
7044,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624954,,
7045,Vss on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624955,,
7046,Vss was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624956,,
7047,Vss in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625129,,
7048,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625130,,
7049,Volume distribution in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625131,,
7050,Volume of distribution in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625132,,
7051,Tested for the oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL872263,,
7060,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624336,,
7061,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624337,,
7062,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624338,,
7063,Bioavailability was measured in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624339,,
7064,Bioavailability in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624340,,
7065,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624341,,
7066,Bioavailability in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624342,,
7067,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624343,,
7068,Oral bioavailability in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624344,,
7069,Oral availability at 50 mg/kg po in male mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624345,,
7070,Oral bioavailability in mouse (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624346,,
7071,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50594,N,1,1,,CHEMBL624347,,
7072,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624348,,
7074,Oral bioavailability in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622754,,
7075,Oral bioavailability in vivo in mice;ND=Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622755,,
7076,Oral bioavailability in mouse at 10 mg/kg of the compound,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622756,,
7077,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622757,,
7078,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622758,,
7079,Tested for bioavailability of the compound,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622759,,
7080,Tested for half life at the dose of 10 mg/kg when administered intravenously,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622760,,
7081,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622761,1969.0,
7082,The plasma half life of compound was determined on heparin prepared by human plasma. ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622762,1969.0,
7083,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622763,1969.0,
7084,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622764,1969.0,
7085,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622765,1969.0,
7086,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622766,,
7087,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622767,,
7088,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622768,,
7089,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875948,178.0,
7090,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622769,178.0,
7091,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622770,178.0,
7092,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622771,178.0,
7093,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622772,178.0,
7094,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622773,178.0,
7095,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622774,178.0,
7096,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621725,10000001.0,
7097,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621726,10000001.0,
7098,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621727,,
7099,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622413,,
7100,Compound was evaluated for cytotoxicity against A2780 cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622414,,
7101,Inhibition of A2780 cell clonogenic assay,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622415,,
7102,Cytotoxic effect on ovarian cancer cell line (A2780),478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL884001,,
7103,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622416,,
7104,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622417,,
7105,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622590,,
7106,Antiproliferative activity against human A2780 cells,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622591,,
7107,Inhibition of human A2780 cell proliferation,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622592,,
7108,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622593,,
7109,Inhibition of human A2780 cell proliferation (No data),478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622594,,
7110,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622595,,
7111,Compound was evaluated against human Ovarian carcinoma cell line A2780,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622596,,
7112,Growth inhibition against A2780 wild-type ovarian cell lines,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622597,,
7113,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622598,,
7114,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,BAO_0000019,Autocuration,,,104766,D,5,1,,CHEMBL622599,,
7115,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622600,,
7116,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622601,,
7117,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622602,,
7118,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622603,,
7119,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622604,,
7120,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622605,,
7121,In vitro inhibition of human ovarian cell line A2780,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL622606,,
7122,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL619463,,
7123,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619464,,
7124,Concentration required to inhibit A2780-cell growth by 50%,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL619465,,
7125,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL619466,,
7126,Cytotoxic effect on human ovarian (A2780) cancer cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL619467,,
7127,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619468,,
7128,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL619469,,
7129,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL619470,,
7130,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619471,,
7131,Cytotoxicity against human ovarian carcinoma A2780 cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619472,,
7132,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL619473,,
7133,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL874368,,
7134,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL884003,,
7135,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622690,,
7136,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622691,,
7137,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL622692,,
7138,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL623406,,
7139,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL884004,,
7140,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL623407,,
7141,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL623408,,
7142,In vitro antitumor activity against A2780 cell line.,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL623409,,
7143,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL623410,,
7144,In vitro cytotoxicity against A2780 human ovarian cancer cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL623576,,
7145,Inhibitory activity against kidney A-CHN tumor cell growth in culture,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623577,,
7146,The IC50 value was measured on ACHN cell line in renal tumor type.,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623578,,
7147,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623579,,
7148,In vitro lethal concentration against most sensitive ACHN cell line,626.0,BAO_0000219,Expert,,ACHN,80025,N,1,1,,CHEMBL623580,,
7149,Tested for cytotoxic activity against renal cancer ACHN cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623581,,
7150,Compound tested for growth inhibition of renal cancer cell line ACHN,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL857456,,
7151,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623582,,
7152,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623583,,
7153,In vitro anticancer activity against ACHN renal cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623584,,
7154,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623585,,
7155,Percent selectivity was evaluated in renal ACHN cell lines,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623586,,
7156,In vitro inhibitory activity against renal ACHN cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623587,,
7157,Tested for cytotoxicity against ACHN cell lines in renal cancer,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL875279,,
7158,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623588,,
7159,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623589,,
7160,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623590,,
7161,Cytotoxic effect on renal cancer line ACHN,626.0,BAO_0000219,Expert,,ACHN,80025,N,1,1,,CHEMBL623591,,
7162,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623592,,
7163,In vitro inhibition of Renal Cancer ACHN cell lines,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623593,,
7164,Antitumor activity against human renal adenocarcinoma ACHN cells,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL623594,,
7165,Antitumor activity against human renal adenocarcinoma ACHN cells.,626.0,BAO_0000219,Expert,,ACHN,80025,N,1,1,,CHEMBL621833,,
7166,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL621834,,
7167,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL621835,,
7168,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL621836,,
7169,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL621837,,
7170,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL875280,,
7171,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL621838,,
7172,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,626.0,BAO_0000219,Intermediate,,ACHN,80025,N,1,1,,CHEMBL621839,,
7173,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621840,,
7174,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,BAO_0000019,Autocuration,,,10647,H,8,1,,CHEMBL621841,,
7175,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,468.0,BAO_0000218,Expert,,HEL,50529,N,1,1,,CHEMBL622979,,
7176,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,BAO_0000218,Intermediate,,,50529,N,1,1,,CHEMBL876595,,
7177,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,BAO_0000357,Autocuration,,,12159,H,8,1,,CHEMBL620221,,
7178,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,BAO_0000357,Autocuration,,,12159,H,8,1,,CHEMBL620222,,
7179,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,979.0,BAO_0000219,Intermediate,,ADDP cell line,80670,N,1,1,,CHEMBL620506,,
7180,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,980.0,BAO_0000219,Intermediate,,ADJ/PC6,80671,N,1,1,,CHEMBL620507,,
7181,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,980.0,BAO_0000219,Intermediate,,ADJ/PC6,80671,N,1,1,,CHEMBL620508,,
7182,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",980.0,BAO_0000219,Intermediate,,ADJ/PC6,80671,N,1,1,,CHEMBL620509,,
7183,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,980.0,BAO_0000219,Intermediate,,ADJ/PC6,80671,N,1,1,,CHEMBL620510,,
7184,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,980.0,BAO_0000219,Intermediate,,ADJ/PC6,80671,N,1,1,,CHEMBL620511,,
7185,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,980.0,BAO_0000219,Intermediate,,ADJ/PC6,80671,N,1,1,,CHEMBL620512,,
7186,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620513,,
7187,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620514,,
7188,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620515,,
7189,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620516,,
7190,AUC value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620517,1969.0,
7191,AUC value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620518,1969.0,
7192,Cmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620519,,
7193,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621386,,
7194,Tmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621387,,
7195,Compound was evaluated for its clearance when administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621388,,
7196,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621389,,
7197,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621390,,
7198,Calculated partition coefficient (clogP),,BAO_0000100,Intermediate,,,22229,U,0,1,,CHEMBL621391,,
7199,Half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621392,,
7200,Time taken for EC90 was determined when tested in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621393,,
7201,Half life (iv) was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621394,,
7202,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621395,2107.0,
7203,Area under the curve was calculated in dog after iv administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621396,,
7204,Area under the curve was calculated in dog after peroral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621397,,
7205,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621398,,
7206,pKa was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618818,,
7207,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618819,,
7208,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618820,,
7209,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873810,,
7210,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876606,,
7211,Compound was evaluated for the half-life (t 1/2) in hours,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618821,,
7212,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618822,178.0,
7213,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618823,178.0,
7214,Half life after intravenous administration of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618824,,
7215,Half life was measured in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618825,,
7216,Half life period in dog after 5 mg/kg dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618826,,
7217,Half life period was evaluated in dog; 4-4.8,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618827,,
7218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618828,,
7219,Half-life was determined in dog after a3 mg/kg of iv dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618829,,
7220,Half-life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618830,,
7221,Half life in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618831,,
7222,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619489,1969.0,
7223,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619649,,
7224,Compound was evaluated for the half life period after iv administration in Beagle dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876607,,
7225,Compound was evaluated for the half life period after oral administration in conscious dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619650,,
7226,Compound was tested for half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619651,,
7227,Compound was tested for its half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619652,,
7228,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619653,,
7229,Half life of compound in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619654,,
7230,Half life (iv) was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619655,,
7231,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619656,178.0,
7232,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873812,1969.0,
7233,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621365,1969.0,
7234,Half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621366,,
7235,Half life in dog plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621367,1969.0,
7236,Half life in dog plasma after administration of 0.25 mg/kg iv,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621368,1969.0,
7237,Half life in dog plasma after administration of 1 mg/kg iv,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621369,1969.0,
7238,Half life in dog plasma was determined at dose 10 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621370,1969.0,
7239,Half life in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621371,,
7240,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621372,,
7241,Half life upon exposure to human plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621373,1969.0,
7242,Half life was calculated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621374,,
7243,Half life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621375,,
7244,Half life was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621376,,
7245,Half life by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619624,,
7246,Half life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875840,,
7247,Half life in dog after intra venous administration of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619625,,
7248,Half life in dog after intra venous administration of the compound; ND means Not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619626,,
7249,Half life in dog after po administration of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619627,,
7250,Half life in dog after po administration of the compound; ND means Not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873817,,
7251,Half life in dog at the single oral dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619628,,
7252,Half life in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619629,,
7253,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619630,,
7254,Half life in rat,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619631,,
7255,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL619632,,
7256,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619633,10000001.0,
7257,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875841,10000001.0,
7258,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619634,10000001.0,
7259,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619635,10000001.0,
7260,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619636,10000001.0,
7261,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619637,10000004.0,
7262,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619638,10000004.0,
7263,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619639,10000004.0,
7264,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619640,10000004.0,
7265,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619641,10000004.0,
7266,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619642,10000004.0,
7267,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619643,10000004.0,
7268,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619644,948.0,
7269,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621112,948.0,
7270,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621113,948.0,
7271,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621114,948.0,
7272,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621115,948.0,
7273,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621116,948.0,
7274,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621117,948.0,
7275,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621118,2113.0,
7276,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621119,2113.0,
7277,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621120,2113.0,
7278,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621757,2113.0,
7279,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621758,2113.0,
7280,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621759,2113.0,
7281,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621760,2113.0,
7282,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621761,2107.0,
7283,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621762,2107.0,
7284,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621763,2107.0,
7285,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624502,2107.0,
7286,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624503,2107.0,
7287,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624504,2107.0,
7288,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624505,2107.0,
7289,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624506,2048.0,
7290,In vitro cytotoxicity against A2780 (human ovarian cancer),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624507,,
7291,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624508,,
7292,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624509,,
7293,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624510,,
7294,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL875956,,
7295,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL839885,,
7296,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL624511,,
7297,In vitro cytotoxicity against A2780 cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624512,,
7298,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624513,,
7299,In vitro inhibitory activity against human ovarian cancer A2780 cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL624514,,
7300,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,478.0,BAO_0000218,Intermediate,,A2780,81034,N,1,1,,CHEMBL618547,,
7301,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618548,,
7302,Inhibition of tubulin polymerization in analogy of ca.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618549,,
7303,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618550,,
7304,Cytotoxic effect in ovarian cancer cell line (A2780),478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618551,,
7305,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618552,,
7306,Tested for the cytotoxicity in A2780 ovarian cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618553,,
7307,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618554,,
7308,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618555,,
7309,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618556,,
7310,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618557,,
7311,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618558,,
7312,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),481.0,BAO_0000219,Intermediate,,A2780cisR,80017,N,1,1,,CHEMBL618559,,
7313,In vivo log of cells killed after administration of compound in A2780 cell line,478.0,BAO_0000218,Intermediate,,A2780,81034,N,1,1,,CHEMBL618560,,
7314,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,478.0,BAO_0000218,Intermediate,,A2780,81034,N,1,1,,CHEMBL618561,,
7315,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618562,,
7316,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618563,,
7317,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618564,,
7318,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618565,,
7319,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),478.0,BAO_0000218,Intermediate,,A2780,81034,N,1,1,,CHEMBL618566,,
7320,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL618567,,
7321,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618568,,
7322,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL618569,,
7323,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621857,,
7324,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621858,,
7325,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621859,,
7326,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621860,,
7327,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621861,,
7328,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621862,,
7329,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621863,,
7330,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621864,,
7331,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621865,,
7332,In vitro antiproliferative activity against A2780 cell line,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621866,,
7333,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,478.0,BAO_0000219,Expert,,A2780,81034,N,1,1,,CHEMBL621867,,
7334,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL621868,,
7335,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,478.0,BAO_0000219,Intermediate,,A2780,81034,N,1,1,,CHEMBL875282,,
7336,Vc value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621869,,
7337,Half life period in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621870,,
7338,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621871,,
7339,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621243,1969.0,
7340,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621244,1969.0,
7341,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621245,,
7342,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621246,,
7343,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621247,,
7344,Oral Bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618386,,
7345,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618387,,
7346,Area under curve value in monkey at a dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618388,,
7347,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618389,,
7348,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618574,,
7349,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618575,,
7350,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618576,,
7351,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618577,,
7352,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL876487,,
7353,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618578,,
7354,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618579,,
7355,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618580,,
7356,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618581,,
7357,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618582,,
7358,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618583,,
7359,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618584,,
7360,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618585,,
7361,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618586,,
7362,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618587,,
7363,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618588,,
7364,Binding towards monkey plasma protein at 10 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618589,,
7365,Binding towards monkey plasma protein at 100 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618590,,
7366,Apparent bioavailability in squirrel monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL872262,,
7367,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618591,,
7368,Bioavailability in monkey (dose 2 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618592,,
7369,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL876488,,
7370,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618593,,
7371,Bioavailability in monkey (i.d. dosing),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618594,,
7372,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618595,,
7373,Clearance of the drug was measured in cynomolgus,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621469,,
7374,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621470,,
7375,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621471,,
7376,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621472,1969.0,
7377,Plasma clearance in rhesus monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621473,,
7378,Plasma clearance in monkey after administration of 1 mg/kg iv,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621474,,
7379,Plasma clearance in cynomolgus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621475,,
7380,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621476,,
7381,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624290,,
7382,The total clearance was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624291,,
7383,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624292,,
7384,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624293,,
7385,Tested for Clearance upon iv administration to african green monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624294,,
7386,Clearance in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624295,,
7387,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624296,,
7388,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624297,,
7389,Half life was evaluated after intravenous administration to dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624298,,
7390,Half life was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624299,,
7391,Half life was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624300,,
7392,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624301,,
7393,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624302,,
7394,Half life period after intravenous administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876026,,
7395,Half life period after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624303,,
7396,Half life period at a dose of 1 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624304,,
7397,Half life period was determine after peroral administration at 10 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624305,,
7398,Half life period was determine after peroral administration at 5 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624306,,
7399,Half life period was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624307,,
7400,Half life period was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624308,,
7401,Half life period by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624309,,
7402,Half life period was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624310,,
7403,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625003,,
7404,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625004,,
7405,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625005,,
7406,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873813,,
7407,Half-life after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625006,,
7408,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625007,,
7409,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876027,,
7410,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625008,,
7411,Half-life of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625009,,
7412,Half-life of compound in plasma of dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625010,1969.0,
7413,Half-life of compound was determined in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625011,,
7414,Half-life after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621553,,
7415,Half-life after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621554,,
7416,Half-life in Dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621555,,
7417,Half-life in Dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621556,,
7418,Half-life in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621557,,
7419,Half-life in dog after oral administration at 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621558,,
7420,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621559,,
7421,Half-life in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621560,,
7422,Half-life in dogs; ND indicates not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876028,,
7423,Half-life in plasma of dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621561,1969.0,
7424,Half-life in plasma of dog at dose of 3-10 mgkg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621562,1969.0,
7425,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621563,,
7426,Half-life was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621564,,
7427,Half-life was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621565,,
7428,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621566,,
7429,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621567,,
7430,Half-life of the compound after 0.3 mg/kg po administration in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622978,,
7431,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL873814,,
7432,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623219,,
7433,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624477,,
7434,t1/2 in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624478,,
7435,Half-life period measured in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624479,,
7436,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624480,,
7437,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623595,,
7438,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623596,,
7439,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623597,1969.0,
7440,In vivo half life period was calculated at 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623598,,
7441,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623599,,
7442,Longer half-life in dog (i.v.) at 0.5 mpk,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623600,,
7443,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623601,,
7444,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623602,,
7445,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623603,,
7446,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623604,,
7447,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623605,2048.0,
7448,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623606,2048.0,
7449,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623607,2048.0,
7450,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623608,2048.0,
7451,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623609,2048.0,
7452,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623610,2048.0,
7453,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623611,2385.0,
7454,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623612,2385.0,
7455,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623613,2385.0,
7456,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623614,2385.0,
7457,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623615,2385.0,
7458,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623616,2385.0,
7459,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623617,2385.0,
7460,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875944,14.0,
7461,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623618,14.0,
7462,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623619,14.0,
7463,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623620,14.0,
7464,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623621,14.0,
7465,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623622,14.0,
7466,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623623,14.0,
7467,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623624,2106.0,
7468,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618521,2106.0,
7469,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618522,2106.0,
7470,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618523,2106.0,
7471,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618524,2106.0,
7472,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618525,2106.0,
7473,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624586,2106.0,
7474,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624587,945.0,
7475,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624588,945.0,
7476,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624589,945.0,
7477,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624590,945.0,
7478,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624591,945.0,
7479,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624592,945.0,
7480,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624593,945.0,
7481,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624594,,
7482,Tested for the bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624595,,
7483,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624596,,
7484,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624597,,
7485,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624598,,
7486,Bioavailability in rat (dose 3-10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624599,,
7487,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875166,,
7488,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624600,1969.0,
7489,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624601,1969.0,
7490,Half life after oral administration was determined in rats at 6 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624602,,
7491,Half life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624603,,
7492,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624604,,
7493,Plasma half life in rat at oral dose 2.8 mg/mk body weight,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624605,1969.0,
7494,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624606,,
7495,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624607,178.0,
7496,Hill coefficient of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624608,,
7497,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624609,178.0,
7498,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624610,178.0,
7499,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624611,178.0,
7500,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624612,178.0,
7501,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875167,178.0,
7502,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624613,178.0,
7503,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624614,178.0,
7504,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624392,,
7505,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624393,955.0,
7506,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624394,955.0,
7507,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624395,955.0,
7508,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624396,955.0,
7509,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624397,955.0,
7510,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624398,2046.0,
7511,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624399,2046.0,
7512,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624400,2046.0,
7513,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624401,2046.0,
7514,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624402,2046.0,
7515,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624403,178.0,
7516,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624404,178.0,
7517,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624405,178.0,
7518,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624406,10000001.0,
7519,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624407,10000001.0,
7520,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624408,10000001.0,
7521,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618644,948.0,
7522,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618645,948.0,
7523,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618646,948.0,
7524,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618647,2113.0,
7525,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618648,2113.0,
7526,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618649,2113.0,
7527,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618650,2107.0,
7528,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618651,2107.0,
7529,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876497,2107.0,
7530,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618652,2048.0,
7531,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618653,2048.0,
7532,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618654,2048.0,
7533,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618655,,
7534,Compound was tested for solubility in water,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618656,,
7535,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,BAO_0000100,Intermediate,,,22229,U,0,1,,CHEMBL618657,,
7536,Solubility was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618658,,
7537,solubility in water (ug/mL) at 37 degree C.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618659,,
7538,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618660,,
7539,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618661,,
7540,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873807,,
7541,Half life in Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618662,,
7542,Half life period after 3 mg/kg iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618663,,
7543,Half life period after 3 mg/kg iv administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618664,,
7544,Half life period after 3 mg/kg iv administration in the rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618665,,
7545,Half life period in female Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876498,,
7546,Half life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618666,,
7547,Half-life in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620440,,
7548,Half-life in rats with metabolic oxidation,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620441,,
7549,Half-life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620442,,
7550,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620443,,
7551,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620444,,
7552,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620445,,
7553,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620446,,
7554,Biological half-life measured in plasma of rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620447,1969.0,
7555,Biological half-life measured in plasma of rat; 22-25,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621129,1969.0,
7556,Biological half-life measured in plasma of rat; 9-16,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621130,1969.0,
7557,Compound was evaluated for its half life when administered intravenously in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873808,,
7558,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876598,,
7559,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621131,,
7560,Half life (T1/2) after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621132,,
7561,Half life of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621133,,
7562,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL621312,,
7563,Half life of compound was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621313,,
7564,Half life of compound was determined in rat blood,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621314,178.0,
7565,Half life at 1 mg/kg was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621315,,
7566,Half life at 10 mg/kg was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621316,,
7567,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621317,,
7568,Half life in rats in hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621318,,
7569,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621319,,
7570,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621377,,
7571,Half life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621378,,
7572,Half life after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876599,,
7573,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621379,,
7574,Half life in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621380,1969.0,
7575,Half life in rat plasma; Not detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621381,1969.0,
7576,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618515,,
7577,Half life period of compound was determined after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618516,,
7578,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618517,,
7579,Half life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618518,,
7580,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618519,,
7581,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618698,,
7582,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618862,,
7583,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618863,,
7584,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618864,,
7585,Half life time in rat the dose of 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618865,,
7586,Half-life 24 hr after 10 mg/kg iv administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618866,,
7587,Half-life 24 hr after 2 mg/kg iv administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618867,,
7588,Half-life consistent with the observed metabolic steady state in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875828,,
7589,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618868,,
7590,Half-life for oxidative metabolic stability was determined using male human,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618869,,
7591,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618870,,
7592,Half-life in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618871,1969.0,
7593,Half-life in rat plasma was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618872,1969.0,
7594,Half-life in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873816,,
7595,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618873,,
7596,Area under curve after oral dose of 0.1 mg//kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621602,,
7597,Area under curve after oral dose of 0.3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621603,,
7598,Area under curve after oral dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621604,,
7599,Area under curve after oral dose of 10 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621605,,
7600,Area under curve after oral dose of 23.4 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621606,,
7601,Area under curve after oral dose of 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621607,,
7602,Area under curve after oral dose of 3.87 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621608,,
7603,Area under curve was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621609,,
7604,Area under curve at a dose of 10 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621610,,
7605,Area under curve was determined; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621611,,
7606,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621612,,
7607,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622308,,
7608,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622309,,
7609,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622310,,
7610,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622311,,
7611,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622312,,
7612,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622931,,
7613,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622932,,
7614,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622736,1969.0,
7615,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622737,1969.0,
7616,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622738,1969.0,
7617,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622739,1969.0,
7618,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622740,1969.0,
7619,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622741,1969.0,
7620,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622742,1969.0,
7621,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622743,1969.0,
7622,AUC in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622744,1969.0,
7623,Area under curve was measured from the graph obtained from concentration Vs time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624134,,
7624,Area under curve value of compound per hour after oral administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624135,,
7625,Area under curve was determined after oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624136,,
7626,Area under curve was determined after oral administration in rats; No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624137,,
7627,Area under curve was determined after oral administration in rats;No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624320,,
7628,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624321,,
7629,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624322,,
7630,Area under curve was determined for the compound after iv dose of 5.06 in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624323,,
7631,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624324,,
7632,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624325,,
7633,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624326,,
7634,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624327,,
7635,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624328,,
7636,Area under curve was determined in Dogs after peroral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627848,,
7637,Area under curve was determined in Rats after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627849,,
7638,Area under curve was determined in carotid blood of rat when administered intradermally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627850,,
7639,Area under curve was determined in portal blood of rat when administered intradermally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627851,,
7640,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627852,,
7641,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627853,,
7642,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627854,,
7643,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627855,,
7644,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627856,,
7645,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875339,,
7646,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627857,,
7647,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627858,2106.0,
7648,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627859,178.0,
7649,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627860,955.0,
7650,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627019,948.0,
7651,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627020,2107.0,
7652,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627021,2048.0,
7653,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627022,2385.0,
7654,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627023,,
7655,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627024,2106.0,
7656,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627025,2046.0,
7657,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627026,2113.0,
7658,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627027,178.0,
7659,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627028,955.0,
7660,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627029,948.0,
7661,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627030,2113.0,
7662,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627031,2107.0,
7663,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627032,2048.0,
7664,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627033,2385.0,
7665,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627034,,
7666,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627035,2106.0,
7667,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627036,2046.0,
7668,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875340,178.0,
7669,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627037,948.0,
7670,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627038,2113.0,
7671,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627039,2107.0,
7672,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627040,2385.0,
7673,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624663,2106.0,
7674,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625963,2046.0,
7675,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876799,955.0,
7676,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626133,2048.0,
7677,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626134,,
7678,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626135,,
7679,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626136,,
7680,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626137,,
7681,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626138,,
7682,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626139,,
7683,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626140,,
7684,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626141,,
7685,C24h in rat p.o. at 20 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626142,,
7686,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627930,2385.0,
7687,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627931,2385.0,
7688,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627932,2385.0,
7689,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627933,2106.0,
7690,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627934,2106.0,
7691,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627935,2106.0,
7692,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627936,178.0,
7693,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627937,178.0,
7694,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627938,178.0,
7695,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627939,178.0,
7696,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627940,178.0,
7697,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627941,178.0,
7698,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876800,178.0,
7699,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627942,178.0,
7700,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627943,178.0,
7701,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627944,178.0,
7702,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627945,178.0,
7703,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628584,178.0,
7704,Biodistribution in rat blood in the presence of GdDTPA at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628585,178.0,
7705,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628586,178.0,
7706,Biodistribution in rat blood in the presence of GdDTPA at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628587,178.0,
7707,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628588,178.0,
7708,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628589,178.0,
7709,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625304,178.0,
7710,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625305,178.0,
7711,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625306,178.0,
7712,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625307,178.0,
7713,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625308,178.0,
7714,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627740,178.0,
7715,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627741,178.0,
7716,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627742,178.0,
7717,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627743,178.0,
7718,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627744,178.0,
7719,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627745,10000001.0,
7720,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627746,10000001.0,
7721,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627747,10000001.0,
7722,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876810,10000001.0,
7723,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627748,10000001.0,
7724,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627749,10000001.0,
7725,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627750,10000001.0,
7726,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618728,10000001.0,
7727,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618729,10000001.0,
7728,Biodistribution in rat bone in the presence of GdDTPA at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618730,10000001.0,
7729,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618731,10000001.0,
7730,Biodistribution in rat bone in the presence of GdDTPA at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618732,10000001.0,
7731,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618733,10000001.0,
7732,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618734,10000001.0,
7733,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618735,10000001.0,
7734,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876602,10000001.0,
7735,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618736,10000001.0,
7736,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618737,10000001.0,
7737,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618738,10000001.0,
7738,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618739,10000001.0,
7739,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618740,10000001.0,
7740,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618741,10000001.0,
7741,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618742,10000001.0,
7742,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618743,10000001.0,
7743,Half-life from rat plasma at a single oral dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618744,1969.0,
7744,Half-life in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618745,,
7745,Half-life in rat after peroral administration at 10 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620479,,
7746,Half-life in rat after peroral administration at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620480,,
7747,Half-life in rat at a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620481,,
7748,Half-life was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620482,,
7749,Half-life was measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876603,,
7750,Half-life period for the compound was determined in rats at 50 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620483,,
7751,Half-life period in rats after intravenous administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620484,,
7752,Half-life period in rat at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620485,,
7753,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620486,,
7754,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620487,,
7755,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620488,,
7756,Half-life time in rat the dose of 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620489,,
7757,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620490,,
7758,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620491,,
7759,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876604,1969.0,
7760,Oral half life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620492,,
7761,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620493,,
7762,Pharmacokinetic property (t1/2) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620494,,
7763,Plasma elimination half-life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620495,1969.0,
7764,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620496,1969.0,
7765,Plasma half life was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620497,1969.0,
7766,Plasma half-life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620498,1969.0,
7767,Plasma half-life following oral administration in Fisher rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620499,1969.0,
7768,Plasma half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620500,1969.0,
7769,Plasmatic Half-life after intravenous administration to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873809,1969.0,
7770,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620501,,
7771,Terminal half life after intravenous administration (1 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620502,,
7772,Terminal half life in Rat at a oral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620503,,
7773,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620504,,
7774,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876605,,
7775,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620505,,
7776,plasma half life was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873811,1969.0,
7777,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL624016,,
7778,Half life of compound determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624017,,
7779,Mean residence time determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624018,,
7780,Plasma half life determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624019,,
7781,Compound was evaluated for Tmax in brain after intravenous administration in male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624020,955.0,
7782,Compound was evaluated for pharmacokinetic parameter maximum time period,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624201,,
7783,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL872528,,
7784,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624202,,
7785,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624203,,
7786,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624350,,
7787,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621320,,
7788,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621321,,
7789,Maximum time (Tmax) required to reach Cmax in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621322,,
7790,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621323,,
7791,Maximum time of clearance of compound in rats after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621324,,
7792,Maximum time at the dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621325,,
7793,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875837,1969.0,
7794,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621326,1969.0,
7795,Tmax in Guinea pig (PO dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621327,,
7796,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621328,,
7797,Pharmacokinetic parameter (Tmax) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621329,,
7798,Pharmacokinetic parameter (Tmax) was estimated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621330,,
7799,Pharmacokinetic property (Tmax) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621331,,
7800,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621332,,
7801,T max in Rat at a oral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621333,,
7802,T max was determined at 10 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621334,,
7803,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621335,,
7804,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621336,,
7805,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621337,,
7806,Area under curve was measured after i.v. administration into Beagle dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621338,,
7807,Area under curve was measured after iv administration into Beagle dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875838,,
7808,Area under curve was measured after po administration into Beagle dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621339,,
7809,Area under curve was measured after po administration into Beagle dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621340,,
7810,Area under curve was measured at peroral dose of 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621341,,
7811,Area under curve was measured by using concentration Vs time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621342,,
7812,Area under curve was measured by using concentration Vs time; not tested,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621343,,
7813,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621344,,
7814,Area under curve(AUC) was measured in mice after oral administration.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621345,,
7815,Area under curve(AUC) value of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621346,,
7816,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621347,,
7817,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621348,,
7818,Area under curve(carotid artery) was determined by the availability in blood,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621349,178.0,
7819,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL621350,178.0,
7820,Area under curve(carotid artery) was determined by the availability in blood; No data,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875839,178.0,
7821,Area under curve(portal vein) was determined by the availability in blood,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620211,178.0,
7822,Area under curve(portal vein) was determined by the availability in blood; ND means no data,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620212,178.0,
7823,Area under curve(portal vein) was determined by the availability in blood; No data,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620213,178.0,
7824,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL620214,1969.0,
7825,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL620215,1969.0,
7826,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL620216,1969.0,
7827,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620888,1969.0,
7828,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620889,1969.0,
7829,Area under plasma concentration vs time curve observed in rats for 0-3 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620890,1969.0,
7830,Area under plasma time curve determined in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620891,1969.0,
7831,Area under the MAP curve measured over 5 min.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL620892,,
7832,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621079,,
7833,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621080,,
7834,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621081,,
7835,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL621082,,
7836,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621083,,
7837,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621084,,
7838,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621085,,
7839,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621086,,
7840,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621087,,
7841,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622607,,
7842,Serum AUC in marmosets (IV dose),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622608,,
7843,Area under the curve after intravenous administration at a dose of 10 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624481,,
7844,Area under the curve after intravenous administration at a dose of 2 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624482,,
7845,Area under the curve after intravenous administration at a dose of 4 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624483,,
7846,Area under the curve after intravenous administration at a dose of 40 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624484,,
7847,Area under the curve after intravenous administration at a dose of 5 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624485,,
7848,Area under the curve for fumarate salt was evaluated in F344 Rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624486,,
7849,Area under the curve for the compound was calculated.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624487,,
7850,Area under the curve in concentration/ time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624488,,
7851,Area under the curve administered intraintestinal in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624489,,
7852,Area under the curve administered intravenously in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625184,,
7853,Area under the curve during intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625185,,
7854,Area under the curve during intravenous administration; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875954,,
7855,Area under the curve during systemic administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625186,,
7856,Area under the curve during systemic administration; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625187,,
7857,Area under the curve was calculated for the compound.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625188,,
7858,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625189,,
7859,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625190,,
7860,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621733,,
7861,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621734,,
7862,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621735,,
7863,Clearance of the drug was measured in the plasma of rat; No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621736,1969.0,
7864,The pharmacokinetic parameter plasma clearance in vivo in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621737,1969.0,
7865,Plasma clearance at the dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621738,,
7866,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622806,,
7867,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623519,,
7868,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623520,,
7869,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623521,,
7870,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623522,,
7871,Clearance rate in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623523,,
7872,Clearance rate in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623690,,
7873,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623691,,
7874,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623692,,
7875,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623693,,
7876,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623694,,
7877,Clearance of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623695,,
7878,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623696,,
7879,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623697,,
7880,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623698,1969.0,
7881,Compound was tested for its plasma clearance rate in Sprague Dawley rats,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623699,1969.0,
7882,Mean (%CV) PK parameters for CL(mL/min/kg).,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623700,,
7883,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623701,,
7884,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623702,1969.0,
7885,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623703,,
7886,Plasma clearance in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623704,,
7887,Plasma clearance in rat after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623705,,
7888,Plasma clearance in rat after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623706,,
7889,Plasma clearance was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623707,,
7890,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623708,,
7891,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623709,,
7892,Plasma clearance in rat by iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623710,,
7893,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623711,,
7894,Plasma clearance in rat p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623712,,
7895,Plasma clearance in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623713,,
7896,Plasma clearance was determined; ND denotes no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623714,,
7897,Plasma clearance was determined; ND denotes not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623715,,
7898,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623716,,
7899,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622980,,
7900,Plasma administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622981,,
7901,Plasma clearance of the compound in female Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622982,,
7902,Plasma clearance was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622983,,
7903,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622984,,
7904,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622985,,
7905,plasma clearance was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623631,1969.0,
7906,In vivo CL/F determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623632,,
7907,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623633,1969.0,
7908,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623634,1969.0,
7909,Compound was tested for the lower blood clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623635,,
7910,Evaluated for the low clearance in rat (in vivo),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621195,,
7911,Pharmacokinetic property (CLb)of the compound was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621196,,
7912,Rapid clearance after intravenous administration in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875287,,
7913,Clearance measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621197,,
7914,Compound was evaluated for plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621198,1969.0,
7915,Low plasma clearance was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621199,1969.0,
7916,Pharmacokinetic property (Clp) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621200,,
7917,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621201,,
7918,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621202,,
7919,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621203,,
7920,Plasma clearance after IV dosing at 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621204,,
7921,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621205,948.0,
7922,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621206,948.0,
7923,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621207,948.0,
7924,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621208,948.0,
7925,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621209,948.0,
7926,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876484,948.0,
7927,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621210,948.0,
7928,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621211,948.0,
7929,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621212,948.0,
7930,Biodistribution in rat heart in the presence of GdDTPA at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621213,948.0,
7931,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621214,948.0,
7932,Biodistribution in rat heart in the presence of GdDTPA at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621215,948.0,
7933,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621216,948.0,
7934,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621217,948.0,
7935,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621218,948.0,
7936,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621219,948.0,
7937,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621220,948.0,
7938,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621221,948.0,
7939,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621222,948.0,
7940,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621223,948.0,
7941,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876485,948.0,
7942,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621224,948.0,
7943,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621225,948.0,
7944,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621226,948.0,
7945,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621227,2113.0,
7946,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621228,2113.0,
7947,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621229,2113.0,
7948,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621230,2113.0,
7949,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621231,2113.0,
7950,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621232,2113.0,
7951,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621233,2113.0,
7952,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621234,2113.0,
7953,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621235,2113.0,
7954,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621236,2113.0,
7955,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621237,2113.0,
7956,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876486,2113.0,
7957,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622436,160.0,
7958,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622437,160.0,
7959,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622438,160.0,
7960,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622439,2107.0,
7961,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622440,2107.0,
7962,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622441,2107.0,
7963,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622442,2107.0,
7964,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622443,2107.0,
7965,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622444,2107.0,
7966,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622445,2107.0,
7967,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622446,2107.0,
7968,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622447,2107.0,
7969,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622448,2107.0,
7970,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622449,2107.0,
7971,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622450,2107.0,
7972,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622451,2107.0,
7973,Biodistribution in rat liver in the presence of GdDTPA at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622452,2107.0,
7974,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622453,2107.0,
7975,Biodistribution in rat liver in the presence of GdDTPA at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622454,2107.0,
7976,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622455,2107.0,
7977,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876024,2107.0,
7978,T max was determined at 3 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622456,,
7979,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622457,,
7980,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622458,,
7981,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622459,,
7982,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873343,,
7983,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622460,,
7984,Time for maximum plasma concentration determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622461,1969.0,
7985,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622462,1969.0,
7986,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622463,,
7987,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622464,,
7988,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622465,,
7989,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622466,,
7990,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622467,,
7991,Time of maximum plasma concentration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622468,1969.0,
7992,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876025,1969.0,
7993,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622469,1969.0,
7994,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622470,1969.0,
7995,Time required to reach maximum concentration (Cmax) after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622471,,
7996,Time required to reach maximum concentration in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622472,1969.0,
7997,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622473,1969.0,
7998,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624282,1969.0,
7999,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624283,1969.0,
8000,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624284,1969.0,
8001,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624285,1969.0,
8002,Time to reach Cmax after oral administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624286,,
8003,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624287,,
8004,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624288,,
8005,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624289,1969.0,
8006,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873344,1969.0,
8007,Tmax after peroral administration (10 mg/kg) was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619623,,
8008,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL621399,,
8009,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621400,,
8010,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621401,,
8011,Tmax was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621402,,
8012,Tmax was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621403,,
8013,Tmax after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621121,,
8014,Tmax after peroral administration in rats at 2.4 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL872525,,
8015,Tmax in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621122,,
8016,Tmax in rat at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621123,,
8017,Tmax in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621124,,
8018,Tmax in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621125,,
8019,Tmax was measured in rats after peroral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621126,,
8020,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621127,,
8021,Tmax value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621128,,
8022,Tmax value at a dose of 10 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618263,,
8023,Tmax value at a dose of 100 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618264,,
8024,Tmax value at a dose of 50 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618265,,
8025,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618266,1969.0,
8026,time required to reach maximum concentration (Cmax) after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618267,,
8027,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618450,1088.0,
8028,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618451,1088.0,
8029,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618452,,
8030,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618453,1088.0,
8031,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618454,1088.0,
8032,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618455,1088.0,
8033,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618456,,
8034,Compound distribution in rat tissues was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618457,,
8035,Volume of distribution was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618458,,
8036,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618459,,
8037,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876733,,
8038,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618460,,
8039,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618461,,
8040,Area under the curve was determined after oral administration (300 uM/Kg),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL618462,,
8041,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618463,,
8042,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618464,,
8043,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618465,,
8044,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618466,,
8045,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618467,,
8046,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618468,,
8047,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618469,1969.0,
8048,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL618470,1969.0,
8049,Plasma drug AUC in rat (PO dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618471,,
8050,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618472,,
8051,Area under was determined at a dose of 30 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL618473,,
8052,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL621699,,
8053,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621700,,
8054,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621701,,
8055,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL621702,,
8056,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621703,,
8057,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621704,,
8058,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624259,,
8059,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624260,,
8060,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624430,,
8061,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624431,,
8062,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624432,,
8063,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624433,,
8064,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624434,,
8065,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624435,,
8066,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618570,,
8067,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618571,,
8068,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618572,,
8069,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618573,,
8070,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619267,,
8071,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619431,,
8072,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619432,,
8073,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619433,,
8074,AUC in mice after oral dose (50 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619434,1969.0,
8075,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619435,1977.0,
8076,AUC (0-4 hr) ug/ml/h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619436,1969.0,
8077,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619437,,
8078,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619438,,
8079,Compound was evaluated for Area under curve in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619439,,
8080,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619440,,
8081,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL619441,,
8082,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619442,,
8083,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875156,,
8084,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619443,,
8085,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL619444,,
8086,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623464,,
8087,Compound was evaluated for area under curve when administered through oral route in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623465,,
8088,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623466,,
8089,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623467,,
8090,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623468,,
8091,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622660,,
8092,Plasma clearance rate in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622661,,
8093,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622662,,
8094,Pharmacokinetic property (total body clearance) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622663,,
8095,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622664,,
8096,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622665,,
8097,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622666,,
8098,Cl in rat i.v. at 2 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621615,,
8099,Clearance of compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621616,,
8100,Clearance was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621617,,
8101,Clearance by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621618,,
8102,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621619,,
8103,Clearance rate after i.v. administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621620,,
8104,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621786,,
8105,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621787,,
8106,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621788,,
8107,Clearance (Cl) after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621789,,
8108,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621790,,
8109,Compound was tested for plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621791,1969.0,
8110,In vitro microsome metabolism clearance in rat was determined,,BAO_0000218,Intermediate,Microsomes,,50597,N,1,1,,CHEMBL621792,,
8111,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,BAO_0000218,Intermediate,Microsomes,,50597,N,1,1,,CHEMBL621793,,
8112,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621794,,
8113,In vivo plasma clearance was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621795,1969.0,
8114,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621796,,
8115,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,401.0,BAO_0000218,Intermediate,,Hepatocyte,50597,N,1,1,,CHEMBL621797,2107.0,
8116,Pharmacokinetic property (Plasma clearance) was measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621798,,
8117,Pharmacokinetic property (clearance) in rat i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621799,,
8118,"Plasma Clearance was evaluated in rats, iv",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621800,,
8119,Plasma clearance (in vivo) in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621801,,
8120,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621802,,
8121,Plasma clearance was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618596,,
8122,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618597,,
8123,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618598,,
8124,Plasma clearance in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618599,,
8125,Plasma clearance rate determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618600,,
8126,Plasma clearance was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618601,,
8127,Plasma clearance was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618602,,
8128,Plasma clearance value in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618603,,
8129,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618604,2107.0,
8130,Clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618605,,
8131,Total body clearance in rat i.v. at 2 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618606,,
8132,Clearance of compound in rats after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618607,,
8133,Clearance after iv administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618608,,
8134,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618609,,
8135,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618610,,
8136,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618611,,
8137,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618612,,
8138,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618613,,
8139,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621076,,
8140,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621077,,
8141,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621078,,
8142,Clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621251,,
8143,Clearance in rat after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621252,,
8144,Clearance in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621253,,
8145,Clearance rate following an oral dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621254,,
8146,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621255,,
8147,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621256,1969.0,
8148,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621257,2107.0,
8149,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621258,2107.0,
8150,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621259,2107.0,
8151,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621260,2107.0,
8152,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876494,2107.0,
8153,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621261,2107.0,
8154,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621262,2107.0,
8155,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621263,2107.0,
8156,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621264,2107.0,
8157,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621265,2385.0,
8158,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621266,2385.0,
8159,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621267,2385.0,
8160,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621268,2385.0,
8161,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621269,2385.0,
8162,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621270,2385.0,
8163,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621271,2385.0,
8164,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621272,2385.0,
8165,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621273,2385.0,
8166,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621274,2385.0,
8167,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876495,2385.0,
8168,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621275,2385.0,
8169,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621276,2385.0,
8170,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621277,2385.0,
8171,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621278,160.0,
8172,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621279,160.0,
8173,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621280,160.0,
8174,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621281,2106.0,
8175,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621282,2106.0,
8176,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621283,2106.0,
8177,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621284,2106.0,
8178,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621285,2106.0,
8179,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621286,2106.0,
8180,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623220,2106.0,
8181,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623221,2106.0,
8182,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876029,2106.0,
8183,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623222,945.0,
8184,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623223,945.0,
8185,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621445,945.0,
8186,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621446,178.0,
8187,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621447,178.0,
8188,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619681,178.0,
8189,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619682,178.0,
8190,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619683,178.0,
8191,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619684,955.0,
8192,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619685,955.0,
8193,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619686,955.0,
8194,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619687,955.0,
8195,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619688,955.0,
8196,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619689,948.0,
8197,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619690,948.0,
8198,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619691,948.0,
8199,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619692,,
8200,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL619693,,
8201,Vc value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619694,,
8202,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619695,,
8203,Compound was evaluated for pharmacokinetic parameter volume of distribution,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619696,,
8204,Compound was evaluated for volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619697,,
8205,Steady state volume distribution was determined; steady state(ss),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619698,,
8206,Steady state volume of distribution after iv administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619699,,
8207,Steady state volume of distribution dosing at 3 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619700,,
8208,The compound was evaluated for volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619701,,
8209,The compound was tested for volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619702,,
8210,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620335,,
8211,Volume distribution (VD) after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620336,,
8212,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620337,,
8213,Volume distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620520,,
8214,Volume distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620521,,
8215,Volume distribution in rat after peroral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875825,,
8216,Volume distribution in rat after peroral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620522,,
8217,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620523,,
8218,Volume of distribution in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620524,,
8219,Volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620525,,
8220,Volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620526,,
8221,Volume of distribution in rat by iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620527,,
8222,Volume of distribution in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620528,,
8223,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620529,,
8224,Volume distribution at the dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620530,,
8225,Steady state volume of distribution was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620531,,
8226,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL620532,,
8227,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL620533,,
8228,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL620534,,
8229,Mean (%CV) PK parameters for Vdss(mL/kg).,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620535,,
8230,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875826,,
8231,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620536,,
8232,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620537,,
8233,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618526,,
8234,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618527,,
8235,Pharmacokinetic property (Vdss) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618528,,
8236,Pharmacokinetic property (vdss) was measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618529,,
8237,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618530,,
8238,Volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618531,,
8239,The pharmacokinetic parameter volume of distribution in vivo in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618532,,
8240,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618533,,
8241,Vdss in rat i.v. at 2 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618534,,
8242,Volume distribution after intravenous administration (1 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618535,,
8243,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618536,,
8244,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618537,,
8245,Volume distribution at a dose of 10 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618538,,
8246,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618539,,
8247,Volume distribution was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618540,,
8248,Volume distribution was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618541,,
8249,Volume of distribution after intravenous administration was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618542,,
8250,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622544,,
8251,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622545,,
8252,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622546,,
8253,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622547,,
8254,Volume of distribution in steady state was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622548,,
8255,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622549,,
8256,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622550,,
8257,Compound was evaluated for area under curve when administered through oral route to mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622551,,
8258,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622552,,
8259,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622553,,
8260,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622554,,
8261,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622555,,
8262,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622556,,
8263,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622557,,
8264,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622558,178.0,
8265,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622559,178.0,
8266,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622560,,
8267,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622561,,
8268,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622562,,
8269,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622563,,
8270,Concentration of compound in Central nervous system,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622564,,
8271,Concentration of compound in Central nervous system; Not detectable,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622565,,
8272,"Concentration of diester in the blood, following oral administration in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622566,,
8273,"Concentration of monoester in the blood, following oral administration in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624515,,
8274,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624516,,
8275,Evaluated for Pharmacokinetic property: Area under the curve,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624517,,
8276,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624518,,
8277,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624519,,
8278,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624520,,
8279,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624521,,
8280,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624522,,
8281,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624523,,
8282,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624409,,
8283,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624410,,
8284,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL624411,,
8285,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623531,,
8286,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623532,,
8287,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623533,,
8288,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623534,,
8289,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623535,,
8290,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623536,,
8291,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623537,,
8292,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623538,,
8293,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623539,,
8294,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623540,,
8295,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623541,,
8296,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623542,,
8297,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623543,,
8298,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623544,,
8299,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623545,,
8300,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623546,,
8301,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623547,1969.0,
8302,High i.v. clearance in Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623548,,
8303,In vitro clearance in rat liver microsomes,,BAO_0000218,Intermediate,Microsomes,,50597,N,1,1,,CHEMBL623549,2107.0,
8304,Intrinsic clearance in rat liver microsomes was determined,,BAO_0000218,Intermediate,Microsomes,,50597,N,1,1,,CHEMBL623550,2107.0,
8305,Intrinsic clearance in rat hepatocytes was determined,401.0,BAO_0000218,Intermediate,,Hepatocyte,50597,N,1,1,,CHEMBL875276,2107.0,
8306,Plasma Clearance was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621872,,
8307,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621873,,
8308,Plasma clearance in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621874,,
8309,Plasma clearance in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621875,,
8310,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621876,,
8311,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621877,,
8312,Plasma clearance was measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621878,,
8313,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621879,,
8314,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621880,1969.0,
8315,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621881,,
8316,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621882,,
8317,Total clearance at 1 mg/kg was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875283,,
8318,Total clearance at 10 mg/kg was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621883,,
8319,Clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621884,,
8320,Plasma clearance rate determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621885,,
8321,Clearance of compound in rat was evaluated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621886,,
8322,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621887,1969.0,
8323,Pharmacokinetic property (blood clearance) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621888,,
8324,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621889,,
8325,Plasma clearance in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621890,,
8326,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,,BAO_0000218,Intermediate,Microsomes,,50597,N,1,1,,CHEMBL621891,2107.0,
8327,Clearance in Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621892,,
8328,Clearance rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621893,,
8329,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621894,,
8330,Clearance rat; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621895,,
8331,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875284,,
8332,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618699,,
8333,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618700,,
8334,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618701,,
8335,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876600,1969.0,
8336,Clearance of compound in rat after 1 mg/kg i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618702,,
8337,Compound was evaluated for Hepatic clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618703,,
8338,In vivo clearance after 5 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618704,,
8339,Compound was tested for plasma clearance in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618705,1969.0,
8340,Hepatic clearance after intravenous administration was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618706,,
8341,Lower clearance in rat (i.v.) at 0.5 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618707,,
8342,Pharmacokinetic parameter expressed as plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618708,1969.0,
8343,Pharmacokinetic property (Clp) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618709,,
8344,Plasma clearance in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618710,,
8345,Plasma clearance (Clp) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618711,,
8346,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618712,,
8347,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618713,,
8348,Plasma clearance after intravenous administration of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618714,,
8349,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618715,,
8350,Plasma clearance in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618716,,
8351,Plasma clearance measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876601,,
8352,Plasma clearance was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618717,,
8353,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618718,,
8354,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618719,,
8355,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618720,,
8356,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618721,,
8357,Plasma clearance in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621477,,
8358,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621478,,
8359,Plasma clearance was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621479,,
8360,Plasma clearance was evaluated in rat; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621480,,
8361,Plasma clearance rate was determined for the compound in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621481,,
8362,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621482,,
8363,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621483,,
8364,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621484,,
8365,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621485,948.0,
8366,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621486,948.0,
8367,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621487,160.0,
8368,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621488,160.0,
8369,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621489,160.0,
8370,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621490,160.0,
8371,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621491,160.0,
8372,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621492,2113.0,
8373,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621493,2113.0,
8374,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621494,2113.0,
8375,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621495,2113.0,
8376,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621496,2113.0,
8377,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621497,2107.0,
8378,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621498,2107.0,
8379,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621499,2107.0,
8380,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618634,2107.0,
8381,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618635,2107.0,
8382,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618636,2048.0,
8383,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619737,2048.0,
8384,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619738,2048.0,
8385,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624329,2048.0,
8386,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624330,2048.0,
8387,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624331,2385.0,
8388,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624332,2385.0,
8389,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624333,2385.0,
8390,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624334,2385.0,
8391,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624335,2385.0,
8392,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620016,2106.0,
8393,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620169,2106.0,
8394,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620170,2106.0,
8395,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620171,2106.0,
8396,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620172,2106.0,
8397,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620173,945.0,
8398,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620174,945.0,
8399,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620175,945.0,
8400,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620176,945.0,
8401,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620177,945.0,
8402,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620178,2037.0,
8403,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620179,2037.0,
8404,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620180,,
8405,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620181,,
8406,Volume of distribution of compound in rats after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620182,,
8407,Volume of distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620183,,
8408,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620184,,
8409,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620185,,
8410,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620186,,
8411,Volume of distribution was determined in Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620187,,
8412,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620188,,
8413,Volume of distribution was reported in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620189,,
8414,Volumes of distribution in rat after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620190,,
8415,Volumes of distribution in rat after po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620191,,
8416,Volumes of distribution in rat after po administration; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620192,,
8417,Pharmacokinetic property (Volume) in rat i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620193,,
8418,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620194,,
8419,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876730,,
8420,Volume distribution in rat after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620195,,
8421,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620196,,
8422,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620197,,
8423,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620198,,
8424,Volume of distribution in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620199,,
8425,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620200,,
8426,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620201,,
8427,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620202,,
8428,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620203,,
8429,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620204,,
8430,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620205,,
8431,Pharmacokinetic parameter (Vss) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624664,,
8432,Pharmacokinetic property (Volume) in rat i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624665,,
8433,Pharmacokinetic property (Vss) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624666,,
8434,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624667,,
8435,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624668,,
8436,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624669,,
8437,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624670,,
8438,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624671,,
8439,Steady state volume distribution in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624672,,
8440,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624673,1969.0,
8441,Steady state volume of distribution determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624674,,
8442,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624675,,
8443,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621728,,
8444,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621729,,
8445,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621730,,
8446,Volume distribution in rat after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621731,,
8447,Volume distribution in rat after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621732,,
8448,Volume in steady state distribution value was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621908,,
8449,Volume in steady state distribution value was determined; ND denotes no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875347,,
8450,Volume in steady state distribution value was determined; ND denotes not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621909,,
8451,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621910,,
8452,Volume of distribution at steady state was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621911,,
8453,Volume of distribution at steady state was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621912,,
8454,Volume of distribution in steady state was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621913,,
8455,Volume of distribution in steady state was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621914,,
8456,Volume of distribution after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621915,,
8457,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621916,,
8458,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621917,2107.0,
8459,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621918,2107.0,
8460,Biodistribution of compound (oxidized form) in spleen tissue,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621919,2106.0,
8461,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621920,2106.0,
8462,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621921,2106.0,
8463,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622401,2106.0,
8464,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875348,2106.0,
8465,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622402,2106.0,
8466,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622403,178.0,
8467,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622404,178.0,
8468,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622405,955.0,
8469,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622406,955.0,
8470,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622407,955.0,
8471,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622408,948.0,
8472,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622409,948.0,
8473,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622410,948.0,
8474,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622411,2113.0,
8475,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627864,2113.0,
8476,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627865,2113.0,
8477,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627866,2107.0,
8478,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627751,2107.0,
8479,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627752,2106.0,
8480,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627753,2106.0,
8481,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627754,2106.0,
8482,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627755,,
8483,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627756,955.0,
8484,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627757,955.0,
8485,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627758,955.0,
8486,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627759,955.0,
8487,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627760,955.0,
8488,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627761,955.0,
8489,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876811,948.0,
8490,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627762,948.0,
8491,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627763,948.0,
8492,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627764,948.0,
8493,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627765,948.0,
8494,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627766,948.0,
8495,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627767,2113.0,
8496,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627768,2113.0,
8497,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628422,2113.0,
8498,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628423,2113.0,
8499,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628424,,
8500,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628425,,
8501,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628426,,
8502,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628427,,
8503,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626938,,
8504,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626939,,
8505,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626940,,
8506,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626941,,
8507,Plasma clearance was reported in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626942,,
8508,Plasma clearance after intravenous administration (1 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876812,,
8509,Plasma clearance of compound in rats was evaluated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626943,,
8510,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626944,,
8511,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626945,,
8512,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626946,,
8513,Plasma clearance rate in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626856,,
8514,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626857,,
8515,The compound was evaluated for plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626858,1969.0,
8516,Total plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627018,1969.0,
8517,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625331,178.0,
8518,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625332,178.0,
8519,C max was determined at 10 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877590,,
8520,C max was determined at 3 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625333,,
8521,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625334,,
8522,Cmax after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625335,,
8523,Cmax of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625336,,
8524,Cmax 24 hr after 10 mg/kg oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625337,,
8525,Cmax 24 hr after 2 mg/kg oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625338,,
8526,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625339,1969.0,
8527,Cmax in rat after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625340,,
8528,Cmax in rat after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625341,,
8529,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622687,,
8530,Cmax wa determined in rat plasma at 30 mg/kg after po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622688,1969.0,
8531,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622689,178.0,
8532,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620295,178.0,
8533,Cmax after 10 mg/kg oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620296,,
8534,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620297,,
8535,Cmax after IV dosing at 1 mg/kg in rat; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620298,,
8536,Cmax after oral administration at 20 mpk in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620299,,
8537,Cmax after oral administration at 20 mpk in rats; Not performed.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620300,,
8538,Cmax after oral administration at 20 mpk in rats d; Not performed.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620301,,
8539,Cmax after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620302,,
8540,Cmax after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620303,,
8541,Cmax after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620304,,
8542,Cmax in rats after 20 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620305,,
8543,Cmax after peroral administration in rats at 2.4 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620306,,
8544,Cmax at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620307,,
8545,Cmax at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620308,,
8546,Cmax by administering at 20 mg/kg p.o. in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620309,,
8547,Cmax in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620310,,
8548,Cmax in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620311,,
8549,Cmax in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620312,,
8550,Cmax in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620313,,
8551,Cmax in rat at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620314,,
8552,Cmax in rat at the dose of 1 mg/kg i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620315,,
8553,Cmax in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620316,,
8554,Cmax in rat p.o. at 20 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620317,,
8555,Cmax in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620318,,
8556,Cmax in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620319,,
8557,Cmax was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620320,,
8558,Cmax was measured in rats after peroral administration at 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620321,,
8559,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620322,,
8560,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620323,,
8561,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620324,1870.0,
8562,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620325,1870.0,
8563,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620326,10000000.0,
8564,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620327,10000000.0,
8565,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620328,,
8566,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620329,,
8567,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620330,1891.0,
8568,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875286,1891.0,
8569,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620331,,
8570,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620332,,
8571,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620333,2435.0,
8572,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620334,2435.0,
8573,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621015,178.0,
8574,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621016,178.0,
8575,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621191,178.0,
8576,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621192,178.0,
8577,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621193,178.0,
8578,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621194,178.0,
8579,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624204,178.0,
8580,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624205,178.0,
8581,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624206,178.0,
8582,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624207,178.0,
8583,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624208,178.0,
8584,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624209,178.0,
8585,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624210,178.0,
8586,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624211,178.0,
8587,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624212,178.0,
8588,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624213,178.0,
8589,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876611,178.0,
8590,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624214,178.0,
8591,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624215,178.0,
8592,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624216,178.0,
8593,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624217,178.0,
8594,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624218,178.0,
8595,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624219,178.0,
8596,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624220,178.0,
8597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624221,178.0,
8598,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624222,,
8599,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624223,,
8600,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624224,,
8601,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624225,,
8602,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622420,,
8603,Volume of steady state distribution after i.v. administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622421,,
8604,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622422,,
8605,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622423,,
8606,Vss was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622424,,
8607,Vss in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622425,,
8608,Vss was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876612,,
8609,volume of distribution at steady state was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622426,,
8610,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622427,,
8611,Pharmacokinetic (PK) parameter Vz in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622428,,
8612,Volume distribution in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622429,,
8613,Volume of distribution in rat; No data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622430,,
8614,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622431,,
8615,% absorption predicted from in vitro rat ileum transport studies,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622432,2116.0,
8616,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622433,,
8617,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622434,,
8618,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622435,,
8619,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618748,,
8620,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618749,,
8621,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618750,,
8622,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618751,,
8623,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618752,,
8624,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618753,,
8625,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618754,1969.0,
8626,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618755,,
8627,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618756,,
8628,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618757,,
8629,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618758,,
8630,Oral bioavailability in rat (dose 30 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621088,,
8631,Pharmacokinetic property (cLogP) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621089,,
8632,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621090,178.0,
8633,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621091,178.0,
8634,Clearance in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876731,,
8635,Compound was evaluated for its clearance when administered intravenously in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621092,,
8636,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621093,,
8637,Blood: Brain distribution ratio is determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621094,,
8638,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621095,,
8639,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621096,,
8640,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621097,2113.0,
8641,Percent dose excreted in 0-48 hours administered ip to male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621098,,
8642,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621099,2037.0,
8643,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621100,2037.0,
8644,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621101,2037.0,
8645,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621102,2037.0,
8646,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876732,2037.0,
8647,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621103,,
8648,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621104,,
8649,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621105,,
8650,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621106,,
8651,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621107,,
8652,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621108,,
8653,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621109,,
8654,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621110,2113.0,
8655,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621111,2113.0,
8656,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622541,2107.0,
8657,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622542,2107.0,
8658,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622543,2107.0,
8659,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624412,2107.0,
8660,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624413,2107.0,
8661,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624414,2107.0,
8662,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624415,2048.0,
8663,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624416,2048.0,
8664,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624417,2048.0,
8665,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624418,2048.0,
8666,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624419,2048.0,
8667,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624420,2048.0,
8668,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624421,2385.0,
8669,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624422,2385.0,
8670,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624423,2385.0,
8671,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625123,2385.0,
8672,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625124,2385.0,
8673,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625125,2385.0,
8674,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625126,14.0,
8675,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626947,14.0,
8676,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626948,14.0,
8677,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626949,14.0,
8678,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626950,14.0,
8679,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626951,14.0,
8680,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626952,2106.0,
8681,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626953,2106.0,
8682,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626954,2106.0,
8683,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626955,2106.0,
8684,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626956,2106.0,
8685,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626957,2106.0,
8686,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626958,178.0,
8687,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626959,178.0,
8688,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626960,178.0,
8689,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626961,178.0,
8690,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627589,178.0,
8691,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627590,178.0,
8692,Time taken for EC90 was determined when tested in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627591,,
8693,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627592,,
8694,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627593,,
8695,Half life in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627594,,
8696,Half life period in mouse after 10 mg/Kg dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876813,,
8697,Half life period in mouse after 10 mg/kg dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627595,,
8698,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627596,,
8699,Cmax value at 5 mg/kg po was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627597,,
8700,Cmax value evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627598,,
8701,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627599,955.0,
8702,Cmax value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627600,,
8703,Cmax value at 1 mg/kg po in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627601,,
8704,Cmax value at 5 mg/kg po in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627776,,
8705,Cmax value at a dose of 10 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627777,,
8706,Cmax value at a dose of 100 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627778,,
8707,Cmax value at a dose of 50 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627779,,
8708,Cmax value in rats at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876814,,
8709,Cmax value was evaluated in rats at a dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627780,,
8710,Cmax value was determined after peroral administration of 20 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627781,,
8711,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627782,,
8712,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627783,1969.0,
8713,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627784,1969.0,
8714,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627785,,
8715,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627786,,
8716,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627787,1969.0,
8717,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627788,1969.0,
8718,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626579,1969.0,
8719,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626580,1969.0,
8720,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876815,,
8721,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626581,1969.0,
8722,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626582,1969.0,
8723,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626583,,
8724,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626205,,
8725,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626206,,
8726,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626207,,
8727,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623882,,
8728,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623883,,
8729,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623884,,
8730,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623885,1969.0,
8731,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623886,1969.0,
8732,Maximal concentration in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623887,,
8733,Maximal concentration after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623888,,
8734,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623889,1969.0,
8735,Maximal plasma concentration in rat after oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623890,1969.0,
8736,Cmax in rat plasma after oral dose (50 mg/Kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623891,1969.0,
8737,Maximal plasma concentration was determined.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623892,1969.0,
8738,Maximal plasma drug concentration was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623893,1969.0,
8739,Maximal concentration in rats after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877616,,
8740,Maximum concentration in rat after 2 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623894,,
8741,Maximum concentration in rat plasma after 5 mg/kg oral gavage,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623895,1969.0,
8742,Maximum concentration of compound in rat was evaluated.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623896,,
8743,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623897,,
8744,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623898,,
8745,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623899,,
8746,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623900,,
8747,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623901,,
8748,Maximum concentration was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623902,,
8749,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623903,1359.0,
8750,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623904,1969.0,
8751,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877617,1969.0,
8752,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623905,,
8753,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623906,,
8754,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623907,1969.0,
8755,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623908,,
8756,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623909,,
8757,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623910,,
8758,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623911,,
8759,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623912,,
8760,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624616,,
8761,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624617,,
8762,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624618,,
8763,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624619,,
8764,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624794,,
8765,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624795,,
8766,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623921,,
8767,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623922,,
8768,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623923,,
8769,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623924,,
8770,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623925,,
8771,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623926,,
8772,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623927,,
8773,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623928,,
8774,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623929,,
8775,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623930,,
8776,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623931,955.0,
8777,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622165,955.0,
8778,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621249,955.0,
8779,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621250,955.0,
8780,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621448,955.0,
8781,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621449,955.0,
8782,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621450,955.0,
8783,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621451,955.0,
8784,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621452,955.0,
8785,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621453,955.0,
8786,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621454,955.0,
8787,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621455,955.0,
8788,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621456,955.0,
8789,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625145,955.0,
8790,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875847,955.0,
8791,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625146,955.0,
8792,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625147,955.0,
8793,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625148,955.0,
8794,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625149,955.0,
8795,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625150,955.0,
8796,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625151,955.0,
8797,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625152,955.0,
8798,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625153,955.0,
8799,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625154,955.0,
8800,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625155,955.0,
8801,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625156,,
8802,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624354,,
8803,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624355,10000000.0,
8804,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624356,10000000.0,
8805,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624357,10000000.0,
8806,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624358,10000000.0,
8807,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624359,2435.0,
8808,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624360,2435.0,
8809,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624361,2435.0,
8810,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624362,2435.0,
8811,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624363,2435.0,
8812,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624364,178.0,
8813,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624365,178.0,
8814,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624366,178.0,
8815,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624367,178.0,
8816,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624368,955.0,
8817,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624369,955.0,
8818,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624370,955.0,
8819,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625069,955.0,
8820,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625070,955.0,
8821,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626051,948.0,
8822,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626052,948.0,
8823,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626053,948.0,
8824,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626054,948.0,
8825,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626055,948.0,
8826,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626056,2113.0,
8827,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626057,2113.0,
8828,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625193,2113.0,
8829,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625194,2113.0,
8830,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625195,2107.0,
8831,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625196,2107.0,
8832,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625197,2107.0,
8833,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625198,2107.0,
8834,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627929,2107.0,
8835,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627074,2048.0,
8836,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627075,2048.0,
8837,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627076,2048.0,
8838,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627077,2048.0,
8839,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627078,2048.0,
8840,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627079,2385.0,
8841,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL873824,,
8842,Half life in mouse plasma was determined at dose 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627080,1969.0,
8843,Half life was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627081,,
8844,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627082,,
8845,Half-life in male mice after 1 mg/kg intravenous dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627083,,
8847,Half life in mice plasma,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627085,1969.0,
8848,Half life in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627086,,
8849,Half life in mouse plasma at dose 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627087,1969.0,
8850,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627088,,
8851,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627089,,
8852,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627090,,
8853,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627091,,
8854,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627092,,
8855,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876785,,
8856,Half-life by iv administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627093,,
8857,Half-life by oral administration in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627094,,
8858,Half-life in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627095,,
8859,Half-life using mouse brain homogenate,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627096,955.0,
8860,Half-life was measured in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627097,,
8861,Half-life was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627098,,
8862,Half-life period was determined in mouse blood,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627099,178.0,
8863,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627100,955.0,
8864,Plasma half life in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627101,1969.0,
8865,Stability of the peptide in the presence of mouse serum,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627102,,
8866,Terminal half life of compound was determined in mouse,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627103,,
8867,Terminal half life was evaluated in mice after intravenous administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627104,,
8868,Terminal half life was evaluated in mice after oral administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627105,,
8869,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876786,,
8870,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL873825,,
8871,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627106,,
8872,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626336,,
8873,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL877462,,
8874,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626337,,
8875,Half life after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626338,,
8876,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626339,,
8877,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626340,,
8878,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625377,,
8879,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625378,,
8880,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625379,,
8881,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL625380,,
8882,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL625381,,
8883,Stability to porcine renal DHP-I,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625382,,
8884,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL873828,,
8885,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625383,,
8886,Half-life of the parent prodrug in porcine esterase solution,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625384,,
8887,"First order rate constant, k was determined in in pig liver Esterase",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625385,,
8888,Half life of the in pig liver Esterase,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL625386,2107.0,
8889,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623571,2107.0,
8890,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623572,2107.0,
8891,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623573,2107.0,
8892,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623574,2107.0,
8893,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623575,2107.0,
8894,Half-life in the presence of pig liver esterase(PLE) was evaluated.,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623749,2107.0,
8895,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623750,2107.0,
8896,Half-life in vitro in pig liver,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623751,2107.0,
8897,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL623752,2107.0,
8898,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623753,1969.0,
8899,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623754,1969.0,
8900,Maximum concentration in rat plasma was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623755,1969.0,
8901,Maximum concentration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623756,,
8902,Maximum concentration in rats at 1-2 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623757,,
8903,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623758,,
8904,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623759,955.0,
8905,Maximum concentration at the dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623760,,
8906,Maximum concentration was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623761,,
8907,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623762,1969.0,
8908,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877594,1969.0,
8909,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623763,1969.0,
8910,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623764,1969.0,
8911,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623765,1969.0,
8912,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623766,178.0,
8913,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623767,178.0,
8914,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623768,178.0,
8915,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623769,1969.0,
8916,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623770,1969.0,
8917,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623771,1969.0,
8918,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623772,1969.0,
8919,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623773,1969.0,
8920,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623774,1969.0,
8921,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623775,1969.0,
8922,Cmax in rat (PO dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623776,,
8923,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622191,1969.0,
8924,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622192,1969.0,
8925,Maximum plasma concentration determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622193,1969.0,
8926,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622194,1969.0,
8927,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622195,1969.0,
8928,Maximum plasma concentration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622196,1969.0,
8929,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622197,1969.0,
8930,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622198,1969.0,
8931,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622199,1969.0,
8932,Maximum plasma concentration of compound was measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622200,1969.0,
8933,Maximum plasma concentration after 20 mg/kg oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622201,1969.0,
8934,Maximum plasma concentration after oral administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623990,1969.0,
8935,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623991,1969.0,
8936,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623992,1969.0,
8937,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623993,1969.0,
8938,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623994,1969.0,
8939,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623995,1969.0,
8940,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623996,1969.0,
8941,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623997,1969.0,
8942,Maximum plasma concentration dosed orally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623998,1969.0,
8943,Maximum plasma concentration dosed orally in rats after 6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623999,1969.0,
8944,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624000,1969.0,
8945,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624001,1969.0,
8946,Maximum plasma concentration in rat after po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624002,1969.0,
8947,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624003,1969.0,
8948,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624004,1969.0,
8949,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624005,948.0,
8950,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624006,948.0,
8951,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624007,948.0,
8952,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624008,948.0,
8953,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624009,948.0,
8954,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874387,948.0,
8955,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624010,948.0,
8956,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624011,948.0,
8957,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624012,948.0,
8958,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624013,948.0,
8959,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624736,948.0,
8960,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624737,948.0,
8961,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624738,948.0,
8962,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624739,948.0,
8963,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624740,948.0,
8964,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624896,948.0,
8965,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624897,948.0,
8966,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624108,948.0,
8967,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624109,948.0,
8968,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624110,948.0,
8969,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624111,948.0,
8970,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624112,948.0,
8971,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624113,948.0,
8972,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619709,948.0,
8973,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619710,948.0,
8974,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619711,2113.0,
8975,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619712,2113.0,
8976,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619713,2113.0,
8977,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619714,2113.0,
8978,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619715,2113.0,
8979,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619716,2113.0,
8980,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619717,2113.0,
8981,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619718,2113.0,
8982,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619719,2113.0,
8983,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875329,2113.0,
8984,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619720,2113.0,
8985,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619721,2113.0,
8986,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619722,2113.0,
8987,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619723,2113.0,
8988,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619724,2113.0,
8989,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619725,2113.0,
8990,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619726,2113.0,
8991,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619727,2113.0,
8992,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619728,2113.0,
8993,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619729,2113.0,
8994,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619730,2385.0,
8995,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619731,2385.0,
8996,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619732,2385.0,
8997,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619733,2385.0,
8998,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619734,2385.0,
8999,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619735,14.0,
9000,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875330,14.0,
9001,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628465,14.0,
9002,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628466,14.0,
9003,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628467,14.0,
9004,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628468,2106.0,
9005,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628469,2106.0,
9006,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628470,2106.0,
9007,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628471,2106.0,
9008,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628472,2106.0,
9009,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625191,2046.0,
9010,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625192,2046.0,
9011,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875337,2046.0,
9012,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626341,2046.0,
9013,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626342,2046.0,
9014,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621943,2107.0,
9015,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621944,,
9016,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621945,,
9017,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621946,,
9018,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621947,,
9019,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621948,,
9020,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621949,,
9021,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621950,,
9022,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621951,,
9023,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621952,178.0,
9024,Stability (%) in rat liver microsomes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621953,2107.0,
9025,Area under curve was calculated after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621954,,
9026,Area under the curve was calculated after iv administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621955,,
9027,Area under the curve was calculated in rat after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621956,,
9028,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621957,,
9029,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621958,,
9030,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621959,,
9031,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621960,,
9032,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621961,,
9033,p value of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621962,,
9034,p value of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876787,,
9035,p value of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621963,,
9036,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622637,945.0,
9037,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622638,945.0,
9038,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626561,945.0,
9039,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626562,,
9040,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626563,,
9041,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626564,,
9042,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626565,,
9043,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626566,,
9044,Clearance rate in rabbits,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626567,,
9045,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626568,,
9046,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626569,,
9047,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626570,,
9048,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626571,,
9049,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626572,,
9050,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626573,1969.0,
9051,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL626574,2107.0,
9052,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL626575,2107.0,
9053,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626576,,
9054,Dose at which bioavailability of perorally administered compound was tested in rabbit,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626577,,
9055,The compound was tested for its bioavailability in rabbit (by oral dosage).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626578,,
9056,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625263,,
9057,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625264,,
9058,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625265,,
9059,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL625266,,
9060,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL876796,,
9061,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625267,,
9062,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625268,1969.0,
9063,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625269,1969.0,
9064,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624689,1969.0,
9065,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624690,,
9066,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624691,1088.0,
9067,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624692,1088.0,
9068,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624693,,
9069,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624694,,
9070,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL877596,,
9071,Time within which only 10% of the drug was degraded,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624695,,
9072,Half life period in rabbit liver homogenate,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL624696,2107.0,
9073,Half life value in rabbits,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624697,,
9074,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624698,178.0,
9075,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624699,178.0,
9076,Half-life period in rabbits following intravenous administration at 2 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624700,,
9077,AUC 0-8 hr value in rats at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622903,1969.0,
9078,AUC after administration at 2000 mg/kg/day in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622904,1969.0,
9079,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622905,1969.0,
9080,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622906,1969.0,
9081,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622907,1969.0,
9082,AUC in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622908,1969.0,
9083,AUC in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622909,1969.0,
9084,AUC in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622910,1969.0,
9085,AUC in rat brain after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622911,955.0,
9086,AUC in rat p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622912,1969.0,
9087,AUC in rat p.o. at 20 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622913,1969.0,
9088,AUC in rat plasma after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622914,1969.0,
9089,AUC in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622915,1969.0,
9090,AUC value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622916,1969.0,
9091,AUC value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622917,1969.0,
9092,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622918,1969.0,
9093,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622919,1969.0,
9094,Maximum plasma concentration was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622920,1969.0,
9095,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622921,1969.0,
9096,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622922,1969.0,
9097,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622923,1969.0,
9098,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877604,1969.0,
9099,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622924,1969.0,
9100,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622925,1969.0,
9101,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622926,1969.0,
9102,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623625,1969.0,
9103,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL623626,1969.0,
9104,Maximum plasma drug concentration was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623627,1969.0,
9105,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623628,,
9106,Mean peak plasma concentration was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623629,1969.0,
9107,Mean peak plasma concentration was observed after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623630,1969.0,
9108,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623804,,
9109,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623805,,
9110,Peak oral plasma concentration was determined in rats by oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623806,1969.0,
9111,Peak plasma concentration (Cmax) was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623807,1969.0,
9112,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623808,1969.0,
9113,Peak plasma concentration (Cmax) in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623809,1969.0,
9114,Peak plasma concentration at 1 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623810,1969.0,
9115,Peak plasma concentration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623811,1969.0,
9116,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623812,1969.0,
9117,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877605,,
9118,Pharmacokinetic property (Cmax) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623813,,
9119,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623814,,
9120,Cmax in rat after 3mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623815,,
9121,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623816,,
9122,Cmax in rats after 20 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623145,,
9123,Cmax in rat plasma after 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623146,1969.0,
9124,Plasma concentration after oral administration of 100 mg/kg to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623147,1969.0,
9125,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623042,955.0,
9126,Tested for the Cmax in rat at 10 mg/kg per orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623043,,
9127,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623044,,
9128,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623045,,
9129,Bioavailability as oral Cmax in rats at 30 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623046,,
9130,Bioavailability as oral Cmax in rats at 6hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623226,,
9131,The maximum concentration of compound was measured at the dose of 100 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623227,,
9132,The maximum concentration of compound was measured at the dose of 300 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623228,,
9133,The maximum concentration of compound was measured at the dose of 30 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623229,,
9134,The maximum plasma levels for the compounds were determined by LC-MS.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623230,1969.0,
9135,mean peak plasma concentration was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623231,1969.0,
9136,mean peak plasma concentration was observed after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623232,1969.0,
9137,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623233,,
9138,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623234,,
9139,Concentration in plasma (portal) following oral dose in rats at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623235,,
9140,Concentration in plasma (portal) following oral dose in rats at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623236,,
9141,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623237,,
9142,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623238,,
9143,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623239,,
9144,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623240,1969.0,
9145,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623241,1898.0,
9146,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623242,1898.0,
9147,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874394,,
9148,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623243,,
9149,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623244,,
9150,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623245,2113.0,
9151,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623246,2113.0,
9152,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623247,2113.0,
9153,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623248,2113.0,
9154,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623249,2113.0,
9155,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625072,2107.0,
9156,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625073,2107.0,
9157,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625074,2107.0,
9158,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625075,2107.0,
9159,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625076,2107.0,
9160,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625077,2107.0,
9161,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625078,2107.0,
9162,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874395,2107.0,
9163,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625079,2107.0,
9164,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625080,2107.0,
9165,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625081,2107.0,
9166,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625082,2107.0,
9167,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625083,2107.0,
9168,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625084,2107.0,
9169,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625085,2107.0,
9170,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625086,2107.0,
9171,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625087,2107.0,
9172,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625088,2107.0,
9173,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622205,2107.0,
9174,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622206,2107.0,
9175,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622207,2107.0,
9176,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622366,2107.0,
9177,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622367,2107.0,
9178,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875331,2107.0,
9179,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622368,2107.0,
9180,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622369,2048.0,
9181,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622370,2048.0,
9182,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622371,2048.0,
9183,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622372,2048.0,
9184,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622373,2048.0,
9185,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622374,2048.0,
9186,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622375,2048.0,
9187,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622376,2048.0,
9188,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622377,2048.0,
9189,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622378,2048.0,
9190,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622379,2048.0,
9191,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622380,2048.0,
9192,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622381,2048.0,
9193,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622382,2048.0,
9194,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622383,2048.0,
9195,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875332,945.0,
9196,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622384,945.0,
9197,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622385,945.0,
9198,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622386,945.0,
9199,The compound was tested for the plasma binding in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622387,,
9200,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622388,,
9201,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622389,,
9202,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622390,,
9203,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622391,,
9204,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622392,,
9205,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622393,,
9206,Plasma level at 2 hr after administration of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622394,,
9207,plasma level at 2 hr after administration of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622395,,
9208,Stability in rat serum measured as % recovery at 1 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622396,1977.0,
9209,Stability in rat serum measured as % recovery at 10 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624894,1977.0,
9210,Stability in rat serum measured as % recovery at 10 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624895,1977.0,
9211,Stability in rat serum measured as % recovery at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624058,1977.0,
9212,Stability in rat serum measured as % recovery at 3 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624059,1977.0,
9213,Stability in rat serum measured as % recovery at 3 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624060,1977.0,
9214,Stability in rat serum measured as % recovery at 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624061,1977.0,
9215,Stability in rat serum measured as % recovery at 5 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624062,1977.0,
9216,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624063,,
9217,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624064,,
9218,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624065,1969.0,
9219,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624066,1969.0,
9220,Half life tested in mature male rat at a dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877490,,
9221,Half life after intravenous administration of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874442,,
9222,Half life period after administration (30 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626890,,
9223,Half life period in rat after 5 mg/Kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626891,,
9224,Half life period in rat after 5 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626892,,
9225,Half life period was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626893,,
9226,Half life period was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626894,,
9227,Half life period was evaluated in rat; 0.5-1.0,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626895,,
9228,Half life period was evaluated in rat; 5.9-7.5,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626896,,
9229,Half-life in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626897,1969.0,
9230,Half-life time in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626898,,
9231,Terminal half-life after iv administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626899,,
9232,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626900,,
9233,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626901,,
9234,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626902,,
9235,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626903,,
9236,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874443,,
9237,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626904,,
9238,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626905,,
9239,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873830,1969.0,
9240,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626906,,
9241,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631076,1969.0,
9242,Biological half-life was measured in plasma of rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631077,1969.0,
9243,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631078,,
9244,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631079,,
9245,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631080,,
9246,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631081,,
9247,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631239,,
9248,Compound was evaluated for plasma half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631240,1969.0,
9249,AUC value at a dose of 5 mg/kg (p.o.) in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631241,1969.0,
9250,AUC value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631242,1969.0,
9251,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631243,1969.0,
9252,AUC0-96 after administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874444,1969.0,
9253,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631244,1969.0,
9254,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631245,,
9255,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627162,,
9256,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627163,,
9257,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627164,,
9258,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627165,2113.0,
9259,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627166,,
9260,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627167,,
9261,Area under curve (AUC) at a dose of 30 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627822,,
9262,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627823,,
9263,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627824,,
9264,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627825,,
9265,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627826,,
9266,Area under curve (Pharmacokinetic property) was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627827,,
9267,Area under curve (Pharmacokinetic property) of the compound; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627828,,
9268,Area under curve after intravenous administration (1 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627829,,
9269,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627830,,
9270,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627831,,
9271,Area under curve in male SD rats was observed after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627832,,
9272,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627833,,
9273,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL627834,,
9274,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL628004,,
9275,Area under curve at 5 mg/kg po was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628005,,
9276,Area under curve in Rat at a oral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628006,,
9277,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628007,,
9278,Area under curve was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625676,,
9279,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631309,,
9280,Area under curve after intravenous administration at 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631310,,
9281,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631311,,
9282,Area under curve at 4 hr in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631312,,
9283,Area under curve at a dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631313,,
9284,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631314,,
9285,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631315,,
9286,Area under curve for a 2-mpk po dose in SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631316,,
9287,Area under curve in SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631317,,
9288,Area under curve in rat after oral administration at 13 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874471,,
9289,Area under curve in rat by po administration at 0-24 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631318,,
9290,Area under curve in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631319,1969.0,
9291,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631320,,
9292,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631321,,
9293,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631322,,
9294,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631323,,
9295,Area under curve value in rat at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631324,,
9296,Area under curve was determined after oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631325,,
9297,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631326,,
9298,Area under curve was determined after peroral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631327,,
9299,Area under curve was determined at a dose 30 mpk administered orally.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631328,,
9300,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631329,,
9301,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627217,,
9302,Area under curve was determined in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626352,,
9303,Area under curve was determined in rat after PO administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626353,,
9304,Area under curve was determined in rat after a 3 mg/kg of oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626354,,
9305,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626355,,
9306,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626356,,
9307,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626357,,
9308,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626358,,
9309,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626359,,
9310,Peak plasma concentration in rat at a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626360,1969.0,
9311,Plasma concentration at 2 hr in rats was evaluated.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626361,,
9312,Plasma concentration at 2 hr in rats was evaluated; Not available,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626362,,
9313,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626363,,
9314,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626970,,
9315,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626971,,
9316,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626972,1969.0,
9317,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626973,1969.0,
9318,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626974,1969.0,
9319,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874592,1969.0,
9320,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626975,,
9321,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626976,,
9322,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626977,,
9323,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626978,,
9324,PK study was carried to determine the relative absorption ranking in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626979,,
9325,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626980,1969.0,
9326,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626981,178.0,
9327,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626982,178.0,
9328,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626983,178.0,
9329,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622522,178.0,
9330,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622523,178.0,
9331,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622524,178.0,
9332,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622525,955.0,
9333,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622526,955.0,
9334,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619849,955.0,
9335,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619850,955.0,
9336,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623864,955.0,
9337,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623865,955.0,
9338,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623866,948.0,
9339,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623867,948.0,
9340,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877615,948.0,
9341,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623868,948.0,
9342,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623869,948.0,
9343,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623870,948.0,
9344,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623871,2048.0,
9345,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623872,2048.0,
9346,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622129,2048.0,
9347,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622130,2048.0,
9348,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622131,2048.0,
9349,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622132,2048.0,
9350,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622133,2048.0,
9351,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622134,2048.0,
9352,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622135,2048.0,
9353,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622136,2048.0,
9354,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622137,2385.0,
9355,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622138,2385.0,
9356,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623017,2385.0,
9357,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623018,2385.0,
9358,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623019,2385.0,
9359,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623020,2385.0,
9360,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623021,2385.0,
9361,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623022,2385.0,
9362,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623023,2385.0,
9363,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623024,2385.0,
9364,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623025,2385.0,
9365,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620545,2385.0,
9366,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620546,2385.0,
9367,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620547,2385.0,
9368,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620548,2385.0,
9369,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620549,2385.0,
9370,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620550,2385.0,
9371,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620551,2385.0,
9372,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620552,2385.0,
9373,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620553,2385.0,
9374,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620554,2385.0,
9375,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875845,2385.0,
9376,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620555,2385.0,
9377,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620556,2385.0,
9378,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620557,2385.0,
9379,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620558,,
9380,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620559,,
9381,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622939,,
9382,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622940,,
9383,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622941,,
9384,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622942,,
9385,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622943,,
9386,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622944,,
9387,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622945,,
9388,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622946,,
9389,Compound was evaluated for terminal half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622947,,
9390,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622948,1969.0,
9391,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622949,1969.0,
9392,Compound was tested for its half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622950,,
9393,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL622951,1969.0,
9394,Compound was tested for its plasma half life in Sprague Dawley rats,,BAO_0000366,Intermediate,,,22224,U,0,1,,CHEMBL622952,1969.0,
9395,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,,BAO_0000366,Intermediate,,,22224,U,0,1,,CHEMBL622953,1969.0,
9396,Compound was tested for plasma half-life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873818,1969.0,
9397,Elimination half life after i.v. administration of compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622954,,
9398,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622955,,
9399,Elimination half-life after IV dosing at 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875229,,
9400,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622956,,
9401,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622957,,
9402,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622958,955.0,
9403,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622959,1969.0,
9404,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622960,955.0,
9405,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622961,1969.0,
9406,Evaluated for the half life in rat (in vivo),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622962,,
9407,Hafl life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622963,,
9408,Hafl life rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622964,,
9409,Hafl life rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622965,,
9410,Hafl life rat; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622966,,
9411,Hafl life rat; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622967,,
9412,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622968,2113.0,
9413,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622969,2107.0,
9414,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875327,2048.0,
9415,Half life in rat after 1 mg/kg i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628638,,
9416,Half life in rat after 2 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628639,,
9417,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625840,,
9418,Half life of 10 mg/kg oral dose determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625841,,
9419,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625842,,
9420,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625843,,
9421,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625844,,
9422,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873822,,
9423,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625845,,
9424,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627059,,
9425,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627060,,
9426,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627061,,
9427,Half life of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627709,,
9428,Half life of compound determined after intravenous administration to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627710,,
9429,Half life of compound was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627711,,
9430,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627712,1969.0,
9431,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627713,,
9432,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627714,,
9433,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL627889,,
9434,Half life determined in rat by intravenous administration,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL627890,,
9435,Half life determined in rats after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627891,,
9436,Half life in rat plasma after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627892,1969.0,
9437,Half life in rat plasma after administration of 2 mg/kg iv,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627893,1969.0,
9438,Half life in rat plasma was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627894,1969.0,
9439,Half life in rat plasma was determined; NA means not applicable,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627895,1969.0,
9440,Half life in rat was tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627896,,
9441,Half life measured in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627897,1969.0,
9442,Half life recorded in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627898,,
9443,Half life was calculated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627899,,
9444,Half life was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873823,,
9445,Half life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627900,,
9446,Half life after 10 mg/kg oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627901,,
9447,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627902,,
9448,Half life after administering orally a dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627903,,
9449,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627904,,
9450,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627905,,
9451,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627906,,
9452,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627907,,
9453,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876783,,
9454,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627908,,
9455,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627909,,
9456,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627910,,
9457,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627911,,
9458,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627912,,
9459,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627913,,
9460,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627914,,
9461,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627915,,
9462,Area under the curve was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627916,,
9463,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627917,,
9464,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627918,,
9465,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627919,,
9466,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627920,,
9467,Area under the curve was evaluated at an oral dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627921,,
9468,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627922,,
9469,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876784,,
9470,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627923,,
9471,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626208,,
9472,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626209,,
9473,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626210,,
9474,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627994,1969.0,
9475,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627995,,
9476,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627996,,
9477,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627997,,
9478,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627998,,
9479,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628640,,
9480,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628641,,
9481,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628642,,
9482,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628643,,
9483,Compound was tested for area under curve in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628644,,
9484,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628645,,
9485,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628646,,
9486,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628647,,
9487,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628648,,
9488,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625358,,
9489,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625359,,
9490,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625360,,
9491,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625361,,
9492,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625362,,
9493,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625363,,
9494,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625364,,
9495,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625365,,
9496,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625366,,
9497,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625367,,
9498,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625368,2113.0,
9499,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625369,2113.0,
9500,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625370,2113.0,
9501,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625371,2113.0,
9502,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625372,2113.0,
9503,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625373,2113.0,
9504,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625374,2107.0,
9505,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877593,2107.0,
9506,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625375,2107.0,
9507,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625376,2107.0,
9508,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621973,2107.0,
9509,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621974,2107.0,
9510,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621975,2048.0,
9511,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622166,2048.0,
9512,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622167,2048.0,
9513,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622168,2048.0,
9514,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622169,2048.0,
9515,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622170,2048.0,
9516,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622171,2046.0,
9517,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622172,2046.0,
9518,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622173,2046.0,
9519,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622174,2046.0,
9520,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622175,2046.0,
9521,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622176,2046.0,
9522,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622177,2046.0,
9523,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622178,2046.0,
9524,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622179,2046.0,
9525,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622180,2046.0,
9526,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622181,,
9527,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622182,,
9528,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622183,,
9529,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622184,,
9530,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622185,,
9531,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622186,,
9532,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622187,,
9533,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625002,,
9534,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622090,,
9535,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622091,,
9536,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622092,,
9537,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622093,,
9538,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622094,,
9539,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622095,,
9540,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622264,,
9541,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622265,2106.0,
9542,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622266,2106.0,
9543,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622267,2106.0,
9544,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622268,2106.0,
9545,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622269,2106.0,
9546,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625071,2106.0,
9547,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621621,2106.0,
9548,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621622,2106.0,
9549,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621623,2106.0,
9550,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621624,2106.0,
9551,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621625,2106.0,
9552,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621626,2106.0,
9553,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621627,2106.0,
9554,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621628,2106.0,
9555,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875328,2106.0,
9556,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621629,2106.0,
9557,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621630,2106.0,
9558,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621631,2106.0,
9559,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621632,2106.0,
9560,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621633,2106.0,
9561,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621634,2106.0,
9562,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621635,2106.0,
9563,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621636,2106.0,
9564,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621637,2106.0,
9565,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621638,2106.0,
9566,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618883,,
9567,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618884,,
9568,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628627,,
9569,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628628,,
9570,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628629,,
9571,Half life after administering orally a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628630,,
9572,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628631,,
9573,Half life after administering intravenously a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628632,,
9574,Half life after oral dosing in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628633,,
9575,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628634,,
9576,Half life by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627789,,
9577,Half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627790,,
9578,Half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627791,,
9579,Half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627792,,
9580,Half life in rat after intravenous administration of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627793,,
9581,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627794,1969.0,
9582,Half life in rat after po administration of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627795,,
9583,Half life in rat after po administration of the compound; ND means Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627796,,
9584,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875335,1969.0,
9585,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627797,1969.0,
9586,Half life in rat i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627798,,
9587,Half life in rat i.v. at 2 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627799,,
9588,Half life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627800,,
9589,Half life in rats after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627801,,
9590,Half life in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627802,,
9591,Half life in rat,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL627803,,
9592,Half life was evaluated after intravenous administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873820,,
9593,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627804,,
9594,Half life was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627805,,
9595,Half life was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627806,,
9596,Half life was evaluated in rat; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627107,,
9597,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627108,,
9598,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627109,,
9599,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627110,178.0,
9600,Half life was measured in monkey at dose of 10 mg/kg by po administration,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL627111,,
9601,Half life was measured in monkey at dose of 10 mg/kg by po administration,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL627112,,
9602,Half life was measured in rat at dose of 30 mg/kg by iv administration,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL627113,,
9603,Half life was measured in rat at dose of 30 mg/kg by po administration,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL627114,,
9604,Half life (t1/2) was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627115,,
9605,Half life period at a dose of 10 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627116,,
9606,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627117,,
9607,Half life period was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627118,,
9608,Half life period after intravenous administration at 20 mpk in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627119,,
9609,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627120,,
9610,Half life period after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626922,,
9611,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626923,,
9612,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626924,,
9613,Half life period in 80% rat plasma at 37 degree Centigrade,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626925,1969.0,
9614,Half life period in SD rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626926,,
9615,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626927,1969.0,
9616,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626928,1969.0,
9617,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626929,1969.0,
9618,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626930,1969.0,
9619,Half life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626931,,
9620,Half life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626932,,
9621,Half life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626933,,
9622,Half life period in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873826,,
9623,Half life period in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626934,,
9624,Half life period in rat after oral administration at 13 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626935,,
9625,Half life period in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626936,,
9626,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626937,,
9627,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625906,,
9628,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625907,,
9629,PK study was carried to determine AUC (area under curve) value in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625908,,
9630,Pharmacokinetic parameter AUC after intravenous administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625909,,
9631,Pharmacokinetic parameter AUC after oral administration to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625910,,
9632,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625911,,
9633,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625912,,
9634,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626538,,
9635,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876794,,
9636,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626539,,
9637,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626540,,
9638,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626541,,
9639,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626542,,
9640,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626543,,
9641,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626544,,
9642,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626545,,
9643,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626546,,
9644,Pharmacokinetic parameter area under curve was reported,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626547,,
9645,Pharmacokinetic property (AUC) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626548,,
9646,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626549,,
9647,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626550,,
9648,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626551,,
9649,Pharmacokinetic property was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623777,,
9650,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623778,,
9651,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623779,,
9652,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623780,1969.0,
9653,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622015,1969.0,
9654,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622016,1969.0,
9655,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622017,,
9656,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622018,,
9657,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622019,,
9658,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622020,,
9659,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622021,,
9660,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622022,,
9661,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622023,,
9662,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622024,,
9663,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622693,,
9664,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622694,,
9665,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622695,,
9666,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622696,,
9667,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622697,,
9668,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622874,,
9669,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622875,,
9670,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622876,,
9671,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622877,,
9672,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622878,,
9673,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622879,1969.0,
9674,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877602,,
9675,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622880,,
9676,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622881,,
9677,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622882,,
9678,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622883,,
9679,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622884,2046.0,
9680,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622885,2046.0,
9681,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622886,,
9682,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622887,,
9683,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622888,1088.0,
9684,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622889,178.0,
9685,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622890,178.0,
9686,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622891,178.0,
9687,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877603,178.0,
9688,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622892,955.0,
9689,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622893,955.0,
9690,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622894,955.0,
9691,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622895,955.0,
9692,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622896,955.0,
9693,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622897,948.0,
9694,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622898,948.0,
9695,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622899,948.0,
9696,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622900,2113.0,
9697,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624114,2113.0,
9698,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624115,2113.0,
9699,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624116,2113.0,
9700,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624117,2107.0,
9701,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624118,2107.0,
9702,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624119,2107.0,
9703,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624120,2107.0,
9704,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624121,2048.0,
9705,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624122,2048.0,
9706,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624123,2048.0,
9707,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624124,2048.0,
9708,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624125,2385.0,
9709,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624126,2385.0,
9710,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624127,2385.0,
9711,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624128,2385.0,
9712,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624129,14.0,
9713,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624130,14.0,
9714,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622340,14.0,
9715,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622341,14.0,
9716,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622342,160.0,
9717,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622343,160.0,
9718,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622344,160.0,
9719,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622345,160.0,
9720,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622346,2106.0,
9721,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622347,2106.0,
9722,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622348,2106.0,
9723,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622349,2106.0,
9724,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622350,,
9725,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622351,,
9726,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622352,,
9727,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622353,,
9728,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622354,,
9729,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622355,,
9730,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622356,,
9731,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622357,,
9732,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622358,,
9733,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622359,,
9734,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874393,,
9735,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622872,,
9736,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622873,,
9737,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623047,,
9738,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623048,,
9739,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623049,,
9740,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623050,,
9741,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623051,,
9742,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623052,,
9743,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626343,,
9744,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626344,,
9745,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626345,,
9746,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626346,,
9747,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626347,,
9748,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626348,,
9749,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626349,,
9750,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626350,,
9751,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626351,,
9752,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627650,,
9753,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627651,,
9754,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627652,,
9755,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627653,,
9756,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627654,,
9757,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627835,,
9758,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627836,,
9759,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627837,,
9760,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627838,,
9761,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875338,,
9762,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627839,,
9763,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627840,,
9764,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627841,,
9765,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627842,,
9766,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627843,,
9767,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627844,,
9768,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627845,,
9769,Half life period in rat by iv administration at a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627846,,
9770,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627847,1969.0,
9771,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873821,1969.0,
9772,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626079,1969.0,
9773,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626080,1969.0,
9774,Half life period was evaluated in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626081,1969.0,
9775,Half life period was evaluated in rat plasma; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875344,1969.0,
9776,Half life period was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626082,,
9777,"Half life period was evaluated in rats, iv",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626250,,
9778,Half life period after intravenous administration at 5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626251,,
9779,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626252,,
9780,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626253,,
9781,Half life stability of compound was evaluated in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626254,1969.0,
9782,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626255,,
9783,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626256,,
9784,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626257,,
9785,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626258,,
9786,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626259,,
9787,Half in rat i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626260,,
9788,Half period in rat after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875345,,
9789,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626261,,
9790,Half-life measured in in vitro Cathepsin B assay in rat liver,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626262,2107.0,
9791,Half-life of compound was determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626263,,
9792,Half-life at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625270,,
9793,Half-life determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625271,,
9794,Half-life determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625272,,
9795,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625273,955.0,
9796,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625274,1969.0,
9797,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625275,,
9798,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625276,1969.0,
9799,Half-life in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625277,1969.0,
9800,Half-life in rat plasma was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625278,1969.0,
9801,Half-life in rat plasma; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625279,1969.0,
9802,Half-life in rat serum,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625280,1977.0,
9803,Half-life in rat serum; na is not available,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876797,1977.0,
9804,Half-life was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625281,,
9805,Half-life was calculated in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873827,1969.0,
9806,Half-life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625282,,
9807,Half-life was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625283,,
9808,Half-life after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625284,,
9809,Half-life after administration of 3.2 mg/kg intravenously in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625285,,
9810,Half-life after intravenous administration in female rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625286,,
9811,Half-life after intravenous administration in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625287,,
9812,Half-life after intravenous dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625288,,
9813,Half-life in a rat liver homogenate preparation,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625289,2107.0,
9814,Half-life in plasma of rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625290,1969.0,
9815,Half-life in plasma of rat at dose of 3-10 mgkg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876798,1969.0,
9816,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625291,,
9817,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625292,,
9818,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625293,,
9819,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622832,,
9820,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622833,,
9821,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622834,,
9822,Half-life in rat after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622835,,
9823,Half-life in rat after po administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622836,,
9824,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622837,,
9825,Half-life in rat at 3 mg/kg dose administered intravenously,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622838,,
9826,Half-life in rat brain homogenate,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622839,955.0,
9827,Half-life in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622840,1969.0,
9828,Half-life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622841,,
9829,Half-life in Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622842,,
9830,Half-life in vitro in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622843,1969.0,
9831,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622844,1969.0,
9832,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622845,,
9833,The area under the curve of compound was measured at the dose of 100 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622846,,
9834,The area under the curve of compound was measured at the dose of 300 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622847,,
9835,The area under the curve of compound was measured at the dose of 30 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622848,,
9836,Bioavailability as oral AUC in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622849,,
9837,The plasma concentration versus time curve (AUC) was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622850,1969.0,
9838,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876807,,
9839,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622851,,
9840,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622852,,
9841,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622853,,
9842,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622854,,
9843,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622855,,
9844,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622856,1969.0,
9845,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622857,1969.0,
9846,AUC in rat after po administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622858,1969.0,
9847,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622859,1969.0,
9848,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622860,,
9849,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622861,,
9850,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622862,,
9851,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622863,,
9852,Area under curve value 6 hr after po administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623817,,
9853,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623818,,
9854,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623819,,
9855,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623820,,
9856,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623821,,
9857,AUC normalized for dose (AUCN) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623822,1969.0,
9858,Area under curve in rat after p.o. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623823,,
9859,Area under curve in rat after p.o. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623824,,
9860,Area under curve in rat after p.o. administration; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623825,,
9861,Area under curve in rat after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622070,,
9862,Area under curve (carotid artery) value of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622071,,
9863,Bioavailability expressed as the area under curve of rat carotid artery,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622072,,
9864,Area under curve in male SD rats was observed after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622073,,
9865,Area under curve of the compound was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622074,,
9866,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622075,,
9867,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622076,1969.0,
9868,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622077,1969.0,
9869,Area under curve (portal vein) value of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622078,,
9870,Bioavailability expressed as the area under curve of rat portal vein,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622079,,
9871,Area Under plasma concentration time curve in rat upon peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622080,1969.0,
9872,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877612,,
9873,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622081,,
9874,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622082,,
9875,Compound was evaluated for oral bioavailability in rats after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622083,,
9876,Compound was evaluated for oral bioavailability in rats; 30-80,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622084,,
9877,Compound was evaluated for oral bioavailability in rats; 50-60,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622085,,
9878,Compound was evaluated for oral bioavailability in rats; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622086,,
9879,Compound was evaluated for oral bioavailability in rats; peptide,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622087,,
9880,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622088,178.0,
9881,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622089,178.0,
9882,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623685,178.0,
9883,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623686,178.0,
9884,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623687,945.0,
9885,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623688,945.0,
9886,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623689,945.0,
9887,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622485,945.0,
9888,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622486,2046.0,
9889,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877613,2046.0,
9890,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622487,2046.0,
9891,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622488,2046.0,
9892,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622489,948.0,
9893,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622490,1088.0,
9894,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622491,1088.0,
9895,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622492,2107.0,
9896,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622493,1088.0,
9897,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622494,1088.0,
9898,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622495,2385.0,
9899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622496,,
9900,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622497,1088.0,
9901,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622498,,
9902,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624918,1088.0,
9903,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624919,1088.0,
9904,Biodistribution of compound in rat blood after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624920,178.0,
9905,Biodistribution of compound in rat blood after 5 min of administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624921,178.0,
9906,Biodistribution of compound in rat brain after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624922,955.0,
9907,Biodistribution of compound in rat heart after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624923,948.0,
9908,Biodistribution of compound in rat heart after 5 min of administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624924,948.0,
9909,Biodistribution of compound in rat kidney after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624925,2113.0,
9910,Biodistribution of compound in rat kidney after 5 min of administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624926,2113.0,
9911,Biodistribution of compound in rat liver after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624927,2107.0,
9912,Biodistribution of compound in rat liver after 5 min of administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874402,2107.0,
9913,Biodistribution of compound in rat lung after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624928,2048.0,
9914,Biodistribution of compound in rat lung after 5 min of administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624929,2048.0,
9915,Biodistribution of compound in rat muscle after 5 min of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624930,2385.0,
9916,Biodistribution of compound in rat muscle after 5 min of administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624931,2385.0,
9917,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624932,948.0,
9918,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624933,948.0,
9919,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624934,2107.0,
9920,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624935,2107.0,
9921,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624936,,
9922,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624937,,
9923,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624938,2106.0,
9924,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624939,2106.0,
9925,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624940,,
9926,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874403,,
9927,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624941,,
9928,Dose required to lower urine osmolality to 300 mOsm/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624942,1088.0,
9929,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624943,1088.0,
9930,% Bioavailability after 1 day of the drug administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624944,,
9931,% Bioavailability after 4 day of the drug administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624945,,
9932,Absolute bioavailability was evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624946,,
9933,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624947,,
9934,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624948,,
9935,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624949,,
9936,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622025,2113.0,
9937,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622026,2113.0,
9938,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622027,2113.0,
9939,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622028,2113.0,
9940,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622029,2107.0,
9941,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622208,2107.0,
9942,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622209,2107.0,
9943,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622210,2107.0,
9944,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622211,,
9945,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622212,,
9946,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622213,,
9947,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874404,,
9948,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620452,2385.0,
9949,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620453,2385.0,
9950,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620454,2385.0,
9951,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624067,2385.0,
9952,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624068,,
9953,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624069,992.0,
9954,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624070,992.0,
9955,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624071,992.0,
9956,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624072,995.0,
9957,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624073,995.0,
9958,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624788,995.0,
9959,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624789,995.0,
9960,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624790,,
9961,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624791,,
9962,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624792,,
9963,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624793,,
9964,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877491,2385.0,
9965,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624957,2385.0,
9966,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624958,2385.0,
9967,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624959,2385.0,
9968,Dissociation constant was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624960,,
9969,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624961,,
9970,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624962,,
9971,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624963,,
9972,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624964,,
9973,LogP value was evaluated in the in situ rat gut perfusion assay,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624965,,
9974,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624966,,
9975,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624967,,
9976,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624968,,
9977,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624969,,
9978,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL624970,,
9979,Half-life was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624971,,
9980,Half-life was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624972,,
9981,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624973,,
9982,Half-life was evaluated in plasma of rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624974,1969.0,
9983,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624975,,
9984,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877492,,
9985,Half-life was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624976,,
9986,Half-life period of compound in rats after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624977,,
9987,Half-life period of compound was measured in rat plasma.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626848,1969.0,
9988,Half-life period of compound was measured in rat plasma; ND is not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626849,1969.0,
9989,Half-life period of compound was measured in rat plasma; not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626850,1969.0,
9990,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626851,,
9991,Half-life period in rat by iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626852,,
9992,Half-life period in rats following intravenous administration at 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626853,,
9993,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626854,,
9994,Half-life period was determined for the compound in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627486,,
9995,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627487,,
9996,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627488,,
9997,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627489,,
9998,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627490,,
9999,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873829,,
10000,Half-life was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627655,,
10001,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625994,,
10002,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625995,,
10003,Half-life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625996,,
10004,In vitro half life in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625850,1969.0,
10005,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625851,1969.0,
10006,In vitro half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625852,,
10007,In vivo half life period after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625853,,
10008,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625854,,
10009,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874450,,
10010,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625855,,
10011,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625856,,
10012,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625857,,
10013,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873831,,
10014,Longer half-life in rat (i.v.) at 0.5 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625858,,
10015,Longer half-life in rat (p.o.) at 2.0 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625859,,
10016,Pharmacokinetic property (half life) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625860,,
10017,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625861,,
10018,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625862,,
10019,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625863,,
10020,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625864,,
10021,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625865,,
10022,Pharmacokinetic half time was determined intravenously in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625866,,
10023,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625867,1969.0,
10024,Plasma half life of hydrolysis of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625868,1969.0,
10025,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625869,1969.0,
10026,Plasma half life period was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874451,1969.0,
10027,Plasma half-life in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625870,1969.0,
10028,Plasma half-life in Sprague-Dawley rats; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625871,1969.0,
10029,Plasma half-life in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625872,1969.0,
10030,Plasma half-life in rats; <MQL,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625873,1969.0,
10031,Plasma half-life period (0-8 h) was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625874,1969.0,
10032,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625875,1969.0,
10033,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625876,1969.0,
10034,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631258,1969.0,
10035,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631259,1969.0,
10036,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631260,1969.0,
10037,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631261,178.0,
10038,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631262,178.0,
10039,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631263,178.0,
10040,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631264,,
10041,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631265,,
10042,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631266,,
10043,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631267,,
10044,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631268,,
10045,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631269,,
10046,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631270,,
10047,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631271,948.0,
10048,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631272,948.0,
10049,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631273,948.0,
10050,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631274,948.0,
10051,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631275,948.0,
10052,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626984,948.0,
10053,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626985,948.0,
10054,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626986,2107.0,
10055,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626987,2107.0,
10056,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626988,2107.0,
10057,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626989,2107.0,
10058,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626990,2107.0,
10059,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626991,2107.0,
10060,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626992,2107.0,
10061,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626993,2048.0,
10062,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874593,2048.0,
10063,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626994,2048.0,
10064,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626995,2048.0,
10065,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626190,2048.0,
10066,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626191,2048.0,
10067,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626364,2048.0,
10068,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626365,2046.0,
10069,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626366,2046.0,
10070,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626367,2046.0,
10071,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626368,2046.0,
10072,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626369,2046.0,
10073,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626370,2046.0,
10074,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626371,,
10075,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626372,,
10076,Bioavailability after a dose of 10 mg/kg p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626373,,
10077,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626374,,
10078,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626375,,
10079,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626376,,
10080,Bioavailability in rat po was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626377,,
10081,Bioavailability of compound at 10 mg/kg in rat after oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626378,,
10082,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626379,,
10083,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626380,,
10084,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626381,,
10085,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626382,,
10086,Bioavailability in rat (Sprague-Dawley) (female),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626383,,
10087,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874652,,
10088,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626384,,
10089,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626385,,
10090,Bioavailability in rat at an oral dose of 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626386,,
10091,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626387,,
10092,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626388,,
10093,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626389,,
10094,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626390,,
10095,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626391,,
10096,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626392,,
10097,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626393,,
10098,Bioavailability was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623026,,
10099,Bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623027,,
10100,Bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623028,,
10101,Bioavailability in rat after 1 day dosing,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623029,,
10102,Bioavailability in rat after 4 day dosing,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623030,,
10103,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623031,,
10104,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623032,,
10105,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623033,,
10106,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623034,,
10107,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623035,,
10108,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623036,,
10109,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623037,,
10110,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623038,,
10111,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874385,1969.0,
10112,Bioavailability in rat (Fisher) (fasted),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623039,,
10113,Bioavailability in monkey after po administration of 10 mg/kg dose,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623040,,
10114,Oral bioavailability in monkey (dose 10 mg/kg),,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623041,,
10115,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623741,,
10116,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623742,,
10117,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623743,,
10118,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623744,,
10119,Bioavailability in rat (dose 2.0 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623745,,
10120,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623746,,
10121,Oral bioavailability in rat (dose 5 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623747,,
10122,Bioavailability in rat after po administration of 30 mg/kg dose,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623748,,
10123,Bioavailability in rat after po administration of 30 mg/kg dose,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL623916,,
10124,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623917,,
10125,Bioavailability in rat (dose 2 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623918,,
10126,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874386,,
10127,Bioavailability in rat; Only traces detected in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623919,1969.0,
10128,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623920,,
10129,Bioavailability upon oral administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623148,,
10130,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623149,,
10131,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623150,,
10132,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623151,,
10133,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623152,,
10134,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL623153,,
10135,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL623154,,
10136,In vitro and metabolic stability was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623155,,
10137,In vitro metabolic stability in rat hepatocytes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623156,,
10138,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623157,,
10139,Metabolic rate for compound was observed in rat hepatocytes,401.0,BAO_0000218,Intermediate,,Hepatocyte,50597,N,1,1,,CHEMBL623158,2107.0,
10140,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623159,,
10141,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874390,,
10142,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623160,,
10143,Metabolism of compound in rat S9 microsomes; Trace,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623161,,
10144,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623162,,
10145,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623163,,
10146,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623164,,
10147,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623165,,
10148,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623166,,
10149,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624983,,
10150,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624984,,
10151,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624985,,
10152,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622970,,
10153,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622971,,
10154,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622972,,
10155,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622973,,
10156,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622974,,
10157,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622975,,
10158,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622976,,
10159,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622977,,
10160,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624351,,
10161,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624352,,
10162,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624353,,
10163,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622397,,
10164,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622398,,
10165,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622399,,
10166,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622400,,
10167,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628428,,
10168,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628590,,
10169,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628591,,
10170,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628592,,
10171,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628593,,
10172,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875333,,
10173,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628594,,
10174,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628595,1969.0,
10175,Stability in rat plasma was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628596,1969.0,
10176,Stability in rat plasma was determined; ND= no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628597,1969.0,
10177,Tested for plasma half life period in rat (0-8 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628598,1969.0,
10178,Tested for plasma half life period in rat (0-8 hr); Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628599,1969.0,
10179,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628600,,
10180,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628601,,
10181,Tested for the half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628602,,
10182,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628603,,
10183,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628604,,
10184,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628605,,
10185,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628606,,
10186,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628607,,
10187,The biological half life the compound was measured at the dose of 100 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628608,,
10188,The biological half life the compound was measured at the dose of 30 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628609,,
10189,The compound was evaluated for plasma half life period in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628610,1969.0,
10190,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL873819,,
10191,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628611,,
10192,The pharmacokinetic parameter half-life period in vivo in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628612,,
10193,"The pharmacokinetic property, Half-life was determined",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628613,,
10194,"The pharmacokinetic property, Half-life in rat in vivo",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628614,,
10195,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628615,,
10196,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628616,,
10197,The plasma half life period in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627924,1969.0,
10198,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627925,2107.0,
10199,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627926,,
10200,t1/2 (apparent elimination)of the compound was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627927,,
10201,t1/2 value in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627928,,
10202,Half life in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627539,,
10203,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876790,1969.0,
10204,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL858186,,
10205,Half-life period in fasted rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627540,,
10206,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627541,,
10207,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627715,,
10208,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627716,,
10209,Maximum time required to achieve Cmax was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627717,,
10210,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627718,,
10211,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627719,,
10212,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627720,,
10213,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627721,,
10214,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627722,,
10215,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627723,,
10216,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626058,,
10217,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626059,,
10218,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626060,,
10219,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626061,1969.0,
10220,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876791,,
10221,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626062,,
10222,Tmax at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626063,,
10223,Tmax at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626064,,
10224,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626065,1969.0,
10225,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626066,1969.0,
10226,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626067,,
10227,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626068,,
10228,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626069,,
10229,Percent total excretion of 3-methoxyacetaminophen glucuronide,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626070,,
10230,Percent total excretion of N-methoxyacetaminophen glucuronide,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626071,,
10231,Percent total excretion of N-methoxyacetaminophen sulfate,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626072,,
10232,Percent total excretion of acetaminophen,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626073,,
10233,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626741,2046.0,
10234,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626742,,
10235,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626743,,
10236,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876792,,
10237,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626744,,
10238,Compound was tested for antidiuretic activity in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626745,,
10239,AUC in rat after 3mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626746,1969.0,
10240,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626747,,
10241,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626748,,
10242,Bioavailability administered orally at a dose of 10 mg/kg to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626749,,
10243,Oral Bioavailability was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626750,,
10244,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626751,,
10245,Oral bioavailability in rat; Not performed.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626913,,
10246,Bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626914,,
10247,Bioavailability was determined; ND denotes no data,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626915,,
10248,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626916,,
10249,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626917,,
10250,Binding towards rat plasma protein at 10 uM,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626918,,
10251,Binding towards rat plasma protein at 100 uM,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626919,,
10252,Bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626920,,
10253,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621976,,
10254,Bioavailability in rat after 5 mg/kg oral gavage,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877599,,
10255,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621977,,
10256,Bioavailability in rat (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621978,,
10257,Bioavailability in rat (dose 3 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621979,,
10258,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621980,,
10259,Bioavailability of the compound in rats after administration of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621981,,
10260,Bioavailability after administration of 10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621982,,
10261,Bioavailability after administration of 2 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL882953,,
10262,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621983,,
10263,Bioavailability in dogs was determined; high,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621984,,
10264,Bioavailability in monkey after intravenous administration at 1 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621985,,
10265,Bioavailability in monkey after peroral administration at 10 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621986,,
10266,Bioavailability in rat after intravenous administration at 1 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621987,,
10267,Bioavailability in rat after intravenous administration at 2 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877600,,
10268,Bioavailability in rat after peroral administration at 30 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621988,,
10269,Bioavailability in rat after peroral administration at at 100 mpk,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621989,,
10270,Bioavailability in rats was evaluated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621990,,
10271,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621991,,
10272,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621992,,
10273,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621993,,
10274,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621994,,
10275,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621995,,
10276,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621996,,
10277,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621997,,
10278,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621998,,
10279,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621999,,
10280,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622000,,
10281,Bioavailability was measured in rat after oral administration; 2-4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622001,,
10282,Bioavailability was measured in rat after oral administration; 3-7,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622002,,
10283,Bioavailability in rat (intraduodenal administration),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622003,,
10284,Bioavailability in rat (intraduodenal administration),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877601,,
10285,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624871,,
10286,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622004,,
10287,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL882954,,
10288,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622005,,
10289,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622006,,
10290,Bioavailability was measured in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622007,,
10291,Bioavailability was reported,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622008,,
10292,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622009,,
10293,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622010,,
10294,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622011,,
10295,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622012,,
10296,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622013,,
10297,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622014,,
10298,Bioavailability was determined at 3 mg/kg po dose in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624749,,
10299,Oral bioavailability in rat (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624750,,
10300,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624751,,
10301,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624752,,
10302,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624753,,
10303,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624754,,
10304,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624755,,
10305,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624756,,
10306,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624757,,
10307,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624758,,
10308,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622270,,
10309,Bioavailability in rat (Sprague-Dawley),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622271,,
10310,Bioavailability in rat at the dose of 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622272,,
10311,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622273,,
10312,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622274,,
10313,Bioavailability value of compound in rats was determined after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622275,,
10314,Oral bioavailability in rat (dose 20 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622276,,
10315,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622277,,
10316,Oral bioavailability in rat (dose 5 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622278,,
10317,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622279,,
10318,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622280,,
10319,Compound was evaluated for oral bioavailability in rats; 15-27 %,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624083,,
10320,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624084,,
10321,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624085,,
10322,Compound was tested for bioavailability in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624086,,
10323,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624087,,
10324,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624088,,
10325,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL624089,,
10326,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,22224,U,0,1,,CHEMBL624090,,
10327,Evaluated for the bioavailability in rat (in vivo),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624091,,
10328,F value of compound in rats was determined after peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624092,,
10329,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624093,,
10330,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624094,,
10331,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624095,,
10332,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624096,,
10333,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624097,,
10334,Maximum fall in carotid flow in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624098,,
10335,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874392,,
10336,Oral bioavailability in rat (dose 5 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624099,,
10337,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624100,,
10338,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624101,,
10339,Oral bioavailability in rat (male Wistar),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624102,,
10340,Oral bioavailability after administration (30 mg/kg) in rat; good,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624103,,
10341,Oral bioavailability at the dose of 2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624104,,
10342,Oral bioavailability determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624105,,
10343,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624106,,
10344,Oral bioavailability in rat (dose single 10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624107,,
10345,Oral bioavailability in rat (dose single 10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623943,,
10346,Oral bioavailability in rat (dose 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623944,,
10347,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623945,,
10348,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623946,,
10349,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623947,,
10350,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623948,,
10351,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623949,,
10352,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623950,,
10353,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874398,,
10354,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623951,,
10355,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623952,,
10356,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623953,,
10357,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623954,,
10358,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623955,,
10359,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623956,,
10360,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627807,,
10361,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627808,,
10362,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627809,,
10363,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627810,,
10364,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627811,,
10365,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627812,,
10366,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627813,,
10367,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627814,,
10368,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875336,,
10369,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627815,,
10370,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627816,,
10371,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627817,,
10372,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627818,,
10373,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627819,,
10374,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627820,,
10375,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627821,,
10376,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628464,,
10377,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626239,,
10378,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626240,,
10379,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626241,,
10380,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626242,,
10381,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626243,,
10382,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626244,,
10383,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626907,,
10384,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626908,,
10385,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626909,,
10386,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626910,,
10387,Percent total excretion of acetaminophen cysteine conjugate,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875342,,
10388,Percent total excretion of acetaminophen glucuronide,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626911,,
10389,Percent total excretion of acetaminophen sulfate,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626912,,
10390,Percent total excretion of acetaminophen-mercapturic acid,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627065,,
10391,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627066,1088.0,
10392,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627067,,
10393,Biodistribution of compound in rat muscle after 5 min of administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627068,2385.0,
10394,Biodistribution of compound in rat muscle after 5 min of administration.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627069,2385.0,
10395,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627070,,
10396,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627071,,
10397,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627072,,
10398,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627073,,
10399,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625387,,
10400,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625388,,
10401,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625389,1969.0,
10402,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875343,1969.0,
10403,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,BAO_0000218,Intermediate,,,50497,N,1,1,,CHEMBL876795,,
10404,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,BAO_0000218,Intermediate,,,50497,N,1,1,,CHEMBL626552,,
10405,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,BAO_0000218,Intermediate,,,50497,N,1,1,,CHEMBL626553,,
10406,The human biological plasma half life of the compound,,BAO_0000366,Autocuration,,,22224,U,0,1,,CHEMBL626554,1969.0,
10407,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626555,1088.0,
10408,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626556,,
10409,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626557,,
10410,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626558,,
10411,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626559,,
10412,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626560,,
10413,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876803,,
10414,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627964,,
10415,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627965,,
10416,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627966,,
10417,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627967,,
10418,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627968,,
10419,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627969,,
10420,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627970,,
10421,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627971,178.0,
10422,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627972,178.0,
10423,Dissociation constant against binding to human cyclophilin A,,BAO_0000357,Expert,,,180,D,9,1,,CHEMBL856029,,
10424,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,BAO_0000019,Expert,,,11591,H,8,1,,CHEMBL627973,,
10425,-Log C was determined by performing the electroshock minimum test,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627974,,
10426,-Log C was determined by performing the foot shock test,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627975,,
10427,-Log C was determined by performing the incl screen test,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627976,,
10428,-Log C was determined by performing the maximum electroshock test,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627977,,
10429,-Log C was determined by performing the pentylenetetrazole test,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627978,,
10430,Tested for experimental arotinoid inhibitory dose,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627979,,
10431,Negative log transformed activity,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876804,,
10432,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627980,,
10433,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL627981,,
10434,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL627982,,
10435,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL627983,,
10436,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL627984,2116.0,
10437,Solubility in water was determined; values expressed as -log,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL627985,,
10438,Ratio of Kcat to that of Km was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627986,,
10439,Observed first order rate constant,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627987,,
10440,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627988,,
10441,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627989,,
10442,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627990,,
10443,Oral Bioavailability after administration of 10 mg/kg in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876805,,
10444,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627991,,
10445,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627992,,
10446,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627993,,
10447,Oral bioavailability at 1 mg/kg was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622817,,
10448,Oral bioavailability at 10 mg/kg was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622818,,
10449,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622819,,
10450,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL872267,,
10451,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622820,,
10452,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622821,,
10453,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622822,,
10454,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622823,,
10455,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622824,,
10456,Oral bioavailability in rat at a dose of 3 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622825,,
10457,Oral bioavailability in rat after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622901,,
10458,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622902,,
10459,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621844,,
10460,Oral bioavailability in Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621845,,
10461,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621846,,
10462,Oral bioavailability in rat (dose 30 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621847,,
10463,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877609,,
10464,Bioavailability in rat (dose 3 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621848,,
10465,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621849,,
10466,Oral bioavailability in rat (dose 60 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622030,,
10467,Percent oral bioavailability determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622031,,
10468,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622032,,
10469,The compound was evaluated for bioavailability in rats; 32-51,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622033,,
10470,Bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622034,,
10471,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622035,,
10472,Bioavailability percent in rat at the dose of 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL882966,,
10473,Bioavailability was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622036,,
10474,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622037,,
10475,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622038,,
10476,Bioavailability in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622039,,
10477,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622040,178.0,
10478,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622041,178.0,
10479,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622042,178.0,
10480,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622043,178.0,
10481,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622044,178.0,
10482,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622045,10000001.0,
10483,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622046,10000001.0,
10484,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622047,10000001.0,
10485,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877610,10000001.0,
10486,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622048,955.0,
10487,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622049,955.0,
10488,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622050,955.0,
10489,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622051,955.0,
10490,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622052,,
10491,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622053,,
10492,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622054,,
10493,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622055,,
10494,Oral bioavailability in rats was determined; High,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622056,,
10495,Oral bioavailability in the rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622057,,
10496,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628008,,
10497,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622058,,
10498,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622059,,
10499,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622060,,
10500,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622061,,
10501,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622062,,
10502,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622063,,
10503,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL877611,,
10504,Oral bioavailability of compound in Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622064,,
10505,Oral bioavailability of compound in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622065,,
10506,Oral bioavailability in rat (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622066,,
10507,Oral bioavailability of compound in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622067,,
10508,Oral bioavailability of compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622068,,
10509,Oral bioavailability of compound was determined in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622069,,
10510,Oral bioavailability at a dose of 30 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624796,,
10511,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624797,,
10512,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623053,,
10513,Oral bioavailability evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623054,,
10514,Oral bioavailability in fasted rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623055,,
10515,Oral bioavailability in fed rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623056,,
10516,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623057,,
10517,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623058,,
10518,Oral bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623059,,
10519,Oral bioavailability in rat after administration of 10 mg/kg po,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623060,,
10520,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623061,,
10521,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623062,,
10522,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623063,,
10523,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623064,,
10524,Oral bioavailability in ratrs,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623065,,
10525,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623066,,
10526,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623067,,
10527,Oral bioavailability in rats was determined; High,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623068,,
10528,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623069,,
10529,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623070,,
10530,Oral bioavailability was calculated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623071,,
10531,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623072,,
10532,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623073,,
10533,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623074,,
10534,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623075,,
10535,Oral bioavailability after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623076,,
10536,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623077,,
10537,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623078,,
10538,Oral bioavailability in Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623079,,
10539,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623080,,
10540,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623081,,
10541,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623082,,
10542,Oral bioavailability in fasted rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874400,,
10543,Oral bioavailability in fed rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623083,,
10544,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623084,,
10545,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623085,,
10546,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623086,,
10547,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623087,,
10548,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623088,,
10549,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623089,,
10550,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623090,,
10551,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623091,,
10552,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623092,,
10553,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623093,,
10554,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874401,,
10555,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623094,,
10556,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623095,,
10557,Oral bioavailability in rat after peroral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623096,,
10558,Oral bioavailability in rat after peroral administration at 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624913,,
10559,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624914,,
10560,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624915,,
10561,Oral bioavailability in rat; Not measured,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624916,,
10562,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624917,,
10563,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625157,,
10564,In vitro metabolic potential in rat liver microsomes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625158,2107.0,
10565,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625159,,
10566,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625160,,
10567,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625161,,
10568,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625162,,
10569,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625163,,
10570,Oral bioavailability in rats at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625164,,
10571,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625165,,
10572,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625166,,
10573,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625167,,
10574,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625168,,
10575,Plasma clearance of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625169,,
10576,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626264,,
10577,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626265,,
10578,The compound was tested for plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626266,1969.0,
10579,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626267,1969.0,
10580,Plasma concentration upon oral administration of 1 mg/Kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626268,,
10581,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626269,,
10582,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626270,,
10583,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626271,,
10584,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626272,,
10585,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626273,,
10586,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875346,,
10587,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626274,,
10588,Compound was tested for protein binding in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626275,,
10589,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624646,,
10590,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624647,,
10591,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624648,2107.0,
10592,Area under curve ratio was determined (po/iv) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624649,,
10593,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624650,,
10594,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624651,,
10595,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624652,,
10596,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624653,,
10597,Ratio of AUCbrain to AUCplasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624654,,
10598,Ratio of brain to plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624655,,
10599,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624656,,
10600,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624657,,
10601,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624658,,
10602,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624659,,
10603,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624660,,
10604,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624661,,
10605,Steady state brain :blood ratio was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624662,,
10606,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625199,,
10607,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625200,,
10608,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625201,,
10609,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625202,,
10610,Percentage recovery after 3h incubation with rat hapatocytes was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625203,,
10611,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625204,,
10612,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625205,,
10613,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625206,,
10614,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625207,,
10615,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625208,,
10616,In vivo absorption in Caco-2 cell line monolayers was determined,495.0,BAO_0000218,Intermediate,,Caco-2,50587,N,1,1,,CHEMBL625209,,
10617,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625210,,
10618,Area under curve was determine after peroral administration at 10 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625211,,
10619,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL625212,,
10620,Area under curve was determine after peroral administration at 160 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625213,,
10621,Area under curve was determine after peroral administration at 20 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625214,,
10622,Area under curve was determine after peroral administration at 50 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874542,,
10623,Calculated partition coefficient (clogP) (AlogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625215,,
10624,Activated partial thromboplastin time measured,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625216,,
10625,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL625217,,
10626,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL625218,,
10627,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622864,1969.0,
10628,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622865,1969.0,
10629,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622866,1969.0,
10630,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622867,1969.0,
10631,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL876808,1969.0,
10632,AUC in brain,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627725,955.0,
10633,AUC in serum,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627726,1977.0,
10634,AUC was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627727,1969.0,
10635,AUC of the compound.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627728,1969.0,
10636,AUC value (0-4 hr),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627729,1969.0,
10637,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627730,1969.0,
10638,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627731,1969.0,
10639,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627732,1969.0,
10640,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627733,1969.0,
10641,AUC(area under curve) was determined after intravenous administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627734,1969.0,
10642,AUC(area under curve) was determined after oral administration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627735,1969.0,
10643,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL627736,1969.0,
10644,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876809,1969.0,
10645,Area Under Curve after oral dosing of 100 uM/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627737,,
10646,Area Under Curve after oral dosing of 30 uM/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627738,,
10647,Area Under Curve was measured by ploting the graph between concentration verses time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627739,,
10648,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626143,,
10649,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626144,,
10650,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL626145,,
10651,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626146,,
10652,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626147,178.0,
10653,Area under curve (AUC) was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626148,,
10654,Area under curve (AUC) following ip administration at 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626149,,
10655,Area under curve (AUC) was determined; ND is Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626150,,
10656,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626151,,
10657,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626152,,
10658,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626153,,
10659,Area under curve (AUR) was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626154,,
10660,Area under curve at 1 uM/dg administered intravenously,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626155,,
10661,Area under curve at 10 uM/dg administered perorally,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626156,,
10662,Area under curve at 2 uM/dg administered intravenously,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626157,,
10663,Area under curve at 20 uM/dg administered perorally,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626158,,
10664,Area under curve at a peroral dose of 3 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626159,,
10665,Area under curve at a peroral dose of 3 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626160,,
10666,Area under curve at an iv dose of 1 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626161,,
10667,Area under curve at an iv dose of 1 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626162,,
10668,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626163,,
10669,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626164,,
10670,Area under curve measured as conc vs time after intravenous administration to mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626165,,
10671,Area under curve measured as conc vs time after peroral administration to mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626166,,
10672,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626167,,
10673,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626168,,
10674,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL877463,,
10675,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626169,,
10676,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626170,948.0,
10677,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626171,948.0,
10678,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626172,948.0,
10679,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626173,948.0,
10680,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626174,2113.0,
10681,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626175,2113.0,
10682,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626176,2113.0,
10683,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626177,2113.0,
10684,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622499,2113.0,
10685,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622500,2107.0,
10686,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622501,2107.0,
10687,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622502,2107.0,
10688,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622503,2107.0,
10689,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877614,2107.0,
10690,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624839,2048.0,
10691,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624840,2048.0,
10692,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624841,2048.0,
10693,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624842,2048.0,
10694,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624843,2385.0,
10695,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624844,2385.0,
10696,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624845,2385.0,
10697,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621904,2385.0,
10698,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621905,178.0,
10699,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874382,178.0,
10700,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621906,178.0,
10701,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621907,955.0,
10702,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622096,955.0,
10703,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622097,955.0,
10704,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622098,948.0,
10705,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622099,948.0,
10706,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622100,948.0,
10707,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622101,2113.0,
10708,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622102,2113.0,
10709,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622103,2113.0,
10710,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622104,2107.0,
10711,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622105,2107.0,
10712,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622106,2107.0,
10713,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622107,2048.0,
10714,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622108,2048.0,
10715,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622109,2048.0,
10716,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622110,2385.0,
10717,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622111,2385.0,
10718,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874383,2385.0,
10719,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622112,14.0,
10720,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622113,14.0,
10721,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622114,14.0,
10722,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622115,2106.0,
10723,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622116,2106.0,
10724,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622117,,
10725,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622118,,
10726,Oral bioavailability in rats at 6 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622119,,
10727,Oral bioavailability in rat (dose 6 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622120,,
10728,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622121,,
10729,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622122,,
10730,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622123,,
10731,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622124,,
10732,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622125,,
10733,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622126,,
10734,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620455,,
10735,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620456,,
10736,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620457,,
10737,Oral bioavailability was evaluated; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620458,,
10738,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620459,,
10739,Oral bioavailability in rat by oral dosing,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620460,,
10740,Oral bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620461,,
10741,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620462,,
10742,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620463,,
10743,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620464,,
10744,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620465,,
10745,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620466,,
10746,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620467,,
10747,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620468,,
10748,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620469,,
10749,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620470,,
10750,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620471,,
10751,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620472,,
10752,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620473,,
10753,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620474,,
10754,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620475,,
10755,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620476,,
10756,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620477,,
10757,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620478,,
10758,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618768,,
10759,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618769,,
10760,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618770,,
10761,Oral bioavailability (dose 20 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618771,,
10762,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618772,,
10763,Oral bioavailability in rat at 10 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618773,,
10764,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875842,,
10765,Bioavailability in rat (dose 3 mg/kg i.v.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618774,,
10766,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618775,,
10767,Oral bioavailability in rat (dose 60 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618776,,
10768,Percent bioavailability (F) in rats after iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618777,,
10769,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618778,,
10770,Bioavailability in rat (dose 5 uM/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618779,,
10771,Oral bioavailability,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618780,,
10772,Bioavailability in rat (dose 2 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618781,,
10773,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618782,,
10774,Oral bioavailability in rat (dose 20 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618783,,
10775,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618784,,
10776,Percent oral bioavailability evaluated in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618785,,
10777,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618786,,
10778,Percent oral bioavailability in rat; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618787,,
10779,Oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618788,,
10780,Bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618789,,
10781,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618790,,
10782,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618791,,
10783,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875843,,
10784,Oral bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL618792,,
10785,Cmax at a dose of 30 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623395,,
10786,Cmax in monkeys at a dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623396,,
10787,Cmax in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623397,,
10788,Cmax in rats at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623398,,
10789,Cmax was measured in mice after an oral dose of 50 mg/kg.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623399,,
10790,"Cmax value at a dose of 12.7 uM/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623400,,
10791,"Cmax value at a dose of 6.3 uM/kg, iv",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623401,,
10792,"Cmax value at a dose of 7.1 uM/kg, iv",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623402,,
10793,Cmax value of compound was determined after 1 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623403,,
10794,Cmax value of the compound,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623404,,
10795,Cmax value administered intraintestinal in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625997,,
10796,Cmax value administered perorally was determined in rat; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625998,,
10797,Cmax value at the dose of 2.3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625999,,
10798,Cmax value at the dose of 5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626000,,
10799,Cmax value in the period of 8 hr after dosing. ,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626001,,
10800,Cmax value at a oral dose of 20 mg/kg; Not tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626002,,
10801,Cmax value at a oral dose of 20 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626003,,
10802,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626004,,
10803,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL626005,,
10804,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626006,,
10805,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626007,1969.0,
10806,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626008,1969.0,
10807,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626009,2107.0,
10808,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626010,,
10809,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626011,178.0,
10810,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626012,178.0,
10811,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626013,178.0,
10812,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626014,178.0,
10813,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL877496,178.0,
10814,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626015,,
10815,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626016,,
10816,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626017,,
10817,Bioavailability as maximal plasma concentration in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626018,1969.0,
10818,Bioavailability as maximal plasma concentration in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626692,1969.0,
10819,Bioavailability as maximal plasma concentration in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626693,1969.0,
10820,Bioavailability as maximal plasma concentration in rats,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626694,1969.0,
10821,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626695,178.0,
10822,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626696,178.0,
10823,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626697,178.0,
10824,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626859,178.0,
10825,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626860,178.0,
10826,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626861,178.0,
10827,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626296,,
10828,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626297,,
10829,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626298,1969.0,
10830,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626299,1969.0,
10831,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626300,1969.0,
10832,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626301,1969.0,
10833,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626962,1969.0,
10834,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626963,1969.0,
10835,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626964,1969.0,
10836,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL626965,1969.0,
10837,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626966,1969.0,
10838,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626967,1969.0,
10839,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL626968,1969.0,
10840,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626969,948.0,
10841,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627126,948.0,
10842,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631276,948.0,
10843,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631277,948.0,
10844,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631278,948.0,
10845,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874457,948.0,
10846,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631279,948.0,
10847,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631280,948.0,
10848,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631281,948.0,
10849,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631968,948.0,
10850,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631969,948.0,
10851,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631970,948.0,
10852,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631971,948.0,
10853,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631972,948.0,
10854,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630435,948.0,
10855,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630436,948.0,
10856,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630437,948.0,
10857,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630438,948.0,
10858,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630439,948.0,
10859,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630440,2113.0,
10860,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630441,2113.0,
10861,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630442,2113.0,
10862,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625234,2113.0,
10863,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625235,2113.0,
10864,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625236,2113.0,
10865,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625237,2113.0,
10866,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626125,2113.0,
10867,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626126,2113.0,
10868,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626127,2113.0,
10869,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626128,2113.0,
10870,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626129,2113.0,
10871,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626130,2113.0,
10872,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626131,2113.0,
10873,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626132,2113.0,
10874,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626752,2113.0,
10875,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626753,2113.0,
10876,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626754,2113.0,
10877,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626755,2113.0,
10878,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626756,2107.0,
10879,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626757,2107.0,
10880,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626758,2107.0,
10881,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626759,2107.0,
10882,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626760,2107.0,
10883,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626394,,
10884,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626395,,
10885,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626396,,
10886,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626397,,
10887,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626398,,
10888,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626399,,
10889,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874653,,
10890,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626400,,
10891,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626401,,
10892,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626402,,
10893,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626403,,
10894,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626404,,
10895,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626405,,
10896,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625529,,
10897,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625530,,
10898,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625531,,
10899,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625532,,
10900,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625533,,
10901,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875474,,
10902,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625534,,
10903,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625535,,
10904,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625536,,
10905,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625537,,
10906,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625538,,
10907,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625539,,
10908,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625540,,
10909,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625541,,
10910,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625542,,
10911,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625543,,
10912,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625544,,
10913,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625545,,
10914,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625546,,
10915,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625547,,
10916,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625548,,
10917,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625549,,
10918,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625550,,
10919,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625551,,
10920,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875475,,
10921,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625552,,
10922,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625553,,
10923,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625554,,
10924,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625555,,
10925,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625556,,
10926,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624986,,
10927,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624987,,
10928,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624988,,
10929,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624989,1637.0,
10930,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624990,1637.0,
10931,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874391,1637.0,
10932,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624991,1637.0,
10933,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624992,1637.0,
10934,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624993,1637.0,
10935,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624994,1637.0,
10936,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624995,1637.0,
10937,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624996,1637.0,
10938,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624997,1637.0,
10939,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624998,1637.0,
10940,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624999,1637.0,
10941,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL882955,1637.0,
10942,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625000,1637.0,
10943,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625001,1637.0,
10944,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625089,1637.0,
10945,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625090,1637.0,
10946,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625091,1637.0,
10947,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625092,1637.0,
10948,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625093,1637.0,
10949,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625094,1637.0,
10950,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625095,1637.0,
10951,Compound was evaluated for its bioavailability in the dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625096,,
10952,Compound was evaluated for its bioavailability in the rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625097,,
10953,Compound was evaluated for oral bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL882956,,
10954,Compound was evaluated for percentage of Oral bioavailability in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625098,,
10955,Bioavailability in guinea pig,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625099,,
10956,Compound was evaluated for the oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625100,,
10957,Compound was evaluated for the oral bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625101,,
10958,Compound was evaluated for the oral bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874396,,
10959,Bioavailability in dog (dosed i.v.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625102,,
10960,Compound was tested for in vivo bioavailability in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625103,,
10961,Compound was tested for in vivo bioavailability in hamsters,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL625104,,
10962,Compound was tested for in vivo bioavailability in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625105,,
10963,Compound was tested for in vivo bioavailability in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625106,,
10964,Oral bioavailability in mouse,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625107,,
10965,Compound was tested for percent of oral bioavailability in mice; 56-74,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625108,,
10966,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625109,,
10967,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625110,,
10968,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625111,,
10969,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625112,,
10970,Oral bioavailability in nude mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875334,,
10971,Bioavailability in monkey (i.d. dosing),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628617,,
10972,Bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628618,,
10973,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628619,,
10974,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628620,,
10975,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628621,,
10976,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628622,,
10977,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628623,,
10978,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628624,1969.0,
10979,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628625,1969.0,
10980,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628626,1969.0,
10981,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627041,1969.0,
10982,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627042,1969.0,
10983,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627043,1969.0,
10984,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627044,1969.0,
10985,Cmax in mouse plasma,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627045,1969.0,
10986,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627046,1969.0,
10987,Maximal plasma concentration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627047,1969.0,
10988,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627048,1969.0,
10989,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627049,,
10990,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627050,,
10991,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627051,,
10992,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627052,,
10993,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627053,,
10994,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627054,,
10995,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627055,,
10996,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627056,,
10997,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627057,,
10998,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627058,,
10999,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626211,,
11000,Maximum Concentration of the compound.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626212,,
11001,Maximum Concentration was measured after iv administration into Beagle dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626213,,
11002,Maximum Concentration was measured after iv administration into Beagle dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626214,,
11003,Maximum Concentration was measured after po administration into Beagle dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626215,,
11004,Maximum Concentration was measured after po administration into Beagle dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626216,,
11005,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626217,178.0,
11006,Maximum blood level reached after an iv dose of 12.2 uM/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626218,178.0,
11007,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626219,178.0,
11008,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626220,178.0,
11009,Maximum blood level reached after an oral dose of 5.0 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626221,178.0,
11010,Maximum blood level reached at dose of 10.6 uM/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626222,178.0,
11011,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL626223,,
11012,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL626224,,
11013,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626225,955.0,
11014,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626226,955.0,
11015,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626227,955.0,
11016,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626228,955.0,
11017,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626229,,
11018,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626921,,
11019,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876793,,
11020,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625309,,
11021,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,Intermediate,,,50278,N,1,1,,CHEMBL625310,,
11022,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625311,,
11023,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625312,,
11024,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625313,,
11025,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625314,,
11026,Maximum concentration in male rats after iv administration of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625315,,
11027,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625316,2107.0,
11028,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625317,2107.0,
11029,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625318,2107.0,
11030,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625319,2107.0,
11031,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625320,2107.0,
11032,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625321,2107.0,
11033,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625322,2107.0,
11034,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876801,2107.0,
11035,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625323,2107.0,
11036,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625324,2107.0,
11037,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625325,2107.0,
11038,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625326,2107.0,
11039,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625327,2107.0,
11040,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625328,2107.0,
11041,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625329,2048.0,
11042,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625330,2048.0,
11043,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627774,2048.0,
11044,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627775,2048.0,
11045,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627949,2048.0,
11046,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627950,2048.0,
11047,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627951,2048.0,
11048,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627952,2048.0,
11049,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627953,2048.0,
11050,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627954,2048.0,
11051,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627955,2048.0,
11052,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627956,2048.0,
11053,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876802,2048.0,
11054,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627957,2048.0,
11055,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627958,2048.0,
11056,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627959,2048.0,
11057,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627960,2048.0,
11058,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627961,2048.0,
11059,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627962,2048.0,
11060,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627963,,
11061,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624759,,
11062,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624760,,
11063,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624761,,
11064,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877607,,
11065,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624762,2107.0,
11066,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624763,2107.0,
11067,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624764,2107.0,
11068,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624765,2107.0,
11069,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624766,2107.0,
11070,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624767,,
11071,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624768,,
11072,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624769,,
11073,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624770,,
11074,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624771,,
11075,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624772,,
11076,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624773,,
11077,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624774,,
11078,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624775,,
11079,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624776,,
11080,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624777,,
11081,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624778,,
11082,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624779,,
11083,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624780,,
11084,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624781,,
11085,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877608,,
11086,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624782,,
11087,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624783,,
11088,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624784,,
11089,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624785,,
11090,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624786,,
11091,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624787,,
11092,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628676,,
11093,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621842,,
11094,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621843,,
11095,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623873,,
11096,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623874,,
11097,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623875,,
11098,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623876,,
11099,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623877,,
11100,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623878,,
11101,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623879,,
11102,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623880,,
11103,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623881,,
11104,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623957,,
11105,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623958,,
11106,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623959,,
11107,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623960,,
11108,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623961,,
11109,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623962,,
11110,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624676,,
11111,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624677,,
11112,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624678,,
11113,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624679,,
11114,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624680,,
11115,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624849,,
11116,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624850,,
11117,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL874399,,
11118,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624851,,
11119,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624852,,
11120,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624853,,
11121,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624854,,
11122,Oral bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624855,,
11123,Oral bioavailability in rats was determined in vivo,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624856,,
11124,Oral bioavailability in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL882957,,
11125,Oral bioavailability of compound in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624857,,
11126,Oral bioavailability of compound in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622202,,
11127,Bioavailability in rat of PMEA prodrug,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622203,,
11128,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625522,,
11129,Serum conc at 3 hours following 25 mg/kg dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622868,,
11130,Urine conc 0-5 hours following 25 mg/kg dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622869,1088.0,
11131,Urine conc 0-24 hours following 25 mg/kg dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622870,1088.0,
11132,Oral bioavailability in African green monkeys; 20-25,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622871,,
11133,Oral bioavailability in cynomolgus monkey.,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL620560,,
11134,Oral bioavailability in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620561,,
11135,Oral bioavailability in dog at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620562,,
11136,Oral bioavailability in hamster at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL620563,,
11137,Oral bioavailability in rat at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL620564,,
11138,Oral bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL872265,,
11139,Oral bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620565,,
11140,Oral bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620566,,
11141,Oral bioavailability was determined; range 49-102%,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620567,,
11142,Oral bioavailability was determined in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL620568,,
11143,Oral bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620569,,
11144,Oral bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620570,,
11145,Oral bioavailability was determined; Not orally available,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620571,,
11146,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620572,,
11147,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620573,,
11148,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620574,,
11149,Oral bioavailability in Rhesus monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620575,,
11150,Oral bioavailability in dog (female mongrel),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620576,,
11151,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875846,,
11152,Oral bioavailability in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620577,,
11153,Percentage Bioavailability was evaluated.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620578,,
11154,Bioavailability in rat administered i.d.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL620579,,
11155,Bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621248,,
11156,Bioavailability in dog (male Beagle) i.v. administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625390,,
11157,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625391,,
11158,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL872266,,
11159,Oral bioavailability in rat (Sprague-Dawley) (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625392,,
11160,The oral bioavailability was measured on rats after oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625393,,
11161,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625394,,
11162,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL625395,,
11163,Bioavailability in rat (dose 10 mg/kg i.d.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625396,,
11164,Bioavailability in dog (male Beagle) i.v. administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625397,,
11165,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625398,,
11166,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625399,178.0,
11167,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626074,2037.0,
11168,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626075,,
11169,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626076,1969.0,
11170,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL626077,1969.0,
11171,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626078,178.0,
11172,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625846,178.0,
11173,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625847,178.0,
11174,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL625848,,
11175,Maximum concentration of compound in plasma administered orally to rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625849,1969.0,
11176,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626023,1969.0,
11177,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626024,1969.0,
11178,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626025,1969.0,
11179,Maximum concentration after 10 mg/kg by oral administration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626026,,
11180,Maximum concentration at a dose of 1.5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626027,,
11181,Maximum concentration at a dose of 2.0 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626028,,
11182,Maximum concentration in dog plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626029,1969.0,
11183,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626030,1969.0,
11184,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626031,1969.0,
11185,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626032,1969.0,
11186,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626033,1969.0,
11187,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626034,1969.0,
11188,Maximum concentration in plasma after oral administration in dog (25 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626035,1969.0,
11189,Maximum concentration in plasma at Tmax,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626036,1969.0,
11190,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL626037,1969.0,
11191,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL626038,1969.0,
11192,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626039,1969.0,
11193,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626040,1969.0,
11194,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL626041,1969.0,
11195,Maximum concentration was calculated,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626042,,
11196,Maximum concentration was calculated.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626043,,
11197,Maximum concentration at a peroral dose of 10 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626044,,
11198,Maximum concentration of the drug at 10 uM/dg administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626045,,
11199,Maximum concentration of the drug at 2 uM/dg administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626046,,
11200,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626047,1969.0,
11201,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL626048,1969.0,
11202,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626049,1969.0,
11203,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626050,1969.0,
11204,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874541,1969.0,
11205,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL622826,1969.0,
11206,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL622827,1969.0,
11207,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622828,1969.0,
11208,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622829,1969.0,
11209,Maximum concentration reached following intravenous administration in male rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876806,,
11210,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622830,,
11211,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622831,,
11212,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626794,,
11213,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626795,,
11214,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626796,,
11215,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626797,,
11216,Maximum drug concentration is determined after oral dosing in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626798,,
11217,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626799,,
11218,Maximum observed concentration in oral (5 mg/kg) fed dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626800,,
11219,Maximum plasma concentration,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626801,1969.0,
11220,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876816,1969.0,
11221,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626802,1969.0,
11222,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626803,1969.0,
11223,Maximum plasma concentration following oral administration of 30 umol/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626804,1969.0,
11224,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626805,1969.0,
11225,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626309,1969.0,
11226,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626310,1969.0,
11227,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626311,1969.0,
11228,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626312,1969.0,
11229,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626313,995.0,
11230,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626314,995.0,
11231,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626315,995.0,
11232,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626316,995.0,
11233,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626317,995.0,
11234,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626318,,
11235,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626319,,
11236,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626320,,
11237,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875053,,
11238,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626321,,
11239,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626322,,
11240,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626323,,
11241,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626324,,
11242,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626325,,
11243,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626326,,
11244,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626327,,
11245,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626328,,
11246,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626329,178.0,
11247,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626330,178.0,
11248,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626331,178.0,
11249,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626332,178.0,
11250,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626333,178.0,
11251,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626334,178.0,
11252,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626335,178.0,
11253,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624798,178.0,
11254,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624799,955.0,
11255,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624800,955.0,
11256,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624801,955.0,
11257,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624802,955.0,
11258,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624803,955.0,
11259,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624804,955.0,
11260,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624805,955.0,
11261,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624806,955.0,
11262,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624807,,
11263,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624808,,
11264,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624809,,
11265,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624810,,
11266,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877618,,
11267,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624811,,
11268,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624812,,
11269,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624813,,
11270,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624814,,
11271,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624815,,
11272,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624816,,
11273,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624817,,
11274,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624818,,
11275,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624819,,
11276,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624820,,
11277,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624821,,
11278,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624822,,
11279,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624823,,
11280,Observed diffusion coefficient in organic solvent for Escherichia coli,,BAO_0000218,Intermediate,,,50212,N,1,1,,CHEMBL624824,,
11281,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624825,178.0,
11282,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624826,178.0,
11283,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876817,2081.0,
11284,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624827,2081.0,
11285,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624828,,
11286,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624829,,
11287,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624830,2107.0,
11288,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624831,2107.0,
11289,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624832,2081.0,
11290,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624833,2081.0,
11291,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624834,,
11292,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624835,,
11293,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624836,2106.0,
11294,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624837,2106.0,
11295,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624838,178.0,
11296,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622188,178.0,
11297,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622189,948.0,
11298,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622190,948.0,
11299,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625170,948.0,
11300,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625171,2113.0,
11301,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625172,2113.0,
11302,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625173,2113.0,
11303,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625174,2107.0,
11304,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625175,2107.0,
11305,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625176,2107.0,
11306,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625177,2048.0,
11307,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625178,2048.0,
11308,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625179,2048.0,
11309,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625180,2048.0,
11310,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625181,,
11311,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625182,1088.0,
11312,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625183,,
11313,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875848,,
11314,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622260,,
11315,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622261,,
11316,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622262,,
11317,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622263,2113.0,
11318,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622418,2113.0,
11319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622419,2107.0,
11320,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623388,,
11321,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623389,2107.0,
11322,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623390,,
11323,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623391,,
11324,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623392,178.0,
11325,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623393,2037.0,
11326,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623394,,
11327,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618885,,
11328,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618886,2107.0,
11329,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618887,,
11330,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619535,,
11331,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619536,178.0,
11332,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619537,2037.0,
11333,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619705,,
11334,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619706,,
11335,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619707,2107.0,
11336,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL619708,,
11337,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625219,,
11338,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625220,178.0,
11339,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625221,2037.0,
11340,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625222,,
11341,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625223,,
11342,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625224,2107.0,
11343,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625225,,
11344,Biodistribution in Rat blood after 24 hours of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625226,178.0,
11345,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625227,178.0,
11346,Biodistribution in Rat blood after 30 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625228,178.0,
11347,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875354,178.0,
11348,Biodistribution in Rat blood after 5 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625229,178.0,
11349,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625230,178.0,
11350,Biodistribution in Rat heart after 24 hours of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625231,948.0,
11351,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625900,948.0,
11352,Biodistribution in Rat heart after 30 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625901,948.0,
11353,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625902,948.0,
11354,Biodistribution in Rat heart after 5 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625903,948.0,
11355,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625904,948.0,
11356,Biodistribution in Rat liver after 24 hours of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625905,2107.0,
11357,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627861,2107.0,
11358,Biodistribution in Rat liver after 30 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627862,2107.0,
11359,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627863,2107.0,
11360,Biodistribution in Rat liver after 30 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627769,2107.0,
11361,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627770,1969.0,
11362,Cmax in cynomolgus monkey (PO dose),,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL627771,,
11363,Cmax in rat (PO dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627772,,
11364,Cmax in rat (PO dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627773,,
11365,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621922,1969.0,
11366,Cmax in rat plasma after oral dose (10 mg/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621923,1969.0,
11367,Cmax in plasma after oral dose (10 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621924,1969.0,
11368,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621925,1969.0,
11369,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621926,1969.0,
11370,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL621927,1969.0,
11371,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621928,1969.0,
11372,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621929,1969.0,
11373,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL621930,1969.0,
11374,Maximum plasma concentration after oral dosing in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621931,1969.0,
11375,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621932,1969.0,
11376,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621933,1969.0,
11377,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621934,1969.0,
11378,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL621935,1969.0,
11379,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621936,1969.0,
11380,Maximum plasma concentration was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621937,1969.0,
11381,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621938,1969.0,
11382,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621939,1969.0,
11383,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621940,1969.0,
11384,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621941,1969.0,
11385,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL621942,1969.0,
11386,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626178,1969.0,
11387,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626179,1969.0,
11388,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626180,1969.0,
11389,Plasma Cmax in rat (PO dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626181,1969.0,
11390,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626182,,
11391,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626183,,
11392,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626184,,
11393,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626185,,
11394,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626186,1969.0,
11395,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL877589,1969.0,
11396,Maximum concentration of the drug at 1 uM/dg administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626187,,
11397,Maximum concentration of the drug at 20 uM/dg administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626188,,
11398,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626189,,
11399,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626855,178.0,
11400,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623781,178.0,
11401,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623782,178.0,
11402,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623783,1969.0,
11403,Cmax in dog plasma after 1mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623784,1969.0,
11404,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623785,1969.0,
11405,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623786,1969.0,
11406,Oral maximum concentration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623787,,
11407,Oral maximum concentration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623788,,
11408,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623789,1969.0,
11409,Peak concentration in blood after intravenous administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623790,178.0,
11410,Peak concentration in blood after peroral administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623791,178.0,
11411,Peak concentration in rat plasma was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623792,1969.0,
11412,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623793,1969.0,
11413,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623794,1969.0,
11414,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623795,1969.0,
11415,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623796,,
11416,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623797,,
11417,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623798,,
11418,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623799,,
11419,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624490,160.0,
11420,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624491,160.0,
11421,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624492,160.0,
11422,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624493,160.0,
11423,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877595,160.0,
11424,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624494,160.0,
11425,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624495,160.0,
11426,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624681,160.0,
11427,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624682,,
11428,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624683,,
11429,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624684,,
11430,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624685,,
11431,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624686,,
11432,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624687,,
11433,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624688,,
11434,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627161,,
11435,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622127,,
11436,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622128,,
11437,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874384,,
11438,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624898,,
11439,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624899,,
11440,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624900,,
11441,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624901,,
11442,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624902,,
11443,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624903,,
11444,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624904,,
11445,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624905,,
11446,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624906,,
11447,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624907,,
11448,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624908,,
11449,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624909,,
11450,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624910,,
11451,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624911,2385.0,
11452,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874388,2385.0,
11453,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624912,2385.0,
11454,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622930,2385.0,
11455,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623121,2385.0,
11456,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623122,2385.0,
11457,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623123,2385.0,
11458,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623124,2385.0,
11459,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623125,,
11460,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623126,,
11461,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623127,,
11462,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623128,,
11463,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623129,,
11464,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623130,,
11465,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623131,,
11466,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623132,,
11467,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623133,2107.0,
11468,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623134,,
11469,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874389,,
11470,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623135,,
11471,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623136,,
11472,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623137,,
11473,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623138,,
11474,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623139,2113.0,
11475,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623140,2113.0,
11476,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623141,2107.0,
11477,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623142,2107.0,
11478,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623143,,
11479,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623144,1088.0,
11480,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623405,1088.0,
11481,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624074,,
11482,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624075,,
11483,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624076,,
11484,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624077,,
11485,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624078,,
11486,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624079,2113.0,
11487,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624261,2113.0,
11488,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624262,,
11489,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624263,,
11490,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624264,,
11491,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624265,,
11492,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624266,,
11493,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624267,,
11494,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624268,,
11495,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875227,,
11496,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624269,2113.0,
11497,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624270,2113.0,
11498,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624271,,
11499,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624272,,
11500,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624273,,
11501,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624274,1088.0,
11502,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624275,1088.0,
11503,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624276,1088.0,
11504,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624277,1088.0,
11505,% dose converted to 2-amino-5-chlorophenyl sulfate,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624278,,
11506,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624279,,
11507,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624280,1988.0,
11508,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624281,1988.0,
11509,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622933,1988.0,
11510,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622934,1988.0,
11511,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622935,2107.0,
11512,Biodistribution in Rat liver after 5 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622936,2107.0,
11513,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875228,2107.0,
11514,Biodistribution in Rat lung after 24 hours of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622937,2048.0,
11515,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622938,2048.0,
11516,Biodistribution in Rat lung after 30 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL619736,2048.0,
11517,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625117,2048.0,
11518,Biodistribution in Rat lung after 5 minutes of iv administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625118,2048.0,
11519,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625119,2048.0,
11520,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625120,2037.0,
11521,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625121,,
11522,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625122,10000006.0,
11523,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622204,178.0,
11524,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877503,178.0,
11525,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627127,178.0,
11526,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627128,10000000.0,
11527,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627129,10000000.0,
11528,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627130,10000000.0,
11529,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627131,955.0,
11530,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627132,955.0,
11531,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627133,955.0,
11532,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627134,2037.0,
11533,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627135,2037.0,
11534,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627136,2037.0,
11535,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628435,,
11536,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628436,,
11537,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628437,,
11538,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628438,948.0,
11539,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628439,948.0,
11540,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628440,948.0,
11541,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628441,10000000.0,
11542,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628442,10000000.0,
11543,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628443,10000000.0,
11544,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628444,2113.0,
11545,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628445,2113.0,
11546,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877504,2113.0,
11547,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628446,2107.0,
11548,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626874,2107.0,
11549,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626875,2107.0,
11550,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626876,2048.0,
11551,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626877,2048.0,
11552,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626878,2048.0,
11553,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626879,2385.0,
11554,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626880,1969.0,
11555,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626881,1969.0,
11556,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626882,1969.0,
11557,Peak plasma concentration was measured in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626883,1969.0,
11558,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626884,,
11559,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626885,,
11560,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626886,,
11561,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626887,,
11562,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626888,,
11563,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626889,,
11564,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626761,,
11565,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626762,,
11566,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626763,,
11567,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626764,,
11568,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626765,,
11569,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626766,,
11570,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626767,,
11571,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626768,,
11572,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626769,,
11573,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874463,,
11574,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626770,,
11575,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626771,,
11576,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626772,,
11577,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL626773,,
11578,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626774,,
11579,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626775,,
11580,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626776,,
11581,Maximum concentration (Cmax) in rat when administered orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626777,,
11582,Maximal concentration in monkey plasma after 25 mg/kg oral dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626778,1969.0,
11583,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626779,,
11584,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626780,,
11585,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626781,1969.0,
11586,Pharmacokinetic profile Cmax was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632164,,
11587,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632165,,
11588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL632166,,
11589,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632167,,
11590,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL632168,,
11591,Cmax in rat plasma,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632169,1969.0,
11592,Cmax in dog plasma after 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632170,1969.0,
11593,Cmax in rat plasma after 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632171,1969.0,
11594,Plasma level in rats at 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632172,1969.0,
11595,Tested for maximum plasma concentration in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL632173,1969.0,
11596,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632174,,
11597,The Cmax values in female wistar rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632175,,
11598,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632176,1969.0,
11599,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632177,1969.0,
11600,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632178,1969.0,
11601,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632179,,
11602,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632180,178.0,
11603,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632181,178.0,
11604,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632182,178.0,
11605,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632183,178.0,
11606,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632184,,
11607,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874470,,
11608,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631302,,
11609,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631303,,
11610,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631304,,
11611,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631305,,
11612,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631306,,
11613,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631307,,
11614,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631308,,
11615,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625557,,
11616,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625558,2106.0,
11617,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625559,2106.0,
11618,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625560,2106.0,
11619,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625561,2106.0,
11620,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625562,2106.0,
11621,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875320,2106.0,
11622,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625563,2106.0,
11623,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625564,2106.0,
11624,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625565,995.0,
11625,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625566,995.0,
11626,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625567,995.0,
11627,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625568,995.0,
11628,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628217,995.0,
11629,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628218,995.0,
11630,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628219,995.0,
11631,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628220,995.0,
11632,Distribution in the blood after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628221,,
11633,Distribution in the blood after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628222,,
11634,Distribution in the blood after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628223,,
11635,Distribution in the blood after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628224,,
11636,Distribution in the blood after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628225,,
11637,Distribution in the blood after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628226,,
11638,Distribution in the bone after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628227,,
11639,Distribution in the bone after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875481,,
11640,Distribution in the bone after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628228,,
11641,Distribution in the bone after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628229,,
11642,Distribution in the bone after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628230,,
11643,Distribution in the bone after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628231,,
11644,Distribution in the heart after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628232,,
11645,Distribution in the heart after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628233,,
11646,Distribution in the heart after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628234,,
11647,Distribution in the heart after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628235,,
11648,Distribution in the heart after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628236,,
11649,Distribution in the heart after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628237,,
11650,Distribution in the kidneys after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628238,,
11651,Distribution in the kidneys after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628239,,
11652,Distribution in the kidneys after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628240,,
11653,Distribution in the kidneys after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628241,,
11654,Distribution in the kidneys after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628242,,
11655,Distribution in the kidneys after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875482,,
11656,Distribution in the liver after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628243,,
11657,Distribution in the liver after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628244,,
11658,Distribution in the liver after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628245,,
11659,Distribution in the liver after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628246,,
11660,Distribution in the liver after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628247,,
11661,Distribution in the liver after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628248,,
11662,Distribution in the lung after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628249,,
11663,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625452,,
11664,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625453,,
11665,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625454,,
11666,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623844,,
11667,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623845,,
11668,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623846,,
11669,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623847,,
11670,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623848,,
11671,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623849,,
11672,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623850,,
11673,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623851,,
11674,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623852,,
11675,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL624551,,
11676,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL624552,,
11677,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624553,,
11678,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624554,,
11679,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624555,,
11680,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624741,,
11681,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624742,,
11682,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL624743,,
11683,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877606,,
11684,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624744,,
11685,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624745,178.0,
11686,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624746,178.0,
11687,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624747,178.0,
11688,Oral absorption expressed as Area under curve was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624748,,
11689,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622504,,
11690,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622505,,
11691,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL622506,,
11692,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL622507,,
11693,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622508,,
11694,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622509,,
11695,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622510,,
11696,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622511,,
11697,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL622512,,
11698,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL622513,,
11699,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL622514,,
11700,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622515,,
11701,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622516,,
11702,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622517,,
11703,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622518,,
11704,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622519,,
11705,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622520,2385.0,
11706,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622521,2385.0,
11707,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625113,14.0,
11708,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625114,14.0,
11709,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874397,14.0,
11710,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625115,2106.0,
11711,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625116,2106.0,
11712,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623932,2106.0,
11713,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623933,2435.0,
11714,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623934,2435.0,
11715,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623935,2435.0,
11716,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623936,2046.0,
11717,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623937,2046.0,
11718,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623938,2046.0,
11719,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623939,,
11720,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623940,,
11721,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623941,,
11722,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627216,,
11723,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623942,,
11724,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618793,955.0,
11725,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618794,955.0,
11726,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618795,955.0,
11727,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618796,,
11728,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618797,,
11729,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618798,2113.0,
11730,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618799,2113.0,
11731,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618800,2113.0,
11732,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618801,2113.0,
11733,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618802,2113.0,
11734,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618803,2113.0,
11735,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618804,2107.0,
11736,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618805,2107.0,
11737,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618806,2107.0,
11738,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618807,2107.0,
11739,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618808,2107.0,
11740,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618809,2107.0,
11741,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618810,2385.0,
11742,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618811,2385.0,
11743,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875844,2385.0,
11744,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618812,2385.0,
11745,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618813,2385.0,
11746,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618814,,
11747,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618815,,
11748,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618816,,
11749,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL618817,,
11750,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL620544,,
11751,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626230,,
11752,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626231,,
11753,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626232,,
11754,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626233,1969.0,
11755,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626234,1969.0,
11756,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875341,1969.0,
11757,The maximum plasma concentration (100 mg/kg) administered orally in human,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL626235,1969.0,
11758,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626236,1969.0,
11759,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626237,1969.0,
11760,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626238,1969.0,
11761,The maximum plasma concentration (200 mg/kg) administered orally in human,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL622412,1969.0,
11762,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623114,1969.0,
11763,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623115,1969.0,
11764,The maximum plasma concentration (25 mg/kg) administered orally in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623116,1969.0,
11765,The maximum plasma concentration (30 mg/kg) administered orally in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623117,1969.0,
11766,The maximum plasma concentration (400 mg/kg) administered orally in human,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL623118,1969.0,
11767,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623119,1969.0,
11768,The maximum plasma concentration (50 mg/kg) administered orally in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623120,1969.0,
11769,The maximum plasma concentration (800 mg/kg) administered orally in human,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL623286,1969.0,
11770,The maximum plasma concentration was measured on rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623287,1969.0,
11771,The maximum plasma concentration was measured on rats after oral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623288,1969.0,
11772,Plasma drug Cmax in rat (PO dose),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623289,1969.0,
11773,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623290,,
11774,maximum Plasma concentration in Dog was determined after Peroral administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623291,1969.0,
11775,maximum Plasma concentration in Rats was determined after Peroral administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623292,1969.0,
11776,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623293,1969.0,
11777,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623294,1969.0,
11778,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623295,1969.0,
11779,maximum concentration was measured when administered through oral route in mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623296,,
11780,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875349,,
11781,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623297,,
11782,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623298,,
11783,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623299,,
11784,Pharmacokinetic parameter was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623300,,
11785,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623301,,
11786,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623302,,
11787,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623303,,
11788,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623304,,
11789,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623305,,
11790,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623306,1969.0,
11791,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623307,1969.0,
11792,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623308,1969.0,
11793,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623309,1969.0,
11794,Plasma Concentration after 120 min of oral administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623310,,
11795,Plasma Concentration after 30 min of oral administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623311,,
11796,Plasma Concentration after 60 min of oral administration to mice,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL623312,,
11797,Plasma Concentration after 60 min of oral administration to mice; Not determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875350,,
11798,Plasma Concentration after 90 min of oral administration to mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628635,,
11799,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628636,,
11800,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628637,,
11801,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628058,,
11802,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628059,,
11803,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628060,,
11804,Distribution in the lung after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628061,,
11805,Distribution in the lung after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628062,,
11806,Distribution in the lung after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628063,,
11807,Distribution in the lung after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628064,,
11808,Distribution in the lung after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628065,,
11809,Distribution in the muscle after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628066,2385.0,
11810,Distribution in the muscle after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628067,2385.0,
11811,Distribution in the muscle after 30 min of intravenous administration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL874646,2385.0,
11812,Distribution in the muscle after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628068,2385.0,
11813,Distribution in the muscle after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628069,2385.0,
11814,Distribution in the muscle after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628070,2385.0,
11815,Distribution in the spleen after 120 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628071,2106.0,
11816,Distribution in the spleen after 15 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628072,2106.0,
11817,Distribution in the spleen after 30 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628073,2106.0,
11818,Distribution in the spleen after 5 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628074,2106.0,
11819,Distribution in the spleen after 60 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628075,2106.0,
11820,Distribution in the spleen after 90 min of intravenous administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628076,2106.0,
11821,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628077,1235.0,
11822,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628078,178.0,
11823,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628079,2107.0,
11824,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628080,992.0,
11825,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628081,2046.0,
11826,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628082,1235.0,
11827,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874647,178.0,
11828,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626406,2107.0,
11829,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626407,992.0,
11830,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626408,2046.0,
11831,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626409,178.0,
11832,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626410,178.0,
11833,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626411,178.0,
11834,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626412,178.0,
11835,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626413,178.0,
11836,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626414,178.0,
11837,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626415,178.0,
11838,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626416,178.0,
11839,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627062,178.0,
11840,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627063,178.0,
11841,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627064,178.0,
11842,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627227,178.0,
11843,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627228,178.0,
11844,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627229,178.0,
11845,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625792,178.0,
11846,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625793,178.0,
11847,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625794,178.0,
11848,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625795,178.0,
11849,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625796,,
11850,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625797,,
11851,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625798,,
11852,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875613,,
11853,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625799,,
11854,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625800,,
11855,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625801,,
11856,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625802,,
11857,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625803,,
11858,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625804,,
11859,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622530,,
11860,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622531,,
11861,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622532,,
11862,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623176,,
11863,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623177,,
11864,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623178,,
11865,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623179,,
11866,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623180,,
11867,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623181,,
11868,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624131,,
11869,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624132,,
11870,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624133,,
11871,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624846,,
11872,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624847,,
11873,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL624848,,
11874,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625012,,
11875,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625013,,
11876,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625014,,
11877,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625015,,
11878,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625016,,
11879,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625017,,
11880,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625018,,
11881,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625019,,
11882,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625020,,
11883,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625021,,
11884,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625022,,
11885,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625023,,
11886,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL625024,,
11887,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL627626,,
11888,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627627,955.0,
11889,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627628,1977.0,
11890,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627629,955.0,
11891,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627630,1977.0,
11892,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627631,,
11893,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629515,,
11894,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629516,2106.0,
11895,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629517,2106.0,
11896,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629518,2106.0,
11897,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL877499,,
11898,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629519,,
11899,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629520,,
11900,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629521,,
11901,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629522,,
11902,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629523,,
11903,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629524,,
11904,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629525,,
11905,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629526,,
11906,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629527,,
11907,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629528,,
11908,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629529,,
11909,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629530,,
11910,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629531,,
11911,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628656,,
11912,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628657,,
11913,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628658,,
11914,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628659,,
11915,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877500,,
11916,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628660,,
11917,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628661,,
11918,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628662,,
11919,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628663,,
11920,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628664,,
11921,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628665,178.0,
11922,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628666,178.0,
11923,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628667,178.0,
11924,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628668,178.0,
11925,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628669,178.0,
11926,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628670,178.0,
11927,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628671,178.0,
11928,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628672,10000001.0,
11929,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630300,10000001.0,
11930,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629787,10000001.0,
11931,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629788,10000001.0,
11932,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629789,955.0,
11933,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629790,955.0,
11934,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629791,955.0,
11935,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629792,955.0,
11936,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629793,955.0,
11937,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629794,955.0,
11938,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874459,,
11939,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629795,,
11940,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629796,,
11941,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629797,,
11942,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629798,,
11943,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629799,2369.0,
11944,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629800,2369.0,
11945,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629801,2369.0,
11946,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629802,2369.0,
11947,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629803,2369.0,
11948,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629804,178.0,
11949,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629805,178.0,
11950,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629806,178.0,
11951,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629807,178.0,
11952,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629808,178.0,
11953,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629809,955.0,
11954,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629810,955.0,
11955,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629811,955.0,
11956,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629812,955.0,
11957,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629813,955.0,
11958,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874460,955.0,
11959,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629814,,
11960,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629815,,
11961,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629816,,
11962,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629817,,
11963,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626643,2113.0,
11964,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626644,2113.0,
11965,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626806,2113.0,
11966,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626807,2113.0,
11967,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627261,2107.0,
11968,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627262,2107.0,
11969,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627263,2107.0,
11970,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627264,2107.0,
11971,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627265,2048.0,
11972,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627266,2048.0,
11973,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627267,2048.0,
11974,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627268,2048.0,
11975,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627269,2385.0,
11976,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627270,2385.0,
11977,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627271,,
11978,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627946,,
11979,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875472,,
11980,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627947,,
11981,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627948,,
11982,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628113,,
11983,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628114,,
11984,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628115,,
11985,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628116,,
11986,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628117,,
11987,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628118,,
11988,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628119,,
11989,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628120,,
11990,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628121,,
11991,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628122,,
11992,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627297,,
11993,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627298,,
11994,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627299,,
11995,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627300,,
11996,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627301,,
11997,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627302,,
11998,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627303,,
11999,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627304,,
12000,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627305,,
12001,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627306,,
12002,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623982,,
12003,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623983,,
12004,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623984,,
12005,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623985,,
12006,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623986,,
12007,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623987,,
12008,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623988,,
12009,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623989,,
12010,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622215,,
12011,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622216,,
12012,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877481,,
12013,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622217,,
12014,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622218,,
12015,Pharmacokinetic profile AUC was evaluated in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622219,,
12016,Pharmacokinetic property (Area under curve),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622220,,
12017,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622221,,
12018,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622222,,
12019,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622223,,
12020,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622224,,
12021,Plasma concentration (AUC) was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622225,,
12022,Plasma concentration (AUC) was determined; Not detectable,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622226,,
12023,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL624154,,
12024,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624155,,
12025,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624156,,
12026,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624157,,
12027,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624158,,
12028,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624159,,
12029,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624160,,
12030,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624161,,
12031,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624162,,
12032,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624163,,
12033,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624164,,
12034,The AUC(0-infinity) values in female wistar rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624165,,
12035,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624166,,
12036,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624167,,
12037,The AUC(0-t)values in female wistar rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624168,,
12038,The Area under the concentration time curve of compound was measured on rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624169,,
12039,The area under curve (100 mg/kg) administered orally in humans,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL624170,,
12040,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624171,,
12041,The area under curve (12.5 mg/kg) administered intravenously in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624172,,
12042,The area under curve (15 mg/kg) administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624173,,
12043,The area under curve (200 mg/kg) administered orally in humans,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL877488,,
12044,The area under curve (25 mg/kg) administered intravenously in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624174,,
12045,The area under curve (25 mg/kg) administered orally in marmoset,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624175,,
12046,The area under curve (25 mg/kg) administered orally in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624176,,
12047,The area under curve (30 mg/kg) administered orally in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624177,,
12048,The area under curve (400 mg/kg) administered orally in humans,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL624178,,
12049,The area under curve (50 mg/kg) administered orally in fasted rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624179,,
12050,The area under curve (50 mg/kg) administered orally in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627689,,
12051,The area under curve (800 mg/kg) administered orally in humans,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL627690,,
12052,The compound was evaluated for area under the curve,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627691,,
12053,The compound was evaluated for area under the curve in marmosets,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627692,,
12054,The compound was evaluated for area under the curve in marmosets,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627693,,
12055,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627694,,
12056,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627695,,
12057,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627696,,
12058,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627697,,
12059,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627698,,
12060,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627699,,
12061,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627700,,
12062,Total drug exposure is determined after oral dosing in rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627701,,
12063,Total drug exposure (5 mg/kg) when administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627702,,
12064,Total drug exposure (5 mg/kg) when administered orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627703,,
12065,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626873,,
12066,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629583,,
12067,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629584,,
12068,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629585,,
12069,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629586,955.0,
12070,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629587,955.0,
12071,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629588,,
12072,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629589,,
12073,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629590,,
12074,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629591,,
12075,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629592,,
12076,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629593,,
12077,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629594,,
12078,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629595,948.0,
12079,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630290,948.0,
12080,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627137,948.0,
12081,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627138,948.0,
12082,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627139,948.0,
12083,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627140,948.0,
12084,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627141,948.0,
12085,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627142,2113.0,
12086,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627143,2113.0,
12087,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874449,2113.0,
12088,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627144,2113.0,
12089,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627145,2113.0,
12090,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627146,2113.0,
12091,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627147,2113.0,
12092,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627148,2107.0,
12093,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627149,2048.0,
12094,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632160,2048.0,
12095,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632161,2048.0,
12096,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632162,2048.0,
12097,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632163,2048.0,
12098,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874469,2048.0,
12099,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627182,2048.0,
12100,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627183,2385.0,
12101,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627184,2385.0,
12102,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627185,2385.0,
12103,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627186,2385.0,
12104,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627187,2385.0,
12105,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627188,2385.0,
12106,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627189,2385.0,
12107,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627190,,
12108,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627191,2107.0,
12109,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627192,2107.0,
12110,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627193,2107.0,
12111,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874590,2385.0,
12112,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627194,2385.0,
12113,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627195,2385.0,
12114,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627196,992.0,
12115,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627197,992.0,
12116,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627198,992.0,
12117,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627199,992.0,
12118,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627200,992.0,
12119,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627201,1969.0,
12120,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627202,1969.0,
12121,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627203,1969.0,
12122,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627204,1969.0,
12123,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627205,2106.0,
12124,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627206,2106.0,
12125,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627207,2106.0,
12126,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627208,2106.0,
12127,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627209,2046.0,
12128,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627210,2046.0,
12129,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627211,2046.0,
12130,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627212,2046.0,
12131,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627213,995.0,
12132,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626599,995.0,
12133,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626600,995.0,
12134,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626601,995.0,
12135,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627484,,
12136,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL627485,1969.0,
12137,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628147,1969.0,
12138,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628148,1969.0,
12139,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628149,1969.0,
12140,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628150,1969.0,
12141,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628318,1969.0,
12142,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628319,1969.0,
12143,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875609,,
12144,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628320,,
12145,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628321,,
12146,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628322,,
12147,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628323,,
12148,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628324,,
12149,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628325,,
12150,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628326,,
12151,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628327,1236.0,
12152,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628328,1236.0,
12153,"Concentration of compound in blood of dog 1, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628329,178.0,
12154,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628330,2107.0,
12155,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628331,2107.0,
12156,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628332,2107.0,
12157,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628333,2107.0,
12158,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628334,2107.0,
12159,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628335,2107.0,
12160,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628336,2107.0,
12161,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628337,2107.0,
12162,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628338,2107.0,
12163,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875610,2107.0,
12164,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628339,2107.0,
12165,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628340,2107.0,
12166,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628341,2107.0,
12167,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622214,2107.0,
12168,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623167,2107.0,
12169,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623168,2107.0,
12170,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623169,2107.0,
12171,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623170,2107.0,
12172,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627224,2048.0,
12173,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875634,2048.0,
12174,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627225,2048.0,
12175,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627226,2048.0,
12176,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626083,2048.0,
12177,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626084,2048.0,
12178,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626085,2048.0,
12179,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626086,2048.0,
12180,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626087,2048.0,
12181,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626088,2048.0,
12182,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626089,2048.0,
12183,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626090,2048.0,
12184,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626091,2048.0,
12185,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626092,2048.0,
12186,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626093,2048.0,
12187,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626094,2048.0,
12188,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626095,2048.0,
12189,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626096,2048.0,
12190,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626097,,
12191,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626098,,
12192,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626099,1969.0,
12193,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626100,1969.0,
12194,AUC 0-inf in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626101,1969.0,
12195,AUC 0-inf in guinea pig,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL626102,1969.0,
12196,AUC 0-t in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626103,1969.0,
12197,AUC 0-t in guinea pig,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL628391,1969.0,
12198,The compound was tested for brain to plasma partition in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628392,,
12199,The compound was tested for brain to plasma partition in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628393,,
12200,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628394,178.0,
12201,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628395,,
12202,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628396,,
12203,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628397,,
12204,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628398,,
12205,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL628399,,
12206,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628400,,
12207,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874907,,
12208,Area under curve of the compound was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628401,,
12209,AUC in monkeys at a dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628402,1969.0,
12210,AUC in rats at a dose of 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628403,1969.0,
12211,Compound was evaluated for the overall absorbance loss at pH of 2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628404,,
12212,Compound was evaluated for the overall absorbance loss at pH of 4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628405,,
12213,Compound was evaluated for the overall absorbance loss at pH of 7,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628406,,
12214,Compound was evaluated for its absorption in the rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628407,,
12215,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628408,1088.0,
12216,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629171,1088.0,
12217,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629172,1088.0,
12218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629173,1088.0,
12219,In vitro percent permeability into rat ileum,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629174,,
12220,In vitro percent permeability into rat ileum; Range is 10-17,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629175,,
12221,In vitro percent permeability into rat ileum; Range is 10-18,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629176,,
12222,In vitro percent permeability into rat ileum; Range is 10-19,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629177,,
12223,In vitro percent permeability into rat ileum; Range is 12-15,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629178,,
12224,In vitro percent permeability into rat ileum; Range is 13-19,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631869,,
12225,In vitro percent permeability into rat ileum; Range is 14-17,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631870,,
12226,In vitro percent permeability into rat ileum; Range is 15-18,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631871,,
12227,In vitro percent permeability into rat ileum; Range is 2-5,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631872,,
12228,In vitro percent permeability into rat ileum; Range is 23-42,,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL875775,2116.0,
12229,In vitro percent permeability into rat ileum; Range is 28-36,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631873,,
12230,In vitro percent permeability into rat ileum; Range is 29-35,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631874,,
12231,In vitro percent permeability into rat ileum; Range is 46-66,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631875,,
12232,In vitro percent permeability into rat ileum; Range is 50-68,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631876,,
12233,In vitro percent permeability into rat ileum; Range is 78-81,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631877,,
12234,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631878,,
12235,In vitro percent permeability into rat ileum; nd indicates not detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631879,,
12236,In vitro percent permeability into rat ileum; nt indicates not detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631880,,
12237,In vitro percent permeability into rat ileum; nt indicates not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631881,,
12238,Compound was tested for oral absorption in bile-duct cannulated rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631882,,
12239,Compound was tested for oral absorption in bile-duct cannulated rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630749,,
12240,Oral absorption using Caco-2 cell monolayers.,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL630750,,
12241,Percent of the drug absorbed after administration to humans was determined,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL630253,,
12242,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630254,1969.0,
12243,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630255,1969.0,
12244,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630256,1969.0,
12245,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875781,2107.0,
12246,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630257,2107.0,
12247,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630258,2107.0,
12248,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630259,,
12249,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630260,2435.0,
12250,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630261,2435.0,
12251,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630262,,
12252,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630263,,
12253,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630264,,
12254,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630265,,
12255,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630266,,
12256,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630267,2113.0,
12257,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630268,2113.0,
12258,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630269,,
12259,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630270,,
12260,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630141,2048.0,
12261,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630142,2048.0,
12262,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630143,2385.0,
12263,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630144,2385.0,
12264,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630145,2367.0,
12265,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630146,2367.0,
12266,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630147,,
12267,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630148,,
12268,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630149,,
12269,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630150,2106.0,
12270,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630151,2106.0,
12271,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632031,2046.0,
12272,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632032,2046.0,
12273,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632033,,
12274,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632034,,
12275,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632035,2385.0,
12276,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632036,,
12277,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632037,2046.0,
12278,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632038,178.0,
12279,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632039,178.0,
12280,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632040,178.0,
12281,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632041,178.0,
12282,"Concentration of compound in blood of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632042,178.0,
12283,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632043,,
12284,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632044,,
12285,"Concentration of compound in liver of dog 1, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632045,2107.0,
12286,"Concentration of compound in liver of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632046,2107.0,
12287,"Concentration of compound in lung of dog 1, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632047,2048.0,
12288,"Concentration of compound in lung of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632048,2048.0,
12289,"Concentration of compound in muscle of dog 1, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632049,2385.0,
12290,"Concentration of compound in muscle of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL876418,2385.0,
12291,"Concentration of compound in spleen of dog 1,after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632050,2106.0,
12292,"Concentration of compound in spleen of dog 2, after administering intravenously",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL632051,2106.0,
12293,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632052,,
12294,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632053,,
12295,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632054,,
12296,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632055,,
12297,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631181,,
12298,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631182,,
12299,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631183,,
12300,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631184,,
12301,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629774,,
12302,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629775,,
12303,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL876549,,
12304,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628172,,
12305,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628173,,
12306,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628174,,
12307,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628175,,
12308,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628176,,
12309,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628177,,
12310,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628178,,
12311,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628179,,
12312,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628180,,
12313,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628181,,
12314,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628182,,
12315,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628183,,
12316,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628184,,
12317,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628185,,
12318,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875617,,
12319,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628186,,
12320,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628187,,
12321,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628188,,
12322,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628189,,
12323,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628190,,
12324,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628191,,
12325,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626513,,
12326,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626514,2046.0,
12327,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626515,2046.0,
12328,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626516,2046.0,
12329,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626517,2046.0,
12330,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626518,2046.0,
12331,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626519,2046.0,
12332,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626520,2046.0,
12333,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626521,2046.0,
12334,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626522,2046.0,
12335,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626523,2046.0,
12336,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626524,2046.0,
12337,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626688,2046.0,
12338,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626689,2046.0,
12339,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626690,2046.0,
12340,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626691,2046.0,
12341,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627319,2046.0,
12342,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624052,2046.0,
12343,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624053,2046.0,
12344,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624054,,
12345,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624055,,
12346,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624056,,
12347,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624057,995.0,
12348,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622281,995.0,
12349,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622282,995.0,
12350,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622283,995.0,
12351,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622284,995.0,
12352,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622285,995.0,
12353,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622286,995.0,
12354,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL622287,,
12355,Partition coefficient (logD7.4),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622288,,
12356,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622289,,
12357,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622290,955.0,
12358,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622291,,
12359,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622292,955.0,
12360,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622293,,
12361,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622294,955.0,
12362,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL622295,,
12363,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622296,955.0,
12364,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874409,1969.0,
12365,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622297,1969.0,
12366,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622298,1969.0,
12367,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622299,1969.0,
12368,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622300,1969.0,
12369,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622301,1969.0,
12370,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622302,1969.0,
12371,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622303,1969.0,
12372,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622304,1969.0,
12373,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622305,1969.0,
12374,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622306,1969.0,
12375,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626864,1969.0,
12376,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626865,1969.0,
12377,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626866,1969.0,
12378,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626867,1969.0,
12379,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626868,1969.0,
12380,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626869,1969.0,
12381,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626870,1969.0,
12382,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626871,1969.0,
12383,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626872,1969.0,
12384,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632185,1969.0,
12385,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632186,1969.0,
12386,Amount of acetic acid produced by the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629310,,
12387,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629311,,
12388,Log of (Cbrain/Cblood) in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629312,,
12389,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL629313,,
12390,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL629314,,
12391,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL629315,,
12392,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,BAO_0000219,Autocuration,,,22224,U,0,1,,CHEMBL629316,,
12393,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000221,Autocuration,,,22224,U,0,1,,CHEMBL629317,,
12394,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629318,,
12395,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL877497,,
12396,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629319,,
12397,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629320,,
12398,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629496,,
12399,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629497,,
12400,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629498,,
12401,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629499,,
12402,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629500,,
12403,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629501,,
12404,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629502,,
12405,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629503,,
12406,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629504,,
12407,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629505,,
12408,Compound was evaluated for total body clearance,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629506,,
12409,Compound was evaluated for volume of distribution at steady state,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629507,,
12410,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL877498,,
12411,Percentage of the diamine which is monoprotonated at pH 7.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629508,,
12412,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629509,,
12413,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629510,178.0,
12414,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629511,178.0,
12415,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629512,178.0,
12416,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629513,178.0,
12417,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629514,178.0,
12418,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628447,178.0,
12419,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628448,178.0,
12420,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628449,178.0,
12421,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631119,178.0,
12422,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631120,178.0,
12423,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631121,178.0,
12424,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874458,178.0,
12425,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631122,178.0,
12426,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631123,178.0,
12427,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631124,178.0,
12428,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631125,178.0,
12429,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631290,178.0,
12430,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631291,178.0,
12431,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631292,178.0,
12432,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631293,178.0,
12433,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631294,178.0,
12434,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631295,178.0,
12435,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631296,178.0,
12436,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631297,178.0,
12437,Maximum biodistribution (Bmax) was determined.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631298,,
12438,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631299,,
12439,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631300,,
12440,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631301,,
12441,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630291,,
12442,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630292,,
12443,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630293,,
12444,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630294,,
12445,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630295,,
12446,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630296,,
12447,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626782,,
12448,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626783,,
12449,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626784,,
12450,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626785,,
12451,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626786,,
12452,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626787,,
12453,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626788,,
12454,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625927,,
12455,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625928,178.0,
12456,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625929,178.0,
12457,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625930,178.0,
12458,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625931,178.0,
12459,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627230,178.0,
12460,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627231,178.0,
12461,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627232,178.0,
12462,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627233,178.0,
12463,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875470,178.0,
12464,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627234,178.0,
12465,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627235,178.0,
12466,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627236,178.0,
12467,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627237,178.0,
12468,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627238,178.0,
12469,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627239,178.0,
12470,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627240,178.0,
12471,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627241,178.0,
12472,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627242,178.0,
12473,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627243,178.0,
12474,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627244,178.0,
12475,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627245,178.0,
12476,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627246,178.0,
12477,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627247,178.0,
12478,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627248,178.0,
12479,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627249,178.0,
12480,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625569,178.0,
12481,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625570,178.0,
12482,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625571,178.0,
12483,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625572,178.0,
12484,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625573,178.0,
12485,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625574,178.0,
12486,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626245,178.0,
12487,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626246,178.0,
12488,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626247,,
12489,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626248,,
12490,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626249,,
12491,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626420,,
12492,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626421,,
12493,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626422,,
12494,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626423,,
12495,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626424,,
12496,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626425,,
12497,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875476,,
12498,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL626426,,
12499,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL626427,,
12500,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL626428,,
12501,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626429,,
12502,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625025,1088.0,
12503,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625026,178.0,
12504,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625027,178.0,
12505,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874410,178.0,
12506,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625028,178.0,
12507,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625029,178.0,
12508,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625030,178.0,
12509,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625031,178.0,
12510,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625032,178.0,
12511,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625033,178.0,
12512,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625034,178.0,
12513,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624872,948.0,
12514,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624873,948.0,
12515,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624874,948.0,
12516,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624875,948.0,
12517,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624876,948.0,
12518,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624877,948.0,
12519,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624878,948.0,
12520,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624879,948.0,
12521,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624880,948.0,
12522,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624881,948.0,
12523,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624882,948.0,
12524,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624883,2113.0,
12525,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624884,2113.0,
12526,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624885,2113.0,
12527,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624886,2113.0,
12528,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624887,2113.0,
12529,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624888,2113.0,
12530,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624889,2113.0,
12531,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624890,2113.0,
12532,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621964,2113.0,
12533,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621965,2113.0,
12534,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621966,2107.0,
12535,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL621967,2107.0,
12536,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622164,2107.0,
12537,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623097,,
12538,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623098,,
12539,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623099,,
12540,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623100,,
12541,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628673,,
12542,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628674,,
12543,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628675,,
12544,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627644,,
12545,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627645,,
12546,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627646,,
12547,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627647,,
12548,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627648,,
12549,Free level in rat plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627649,,
12550,Level reaching in blood plasma of rat or human was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628313,,
12551,Log (Cbrain/Cblood) in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628314,,
12552,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628315,,
12553,Mean percentage of compound transport through membrane; expressed as membrane transport,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628316,,
12554,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628317,,
12555,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628473,,
12556,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628474,,
12557,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628475,,
12558,Net water uptake by a carrier mediated transport (%cm) mechanism,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628476,,
12559,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628477,,
12560,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL628478,,
12561,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL628479,,
12562,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628480,,
12563,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628481,,
12564,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628482,,
12565,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628483,,
12566,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628484,1969.0,
12567,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628485,1969.0,
12568,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628486,1969.0,
12569,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL628487,1969.0,
12570,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628488,1969.0,
12571,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628489,1969.0,
12572,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628490,1969.0,
12573,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL628491,,
12574,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL877507,,
12575,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628492,,
12576,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628493,,
12577,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628494,,
12578,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628495,,
12579,Permeability in Caco-2 assay at 10E-6,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL628496,,
12580,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628497,955.0,
12581,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628498,955.0,
12582,Plasma protein binding was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628499,,
12583,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627656,,
12584,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627657,,
12585,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626808,,
12586,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626809,,
12587,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626810,,
12588,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626811,,
12589,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL874465,,
12590,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626812,,
12591,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626813,,
12592,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626814,,
12593,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626815,,
12594,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628566,,
12595,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL628567,,
12596,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL628568,,
12597,C max in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628569,,
12598,C max in guinea pig,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL628570,,
12599,C max value was evaluated,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628571,,
12600,Cmax value after oral dose of 0.1 mg//kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628572,,
12601,Cmax value after oral dose of 0.3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628573,,
12602,Cmax value after oral dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628574,,
12603,Cmax value after oral dose of 10 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628575,,
12604,Cmax value after oral dose of 23.4 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628576,,
12605,Cmax value after oral dose of 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628577,,
12606,Cmax value after oral dose of 3.87 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628578,,
12607,Cmax value in female Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874466,,
12608,Cmax value in male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628579,,
12609,Cmax value in rat plasma when administered 20 mg/kg perorally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628580,1969.0,
12610,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628581,1969.0,
12611,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628582,1969.0,
12612,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628583,,
12613,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625782,,
12614,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625783,,
12615,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625784,,
12616,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL625785,1969.0,
12617,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625786,,
12618,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874467,,
12619,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625787,,
12620,cytotoxicity against HIV protease enzyme.,,BAO_0000218,Intermediate,,,50677,N,1,1,,CHEMBL625964,,
12621,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625965,,
12622,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625966,,
12623,The plasma clearance in dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625967,1969.0,
12624,The plasma clearance in rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625968,1969.0,
12625,Clearance from plasma in male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625969,1969.0,
12626,Clearance from plasma in male cynomolgus monkeys,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL625970,1969.0,
12627,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625971,1969.0,
12628,Clearance of compound in dog plasma,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625972,1969.0,
12629,Clearance of compound in human plasma,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625973,1969.0,
12630,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625974,,
12631,Clearance of compound when administered intravenously as an individual dose to a single dog.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625975,,
12632,"Clearance (10 mg/kg, intravenously) in dog plasma",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625976,1969.0,
12633,Clearance value in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625977,,
12634,Clearance value in guinea pig,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL625978,,
12635,Clearance values in rats after iv administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874468,,
12636,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625421,1969.0,
12637,In vivo clearance (5 mg/kg) was determined in rabbits,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625422,,
12638,Plasma Clearance rate was determined for the compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625423,,
12639,Plasma Clearance rate was determined for the compound in squirrel monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625424,,
12640,Plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625425,,
12641,Plasma clearance of the compound,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625426,,
12642,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL625427,,
12643,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL625428,,
12644,Plasma clearance was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625429,,
12645,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625430,,
12646,Plasma clearance rate was determined for the compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625431,,
12647,Plasma clearance rate was determined for the compound in squirrel monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627307,,
12648,Slow clearance (CL) was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627308,,
12649,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627309,,
12650,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627310,,
12651,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627311,,
12652,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627312,,
12653,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627313,,
12654,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627314,,
12655,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627315,,
12656,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627316,,
12657,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627317,,
12658,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627318,,
12659,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627999,,
12660,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628000,,
12661,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628001,,
12662,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628002,,
12663,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625610,,
12664,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625611,,
12665,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625612,,
12666,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625613,,
12667,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875479,,
12668,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625614,,
12669,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625615,,
12670,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626302,,
12671,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626303,178.0,
12672,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627420,178.0,
12673,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627421,,
12674,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625695,,
12675,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625696,,
12676,Distribution of compound in mice brain was measured after 1 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875606,955.0,
12677,Distribution of compound in mice brain was measured after 24 hr r,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625697,955.0,
12678,Distribution of compound in mice brain was measured after 2 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625698,955.0,
12679,Distribution of compound in mice brain was measured after 3 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625699,955.0,
12680,Distribution of compound in mice brain was measured after 6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625700,955.0,
12681,Distribution of compound in mice liver was measured after 1 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625701,,
12682,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625702,,
12683,Distribution of compound in mice liver was measured after 2 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625703,,
12684,Distribution of compound in mice liver was measured after 3 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625704,,
12685,Distribution of compound in mice liver was measured after 6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625705,,
12686,Distribution in dog adrenal medulla 30 min after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625706,1236.0,
12687,Distribution in dog adrenal medulla 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625707,1236.0,
12688,Distribution in female dog Ovary 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625708,,
12689,Distribution in female dog Ovary 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625709,,
12690,Distribution in female dog adipose 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624180,,
12691,Distribution in female dog adipose 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624181,,
12692,Distribution in female dog adrenal cortex 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624182,1235.0,
12693,Distribution in female dog adrenal cortex 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624183,1235.0,
12694,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624184,2107.0,
12695,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877489,2107.0,
12696,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624185,2107.0,
12697,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624186,2107.0,
12698,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624187,2107.0,
12699,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624188,2107.0,
12700,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624189,2048.0,
12701,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624190,2048.0,
12702,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624191,2048.0,
12703,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624192,2048.0,
12704,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624193,2048.0,
12705,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624194,2048.0,
12706,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624891,2048.0,
12707,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624892,2048.0,
12708,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624893,2048.0,
12709,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627632,2048.0,
12710,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627633,,
12711,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627634,,
12712,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627635,,
12713,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627636,,
12714,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626816,,
12715,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626817,,
12716,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626818,,
12717,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626819,,
12718,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626820,,
12719,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626821,,
12720,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626822,2046.0,
12721,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626823,2046.0,
12722,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626824,2046.0,
12723,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626825,2046.0,
12724,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626826,2046.0,
12725,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626827,2046.0,
12726,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626828,2046.0,
12727,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626829,2046.0,
12728,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626830,2046.0,
12729,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627150,,
12730,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627151,,
12731,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627152,,
12732,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627153,,
12733,Rate of acetate production by the compound was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627154,,
12734,Rate of acetate production by the compound was determined; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627155,,
12735,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627156,,
12736,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627157,,
12737,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627158,,
12738,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627159,1969.0,
12739,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627160,,
12740,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628540,,
12741,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628541,1969.0,
12742,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628542,1969.0,
12743,Solubility after at a pH 1.2,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL628543,,
12744,Solubility after at pH 1.2,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL628544,,
12745,Solubility after injection of water,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL628545,,
12746,Statistical significance of IC 50 values; Expressed as R value,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628546,,
12747,Systemic availability with respect to methyldopa was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874455,,
12748,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628547,,
12749,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628548,1969.0,
12750,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628549,1988.0,
12751,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628550,1988.0,
12752,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628551,1988.0,
12753,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628552,1088.0,
12754,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628553,1088.0,
12755,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628554,1088.0,
12756,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628555,1088.0,
12757,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628556,1088.0,
12758,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628557,2113.0,
12759,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628558,1988.0,
12760,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628559,1988.0,
12761,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628560,1988.0,
12762,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL874456,1088.0,
12763,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628561,1988.0,
12764,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628562,1988.0,
12765,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628563,1088.0,
12766,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628564,1088.0,
12767,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628565,1088.0,
12768,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL631248,1088.0,
12769,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL631249,1088.0,
12770,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627214,2113.0,
12771,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL874591,1988.0,
12772,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627215,1988.0,
12773,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625471,1988.0,
12774,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625472,,
12775,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625473,,
12776,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625474,,
12777,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625475,,
12778,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625476,,
12779,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625477,,
12780,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625478,,
12781,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625479,,
12782,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625480,,
12783,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625481,1969.0,
12784,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625482,,
12785,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625483,,
12786,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625484,,
12787,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625485,,
12788,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625486,1969.0,
12789,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625487,1969.0,
12790,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625488,1969.0,
12791,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625489,1969.0,
12792,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625490,1969.0,
12793,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625491,1969.0,
12794,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625492,1969.0,
12795,plasma clearance in human,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625493,1969.0,
12796,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625494,,
12797,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625495,,
12798,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625496,,
12799,1-Octanol/water partition coefficient measured at 7.4,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625497,,
12800,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625498,,
12801,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625499,,
12802,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625500,,
12803,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625501,,
12804,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625502,,
12805,Calculated partition coefficient (clogP) (relative to BAY K 8644),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625503,,
12806,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625504,,
12807,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625505,,
12808,Calculated partition coefficient of the compound,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625506,,
12809,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625507,,
12810,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625508,,
12811,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625509,,
12812,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625510,,
12813,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL883125,,
12814,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625511,,
12815,Partition coefficient of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874650,,
12816,Partition coefficient of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625512,,
12817,Partition coefficient of compound was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625513,,
12818,Partition coefficient was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625514,,
12819,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625515,,
12820,partition coefficient of compound was determined,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625516,,
12821,The total body administered intravenously in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625517,,
12822,The total body administered intravenously in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625518,,
12823,Time taken for the administration to female NIH mice weighing 25-30 g.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625519,,
12824,Time taken for the administration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625520,,
12825,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874651,,
12826,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625521,,
12827,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL623171,,
12828,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623853,,
12829,Plasma clearance for the compound was determined.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623854,,
12830,CLog P value of the compound,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL874405,,
12831,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL623855,,
12832,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL623856,,
12833,ClogP value of the compound; nd ='no data',,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL623857,,
12834,ClogP value of the compound; nd ='not determined',,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL623858,,
12835,CLog P was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL623859,,
12836,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL839829,,
12837,CLogP was calculated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623860,,
12838,CLogP value was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623861,,
12839,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623862,,
12840,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL874406,,
12841,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL623863,,
12842,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624021,,
12843,Distribution in female dog adrenal medulla 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624022,1236.0,
12844,Distribution in female dog adrenal medulla 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624023,1236.0,
12845,Distribution in female dog bile 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624024,,
12846,Distribution in female dog bile 72 hr after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624025,,
12847,Distribution in female dog blood 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624026,,
12848,Distribution in female dog blood 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624027,,
12849,Distribution in female dog heart 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624028,,
12850,Distribution in female dog heart 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624029,,
12851,Distribution in female dog kidney 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624030,,
12852,Distribution in female dog kidney 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624031,,
12853,Distribution in female dog large intestine 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624032,160.0,
12854,Distribution in female dog large intestine 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874407,160.0,
12855,Distribution in female dog liver 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624033,,
12856,Distribution in female dog liver 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624034,,
12857,Distribution in female dog lung 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624035,,
12858,Distribution in female dog lung 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624036,,
12859,Distribution in female dog muscle 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624037,2385.0,
12860,Distribution in female dog muscle 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624038,2385.0,
12861,Distribution in female dog pancreas 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624039,,
12862,Distribution in female dog pancreas 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624040,,
12863,Distribution in female dog small intestine 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624041,160.0,
12864,Distribution in female dog small intestine 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624042,160.0,
12865,Distribution in female dog spleen 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624043,2106.0,
12866,Distribution in female dog spleen 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624044,2106.0,
12867,Distribution in female dog stomach 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624045,945.0,
12868,Distribution in female dog stomach 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624046,945.0,
12869,Distribution in female dog thyroid 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624047,2046.0,
12870,Distribution in female dog thyroid 72 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624048,2046.0,
12871,Distribution in female dog urine 24 hours after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874408,1088.0,
12872,Distribution in female dog urine 72 hr after administration.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624049,1088.0,
12873,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL624050,1969.0,
12874,Plasma concentration at 7 hr after intravenous dosing,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624051,,
12875,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623278,,
12876,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623279,,
12877,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623280,,
12878,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623963,,
12879,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623964,,
12880,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623965,,
12881,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623966,,
12882,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874415,,
12883,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623967,,
12884,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623968,,
12885,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623969,,
12886,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628409,,
12887,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628410,,
12888,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628411,,
12889,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628412,,
12890,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628413,,
12891,The concentration in plasmat; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628414,1969.0,
12892,Tissue level at 10 mg/kg/po in wistar rats in blood,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628415,,
12893,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628416,,
12894,Tissue level at 10 mg/kg/po in wistar rats in heart,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628417,,
12895,Tissue level at 10 mg/kg/po in wistar rats in liver,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874908,2107.0,
12896,Tissue level at 10 mg/kg/po in wistar rats in plasma,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628418,,
12897,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628419,2385.0,
12898,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628420,,
12899,Water solubility at 37 degree C.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628421,,
12900,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626726,,
12901,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626727,,
12902,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626728,178.0,
12903,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626729,178.0,
12904,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626730,178.0,
12905,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626731,178.0,
12906,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626732,178.0,
12907,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626733,948.0,
12908,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626734,948.0,
12909,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626735,948.0,
12910,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874909,948.0,
12911,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626736,948.0,
12912,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626737,2113.0,
12913,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630999,2113.0,
12914,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631000,2113.0,
12915,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631001,2113.0,
12916,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631002,2113.0,
12917,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631003,2107.0,
12918,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631004,2107.0,
12919,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631005,2107.0,
12920,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631006,2107.0,
12921,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631007,2107.0,
12922,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631008,2048.0,
12923,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631009,2048.0,
12924,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631010,2048.0,
12925,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631011,2048.0,
12926,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631012,2048.0,
12927,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630271,2046.0,
12928,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630272,2046.0,
12929,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630273,2046.0,
12930,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630274,2046.0,
12931,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630275,2046.0,
12932,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875782,,
12933,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630276,,
12934,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630277,,
12935,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630278,,
12936,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630279,,
12937,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630280,,
12938,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630281,,
12939,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630282,,
12940,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630283,,
12941,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630284,,
12942,Alkylating activity was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630285,,
12943,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,BAO_0000251,Autocuration,Microsomes,,22224,U,0,1,,CHEMBL630286,,
12944,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630069,,
12945,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630070,,
12946,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630071,,
12947,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630072,,
12948,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL875110,,
12949,Compound was tested for antidiuretic activity in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630073,,
12950,Compound was tested for inactivation kinetic values,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630074,,
12951,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630075,,
12952,Dissociation rate calculated from the first-order equation using the t1/2 value,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630076,,
12953,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL630077,,
12954,Aqueous solubility was measured,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL630078,,
12955,Aqueous solubility was measured at a pH 4,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL630079,,
12956,Aqueous solubility (pH 7),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL630080,,
12957,Aqueous solubility was measured at a pH 9,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL630081,,
12958,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630082,,
12959,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630083,,
12960,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630084,,
12961,Aqueous solubility of the compound,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL629198,,
12962,Aqueous solubility at 37 degree Celsius at pH 7.38,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL629199,,
12963,Aqueous solubility in pH 7.4 phosphate buffer,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL629200,,
12964,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629201,,
12965,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629202,,
12966,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL875111,,
12967,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL629203,,
12968,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL629204,,
12969,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL629205,,
12970,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL629206,,
12971,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631185,,
12972,Compound was evaluated for the average bile flow rat in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631186,,
12973,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL631187,,
12974,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL631188,,
12975,Average half life period was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876419,,
12976,Average half life period was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631189,,
12977,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL631190,,
12978,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL631191,,
12979,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL631192,,
12980,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL632400,,
12981,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL630564,,
12982,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL630565,,
12983,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL630566,,
12984,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL631229,,
12985,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL631230,,
12986,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL876428,,
12987,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631231,,
12988,Calculated partition coefficient (clogP) (MacLogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631232,,
12989,Hydrophilicity was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631233,,
12990,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631234,,
12991,Increased absorption was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL883126,,
12992,Lipophilicity value was evaluated,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL631235,,
12993,Log P value of the compound.,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL631236,,
12994,Partition coefficient of compound was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631237,,
12995,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631238,,
12996,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL876429,,
12997,Partition coefficient was measured by medchem software; Not calculated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631414,,
12998,Partition coefficient was measured by octanol-water using standard shake-flask method,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL631415,,
12999,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631416,,
13000,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631417,,
13001,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631418,,
13002,The Octanol/Water partition coefficient CLogP,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631419,,
13003,The pharmacokinetic parameter C Log p was reported,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631420,,
13004,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631421,,
13005,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631422,,
13006,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL631423,,
13007,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876430,1969.0,
13008,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631424,1969.0,
13009,Compound was administered intravenously in dog to evaluate plasma clearance values,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631425,1969.0,
13010,Compound was administered intravenously in monkey to evaluate plasma clearance values,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631426,1969.0,
13011,Compound was administered intravenously in mouse to evaluate plasma clearance values,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631427,1969.0,
13012,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631428,1969.0,
13013,Intrinsic clearance in Rhesus liver microsome,,BAO_0000218,Intermediate,Microsomes,,50797,N,1,1,,CHEMBL631429,2107.0,
13014,Intrinsic clearance in dog liver microsome,,BAO_0000218,Intermediate,Microsomes,,50588,N,1,1,,CHEMBL631430,2107.0,
13015,Intrinsic clearance in rat liver microsome,,BAO_0000218,Intermediate,Microsomes,,50597,N,1,1,,CHEMBL631431,2107.0,
13016,Low plasma clearance was calculated in rhesus monkey,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL631432,1969.0,
13017,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631433,,
13018,Plasma clearance after intravenous dose of 0.3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631434,,
13019,Plasma clearance after intravenous dose of 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631435,,
13020,Plasma clearance after intravenous dose of 3 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631436,,
13021,Plasma clearance after intravenous dose of 3.87 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631437,,
13022,Plasma clearance after peroral administration at 10 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631438,,
13023,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL876431,,
13024,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631439,,
13025,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631440,,
13026,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631441,,
13027,Critical Micellar concentration was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631442,,
13028,Critical Micellar concentration of the compound. was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626525,,
13029,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627168,,
13030,Critical micellar concentration was measured in water by the dye solubilization method,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875618,,
13031,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626612,,
13032,CMR value (relative to BAY K 8644),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626613,,
13033,Carbamoylating activity was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626614,,
13034,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626615,,
13035,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626616,,
13036,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626617,,
13037,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626618,1969.0,
13038,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626619,1969.0,
13039,"Clearance rate at 0.46 mg/kg, iv, in dogs",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626620,,
13040,"Clearance rate at 5.5 mg/kg, iv, in rat",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626621,,
13041,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL626622,,
13042,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL626623,,
13043,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626624,,
13044,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626625,,
13045,Clearance rate constant using isolated perfused rat liver (IPRL) assay,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626626,2107.0,
13046,Tested for the total clearance of the compound,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626627,,
13047,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626628,,
13048,Total body clearance was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626629,,
13049,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626630,,
13050,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626631,,
13051,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626632,,
13052,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626633,,
13053,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626634,,
13054,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626635,,
13055,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626636,,
13056,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626637,,
13057,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL626638,,
13058,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL626639,,
13059,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL626640,,
13060,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL626641,,
13061,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL627272,,
13062,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL627273,,
13063,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL627441,,
13064,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL628355,,
13065,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL628356,,
13066,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL628357,,
13067,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL628358,,
13068,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,BAO_0000218,Intermediate,,,50339,N,1,1,,CHEMBL622307,,
13069,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622527,,
13070,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622528,,
13071,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622529,,
13072,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622992,,
13073,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622993,,
13074,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622994,,
13075,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622995,,
13076,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622996,,
13077,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622997,,
13078,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622998,,
13079,Cp max following ip administration at 1 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622999,,
13080,Maximum concentration in plasma was reported at 0.5 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623000,1969.0,
13081,Maximum concentration in plasma was reported at 2 hour,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623001,1969.0,
13082,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL623002,,
13083,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL623003,,
13084,Steady state concentration was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623004,,
13085,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623005,,
13086,Partition coefficient (logD7.4),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623006,,
13087,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623007,2107.0,
13088,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623008,10000001.0,
13089,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876654,2037.0,
13090,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623009,,
13091,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623010,,
13092,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623011,948.0,
13093,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623012,160.0,
13094,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623013,,
13095,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623014,,
13096,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623015,1088.0,
13097,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623016,1088.0,
13098,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624858,1088.0,
13099,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624859,,
13100,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624860,,
13101,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624861,,
13102,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624862,,
13103,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624863,,
13104,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876655,,
13105,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624864,,
13106,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624865,,
13107,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624866,,
13108,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,BAO_0000218,Expert,,,50588,N,1,1,,CHEMBL624867,,
13109,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624868,,
13110,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628450,,
13111,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628451,,
13112,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628452,,
13113,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628453,,
13114,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628454,,
13115,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628455,,
13116,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628456,,
13117,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628457,,
13118,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL877505,,
13119,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628458,,
13120,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628459,,
13121,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628460,,
13122,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628461,,
13123,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628462,,
13124,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628463,,
13125,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL625666,,
13126,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625667,,
13127,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,Expert,,,50597,N,1,1,,CHEMBL625668,,
13128,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625669,,
13129,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625670,,
13130,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625671,,
13131,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL625672,,
13132,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL625673,,
13133,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL625674,,
13134,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL625675,,
13135,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL627637,,
13136,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL627638,,
13137,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL627639,,
13138,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL627640,,
13139,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL627641,,
13140,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL627642,,
13141,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL877506,,
13142,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627275,,
13143,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL627643,,
13144,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL631246,,
13145,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL631247,,
13146,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL629532,,
13147,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL629533,,
13148,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL629534,,
13149,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,BAO_0000218,Intermediate,,,50506,N,1,1,,CHEMBL629535,,
13150,Pharmacokinetic parameter :drug bound to plasma was reported,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625932,,
13151,compound was evaluated for drug bound in plasma,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625933,,
13152,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625934,,
13153,Bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625935,,
13154,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625936,,
13155,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625937,,
13156,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625938,,
13157,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625939,1970.0,
13158,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625940,1970.0,
13159,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874464,1970.0,
13160,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625941,1970.0,
13161,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625942,1970.0,
13162,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625943,1970.0,
13163,In vitro protein binding in human serum at 5 ug/ml,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625944,1977.0,
13164,Serum protein binding ability was measured,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625945,,
13165,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625946,,
13166,Oral bioavailability in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625947,,
13167,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625948,,
13168,Absolute oral bioavailability at an iv dose of 14 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625949,,
13169,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625950,,
13170,Oral bioavailability (dose 15 mg/kg i.v.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625951,,
13171,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625952,,
13172,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625953,,
13173,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625954,,
13174,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL882959,,
13175,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625955,,
13176,Bioavailability in ferret,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625956,,
13177,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL625957,,
13178,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625958,,
13179,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625959,,
13180,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626642,,
13181,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631330,,
13182,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631331,,
13183,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631332,,
13184,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631333,,
13185,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632018,,
13186,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632019,,
13187,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632020,,
13188,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632021,,
13189,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632022,,
13190,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632023,,
13191,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632024,,
13192,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874472,,
13193,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632025,,
13194,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632026,,
13195,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632027,,
13196,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632028,,
13197,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626430,,
13198,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626431,,
13199,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626432,,
13200,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626433,,
13201,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626434,,
13202,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627280,,
13203,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627281,,
13204,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627282,,
13205,Total body clearance was measured at given dose,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627283,,
13206,Total body clearance was measured at given dose.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627284,,
13207,Metabolic clearance from the body in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627285,,
13208,Renal clearance from the body,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627286,,
13209,Renal clearance from the body in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875477,,
13210,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627287,,
13211,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627288,,
13212,Total clearance from the body in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627289,,
13213,Clearance into cortex from rat plasma or PBS,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627290,1969.0,
13214,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627291,,
13215,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627292,,
13216,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627293,,
13217,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627294,,
13218,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875478,,
13219,Clearance was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627295,,
13220,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627296,,
13221,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL626119,,
13222,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626120,,
13223,Clearance in rat after iv dose (100 ug/kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626121,,
13224,Clearance in guinea pig,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626122,,
13225,Compound was evaluated for clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626123,,
13226,Compound was evaluated for the clearance in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623456,,
13227,Compound was evaluated for the clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623457,,
13228,Compound was tested in vivo for clearance after iv administration in the rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623458,,
13229,IV clearance determined at an iv dose of 14 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623459,,
13230,IV clearance determined at an iv dose of 15.2 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875484,,
13231,IV clearance determined at an iv dose of 15 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623460,,
13232,IV clearance determined at an peroral dose of 30 mg/kg.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623461,,
13233,IV clearance determined at an peroral dose of 30.2 mg/kg.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL623462,,
13234,IV clearance determined at an peroral dose of 30.3 mg/kg.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627386,,
13235,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627387,2113.0,
13236,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627388,2107.0,
13237,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627389,2048.0,
13238,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627390,2385.0,
13239,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627391,1969.0,
13240,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627392,,
13241,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627393,2106.0,
13242,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627394,3126.0,
13243,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627395,10000001.0,
13244,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875485,2037.0,
13245,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627396,,
13246,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627397,,
13247,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627398,948.0,
13248,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627399,10000001.0,
13249,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627400,2113.0,
13250,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627401,2107.0,
13251,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627402,2048.0,
13252,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627403,2385.0,
13253,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627404,1969.0,
13254,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623101,,
13255,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877480,2106.0,
13256,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623102,3126.0,
13257,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623103,10000001.0,
13258,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623104,2037.0,
13259,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623105,,
13260,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623106,,
13261,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623107,948.0,
13262,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623108,160.0,
13263,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623109,2113.0,
13264,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623110,2107.0,
13265,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623111,2048.0,
13266,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625060,2385.0,
13267,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625061,1969.0,
13268,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625062,,
13269,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625063,2106.0,
13270,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625064,3126.0,
13271,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625065,10000001.0,
13272,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625066,2037.0,
13273,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625067,,
13274,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625068,,
13275,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622159,948.0,
13276,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622160,160.0,
13277,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622161,2113.0,
13278,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622162,2048.0,
13279,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622163,2385.0,
13280,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622313,1969.0,
13281,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622314,,
13282,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622315,2106.0,
13283,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622316,3126.0,
13284,Normal diffusion coefficient in water for Escherichia coli,,BAO_0000218,Intermediate,,,50212,N,1,1,,CHEMBL877486,,
13285,Average max percent decrease in RVR (renal vascular resistance) was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622317,,
13286,Average max percent decrease in RVR (renal vascular resistance) was determined.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622318,,
13287,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622319,,
13288,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622320,,
13289,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622321,,
13290,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622322,,
13291,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622323,,
13292,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622324,,
13293,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622325,1088.0,
13294,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622326,1088.0,
13295,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL877487,1088.0,
13296,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622327,1088.0,
13297,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622328,1088.0,
13298,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622329,1088.0,
13299,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622330,1088.0,
13300,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622331,1088.0,
13301,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622332,1088.0,
13302,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622333,1088.0,
13303,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627658,1088.0,
13304,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630428,1088.0,
13305,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630429,1088.0,
13306,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630430,1088.0,
13307,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL630431,1088.0,
13308,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630432,1088.0,
13309,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630433,1088.0,
13310,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630434,1088.0,
13311,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629372,1088.0,
13312,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629553,1088.0,
13313,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629554,1088.0,
13314,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874447,1088.0,
13315,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629555,1088.0,
13316,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629556,1088.0,
13317,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629557,1088.0,
13318,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629558,1088.0,
13319,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629559,1088.0,
13320,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629560,1088.0,
13321,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629561,1088.0,
13322,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629562,1088.0,
13323,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629563,1088.0,
13324,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629564,1088.0,
13325,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629565,1088.0,
13326,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629566,1088.0,
13327,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629567,1088.0,
13328,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629568,1088.0,
13329,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629569,1088.0,
13330,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629570,1088.0,
13331,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629571,1088.0,
13332,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629572,,
13333,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629573,,
13334,Bioavailability (dose 20 mg/kg),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629574,,
13335,Bioavailability in dog,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629575,,
13336,Bioavailability in rat (Sprague-Dawley) (male),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL874448,,
13337,Bioavailability in monkey (dose 10 mg/kg i.d.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629576,,
13338,Bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629577,,
13339,Bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629578,,
13340,Bioavailability in dog (dose 3.0 mg/kg p.o.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629579,,
13341,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL882958,,
13342,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,BAO_0000218,Intermediate,,,50505,N,1,1,,CHEMBL629580,,
13343,Bioavailability,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629581,,
13344,Bioavailability in squirrel monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629582,,
13345,Bioavailability was evaluated in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628522,,
13346,Bioavailability was evaluated in hamster,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL625432,,
13347,Bioavailability in rat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625433,,
13348,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625434,1969.0,
13349,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625435,1969.0,
13350,Bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625436,,
13351,Bioavailability was measured in cynomolgus monkeys.,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL874588,,
13352,Bioavailability was measured in nude mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625437,,
13353,Bioavailability in ferret (dose 10 mg/kg i.d.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625438,,
13354,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625439,,
13355,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625440,,
13356,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625441,,
13357,Bioavailability in rat (dose 10 mg/kg i.d.),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625442,,
13358,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625443,,
13359,Bioavailability was determined; extremely poor,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625444,,
13360,% bioavailability in mice after oral administration of prodrug,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625445,,
13361,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625446,,
13362,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL882960,,
13363,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625447,,
13364,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625448,,
13365,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625449,,
13366,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874589,,
13367,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625450,,
13368,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625451,,
13369,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626584,,
13370,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626585,,
13371,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626586,,
13372,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626587,,
13373,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626588,,
13374,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626589,,
13375,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626590,,
13376,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626591,,
13377,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627181,,
13378,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628083,,
13379,IV clearance determined at an peroral dose of 15 mg/kg.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628084,,
13380,Mouse oral clearance was measured against Hymenolepiasis nana.,,BAO_0000218,Expert,,,50064,N,1,1,,CHEMBL628085,,
13381,Mouse oral clearance was measured against Nematospiroides dubius,,BAO_0000218,Expert,,,50545,N,1,1,,CHEMBL628086,,
13382,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628087,,
13383,Mouse oral clearance was measured against N. nana; NT is Not Tested,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628088,,
13384,Mouse oral clearance was measured against N. nana; NT is Not Tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628089,,
13385,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628090,,
13386,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628091,,
13387,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628092,,
13388,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628093,,
13389,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875607,,
13390,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625710,,
13391,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625711,,
13392,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625712,,
13393,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625713,,
13394,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625714,,
13395,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL625715,,
13396,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625716,,
13397,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625717,,
13398,Plasma clearance was determined for the compound in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625718,,
13399,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625719,,
13400,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625720,,
13401,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625721,,
13402,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625722,,
13403,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625723,,
13404,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,BAO_0000218,Intermediate,,,50545,N,1,1,,CHEMBL625724,,
13405,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,BAO_0000218,Intermediate,,,50545,N,1,1,,CHEMBL625725,,
13406,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,BAO_0000218,Intermediate,,,50545,N,1,1,,CHEMBL625726,,
13407,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,BAO_0000218,Intermediate,,,50545,N,1,1,,CHEMBL875608,,
13408,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,BAO_0000218,Intermediate,,,50545,N,1,1,,CHEMBL625727,,
13409,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625728,1088.0,
13410,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625729,,
13411,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625730,,
13412,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625731,1088.0,
13413,Urinary clearance was determined in rat at 25 mg/kg os dosage,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626417,1088.0,
13414,Urinary clearance was determined at 100 mg/kg oral dosage in human,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL626418,1088.0,
13415,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626419,1088.0,
13416,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626592,1969.0,
13417,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626593,1969.0,
13418,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626594,,
13419,Clearance rate in dogs,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625035,,
13420,Compound was measured for intrinsic clearance,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625036,,
13421,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625037,,
13422,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625038,,
13423,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625039,,
13424,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625040,,
13425,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625041,,
13426,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625042,,
13427,Partition coefficient of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874411,,
13428,Permeability,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625043,,
13429,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625044,,
13430,Partition coefficient (logD),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625045,,
13431,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625046,,
13432,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625047,,
13433,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625048,,
13434,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625049,,
13435,Calculated logarithm of partition coefficient (P) was determined,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625050,,
13436,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625051,,
13437,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL874412,,
13438,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625052,,
13439,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL625053,,
13440,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623250,,
13441,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623251,,
13442,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623252,,
13443,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623253,,
13444,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623254,,
13445,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623255,,
13446,Percent degradation of compound at a pH of 1 over a 18 hr period,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626831,,
13447,Percent degradation of compound at pH of 1 over an 18 hr period,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL877494,,
13448,Delta Logarithm of Partition Coefficient value was determined.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626832,,
13449,Delta logPoct-cyc,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626833,,
13450,Lipophilicity estimated on reversed phase TLC,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL626834,,
13451,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626835,,
13452,Delta logPoct-cyc,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626836,,
13453,Change in logarithm of partition coefficient of the compound,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626837,,
13454,Delta logD (pH 6.5),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626838,,
13455,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL626839,,
13456,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626840,,
13457,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626841,,
13458,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,BAO_0000219,Autocuration,,,22224,U,0,1,,CHEMBL626842,,
13459,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,BAO_0000219,Autocuration,,,22224,U,0,1,,CHEMBL626843,,
13460,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626844,,
13461,Amount of deuterium retained was reported after normal workup in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877495,,
13462,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626845,,
13463,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626846,,
13464,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626847,,
13465,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628677,,
13466,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628678,,
13467,Compound was subjected to electrochemical oxidation,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628679,,
13468,Compound was subjected to photochemical oxidation,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628680,,
13469,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628681,,
13470,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628682,,
13471,Oxidation of compound by methemoglobin in presence of hydroperoxide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628683,,
13472,Percent diffusion through fuzzy rat skin after 48 h of incubation,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628684,,
13473,Dissociation constant (pKa),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL877501,,
13474,Dissociation constant value of the compound; ND means not determined.,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL628685,,
13475,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628686,178.0,
13476,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628687,178.0,
13477,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628688,,
13478,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628689,,
13479,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628690,2107.0,
13480,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629363,2107.0,
13481,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629364,2106.0,
13482,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629365,2106.0,
13483,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629366,,
13484,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629367,1088.0,
13485,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629368,1988.0,
13486,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877502,1088.0,
13487,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629369,2037.0,
13488,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629370,955.0,
13489,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629371,1088.0,
13490,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626276,1088.0,
13491,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626277,1088.0,
13492,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631250,1088.0,
13493,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631251,1088.0,
13494,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631252,1088.0,
13495,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631253,1088.0,
13496,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631254,1088.0,
13497,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631255,1088.0,
13498,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631256,1088.0,
13499,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631257,1088.0,
13500,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628009,1088.0,
13501,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628010,1088.0,
13502,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628011,1088.0,
13503,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628012,1088.0,
13504,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628013,1088.0,
13505,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628014,1088.0,
13506,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628015,1088.0,
13507,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628016,1088.0,
13508,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL874461,1088.0,
13509,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628017,1088.0,
13510,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628018,1088.0,
13511,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628019,1088.0,
13512,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628020,1088.0,
13513,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628021,1088.0,
13514,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628022,1088.0,
13515,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628023,1088.0,
13516,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628024,1088.0,
13517,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628025,1088.0,
13518,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628026,1088.0,
13519,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628027,1088.0,
13520,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628028,1088.0,
13521,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628029,1088.0,
13522,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628030,1088.0,
13523,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628031,1088.0,
13524,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628032,1088.0,
13525,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628033,1088.0,
13526,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628034,1088.0,
13527,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628035,1088.0,
13528,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628036,1088.0,
13529,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874462,1088.0,
13530,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628037,,
13531,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628123,,
13532,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628124,,
13533,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628125,,
13534,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628126,,
13535,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628127,,
13536,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628128,,
13537,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628129,,
13538,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628130,,
13539,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628131,,
13540,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628132,,
13541,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628133,,
13542,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628134,,
13543,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628135,,
13544,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628136,,
13545,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628137,,
13546,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628138,,
13547,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628139,,
13548,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628140,,
13549,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628141,,
13550,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628142,,
13551,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628143,,
13552,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628144,,
13553,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628145,,
13554,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL628146,,
13555,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625355,,
13556,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625356,,
13557,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625357,,
13558,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625527,,
13559,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875473,,
13560,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625528,,
13561,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626304,,
13562,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624138,1637.0,
13563,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624139,,
13564,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624140,,
13565,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624141,,
13566,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624142,,
13567,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624143,,
13568,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624144,,
13569,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624145,,
13570,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624146,,
13571,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624147,,
13572,Calculated partition coefficient (clogP) (MacLogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL883123,,
13573,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624148,,
13574,Kinetic parameter was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874416,,
13575,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624149,,
13576,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624150,,
13577,Lipophilicity was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL624151,,
13578,Lipophilicity was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL624152,,
13579,Lipophilicity was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL622139,,
13580,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622140,,
13581,Lipophilicity was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL622141,,
13582,Lipophilicity in octanol-water,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL622142,,
13583,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622143,,
13584,Octanol-water partition coefficient was determined,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622144,,
13585,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL877473,,
13586,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622145,,
13587,Partition coefficient was determined; ND means not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622146,,
13588,Calculated partition coefficient (clogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622147,,
13589,Partition coefficient of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622148,,
13590,Permeability was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL883124,,
13591,The compound was evaluated for the partition coefficient,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622149,,
13592,Partition coefficient (logP),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622150,,
13593,The lipophilicity was reported,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL622151,,
13594,logarithm of the octanol-water partition coefficient for the compound,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL622152,,
13595,Clogp value was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL622153,,
13596,Clp at a dose of 1.5 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL877474,,
13597,Clp at a dose of 2.0 mg/kg,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622154,,
13598,"Clp, plasma clearance at a dose of 10 mg/kg",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622155,1969.0,
13599,"Clp, plasma clearance at a dose of 50 mg/kg",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622156,1969.0,
13600,Compound was tested for plasma clearance in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622157,1969.0,
13601,Compound was tested for plasma clearance in rat; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622158,1969.0,
13602,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622807,,
13603,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL622808,,
13604,Plasma clearance by iv administration at a dose 0.003 ug/mL,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622809,,
13605,Plasma clearance determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622810,,
13606,Plasma clearance after iv administration at 3 mg/kg in hamster,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL876653,,
13607,Plasma clearance after iv administration at 4 mg/kg in hamster,,BAO_0000218,Intermediate,,,100712,N,1,1,,CHEMBL622811,,
13608,Rate of clearance in rat was determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622986,,
13609,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622987,1969.0,
13610,Total plasma clearance after iv dose of 5.10 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622988,1969.0,
13611,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622989,1969.0,
13612,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622990,1969.0,
13613,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622991,1969.0,
13614,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622227,1969.0,
13615,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622228,1969.0,
13616,Clpl value in rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622229,,
13617,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL622230,,
13618,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622231,,
13619,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,BAO_0000218,Intermediate,,,100710,N,1,1,,CHEMBL622232,,
13620,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622233,,
13621,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622234,,
13622,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622235,,
13623,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622236,,
13624,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622237,,
13625,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL877482,,
13626,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622238,,
13627,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622239,,
13628,Cmax was calculated as maximum concentration reached in the blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622240,178.0,
13629,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL622241,178.0,
13630,Cmax was determine after peroral administration at 10 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631013,,
13631,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,Intermediate,,,50797,N,1,1,,CHEMBL631014,,
13632,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631015,,
13633,Cmax was determine after peroral administration at 160 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631016,,
13634,Cmax was determine after peroral administration at 20 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631017,,
13635,Cmax was determine after peroral administration at 50 mpk in Rat,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631018,,
13636,Cmax was determined,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL631019,,
13637,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL875761,955.0,
13638,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631020,955.0,
13639,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631669,955.0,
13640,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631670,955.0,
13641,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631671,2435.0,
13642,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631672,178.0,
13643,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631673,178.0,
13644,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631856,178.0,
13645,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631857,178.0,
13646,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631858,178.0,
13647,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631859,178.0,
13648,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631860,178.0,
13649,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631861,178.0,
13650,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631862,178.0,
13651,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631863,178.0,
13652,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631864,178.0,
13653,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631865,178.0,
13654,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631866,178.0,
13655,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629360,178.0,
13656,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629361,178.0,
13657,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629362,178.0,
13658,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630740,178.0,
13659,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630741,178.0,
13660,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630742,178.0,
13661,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630743,,
13662,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630744,,
13663,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630745,,
13664,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630746,,
13665,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630747,,
13666,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630748,,
13667,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632056,,
13668,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632057,,
13669,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632058,,
13670,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632059,,
13671,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632060,,
13672,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632061,,
13673,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629207,,
13674,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629208,,
13675,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629209,,
13676,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629210,,
13677,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629211,,
13678,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629212,,
13679,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629213,,
13680,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629214,1088.0,
13681,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629215,1088.0,
13682,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL635154,1088.0,
13683,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629216,,
13684,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629217,,
13685,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629218,,
13686,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629219,,
13687,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629220,,
13688,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629221,,
13689,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631127,,
13690,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631128,,
13691,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631129,,
13692,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631130,,
13693,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631131,,
13694,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631132,,
13695,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631133,,
13696,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631134,,
13697,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875120,,
13698,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631135,,
13699,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631136,,
13700,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631137,,
13701,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631138,,
13702,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631139,,
13703,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631140,,
13704,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631141,,
13705,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631142,,
13706,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631143,,
13707,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631144,,
13708,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631145,,
13709,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631146,,
13710,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631147,,
13711,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631148,,
13712,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631149,,
13713,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631150,,
13714,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631151,,
13715,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631152,,
13716,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631443,,
13717,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631444,,
13718,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631445,,
13719,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631446,,
13720,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631447,,
13721,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631448,,
13722,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631449,,
13723,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL631450,,
13724,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629724,,
13725,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629725,14.0,
13726,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629726,14.0,
13727,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629727,2106.0,
13728,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630404,2106.0,
13729,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630405,2106.0,
13730,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630406,2106.0,
13731,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630407,945.0,
13732,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630573,945.0,
13733,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630574,945.0,
13734,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630575,945.0,
13735,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630576,,
13736,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630577,,
13737,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630578,,
13738,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630579,,
13739,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630580,2113.0,
13740,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630581,2113.0,
13741,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630582,2113.0,
13742,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630583,,
13743,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630584,,
13744,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630585,,
13745,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630586,,
13746,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630587,,
13747,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630588,,
13748,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630589,,
13749,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630590,,
13750,Removal of 238-Plutonium(IV) in feces at 24 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630591,1988.0,
13751,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630592,1988.0,
13752,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630593,,
13753,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630594,,
13754,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630595,1088.0,
13755,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630596,1088.0,
13756,Removal of 238-Plutonium(IV) in urine after 0-24 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630597,1088.0,
13757,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630598,1088.0,
13758,Removal of 238-Plutonium(IV) in urine after 0-4 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630599,1088.0,
13759,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630600,1088.0,
13760,Removal of 238-Plutonium(IV) in urine after 4-24 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630601,1088.0,
13761,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630602,1088.0,
13762,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630603,1088.0,
13763,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630604,1088.0,
13764,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624869,178.0,
13765,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624870,178.0,
13766,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623189,178.0,
13767,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623190,178.0,
13768,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623191,178.0,
13769,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623192,,
13770,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623193,,
13771,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623194,,
13772,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623195,,
13773,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623196,,
13774,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623197,,
13775,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623198,,
13776,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623199,,
13777,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623200,2385.0,
13778,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623201,2385.0,
13779,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623202,2385.0,
13780,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623203,2385.0,
13781,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623204,2385.0,
13782,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623205,2385.0,
13783,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623206,2385.0,
13784,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623207,2385.0,
13785,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623208,2385.0,
13786,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623209,2385.0,
13787,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623210,2385.0,
13788,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623211,,
13789,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623212,995.0,
13790,Tested in vitro for intrinsic activity relative to quinpirole,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623213,,
13791,"Relative ion enhancement, determined in pulsed ultrafiltration",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623214,,
13792,% ionization at the pH 7.4 at 37 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623215,,
13793,Percentage ionization was measured,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623216,,
13794,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,BAO_0000218,Intermediate,,,50591,N,1,1,,CHEMBL623217,,
13795,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623218,,
13796,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623913,,
13797,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL623914,,
13798,Compound was evaluated for the partition coefficient in octanol/water,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL623915,,
13799,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL624080,,
13800,Equilibrium constant measured by the pulse radiolysis at pH 7,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL624081,,
13801,In vitro hydrolytic rate constant determined in human blood,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL624082,,
13802,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625054,,
13803,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL877485,,
13804,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625055,,
13805,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625056,,
13806,In vitro oxidation of compound in presence of human plasma,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625057,,
13807,In vitro oxidation of compound in presence of hydrogen peroxide,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625058,,
13808,In vitro oxidation of compound in presence of mouse brain homogenate,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625059,,
13809,In vitro oxidation of compound in presence of mouse liver homogenate,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629536,,
13810,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629537,,
13811,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629538,,
13812,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629539,,
13813,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874445,,
13814,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629540,,
13815,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629541,,
13816,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629542,,
13817,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630243,,
13818,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630244,,
13819,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630245,,
13820,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630246,,
13821,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630247,,
13822,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630248,,
13823,Biodistribution in rat blood at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630249,178.0,
13824,Biodistribution in rat blood at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630250,178.0,
13825,Biodistribution in rat blood at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630251,178.0,
13826,Biodistribution in rat blood at 3 hr after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630252,178.0,
13827,Biodistribution in rat blood at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630408,178.0,
13828,Biodistribution in rat cerebellum at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630409,2037.0,
13829,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874446,2037.0,
13830,Biodistribution in rat cerebellum at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630410,2037.0,
13831,Biodistribution in rat cerebellum at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630411,2037.0,
13832,Biodistribution in rat cerebellum at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630412,2037.0,
13833,Biodistribution in rat cerebellum at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630413,2037.0,
13834,Biodistribution in rat cerebellum at 3 hr after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630414,2037.0,
13835,Biodistribution in rat cerebellum at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630415,2037.0,
13836,Biodistribution in rat cortex at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630416,,
13837,Biodistribution in rat cortex at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630417,,
13838,Biodistribution in rat cortex at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630418,,
13839,Biodistribution in rat cortex at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630419,,
13840,Biodistribution in rat cortex at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630420,,
13841,Biodistribution in rat cortex at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630421,,
13842,Biodistribution in rat cortex at 3 hr after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630422,,
13843,Biodistribution in rat cortex at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630423,,
13844,Biodistribution in rat heart at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630424,948.0,
13845,Biodistribution in rat heart at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630425,948.0,
13846,Biodistribution in rat heart at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629462,948.0,
13847,Biodistribution in rat heart at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630426,948.0,
13848,Biodistribution in rat heart at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630427,948.0,
13849,Biodistribution in rat heart at 3 hr after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625877,948.0,
13850,Biodistribution in rat heart at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625878,948.0,
13851,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625879,10000000.0,
13852,Biodistribution in rat hippocampus at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625880,10000000.0,
13853,Biodistribution in rat hippocampus at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625881,10000000.0,
13854,Biodistribution in rat hippocampus at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625882,10000000.0,
13855,Biodistribution in rat hippocampus at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625883,10000000.0,
13856,Biodistribution in rat kidney at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625884,2113.0,
13857,Biodistribution in rat kidney at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625885,2113.0,
13858,Biodistribution in rat kidney at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628649,2113.0,
13859,Biodistribution in rat kidney at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628650,2113.0,
13860,Biodistribution in rat kidney at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628651,2113.0,
13861,Biodistribution in rat kidney at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628652,2113.0,
13862,Biodistribution in rat kidney at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628653,2113.0,
13863,Biodistribution in rat liver at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628654,2107.0,
13864,Biodistribution in rat liver at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628655,2107.0,
13865,Biodistribution in rat liver at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625238,2107.0,
13866,Biodistribution in rat liver at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625239,2107.0,
13867,Biodistribution in rat liver at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625240,2107.0,
13868,Biodistribution in rat liver at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625241,2107.0,
13869,Biodistribution in rat liver at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625242,2107.0,
13870,Biodistribution in rat lung at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874587,2048.0,
13871,Biodistribution in rat lung at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625405,2048.0,
13872,Biodistribution in rat lung at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625406,2048.0,
13873,Biodistribution in rat lung at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625407,2048.0,
13874,Biodistribution in rat lung at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625408,2048.0,
13875,Biodistribution in rat lung at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625409,2048.0,
13876,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625410,1515.0,
13877,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625411,1515.0,
13878,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625412,1515.0,
13879,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625413,1515.0,
13880,Percent of maximal contractile response to compound in rat thoracic aorta strips v,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625414,1515.0,
13881,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625415,1515.0,
13882,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625416,1515.0,
13883,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625417,1088.0,
13884,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625418,1988.0,
13885,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625419,1088.0,
13886,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625420,,
13887,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626996,,
13888,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626997,1988.0,
13889,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626998,1088.0,
13890,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626999,,
13891,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627000,,
13892,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627001,,
13893,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627002,,
13894,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627003,,
13895,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627004,1088.0,
13896,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627005,1088.0,
13897,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL874594,1088.0,
13898,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627006,1088.0,
13899,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627007,1088.0,
13900,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627884,1088.0,
13901,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627885,1088.0,
13902,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627886,1088.0,
13903,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627887,1088.0,
13904,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627888,1088.0,
13905,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628057,1088.0,
13906,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627405,1088.0,
13907,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627406,1088.0,
13908,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627407,1088.0,
13909,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627408,1088.0,
13910,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627409,1088.0,
13911,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875486,1088.0,
13912,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627410,1088.0,
13913,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627411,1088.0,
13914,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627412,1088.0,
13915,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627413,1088.0,
13916,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627414,1088.0,
13917,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627415,1088.0,
13918,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627416,1088.0,
13919,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627417,1088.0,
13920,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627418,1088.0,
13921,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627419,1088.0,
13922,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627320,1088.0,
13923,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627321,1088.0,
13924,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627322,2113.0,
13925,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627323,2113.0,
13926,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627491,2113.0,
13927,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627492,2113.0,
13928,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627493,2113.0,
13929,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627494,2107.0,
13930,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627495,2107.0,
13931,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627496,2107.0,
13932,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627497,2107.0,
13933,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627498,2107.0,
13934,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627499,2048.0,
13935,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627500,2048.0,
13936,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627501,2048.0,
13937,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625616,2048.0,
13938,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625617,2048.0,
13939,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625618,2385.0,
13940,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625619,2385.0,
13941,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625620,2385.0,
13942,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625621,2385.0,
13943,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625622,2385.0,
13944,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625788,2106.0,
13945,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625789,2106.0,
13946,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625790,2106.0,
13947,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625791,2106.0,
13948,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622334,2106.0,
13949,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622335,2046.0,
13950,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622336,2046.0,
13951,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622337,2046.0,
13952,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622338,2046.0,
13953,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622339,2046.0,
13954,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624153,,
13955,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628430,,
13956,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628431,,
13957,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628432,,
13958,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628433,,
13959,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628434,2106.0,
13960,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626789,2106.0,
13961,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626790,2106.0,
13962,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626791,2106.0,
13963,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626792,2106.0,
13964,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626793,2106.0,
13965,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627436,,
13966,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627437,,
13967,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627438,,
13968,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627439,,
13969,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627440,,
13970,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627602,,
13971,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627603,,
13972,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627604,,
13973,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627605,,
13974,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627606,,
13975,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627607,,
13976,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627608,,
13977,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627609,,
13978,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627610,,
13979,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627611,,
13980,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627612,,
13981,Octanol:water partition coefficient is evaluated,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL627613,,
13982,Partition coefficient in 1-octanol/water system,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL627614,,
13983,Partition coefficient in 1-octanol/water system measured using radio active compounds,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL627615,,
13984,Partition coefficient in octanol/water system was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL627616,,
13985,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL627617,,
13986,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627618,,
13987,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627619,,
13988,Pseudo-first-order rate constant of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627620,,
13989,Pseudo-first-order rate constant with 1-min time point,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627621,,
13990,Pseudo-first-order rate constant without 1-min time point,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627622,,
13991,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627623,,
13992,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627624,,
13993,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627625,,
13994,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628523,,
13995,The alkaline hydrolysis second order rate constant(K OH) of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628524,,
13996,The efflux rate constant of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628525,,
13997,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625732,,
13998,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625733,,
13999,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625734,,
14000,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625913,,
14001,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625914,,
14002,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625915,,
14003,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625916,,
14004,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625917,,
14005,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625918,,
14006,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625919,,
14007,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625920,,
14008,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874453,,
14009,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625921,,
14010,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625922,,
14011,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625923,,
14012,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625924,,
14013,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625925,,
14014,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625926,,
14015,Biodistribution in rat lung at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627704,2048.0,
14016,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627705,,
14017,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627706,,
14018,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627707,,
14019,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627708,,
14020,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628361,,
14021,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628362,,
14022,Biodistribution in rat striatum at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628363,2435.0,
14023,Biodistribution in rat striatum at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628364,2435.0,
14024,Biodistribution in rat striatum at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628365,2435.0,
14025,Biodistribution in rat striatum at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874454,2435.0,
14026,Biodistribution in rat striatum at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628531,2435.0,
14027,Biodistribution in rat striatum at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628532,2435.0,
14028,Biodistribution in rat striatum at 3 hr after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628533,2435.0,
14029,Biodistribution in rat striatum at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628534,2435.0,
14030,Biodistribution in rat thyroid at 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628535,2046.0,
14031,Biodistribution in rat thyroid at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628536,2046.0,
14032,Biodistribution in rat thyroid at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628537,2046.0,
14033,Biodistribution in rat thyroid at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628538,2046.0,
14034,Biodistribution in rat thyroid at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628539,2046.0,
14035,Biodistribution in rat thyroid at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630297,2046.0,
14036,Biodistribution in rat thyroid at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630298,2046.0,
14037,Biodistribution in rest of brain of rat 120 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630299,955.0,
14038,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628094,955.0,
14039,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628095,955.0,
14040,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874648,955.0,
14041,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628096,955.0,
14042,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628097,955.0,
14043,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628098,955.0,
14044,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628099,,
14045,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628100,,
14046,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628101,,
14047,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628102,,
14048,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628103,,
14049,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628104,,
14050,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628105,,
14051,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628106,,
14052,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628107,1088.0,
14053,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628108,1088.0,
14054,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628109,1088.0,
14055,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL625299,1088.0,
14056,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625300,1088.0,
14057,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625301,1088.0,
14058,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625302,1088.0,
14059,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874649,1088.0,
14060,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625303,,
14061,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625463,,
14062,In vitro metabolism in human liver microsomes,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625464,2107.0,
14063,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL625465,,
14064,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625466,1088.0,
14065,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625467,1088.0,
14066,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625468,1088.0,
14067,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625469,1088.0,
14068,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625470,1088.0,
14069,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632418,1088.0,
14070,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627250,1088.0,
14071,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627251,1088.0,
14072,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627252,1088.0,
14073,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627253,1088.0,
14074,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627254,1088.0,
14075,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875471,1088.0,
14076,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627255,1088.0,
14077,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627256,1088.0,
14078,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627257,1088.0,
14079,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627258,1088.0,
14080,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627259,1088.0,
14081,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627260,1088.0,
14082,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623256,1088.0,
14083,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874413,1088.0,
14084,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623257,1088.0,
14085,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623258,1088.0,
14086,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623259,1088.0,
14087,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623260,1088.0,
14088,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623261,1088.0,
14089,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623262,1088.0,
14090,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623263,1088.0,
14091,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623264,1088.0,
14092,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623265,1088.0,
14093,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623266,1088.0,
14094,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623267,1088.0,
14095,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623268,1088.0,
14096,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623269,1088.0,
14097,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623270,1088.0,
14098,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623271,1088.0,
14099,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623272,1088.0,
14100,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623273,1088.0,
14101,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623274,1088.0,
14102,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874414,1088.0,
14103,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623275,1088.0,
14104,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629150,1088.0,
14105,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623276,1088.0,
14106,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623277,1088.0,
14107,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623112,1088.0,
14108,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623113,1088.0,
14109,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623800,1088.0,
14110,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623801,1088.0,
14111,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623802,2106.0,
14112,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623803,995.0,
14113,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623970,995.0,
14114,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623971,995.0,
14115,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623972,178.0,
14116,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623973,178.0,
14117,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623974,178.0,
14118,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623975,178.0,
14119,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623976,955.0,
14120,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623977,955.0,
14121,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623978,955.0,
14122,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623979,955.0,
14123,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623980,,
14124,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623981,,
14125,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626278,,
14126,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626279,,
14127,Biodistribution in mice bladder plus excreted urine was determined,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626280,,
14128,"Percentage biodistribution in mouse blood, 10 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626281,,
14129,"Percentage biodistribution in mouse blood, 30 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626282,,
14130,"Percentage biodistribution in mouse blood, 5 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626283,,
14131,"Percentage biodistribution in mouse blood, 60 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626284,,
14132,"Percentage biodistribution in mouse brain, 10 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626285,955.0,
14133,"Percentage biodistribution in mouse brain, 30 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626286,955.0,
14134,"Percentage biodistribution in mouse brain, 5 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626287,955.0,
14135,"Percentage biodistribution in mouse brain, 60 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626288,955.0,
14136,"Percentage biodistribution in mouse heart, 10 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626289,,
14137,"Percentage biodistribution in mouse heart, 30 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626290,,
14138,"Percentage biodistribution in mouse heart, 5 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626291,,
14139,"Percentage biodistribution in mouse heart, 60 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL839888,,
14140,"Percentage biodistribution in mouse intestine, 10 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626292,160.0,
14141,"Percentage biodistribution in mouse intestine, 30 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626293,160.0,
14142,"Percentage biodistribution in mouse intestine, 5 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626294,160.0,
14143,"Percentage biodistribution in mouse intestine, 60 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL626295,160.0,
14144,"Percentage biodistribution in mouse liver, 10 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627659,2107.0,
14145,"Percentage biodistribution in mouse liver, 30 minutes of post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627660,2107.0,
14146,"Percentage biodistribution in mouse liver, 5 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627661,2107.0,
14147,Biodistribution in mice liver at 60 minutes of post injection,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627662,2107.0,
14148,Biodistribution in mice lungs at 10 min of post injection,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627663,2048.0,
14149,"Percentage biodistribution in mouse lung, 30 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627664,,
14150,"Percentage biodistribution in mousee lung, 5 minutes post injection",,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627665,,
14151,Biodistribution in mice lungs at 60 min of post injection,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627666,2048.0,
14152,Percentage biodistribution in mouse spleen,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627667,2106.0,
14153,Percentage biodistribution in mouse stomach,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627668,945.0,
14154,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL627669,1088.0,
14155,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627670,1255.0,
14156,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627671,178.0,
14157,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627672,1474.0,
14158,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627673,,
14159,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627674,2113.0,
14160,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627675,2107.0,
14161,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627676,2048.0,
14162,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627677,2385.0,
14163,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627678,,
14164,Affinity for protein binding expressed as association constant in fresh rat serum,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627679,1977.0,
14165,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627680,,
14166,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627681,,
14167,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627682,,
14168,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627683,,
14169,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627684,,
14170,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874441,,
14171,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627685,,
14172,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627686,,
14173,Apparent rate constant Koff for inactivation of dTMP synthase.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627687,,
14174,The irreversible inhibitor activity by second order rate equation.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627688,,
14175,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628038,,
14176,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628039,,
14177,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628040,,
14178,Dissociation rate calculated from the first-order equation using t1/2 value,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628041,,
14179,The compound was tested for Binding constant against DNA,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630226,,
14180,First order rate constant for cyclization of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628042,,
14181,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625232,,
14182,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625233,,
14183,Hydrolysis rate constant was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625979,,
14184,Observed first order rate constant,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625980,,
14185,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625981,,
14186,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625982,,
14187,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625983,,
14188,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625984,,
14189,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625985,,
14190,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625986,,
14191,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625987,,
14192,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625988,,
14193,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625989,,
14194,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625990,,
14195,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625991,,
14196,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625992,,
14197,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625993,,
14198,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631973,,
14199,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632143,,
14200,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632144,,
14201,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632145,,
14202,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632146,,
14203,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632147,,
14204,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632148,,
14205,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632149,,
14206,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632150,,
14207,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632151,,
14208,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL632152,,
14209,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL632153,,
14210,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL632154,,
14211,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL632155,,
14212,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL632156,,
14213,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL632157,,
14214,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL632158,,
14215,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL632159,,
14216,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL626305,,
14217,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL626306,,
14218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL626307,,
14219,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL626308,,
14220,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL626479,,
14221,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,BAO_0000218,Intermediate,,,50602,N,1,1,,CHEMBL626480,,
14222,Calculated partition coefficient (clogP) (MlogP),,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626481,,
14223,Equipotent potent ratio relative to carbachol (nicotinic activity),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626482,,
14224,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626483,,
14225,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626484,,
14226,Solubility at pH 7.4 in micro g/mL;NA denotes available,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626485,,
14227,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626486,,
14228,Solubility at pH 7.4 in ug/mL;NA denotes not available,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626487,,
14229,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL626488,1969.0,
14230,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626489,1977.0,
14231,Area under the MAP curve measured over 5 min; ND means Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626490,,
14232,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL626491,,
14233,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL626492,,
14234,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626493,,
14235,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626494,,
14236,Half life after oral tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626495,,
14237,Half life was determined in plasma of rat; NT indicates not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626496,1969.0,
14238,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626497,,
14239,Oral bioavailability after oral tested,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL626498,,
14240,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626499,,
14241,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626500,,
14242,half life was determined in plasma of rat; NT indicates not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626501,1969.0,
14243,half life was determined in plasma of rat; NT means not tested,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626502,1969.0,
14244,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626503,,
14245,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626504,,
14246,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626505,,
14247,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626506,,
14248,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626507,,
14249,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626508,,
14250,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626509,,
14251,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875480,,
14252,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626510,,
14253,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626511,,
14254,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626512,,
14255,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628208,,
14256,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628209,,
14257,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628210,,
14258,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628211,,
14259,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628212,,
14260,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628213,,
14261,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628214,1088.0,
14262,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628215,1088.0,
14263,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628216,1088.0,
14264,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626595,1088.0,
14265,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626596,1088.0,
14266,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626597,1088.0,
14267,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626598,1088.0,
14268,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622242,1088.0,
14269,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622243,1088.0,
14270,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622244,1088.0,
14271,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622245,1088.0,
14272,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622246,1088.0,
14273,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622247,1088.0,
14274,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622248,1088.0,
14275,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877483,1088.0,
14276,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL622249,1088.0,
14277,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622250,1088.0,
14278,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622251,1088.0,
14279,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622252,1088.0,
14280,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622253,1088.0,
14281,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622254,1088.0,
14282,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622255,1088.0,
14283,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622256,1088.0,
14284,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622257,1088.0,
14285,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622258,1088.0,
14286,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622259,1088.0,
14287,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622927,1088.0,
14288,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622928,1088.0,
14289,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL622929,1088.0,
14290,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623182,1088.0,
14291,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL623183,1088.0,
14292,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623184,1088.0,
14293,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623185,1088.0,
14294,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877484,1088.0,
14295,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627274,1088.0,
14296,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623186,1088.0,
14297,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623187,1088.0,
14298,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL623188,1088.0,
14299,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628055,1088.0,
14300,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628056,1088.0,
14301,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628200,1088.0,
14302,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628201,1088.0,
14303,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628202,1088.0,
14304,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628203,1088.0,
14305,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628204,1088.0,
14306,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628205,1088.0,
14307,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628206,1088.0,
14308,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL628207,2367.0,
14309,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627220,2367.0,
14310,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627221,2385.0,
14311,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627222,2367.0,
14312,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627223,,
14313,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632062,2385.0,
14314,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632063,2106.0,
14315,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632064,1255.0,
14316,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632065,178.0,
14317,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632066,1474.0,
14318,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL632067,,
14319,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629188,2113.0,
14320,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629189,2107.0,
14321,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629190,2048.0,
14322,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629191,2385.0,
14323,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629192,2367.0,
14324,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629193,2385.0,
14325,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629194,2367.0,
14326,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629195,,
14327,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629373,2385.0,
14328,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629374,2106.0,
14329,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629375,2367.0,
14330,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629376,1255.0,
14331,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629377,178.0,
14332,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629378,1474.0,
14333,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629379,,
14334,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629151,2113.0,
14335,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629152,2107.0,
14336,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629153,2048.0,
14337,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629154,2385.0,
14338,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629155,2367.0,
14339,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629156,2367.0,
14340,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629157,2385.0,
14341,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629158,2367.0,
14342,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629159,,
14343,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629160,2385.0,
14344,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629161,2106.0,
14345,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629162,1255.0,
14346,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629163,178.0,
14347,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629164,1474.0,
14348,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629165,,
14349,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629166,2107.0,
14350,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629167,2048.0,
14351,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629168,2385.0,
14352,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629169,,
14353,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629170,,
14354,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631153,,
14355,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875121,,
14356,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631154,,
14357,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631155,,
14358,Hydrolysis rate constant was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631156,,
14359,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631157,,
14360,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631158,,
14361,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631159,,
14362,Observed second order rate constant,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631160,,
14363,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631161,,
14364,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631162,,
14365,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630313,,
14366,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630314,,
14367,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630315,,
14368,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630316,,
14369,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630986,,
14370,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630987,,
14371,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630988,,
14372,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630989,,
14373,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630990,,
14374,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630991,,
14375,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630992,,
14376,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630993,,
14377,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630994,,
14378,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630995,,
14379,Association constant for compound at 31 degree C was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629252,,
14380,Calculated antagonist equilibrium dissociation constant of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629253,,
14381,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629944,,
14382,Dissociation constants vs LTE4 on guinea pig trachea,,BAO_0000218,Intermediate,,,50512,N,1,1,,CHEMBL629945,3126.0,
14383,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629946,,
14384,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629947,,
14385,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629948,,
14386,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL856024,,
14387,Affinity constant KD value was derived from TMP,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629949,,
14388,Apparent dissociation (binding) rate constant was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629950,,
14389,Dissociation constant (KD) of the compound,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL630127,,
14390,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL630128,,
14391,Dissociation constant from ESR titration experiments,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL630129,,
14392,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630130,,
14393,Dissociation constant was evaluated.,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL875234,,
14394,Dissociation constant was reported,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL630131,,
14395,Dissociation constant was determined in rat pituitary cells.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630132,,
14396,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630133,,
14397,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630134,,
14398,Equilibrium dissociation constant of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630135,,
14399,Equilibrium dissociation constant was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630136,,
14400,Kinetic constant KD was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630137,,
14401,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630138,,
14402,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630139,,
14403,Rate constant for hydrolysis in aqueous acetone.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630140,,
14404,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875235,,
14405,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876439,,
14406,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630605,,
14407,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630606,,
14408,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630607,,
14409,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630608,,
14410,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630609,,
14411,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630610,,
14412,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630611,,
14413,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629552,,
14414,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629733,,
14415,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629734,,
14416,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629735,,
14417,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629736,,
14418,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629737,,
14419,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629738,,
14420,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629739,,
14421,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629740,,
14422,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629741,,
14423,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629742,,
14424,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629743,,
14425,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629744,,
14426,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629745,,
14427,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629746,,
14428,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629747,,
14429,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629748,,
14430,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629749,,
14431,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629750,,
14432,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629751,,
14433,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629752,,
14434,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629753,,
14435,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629754,,
14436,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629755,,
14437,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629756,,
14438,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629757,,
14439,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629758,,
14440,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629759,,
14441,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629760,,
14442,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876443,,
14443,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629761,,
14444,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629762,,
14445,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629763,,
14446,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629764,,
14447,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629765,,
14448,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629766,,
14449,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629767,,
14450,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629768,,
14451,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629769,,
14452,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629770,,
14453,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL629771,,
14454,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629772,,
14455,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL629773,,
14456,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625455,,
14457,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625456,,
14458,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL625457,,
14459,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625458,1088.0,
14460,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625459,1088.0,
14461,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875483,1088.0,
14462,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL634779,1088.0,
14463,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625460,1088.0,
14464,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626117,1088.0,
14465,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626118,1088.0,
14466,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628342,1088.0,
14467,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628343,1088.0,
14468,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628344,1088.0,
14469,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628345,1088.0,
14470,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628346,1088.0,
14471,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628347,1088.0,
14472,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628348,1088.0,
14473,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628349,1088.0,
14474,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875611,1088.0,
14475,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628350,1088.0,
14476,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628351,1088.0,
14477,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628352,1088.0,
14478,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628353,1088.0,
14479,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628354,1088.0,
14480,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626667,1088.0,
14481,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626668,1088.0,
14482,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626669,1088.0,
14483,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626670,1088.0,
14484,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626671,1088.0,
14485,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626672,1088.0,
14486,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626673,1088.0,
14487,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626674,1088.0,
14488,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626675,1088.0,
14489,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626676,1088.0,
14490,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626677,1088.0,
14491,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626678,1088.0,
14492,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626679,1088.0,
14493,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875612,1088.0,
14494,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626680,1088.0,
14495,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626681,1088.0,
14496,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626682,1088.0,
14497,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626683,1088.0,
14498,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626684,1088.0,
14499,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626685,1088.0,
14500,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626686,1088.0,
14501,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626687,1088.0,
14502,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624978,1088.0,
14503,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624979,1088.0,
14504,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624980,1088.0,
14505,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL624981,1088.0,
14506,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL624982,1088.0,
14507,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627564,2367.0,
14508,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627565,2367.0,
14509,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627566,,
14510,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627567,2385.0,
14511,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627568,2106.0,
14512,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627569,2113.0,
14513,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627570,1255.0,
14514,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627571,178.0,
14515,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627572,1474.0,
14516,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627573,,
14517,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627574,2113.0,
14518,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627575,2107.0,
14519,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627576,2048.0,
14520,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627577,2385.0,
14521,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627578,2367.0,
14522,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627579,2367.0,
14523,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627580,2385.0,
14524,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627581,2367.0,
14525,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627582,,
14526,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627583,2385.0,
14527,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627584,2106.0,
14528,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627585,2367.0,
14529,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL627586,2385.0,
14530,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627587,,
14531,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627588,,
14532,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628250,,
14533,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628251,,
14534,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628252,10000000.0,
14535,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628253,10000000.0,
14536,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628254,1898.0,
14537,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL877493,1898.0,
14538,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628255,,
14539,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628256,,
14540,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628257,10000000.0,
14541,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628258,1898.0,
14542,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628259,,
14543,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628429,,
14544,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626862,10000000.0,
14545,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626863,1898.0,
14546,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625886,2037.0,
14547,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625887,2037.0,
14548,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625888,,
14549,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625889,,
14550,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625890,10000000.0,
14551,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625891,10000000.0,
14552,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625892,1898.0,
14553,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625893,1898.0,
14554,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625894,2037.0,
14555,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625895,,
14556,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625896,,
14557,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625897,,
14558,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625898,,
14559,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL625899,,
14560,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL626124,,
14561,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,BAO_0000218,Intermediate,,,50212,N,1,1,,CHEMBL628500,,
14562,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL857856,,
14563,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628501,,
14564,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628502,,
14565,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628503,,
14566,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628504,,
14567,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628505,,
14568,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL874452,,
14569,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628506,,
14570,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628507,,
14571,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628508,,
14572,Michaelis constant (KM) was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628509,,
14573,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628510,,
14574,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628511,,
14575,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628512,,
14576,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628513,,
14577,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628514,,
14578,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628515,,
14579,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628516,,
14580,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628517,,
14581,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628518,,
14582,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628519,,
14583,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628520,,
14584,Binding constant was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628521,,
14585,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630443,,
14586,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630444,,
14587,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL857732,,
14588,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL630445,,
14589,Catalytic rate constant of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630446,,
14590,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630447,,
14591,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630448,,
14592,Catalytic rate constant against phospholipase A2 was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630449,,
14593,"Compound was evaluated for catalytic constant, Kcat",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630450,,
14594,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630451,,
14595,Kcat calculated from 0.693/T1/2,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630452,,
14596,Kcat was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630453,,
14597,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630454,,
14598,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630455,,
14599,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631487,,
14600,Kcat value was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631488,,
14601,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL876440,,
14602,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631489,,
14603,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL857742,,
14604,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631490,,
14605,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631491,,
14606,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631492,,
14607,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631493,,
14608,Kinetic parameter for rate of conversion to PABA was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631494,,
14609,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631495,,
14610,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631496,1988.0,
14611,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631497,1088.0,
14612,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631498,1088.0,
14613,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629776,1088.0,
14614,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629777,1088.0,
14615,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629778,1088.0,
14616,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630456,,
14617,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630457,,
14618,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630458,,
14619,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630459,,
14620,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630460,,
14621,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876550,,
14622,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630461,,
14623,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630462,,
14624,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630463,,
14625,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630464,,
14626,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630465,,
14627,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630466,,
14628,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630467,,
14629,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630633,,
14630,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630634,,
14631,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630635,,
14632,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630636,,
14633,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630637,,
14634,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630638,1988.0,
14635,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630639,1988.0,
14636,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630640,1988.0,
14637,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL876551,1988.0,
14638,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630641,1088.0,
14639,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630642,1088.0,
14640,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630643,1088.0,
14641,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630644,1088.0,
14642,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL630645,1088.0,
14643,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625599,1988.0,
14644,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625600,1988.0,
14645,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625601,1988.0,
14646,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL625602,1988.0,
14647,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627470,1088.0,
14648,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627471,1088.0,
14649,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627472,1088.0,
14650,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627473,1088.0,
14651,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL627474,1088.0,
14652,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627475,178.0,
14653,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL627476,178.0,
14654,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627477,1088.0,
14655,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627478,1088.0,
14656,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627479,1088.0,
14657,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627480,1088.0,
14658,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627481,1088.0,
14659,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627482,1088.0,
14660,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL627483,1088.0,
14661,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL875636,1088.0,
14662,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625764,1088.0,
14663,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625765,1088.0,
14664,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625766,1088.0,
14665,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625767,1088.0,
14666,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625768,1088.0,
14667,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625769,1088.0,
14668,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625770,1088.0,
14669,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625771,1088.0,
14670,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625772,1088.0,
14671,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50588,N,1,1,,CHEMBL625773,1088.0,
14672,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625774,1088.0,
14673,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625775,1088.0,
14674,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625776,1088.0,
14675,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625777,1088.0,
14676,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625778,1088.0,
14677,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625779,1088.0,
14678,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625780,1088.0,
14679,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625781,1088.0,
14680,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875637,1088.0,
14681,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626473,1088.0,
14682,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626474,1088.0,
14683,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626475,1088.0,
14684,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626476,1088.0,
14685,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL634397,1088.0,
14686,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL626477,1088.0,
14687,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631069,1088.0,
14688,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631070,1088.0,
14689,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631071,1088.0,
14690,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631072,1088.0,
14691,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631073,1088.0,
14692,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631074,1088.0,
14693,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631075,1088.0,
14694,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631725,1088.0,
14695,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631726,1088.0,
14696,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631727,1088.0,
14697,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631728,1088.0,
14698,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631729,1088.0,
14699,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631730,1088.0,
14700,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631731,1088.0,
14701,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631910,1088.0,
14702,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631911,10000000.0,
14703,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631912,1898.0,
14704,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631913,1898.0,
14705,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631914,178.0,
14706,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631915,178.0,
14707,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875778,178.0,
14708,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631916,178.0,
14709,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631917,178.0,
14710,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631918,178.0,
14711,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631919,178.0,
14712,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631920,178.0,
14713,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631921,178.0,
14714,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631922,178.0,
14715,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631923,178.0,
14716,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631924,,
14717,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630234,,
14718,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630235,,
14719,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630236,,
14720,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630237,,
14721,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630238,,
14722,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630239,,
14723,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630303,,
14724,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630304,,
14725,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630305,,
14726,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630306,2113.0,
14727,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630307,2113.0,
14728,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630308,2113.0,
14729,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630309,2113.0,
14730,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629309,2113.0,
14731,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629993,2113.0,
14732,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629994,2113.0,
14733,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629995,2113.0,
14734,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631993,2113.0,
14735,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631994,2113.0,
14736,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631995,2113.0,
14737,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631996,2107.0,
14738,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631997,2107.0,
14739,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631998,2107.0,
14740,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631999,2107.0,
14741,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632000,2107.0,
14742,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632001,2107.0,
14743,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL874424,2107.0,
14744,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632002,2107.0,
14745,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632003,2107.0,
14746,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632004,,
14747,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632005,,
14748,Compound was tested for amidase rate in the presence of N62C screen enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632006,,
14749,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632007,,
14750,Compound was tested for amidase rate in the presence of S166C screen enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632008,,
14751,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632009,,
14752,Compound was tested for esterase rate in the presence of N62C screen enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632010,,
14753,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL857750,,
14754,Compound was tested for esterase rate in the presence of S166C screen enzyme,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632011,,
14755,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632012,,
14756,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632013,,
14757,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL632014,,
14758,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629622,,
14759,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629623,,
14760,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629624,,
14761,Ratio of Kcat to that of Km was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629625,,
14762,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629626,,
14763,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629627,,
14764,"Compound was evaluated for constant, Kd",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629628,,
14765,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629629,,
14766,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629630,,
14767,Dissociation Constant of compound determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL856030,,
14768,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629631,,
14769,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629632,,
14770,Dissociation constant of compound with Fructose was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629633,,
14771,Dissociation constant of compound with Fructose was determined; Not determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629634,,
14772,Dissociation constant of compound with Lactulose was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629635,,
14773,Dissociation constant of compound with Lactulose was determined; Not determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629636,,
14774,Dissociation constant of the Compound,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629637,,
14775,Dissociation constant by non-linear regression analysis,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629638,,
14776,Dissociation constant was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629639,,
14777,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629640,,
14778,Dissociation constant was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629641,,
14779,Dissociation constant was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL631344,,
14780,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631345,2385.0,
14781,The dissociation constant determined by fluorescence displacement assay,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631346,,
14782,kd value surface plasmon resonance (SPR) method,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631524,,
14783,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631525,2385.0,
14784,First dissociation constant of the binding of compound to V30M TTR,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631526,,
14785,Second dissociation constant of the binding of compound to V30M TTR,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631527,,
14786,"Compound was evaluated for equilibrium constant, Ke",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631528,,
14787,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631529,1898.0,
14788,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631530,1898.0,
14789,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631531,,
14790,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631532,,
14791,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL631533,,
14792,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876552,,
14793,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631534,,
14794,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631535,,
14795,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631536,,
14796,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631537,,
14797,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631538,,
14798,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631539,,
14799,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631540,,
14800,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625637,,
14801,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625638,,
14802,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625639,,
14803,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625640,955.0,
14804,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625641,955.0,
14805,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625642,948.0,
14806,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625643,948.0,
14807,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625644,2113.0,
14808,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625645,2113.0,
14809,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625646,2107.0,
14810,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625647,2107.0,
14811,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625648,2048.0,
14812,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625649,2048.0,
14813,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625650,2385.0,
14814,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625651,2385.0,
14815,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625652,14.0,
14816,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625653,14.0,
14817,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625654,2106.0,
14818,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625655,2106.0,
14819,Biodistribution of Compound in rat blood after 15 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625656,178.0,
14820,Biodistribution of Compound in rat blood after 2 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625657,178.0,
14821,Biodistribution of Compound in rat brain after 15 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625658,955.0,
14822,Biodistribution of Compound in rat brain after 2 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625659,955.0,
14823,Biodistribution of Compound in rat heart after 15 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625660,948.0,
14824,Biodistribution of Compound in rat heart after 2 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625661,948.0,
14825,Biodistribution of Compound in rat liver after 15 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625662,2107.0,
14826,Biodistribution of Compound in rat liver after 2 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL625663,2107.0,
14827,Biodistribution of Compound in rat lung after 15 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875621,2048.0,
14828,Biodistribution of Compound in rat lung after 2 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628382,2048.0,
14829,Biodistribution of Compound in rat muscle after 15 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628383,2385.0,
14830,Biodistribution of Compound in rat muscle after 2 minutes of administration,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628384,2385.0,
14831,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628385,,
14832,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875753,,
14833,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628386,,
14834,Organ distribution in rat blood 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628387,,
14835,Organ distribution in rat blood 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628388,,
14836,Organ distribution in rat blood 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628389,,
14837,Organ distribution in rat blood 30 min after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632756,,
14838,Organ distribution in rat brain 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628390,,
14839,Organ distribution in rat brain 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631811,,
14840,Organ distribution in rat brain 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631812,,
14841,Organ distribution in rat heart 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631813,,
14842,Organ distribution in rat heart 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631814,,
14843,Organ distribution in rat heart 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631815,,
14844,Organ distribution in rat kidney 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631816,,
14845,Organ distribution in rat kidney 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875758,,
14846,Organ distribution in rat kidney 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631817,,
14847,Organ distribution in rat liver 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631818,2107.0,
14848,Organ distribution in rat liver 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631819,2107.0,
14849,Organ distribution in rat liver 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631820,2107.0,
14850,Organ distribution in rat lung 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631821,,
14851,Organ distribution in rat lung 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631822,,
14852,Organ distribution in rat lung 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631823,,
14853,Organ distribution in rat muscle 2 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631824,2385.0,
14854,Organ distribution in rat muscle 2 hr after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631825,2385.0,
14855,Organ distribution in rat muscle 30 minutes after intravenous injection,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631826,2385.0,
14856,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631827,,
14857,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631828,,
14858,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL631829,,
14859,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875759,1088.0,
14860,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631830,1088.0,
14861,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631831,1088.0,
14862,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631832,1088.0,
14863,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631833,1088.0,
14864,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631834,1088.0,
14865,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631835,1088.0,
14866,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631836,1088.0,
14867,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631837,1088.0,
14868,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631838,1088.0,
14869,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631839,1088.0,
14870,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631840,1088.0,
14871,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631841,1088.0,
14872,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631842,1088.0,
14873,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631843,1088.0,
14874,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631844,1088.0,
14875,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631845,1088.0,
14876,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631846,1088.0,
14877,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL875760,1088.0,
14878,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL632199,1088.0,
14879,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631847,1088.0,
14880,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631848,1088.0,
14881,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628707,1088.0,
14882,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628708,1088.0,
14883,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628709,1088.0,
14884,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628710,1088.0,
14885,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628711,1088.0,
14886,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628712,1088.0,
14887,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628713,1088.0,
14888,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628714,1088.0,
14889,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL628715,,
14890,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629179,,
14891,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629180,,
14892,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875108,,
14893,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629181,1235.0,
14894,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629182,1235.0,
14895,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629183,,
14896,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629184,,
14897,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629185,1235.0,
14898,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629186,1235.0,
14899,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629187,,
14900,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629887,,
14901,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629888,,
14902,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629889,,
14903,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629890,1235.0,
14904,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629891,,
14905,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629892,,
14906,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629893,1235.0,
14907,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629894,,
14908,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629895,,
14909,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL875109,,
14910,Absolute bioavailability in male cynomolgus monkeys,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629896,,
14911,Absolute bioavailability in maleSprague-Dawley rats,,BAO_0000218,Autocuration,,,22224,U,0,1,,CHEMBL629897,,
14912,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL629898,2107.0,
14913,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630057,2107.0,
14914,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630058,2107.0,
14915,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630059,2048.0,
14916,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630060,2048.0,
14917,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630061,2048.0,
14918,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630062,2048.0,
14919,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630063,2048.0,
14920,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630064,2048.0,
14921,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630065,2048.0,
14922,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630066,2048.0,
14923,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630067,2048.0,
14924,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630068,2048.0,
14925,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631113,2385.0,
14926,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631114,2385.0,
14927,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631115,2385.0,
14928,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL631116,2385.0,
14929,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630528,2385.0,
14930,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630529,2385.0,
14931,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630530,2385.0,
14932,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630531,2385.0,
14933,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630532,2385.0,
14934,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630533,2385.0,
14935,Biodistribution in normal mice blood after 120 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630534,178.0,
14936,Biodistribution in normal mice blood after 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630535,178.0,
14937,Biodistribution in normal mice blood after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630536,178.0,
14938,Biodistribution in normal mice bone after 120 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630537,10000001.0,
14939,Biodistribution in normal mice bone after 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630538,10000001.0,
14940,Biodistribution in normal mice bone after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630539,10000001.0,
14941,Biodistribution in normal mice heart after 120 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630540,948.0,
14942,Biodistribution in normal mice heart after 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630541,948.0,
14943,Biodistribution in normal mice heart after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630542,948.0,
14944,Biodistribution in normal mice kidney after 120 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630543,2113.0,
14945,Biodistribution in normal mice kidney after 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630544,2113.0,
14946,Biodistribution in normal mice kidney after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630545,2113.0,
14947,Biodistribution in normal mice liver after 120 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630546,2107.0,
14948,Biodistribution in normal mice liver after 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630547,2107.0,
14949,Biodistribution in normal mice liver after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630548,2107.0,
14950,Biodistribution in normal mice spleen after 120 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630549,2106.0,
14951,Biodistribution in normal mice spleen after 24 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL630550,2106.0,
14952,Biodistribution in normal mice spleen after 4 hr,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL876426,2106.0,
14953,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630551,2106.0,
14954,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630552,2106.0,
14955,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630553,2106.0,
14956,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630554,2106.0,
14957,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630555,2106.0,
14958,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630556,2106.0,
14959,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630557,2106.0,
14960,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630558,2106.0,
14961,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630559,2106.0,
14962,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630560,2106.0,
14963,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL876427,2046.0,
14964,The Kel values in female wistar rats.,,BAO_0000218,Intermediate,,,50597,N,1,1,,CHEMBL630561,,
14965,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630562,,
14966,Hydrolysis rate constant of the compound,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL630563,,
14967,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,BAO_0000100,Autocuration,,,22229,U,0,1,,CHEMBL629673,,
14968,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629674,,
14969,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629675,,
14970,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629676,,
14971,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629677,,
14972,Apparent inactivation rate constant was evaluated,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629678,,
14973,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629679,,
14974,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629680,,
14975,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629681,,
14976,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629682,,
14977,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629683,,
14978,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL629684,,
14979,Dissociation constant was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629685,,
14980,Dissociation constant was determined,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629686,,
14981,Dissociation constant at pH 7.4,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL872932,,
14982,Dissociation constant in presence of 1 mM dithiothreitol,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL629687,,
14983,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL872931,,
14984,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628151,,
14985,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628152,,
14986,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628153,,
14987,Kinetic constant for aromatization of androstenedione,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628154,,
14988,Kinetic constant for aromatization of testosterone,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628155,,
14989,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628156,,
14990,Local inhibition constant was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628157,,
14991,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,BAO_0000218,Intermediate,,,50347,N,1,1,,CHEMBL857533,,
14992,Dissociation constant value of the compound,,BAO_0000100,Autocuration,,,22224,U,0,1,,CHEMBL628158,,
14993,In vitro permeability through cornea without epithelium,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628159,964.0,
14994,In vitro permeability through intact cornea,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL875616,964.0,
14995,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,,BAO_0000218,Intermediate,,,50592,N,1,1,,CHEMBL628160,964.0,
14996,Rate of enzyme inactivation for the compound was determined,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628161,,
14997,In vitro permeability through cornea without epithelium,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628162,964.0,
14998,In vitro permeability through intact cornea,,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628163,964.0,
14999,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628164,,
15000,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628165,,
15001,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628166,,
15002,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628167,,
15003,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628168,,
15004,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628169,,
15005,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628170,,
15006,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628171,,
15007,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627434,,
15008,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL627435,,
15009,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628110,,
15010,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628111,,
15011,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628112,,
15012,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628260,,
15013,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,Autocuration,,,22224,U,0,1,,CHEMBL628261,,
15014,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628262,,
15015,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,BAO_0000218,Intermediate,,,50587,N,1,1,,CHEMBL628263,,
15016,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628264,,
15017,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628265,,
15018,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628266,,
15019,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628267,,
15020,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628268,,
15021,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628269,,
15022,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628270,,
15023,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628271,,
15024,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,Intermediate,,,50594,N,1,1,,CHEMBL628272,,
